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Between 10-15% of women suffer from polycystic ovary syndrome (PCOS), 
making it the most common cause of female infertility. Clinical features of PCOS 
include high circulating levels of ovarian androgens (T and A4), anovulation and 
obesity. The aetiology of this reproductive endocrinopathy is likely to be multi-
factorial, through the interplay of genetics, epigenetics and environmental factors. 
Primate research into sexual behaviour development noted that fetally androgenised 
monkeys developed symptoms like those of PCOS. There are now multiple animal 
models of PCOS using primates, sheep, rats and transgenic mice. The investigations 
described in this thesis use rodent models to examine the role of androgens in the 
pathogenesis of female infertility. An attempt to generate a granulosa cell specific 
androgen receptor knockout mouse model will first be described, followed by several 
studies into the developmental programming of female Wistar rat infertility and 
metabolism by steroid hormones. 
 
Initial investigations showed that testosterone proprionate (TP) administered 
to female rats during different windows of fetal and neonatal life alters the 
reproductive and metabolic axes of the adult animals. Fetal plus neonatal TP 
exposure led to complete ovarian dysgenesis, while postnatal exposure produced a 
PCOS-like phenotype. Animals which received TP postnatally were heavier and had 
an increased proportion of primordial follicles in their ovaries by postnatal day (pnd) 
90 of life. 
 
Evaluation of this PCOS model showed that neonatally androgenised rats had 
ovarian follicles with larger antra and a greater ovarian stromal compartment. In 
addition, these animals were heavier when compared to controls. However, unlike 
human studies, neonatally androgenised rats showed no differences in circulating 
gonadotrophin or ovarian androgen levels. Nor did they show any programming 
effect of neonatal TP upon the theca interna by pnd 90. Further investigations to 
narrow the windows and dose of TP required to produce a PCOS phenotype showed 
that TP administered in an early window of neonatal life, between postnatal days 
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(pnd) 1-6 not only led to anovulation, but potentially reprogrammed the 
hypothalamic-pituitary axis, as there was minimal gonadotrophin response to 
reduced ovarian negative feedback (inhibin B and estradiol) in these rats. 
 
Neonatal TP also affected the rat metabolic axis with adult animals becoming 
heavier after weaning without any change in food intake. Animals developed 
mesenteric and retroperitoneal obesity along with insulin resistance (IR). Increased 
hepatic glucocorticoid turnover and altered adipokine expression were also noted in 
neonatally androgenised females, possibly contributing to the pathogenesis of 
obesity. No effect of TP dose upon the severity of infertility or metabolic 
abnormalities in adult animals was observed. 
 
To delineate which features of the rat PCOS model resulted from androgenic, 
estrogenic or corticosteroid action, a final study used administration of different 
steroids during the early window of postnatal life: TP, estradiol valerate (EV), 
dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA) and dexamethasone 
(DEX). The anovulatory PCO-like phenotype observed with TP was also seen in 
animals which received EV, but not those which received DHT, DHEA or DEX. TP 
and EV treatment also resulted in a reduction of ovarian follicle numbers and 
activated follicle proportions, with an increase in primordial follicle proportions. 
Although glucose tolerant, animals treated with TP and EV were highly IR. Unlike 
dexamethasone, DHT and DHEA also produced IR in adult animals, to a lesser 
extent than TP and EV. 
 
Taken collectively, the results described in this thesis demonstrate that the 
PCOS-like phenotype observed in the neonatally androgenised female rat is likely to 
be due to the estrogenic actions of testosterone, potentially through as yet unknown 
epigenetic mechanisms. The programming of the metabolic components described 
may additionally be due to the actions of androgens. Furthermore, these studies 
demonstrate a novel estrogenic effect of neonatal steroids upon primordial follicle 
populations and show that the neonatally androgenised rat may be a rational PCOS 
model in a poly-ovulatory species. 
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Chapter 1. Introduction: Literature Review 
1.1. Introduction 
Female reproductive dysfunction accounts for approximately 50% of all 
infertility, around one third of which is due to problems with ovulation (Templeton 
2000; Case 2003). This literature review will cover sexual development and function 
of the ovary and hypothalamic-pituitary gonadal (HPG) axes, before discussing the 
role of androgens and steroid hormones in female reproduction. Finally, female 
infertility disorders and animal models of reproductive dysfunction will be 
introduced. 
 
A strictly orchestrated reproductive cycle preserves several key functionalities 
important for a successful pregnancy; a healthy egg, properly timed ovulation, 
implantation in the correct place, and a receptive uterine environment for both 
spermatozoa and blastocyst. When these aspects of reproduction are out of 
synchronisation, or do not function correctly, female sub-fertility and infertility 
result. Infertility can be defined clinically as “Failure to conceive after one year of 
unprotected intercourse” (Case 2003). It is known that exposure to steroid hormones 
or their analogues can alter mammalian reproductive system in utero or in early life 
so that it functions incorrectly within the adult animal (Sharpe, Rivas et al. 2003; 
Ortega, Rey et al. 2010). The investigations of this thesis examine the role which 
steroid hormones, specifically androgens and their cognate receptor, play in female 
infertility using the rodent as a model system. 
 
1.2. Sex determination 
The physical traits of offspring are largely determined by genetic inheritance 
from the parental generation, and the characteristic of sex is no exception. At the 
point of fertilization a mammalian zygote will inherit an X chromosome from the 
female gamete and can receive either an X or Y from the male gamete depending 
which sex chromosome the sperm is conveying (Bridges 1916). The presence or 
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absence of the Y chromosome predestines offspring to develop as XY males or XX 
females (Ford, Jones et al. 1959; Jacobs and Strong 1959). 
 
When elucidating exactly how the Y chromosome instructs sexual 
development down a male pathway, human instances of sex reversal were 
informative, allowing researchers to pinpoint this „testis determining factor‟ (TDF) 
(Buckle, Boyd et al. 1987). The TDF specific to the Y chromosome was identified as 
a conserved 35 kilobase area, known as Sry –„sex determining region-Y‟ (Berta, 
Hawkins et al. 1990; Sinclair, Berta et al. 1990). Sry encodes a 79 amino acid protein 
product, transiently expressed in the pre-Sertoli cells of the testis, that up-regulates 
expression of Sox9, driving the establishment of Sertoli cells, testosterone (T) release 
and testis formation (Sekido, Bar et al. 2004).  
 
This process of sex determination in the male occurs at around 42 days post 
coitum (dpc) in humans and 11.5 dpc in mice. In females, sex determination occurs 
slightly later in both species; around 49 and 13.5 dpc respectively (Soder 2007). 
Initially, the process of sex determination in females was thought to occur via a 
default pathway of sexual development, being driven by the absence of Sry. 
However, recent research indicates that an antagonistic set of signalling molecules in 
XX females repress male pathway gene expression, in addition to driving ovarian 
differentiation. Although the exact mechanisms of female gonad differentiation are 
still unclear, Rspo1, a member of the R-Spondin family, is thought to be the gene 
responsible for tipping the bipotential gonad towards ovarian development. It is 
postulated that Rspo1 activates and synergises with Wnt4 expression in the XX 
gonad, stabilising β-catenin expression, and activating target genes associated with 
ovarian differentiation (Yao, Matzuk et al. 2004; Lau and Li 2009). Indeed, Wnt4 is 
present in the bipotential gonad of both mammalian sexes, but is strongly up 
regulated in XX gonads as they begin to differentiate (Chassot, Gregoire et al. 2008). 
Additional studies have also demonstrated that male pathway genes SRY and Sox9 
act to repress Wnt4/βcatenin signalling, and the interactions of the main sex 
determining factors are summarised in Figure 1.1. 
 




Figure 1.1: Sex determining factors in XY males and XX females: In the absence of 
SRY, ovary determining factors suppress testis-determining factors (Adapted from Vainio, 
Heikkila et al. 1999; Yao, Matzuk et al. 2004; Chassot, Ranc et al. 2008). 
 
The expression of SRY in the male leads to testosterone production which 
functions to masculinise the male reproductive tract and neuroendocrine axis, the 
latter via the aromatisation of testosterone to estrogen in the brain (Morris, Jordan et 
al. 2004). 
 
1.2.1. Sexual dimorphism of the neuroendocrine system 
Many aspects of the mammalian neuroendocrine system are sexually 
dimorphic due to differing hormonal milieus during fetal and neonatal development, 
key examples of which are shown in Table 1.1 (Ward, Wexler et al. 1996; Morris, 
Jordan et al. 2004). We now know that masculinisation of certain reproductive 
features in the male brain occurs through the aromatisation of testicular T (released 
both before and after birth) to estrogen (Lephart, Call et al. 2001). In addition 











XY male XX female
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(Dohler, Srivastava et al. 1984; Dohler, Coquelin et al. 1986). Furthermore, structural 
changes in the neuroendocrine system occur in both sexes at puberty, when again 
circulating steroidal milieu becomes particularly important (Ahmed, Zehr et al. 2008; 
Evuarherhe, Leggett et al. 2009; Schulz, Molenda-Figueira et al. 2009). 
 
Table 1.1: Summary of the sexually dimorphic areas of the mammalian nervous 
system: These areas are affected by changes hormonal milieu during neonatal development 
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1.3. The Ovary 
Unlike the testes where spermatozoa are perpetually produced from a germ cell 
population under the influence of testosterone, the ovary contains all the gametes a 
female mammal will possess during the course of her reproductive lifespan 
(Bukovsky, Caudle et al. 2005). Each oocyte is meiotically arrested within the 
follicle and resumes meiosis to achieve a fertilizable capacity after ovulation 
(Reviewed in Marteil, Richard-Parpaillon et al. 2009). Before ovulation, the somatic 
cells of the follicle proliferate and differentiate around the somewhat quiescent 
oocyte (Eppig 2001; Edson, Nagaraja et al. 2009). Timing is crucial in the human 
menstrual cycle and the rodent estrus cycle, the physiological purpose being a 
successful pregnancy through specifically scheduled events which are regulated by 
hormonal signals between the ovary and the brain. The following section will cover 
an overview of fembale reproduction in humans followed by a more detailed 
description of rodent follicle development and reproduction that has particular 
relevance to the findings presented in this thesis. 
 
1.4. Overview of human female reproduction 
The human ovary is formed by around 75 dpc and contains between six and 
seven million germ cells with the potential to become oocytes (Matzuk, Burns et al. 
2002; Bukovsky, Caudle et al. 2005). Most of these germ cells subsequently undergo 
programmed cell death during prenatal development. A proportion which do not 
develop into primordial and primary follicles by gestational day 170 (Forabosco, 
Sforza et al. 1991). At birth the human ovary contains around 4-700,000 oocytes, 
which are further depleted through natural atretic mechanisms to around just 4000 
oocytes by puberty, up to half of which may be pre-antral follicles (Bukovsky, 
Caudle et al. 2004). 
 
 Each oocyte is enclosed by a follicle of supporting somatic cells. Most 
follicles are quiescent primordial follicles and develop later in life, but a sub-
population of follicles is recruited to grow with each reproductive cycle, most of 
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which undergo atresia (Quirk, Cowan et al. 2004). The process of follicle 
development comprises several stages in humans and takes around three months 
from the primordial stage through to ovulation of a single oocyte (Figure 1.2). 
 
 
Figure 1.2: Follicle recruitment and development across three human menstrual 
cycles. An LH surge mid-cycle induces ovulation (Taken from S.S. Nussey 2001). 
 
The gonadotrophins, follicle stimulating hormone (FSH) and luteinizing 
hormone (LH), are two glycoprotein hormones released by the pituitary gland in 
response to signals from the hypothalamus (discussed in Section 6 of this Chapter). 
Under the stimulation of pituitary FSH released during the follicular phase of the 
cycle, selected follicles develop and produce increasing amounts of the steroid-
hormone estrogen (Figure 1.3). Ovarian estrogen secretion rises as a dominant 
follicle becomes ready for ovulation (Baird and Fraser 1974). Estrogen also 
stimulates mucosal secretion and vascularisation of the endometrial lining, which 
helps to facilitate entry of spermatozoa into the mucosa (Reviewed in Kelly and 
Critchley 1997; Critchley, Kelly et al. 2006; Jabbour, Kelly et al. 2006). Once a 
threshold of estrogen production is reached, a gonadotrophin releasing hormone 
(GnRH) surge from the hypothalamus, stimulates a further surge of pituitary LH into 
the circulation which induces ovulation (Midgley and Jaffe 1968; Midgley and Jaffe 
1971; Knobil 1974). 
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Figure 1.3: Timing is everything: gonadotrophin, progesterone and estradiol changes 
across the human female menstrual cycle. Development of one oocyte from a primordial 
follicle through to ovulation occurs over the course of several menses (Adapted from Speroff 
and Vande Wiele 1971; Edson, Nagaraja et al. 2009)  
 
Ovulation is inflammatory; the follicle luteinizes and ruptures, releasing the egg 
and leaving behind the supporting cells which regress to form the corpus luteum 
(CL). During the subsequent luteal phase of the cycle, the CL releases E2 and 
progesterone (P4), another steroid hormone that causes the endometrial lining to 
become more viscous and less alkaline in preparation for embryo implantation (Short 
1964; Baird and Fraser 1975; Jabbour, Kelly et al. 2006). Activin A produced by the 
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CL acts in a paracrine manner and stimulates CL regression during the luteal phase 
(Myers, Gay et al. 2007; Myers, van den Driesche et al. 2008). After ovulation, the 
egg moves into the oviduct and through the fallopian tubes, at which point if sperm 
are present fertilization can occur as haploid male and female gametes fuse to form a 
zygote. Once the initial stages of implantation are complete, the blastocyst releases a 
further endocrine regulator, human chorionic gonadotrophin (hCG), which maintains 
CL function and P4 release during early pregnancy (Reviewed in Sonderegger, 
Pollheimer et al.). Without hCG, CL function is not maintained and P4 withdrawal 
occurs as the CL regresses and the superficial layer of the endometrium is shed 
(Baird, Brown et al. 2003). This process is known as menstruation, and in women a 
menstrual period usually lasts between four and six days. 
 
 
1.5. Rodent follicle development and ovulation 
Female rodent endocrinology is different to that of humans in that rodents are 
poly-ovulatory and have an estrus cycle of around four days instead of a 28 day 
menstrual cycle. The stages of the rodent estrus cycle can be identified by the cell 
types present in the vagina when examining smear samples under a light microscope 
(Table 1.2).  
 
Table 1.2: Length and cell types present in the vaginal epithelium across each stage 
of the rodent estrus cycle (Adapted from Larsen, Markovetz et al. 1977). 
Estrus cycle stage Length (hours) Vaginal smear pattern (cell types present) 
Proestrus 12 – 14 Clusters of round nucleated epithelial cells 
Estrus 25 – 27 Mainly cornified squamous epithelial cells 
Metestrus (Diestrus 1) 6 – 8 Granular leukocytes 
Diestrus-2 55 – 57 Leukocytes, some nucleated epithelial cells 
 
This section will describe rodent ovarian physiology and follicle 
development; a four day estrus cycle allows rodents to breed frequently (Figure 1.4). 
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Figure 1.4: Hormone levels across the rodent estrus cycle: From top to bottom – 
progesterone, prolactin, 
estradiol, LH and FSH levels at 
the estrus, diestrus(1), metestrus 
(also known as diestrus 2) and 
proestreus phases of the four 
day cycle. Samples were taken 
at 2 hour intervals and black bars 
represent hours of darkness. X-
axis numbers represent the time 
of day by 24 hour clock (Taken 











1.5.1. Germ cell nest breakdown and primordial follicle assembly 
During rodent embryonic gestation a founder population of about 45 
primordial germ cells (PGCs) migrate through the hindgut and by embryonic day (e) 
11.5 have colonised the developing gonad (Greenfeld, Pepling et al. 2007). These 
PGCs, now termed oogonia, proliferate by mitosis to a point of incomplete 
cytokinesis until embryonic day e13.5, at which point these clusters (or nests) of 
oogonia are connected by intercellular bridges (Pepling 2006). Oogonia are then able 
to enter meiosis, arresting at the diplotene stage of meiotic prophase I and forming a 
finite founder population of germ cells now termed oocytes (Spradling, de Cuevas et 
al. 1997; Steckler, Wang et al. 2005). 
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At birth (corresponding to e75 in humans) around 70% of germ cells are lost, 
mostly via programmed atresia (McNatty 2000). Accordingly, the germ cell nests 
breakdown and the remaining oocytes become surrounded by a flattened layer of 
squamous pre-granulosa somatic cells, to form primordial follicles (Matzuk 2000). 
Pooled recruitment of primordial follicles can subsequently occur, but 
folliculogenesis before puberty is restricted up to the small antral stage due to low-
activity of the gonadotrophin releasing hormone (GnRH) „pulse generator‟ to the 
pituitary and correspondingly low levels of LH and FSH (Section 6). 
 
 Studies into rodent germ cell nest breakdown and subsequent primordial 
follicle assembly conducted in mice used the bioavailable phytoestrogen genistein, 
which disrupts nest breakdown, but doesn‟t affect granulosa cell (GC) association 
with the developing oocyte. In vivo mouse follicle assembly and ex-vivo rat 
primordial follicle assembly are also inhibited by P4 as well as estrogens (Kezele and 
Skinner 2003). It is now believed that these hormones are essential during rodent 
fetal life to prevent breakdown of clusters and maintain germ cells as arrested 
oogonia. At birth, and outside the endocrine environment of the mother, levels of 
estrogens and P4 in the neonate fall and nest breakdown and programmed germ cell 
loss initiates (Figure 1.5), possibly driven by local tumour-necrosis factor (TNF) 
expression and Notch signalling (Pepling and Spradling 2001). Recent research also 
indicates a role for activin in the breakdown of germ cell nests; in the mouse local 
inhibin levels decline at birth and injection of mice with activin at this point leads to 
an increase in the number of primordial follicles formed in the neonate (Trombly, 
Woodruff et al. 2009). Proteins with nuclear binding properties such as factor in the 
germline α (Figla), octamer-binding transcription factor 4 (Oct-4) and members of 
the leucine-rich repeat and pyrin domain containing (Nlrp) gene family are also 
thought to initially drive primordial follicle formation (Edson, Nagaraja et al. 2009).  
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Figure 1.5: Timeline of germ cell nest breakdown after birth in the rodent and 
primordial follicle formation: After arriving at the gonad, germ cells cluster in nests and 
progress through the various mitotic stages and arresting at the diplotene stage. After birth 
germ cells undergo programmed cell death, with the remaining germ cell population 
continuing into postnatal life. Each germ cell becomes surrounded by squamous granulosa 
cells as a primordial follicle (Adapted from Jefferson, Newbold et al. 2006). 
 
1.5.2. Primordial follicle recruitment  
 Transition of a quiescent primordial follicle into a developing primary follicle 
is thought to involve a number of oocyte derived and squamous GC derived factors, 
many belonging to the transforming growth factor-β (TGFβ) superfamily of proteins 
(Figure 1.6). For instance, growth differentiation factor-9 (GDF-9) secreted by the 
oocyte is required for follicle development (Nicol, Bishop et al. 2009; Sugiura, Su et 
al. 2010). GDF-9 deficient female mice are infertile and unable to develop follicles 
which have more than a single layer of cuboidal granulosa cells (Dong, Albertini et 
al. 1996). Further knockout studies have shown that GDF-9 is not only essential in 
mediating somatic cell growth in early follicle development, but is required for 
proper granulosa cell steroidogenic gene expression and oocyte growth (Carabatsos, 
Elvin et al. 1998; Elvin, Clark et al. 1999; Elvin, Yan et al. 1999). 
 
Conservation of the primordial follicle pool is also important in maintaining 
female fertility. Mice with phosphatase and tensin homologue (Pten) deficient 
14 15 16 17 18 19 20 21 0 1 2 3 4
Nests begin to
form
Germ cells cluster in nests Primordial follicles form
Germ cell death
Germ cell Zygotene
arrival Mitosis Leptotene Pachytene Diplotene
at gonad BIRTH
Germ cell development in the rat; after arriving a the gonad the germ cells begin to cluster in nests and enter into mitosis, prgressing 
through it’s varous phases (leptotene zygotene pachytene, arresting in diplotene). At the diplotene stage, germ cells undergo
programmed cell death; the remaining germ cell population continues into postnatal life and becomes surrounded by squamous 
granulosa cells as primordial follicles
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oocytes show depletion of primordial follicles and eventually complete follicle loss 
much earlier than occurs in normal ovarian ageing (Reddy, Liu et al. 2008). Oocytes 
from these mutant animals have high levels of Akt, which phosphorylates and thus 
inactivates Foxo3a (Reddy, Shen et al. 2005). Foxo3a is expressed in the nuclei of 
primordial and early primary follicles and expression levels decrease in more 
developed follicles (Castrillon, Miao et al. 2003). Foxo3a knockout female
 
mice have 
complete follicle loss by week 15 of life leading to the conclusion that Foxo3a is 
another inhibitory regulator of primordial follicle recruitment shown in Figure 1.6 
(Castrillon, Miao et al. 2003; Liu, Rajareddy et al. 2007). 
 
 
Figure 1.6: Summary of induction and inhibition of primordial follicle transition into 
the transitory primary follicle: (A) Oocyte transcription factors in the primordial follicle 
instigate follicle recruitment  leading to production of further transcription factors and TGFβ 
family proteins: These factors initiate oocyte enlargement and establish the formation of 
cuboidal GCs; (B) NOBOX signalling leads to the expression of GDF-9 in addition to bone 
morphogenetic protein-15 (BMP15). Expression of zona pellucida proteins ZP1 and ZP3 
begins after the activation of spermatogenesis and oogenesis helix-loop-helix 1 (SOHLH) 
proteins (not shown). In addition, kit ligand (KL) signalling is essential for healthy primordial 
to primary transition. In terms of GCs, the transcription factor forkheadbox ligand-2 (FOXL2) 
is also required the transition from a squamous to a cuboidal phenotype. Nuclear 
forkheadbox O3 (FOXO3) signalling in addition to anti-Müllerian hormone (AMH) produced 
by cuboidal GCs are known to prevent primordial to primary follicle activation, but the precise 
mechanisms involved remain to be elucidated (Adapted from Eppig 2001; Su, Sugiura et al. 
2008; Edson, Nagaraja et al. 2009). 
 
TGFβ proteins are a superfamily of secreted molecules which hetero- or 
homodimerize to activate serine/threonine kinase Alk receptors at the cell membrane. 
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phosphorylation and signal transduction via receptor smad proteins (Reviewed in 
Knight and Glister 2003). Sub-group proteins of the TGFβ superfamily include the 
bone morphogenetic proteins (BMPs) in addition to activin and inhibin dimers which 
play major roles in the auto- and paracrine regulation of follicle development 
(Trombly, Woodruff et al. 2009). 
 
Recent computational analysis of follicle spatial patterns points towards a 
potential inhibitor of primordial follicle recruitment, since closer proximity to a 
primordial follicle reduces the likelihood of recruitment (Da Silva-Buttkus, Marcelli 
et al. 2009). Conversely proximity to already growing follicles denotes an increased 
likelihood of recruitment. However, the paracrine signal which in theory emanates 
from primordial follicles has yet to be found (Da Silva-Buttkus, Marcelli et al. 2009).  
 
At this point in follicle development, the oocyte-derived GDF-9 and BMP-15, 
together with granulosa-derived KL, form a regulatory loop leading to cuboidal GC 
(cGC) formation and oocyte enlargement, thus establishing a primary follicle (Eppig 
2001). In mammals grouped recruitment of follicles from the primordial pool into the 
growing pool occurs once per cycle (every four days in rodents and roughly every 28 
days in humans). This recruitment from the pool of primordial follicles is thought to 
be mainly regulated by the intra-ovarian AMH level. AMH is secreted by 
proliferating cuboidal GCs and inhibits further follicle recruitment until a cohort of 
follicles die/are ovulated; thus intra-ovarian AMH levels decline and a second cycle 
of recruitment initiates (Rey, Lukas-Croisier et al. 2003). Next, outward proliferation 
of cGCs surrounding the oocyte leads to the formation of multilayered secondary 
preantral follicles, which are subsequently enclosed in a basal lamina that structurally 
maintains follicle configuration during follicle growth and prevents blood vessel 
invasion from the newly forming theca cell layer (Da Silva-Buttkus, Jayasooriya et 
al. 2008; Young and McNeilly 2010). 
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1.5.3. Follicle growth and atresia 
One of two possible fates will befall an ovarian follicle, either it will proceed 
to ovulation, or it will become atretic and die. Follicle development is influenced by 
paracrine, autocrine and endocrine factors from the primary right through to the 
ovulatory stage (Edson, Nagaraja et al. 2009). Before puberty the gonadotrophins 
have a permissive role in directing follicle development, with growth factors 
dictating the earlier stages as previously described. However, these growth factors 
may still be indirectly influenced by the gonadotrophins (Figure 1.7). 
 
 
Figure 1.7: Follicle 
development in the 
mammal is initially 
growth factor dependent 





follicles die via 
programmed atresia 
(Adapted from Irving-
Rodgers, Krupa et al. 
2003; Matsuda-Minehata, 
Inoue et al. 2006). 
 
Early preantral folliculogenesis is influenced by local GC estrogen 
production, in addition to insulin-like growth factor (IGF) interactions (Demeestere, 
Gervy et al. 2004; Quirk, Cowan et al. 2004). Preantral GCs have been shown to 
express IGF binding protein 2 (IGFBP-2) and the IGF-1 receptor; IGFBP2 is able to 
regulate the bioavailability of both IGF1 and IGF2 proteins released by adjacent 
antral follicles (Webb et al 2004). Since IGF1 and EGF are known in vitro stimulants 
of preantral follicle growth, it may be that early antral follicles influence 
neighbouring preantral folliculogenesis in a paracrine fashion (Spicer, Voge et al. 
2004). Furthermore, high levels of IGF1 may inhibit oocyte growth thus contributing 
to atresia (Webb et al 2004). However, it should be noted that such in vitro 
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investigations studies have not been performed across all model species or in 
humans.  
 
 Apoptosis of GCs occurs via caspase pathways; members of the TNF protein 
superfamily activate cell surface death receptors which trimerize and induce caspase 
cleavage and subsequent cell death (Matsuda-Minehata, Inoue et al. 2006). Work by 
Irving-Rodgers and colleagues in the last decade documented two specific types of 
follicular atresia in rodents. Firstly antral atresia, whereby GCs lining the antrum 
become apoptotic and cell death spreads outwards towards the basal lamina. 
Secondly, in basal atresia the reverse occurs whereby mGCs become apoptotic and 
the basal lamina develops convolutions, with cell death spreading inwards towards 
the oocyte. In both types of atresia macrophages and other immune cells are recruited 
by the apoptotic elements to endocytose any cellular remnants (Irving-Rodgers, 
Krupa et al. 2003). In the rodent, atretic events are marked by GC pyknotic nuclei, 
oocyte degeneration and the infiltration of immune cells. Although GC apoptosis is 
one known cause of follicle death across species, other mechanisms of cell death 
may exist within the mammalian follicle. Autophagy is one such process and has 
been shown to occur alongside apoptosis in Chinese hamster ovary cultures, where in 
nutrient deficient cultures, cells develop autophagosomes and self-degrade (Hwang 
and Lee 2008; Han, Kim et al. 2010). However, the precise mechanisms which 
earmark one follicle for atresia and another for ovulation remain poorly understood 
(Quirk, Cowan et al. 2004). 
 
Earlier research into follicular hormone concentrations suggests that an 
increased androgen to estrogen ratio may also contribute towards atresia (Diaz, 
Sugiura et al. 2008). Furthermore, other studies indicate that an imbalance between 
follicular concentrations of P4 and estrogens may also influence follicle death. IGF-1 
levels are lower in ruminant follicles undergoing atresia. However, it should be noted 
that significant differences in IGF expression patterns exist across species which 
remain to be fully characterised (Yu, Sui et al. 2004; Luo and Wiltbank 2006). As 
GCs become multi-layered and are surrounded by a basal lamina, follicles recruit a 
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steroidogenically inactive thecal cell layer from the contiguous cortical stroma 
known as the theca externa (Figure 1.8). 
 
These cells proliferate adjacent to the basal lamina to form the theca interna, 
a highly vascularised layer of endocrine cells providing increased structural support; 
this differentiation of thecal cells is induced by paracrine signalling from GCs 
(Reviewed in Young and McNeilly 2010). Although the specific molecules involved 
have yet to be identified, candidates include follistatin, members of the IGF 
signalling family, stem cell factor (SCF) and GDF-9 (Magoffin 2005). The theca 
interna is steroidogenically active, producing the androgens androstenedione (A4) 
and T in response to LH, which in preantral follicles serve to augment GC 
proliferation as the follicle develops (Murray, Swales et al. 2008).  
  
 












Figure 1.8: Summary of known bi directional paracrine communication in the 
induction and proliferation of the theca (A) basic fibroblast growth factor (bFGF) from the 
oocyte together with Kit ligand (KL) and insulin like growth factpr-1 (IGF-1) from granulosa 
cells (GCs), signal to the cortical stroma and induce theca externa formation. BMP-4 from 
pre-theca cells signals back to GCs indicating the presence of stroma. (B) Theca externa 
proliferates into steroidogenically active theca interna, forming a larger secondary preantral 
follicle within which GDF-9 produced by the oocyte acts to induce GC and theca cell 
proliferation, the resulting androgen produced by the theca acts on GCs to increase their 
proliferative capacity (Adapted from Orisaka, Tajima et al. 2009) 
 
At the antral follicle stage, follicle expansion is rapid and GCs differentiate 
into two sub-populations, the first few layers in contact with the basal lamina known 
as mural GCs (mGCs) and those in contact with and surrounding the oocyte are 
known as cumulus GCs (cGCs). Exposure to FSH primes the cGCs which, in concert 
with EGF released from the oocyte, induces rapid cGC expansion forming a 
cumulus-oocyte-complex (COC) (Diaz, Wigglesworth et al. 2007). Concurrently the 
fluid-filled spaces between cGCs coalesce around the COC forming an antrum. 
However, the absence of tight junctions at the mGCs surrounding the basal lamina 
suggests that fluid accumulation cannot occur through an ionic osmotic gradient, i.e. 
through a high antral ion concentration. Fluid accumulation into the antrum is in fact 
determined by the presence of macromolecues such as glycosaminoglycans, 
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osmotic gradient. It is also interesting to note that healthy antral follicles have twice 
the osmolality of atretic follicles (Clarke, Hope et al. 2006).  
 
Antrum formation is FSH dependent and GCs serve as a blood-follicle 
barrier, with fluid transport occurring largely via a passive aquaporin protein 
mechanism through the GCs themselves (McConnell, Yunus et al. 2002). Subsequent 
to antrum formation FSH, augmented by androgens and estrogens, induces p450 
aromatase expression in mGCs allowing A4 and T produced by the theca interna to 
be converted to estrogens (Figure 1.9). Although follicle survival is now 
gonadotrophin dependent, growth factors still play a role in follicular growth; GDF-9 
is involved in GC proliferation and cGC expansion as well as in the induction of FSH 
receptor expression (Young and McNeilly 2010). Furthermore, expression of p450 
aromatase in mGCs is FSH and steroid hormone dependent, but may be affected by a 
wide range of growth factors and protein molecules (Stocco 2008). Induction of 
aromatase and estrogen production is essential for follicle survival, the dominant 
follicles feeds back to the pituitary through the production of estradiol and inhibin, 
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Figure 1.9: The two-cell two-gonadotrophin model: LH stimulates induction of 
steroidogenic enzymes within the theca interna via the LH GPCR while FSH activates a 
second cognate GPCR on mural GCs to induce P450 aromatase expression. 
Androstenedione and testosterone (A4/T) produced in the theca diffuses across the basal 
lamina and is converted to estrogens by P450 Aromatase which feeds-back to the pituitary 
(Adapted from Magoffin 2005; Young and McNeilly 2010). 
 
1.5.4. Ovulation and CL function in the rodent 
At the point of LH surge, follicles which do not express LH receptor (LHr) in 
mGCs undergo atresia (Pakarainen, Zhang et al. 2005). In follicles with functional 
mGC LHr expression, the LH surge induces ovulation and mGC steroid production 
switches from E2 to P4 as the supporting follicle cells luteinise (Hillier, Knazek et al. 
1977; Daniel and Armstrong 1980; Hillier, Zeleznik et al. 1980; Jia, Kessel et al. 
1985). Activation of mGC LHr at ovulation terminates GC proliferation at the G0/G1 
phase of the cell cycle, inducing luteinisation of GCs and theca cells. In humans and 
non-human primates, the specific differentiation GCs into large hypertrophic 
granulosa-lutein cells, and luteinisation of the theca cells into smaller steroidogenic 
theca-lutein cells is well documented, although no such differentiation pattern is 
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A surge of prolactin (PRL) occurs in the evening of the LH proestrus surge 
(Figure 1.4) and after of P4 production ceases, caspase-3 mediated apoptosis of 
rodent CL tissue occurs; either in the current CL or those CL which are still present 
from previous estrus cycles (Gaytan, Morales et al. 1998; Gaytan, Morales et al. 
1998). PRL induces tissue remodelling of the CL, with cleavage of the basement 
membrane by matrix metalloproteinases (MMP) into component collagens, 
fibronectins and laminins which help instigate GC luteinisation (Gaytan, Bellido et 
al. 1998; Rodgers, Irving-Rodgers et al. 2003). Concomitantly, pericytes invade from 
the theca cell layer and angiogenesis factors derived from the developing CL, such as 
vascular endothelial growth factor (VEGF), angiogenesis factor-2 (Ang2) and 
prokineticin-1 (Prok1), stimulate the formation of capillary blood vessels (Smith, 
McIntush et al. 1994). 
 
Vascularisation of the CL provides the luteal cells with hormones, proteins 
and cholesterol required for steroid hormone (P4) production. Vascularised areas of 
the CL are recycled by fibroblasts and macrophages into collagen bundles, leaving 
behind an involuted „scar‟ within the ovary known as the corpus albicans (Stocco, 
Telleria et al. 2007). 
 
Inhibin B and P4 secreted by the rodent CL act at hypothalamo-pituitary sites 
to negatively regulate FSH synthesis and secretion immediately after ovulation 
during the evening of proestrus. Regression of the rodent CL takes place over several 
subsequent estrus cycles (Gaytan, Bellido et al. 1998). As the rodent CL produces no 
E2, negative feedback inhibiting pituitary gonadotrophin release is removed after CL 
formation. This allows the immediate recruitment and development of a further 
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1.6. The Hypothalamic-Pituitary Gonadal axis 
The hypothalamus is located at the middle of the base of the brain, directly 
beneath which the pituitary rests in sella turcica cleft of the skull (Amar and Weiss 
2003). The pituitary is divided into the anterior and posterior lobes, controlled by the 
hypothalamus. Hypothalamic neurons contact the hypophyseal portal system, a 
network of isolated blood capillaries with the pituitary gland allowing hormones and 
neurotransmitters released by the hypothalamus to be transported directly to the 
anterior pituitary where they act on receptors at the cell membrane of the various 
trophic cell types within the anterior pituitary gland (Amar and Weiss 2003). 
 
 In males, LH released from the pituitary into the circulation stimulates 
testicular Leydig cells to secrete T, production of which is further augmented by 
prolactin (also released by the pituitary) and inhibin. FSH and testosterone act in 
concert upon testicular Sertoli cells, facilitating spermatogenesis within the 
seminiferous tubules. Spermatozoa are produced from a pluripotent self-replenishing 
„stock‟ of spermatogonial stem cells (Reviewed in Huhtaniemi and Bartke 2001). 
Inhibin and testosterone produced by the testis negatively feedback to the pituitary 
and hypothalamus to regulate spermatogenesis (Meachem, Nieschlag et al. 2001). 
 
In the female reproductive system, feedback regulation by the hypothalamus 
and pituitary is more complicated since unlike the testis, the pattern of gamete 
development and release is not continuous. The ovary contains no gamete-
replenishing stem cells, and so release of an ovum is tightly regulated by the brain 
and pituitary to occur at a specific point during the menstrual and estrus cycles as 
previously described. The gonadotrophins act in concert to facilitate follicular 
development prior to ovulation. Estradiol and inhibin produced by the ovary in 
response to FSH and LH, feed back to the pituitary and hypothalamus. Before 
ovulation, estradiol production is highest (Figure 1.3 and Figure 1.4) and feeds 
forward to the hypothalamus which produces a GnRH surge, inducing a pituitary LH 
surge and causing ovulation (Sections 3-5 of this Chapter). 
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 Differences exist across species between the feedback systems which regulate 
ovulation, CL formation and hence the length of the menstrual and estrus cycles. In 
ruminants, no E2 is produced by the CL and thus some negative regulation is 
removed from the pituitary allowing FSH secretion to rise again. Thus follicle 
development recommences earlier and the ruminant estrus cycle is shorter than the 
human menstrual cycle; between 17 to 21 days in length (Baird, Baker et al. 1975). 
Rodents have a four day estrus cycle, as the rodent CL continues to secrete P4 for 
just one to two days after ovulation (Sanchez-Criado, Ruiz et al. 1996). 
 
1.6.1. Pituitary development and ontogeny of the gonadotrophs 
During development, the hypophyseal placode of the oral ectoderm 
envaginates into Rathke‟s pouch while at the same time a second envagination of 
neural ectoderm occurs in the opposite direction allowing the two cell lineages to 
unite and develop into the distinct lobes of the adult pituitary, the secretory anterior 
lobe and the neural posterior lobe (Rizzoti and Lovell-Badge 2005; Kelberman, 
Rizzoti et al. 2009). The posterior pituitary is an extension of hypothalamic neurons 
in which hormonal proteins are synthesized at the hypothalamic apex (Rizzoti and 
Lovell-Badge 2005). These neuronal fibers traverse the hypophyseal space as the 
pituitary stalk where the hormones oxytocin and vasopressin, are stored in granules 
within neuronal terminals for release into the hypophyseal vein (Clarke and 
Cummins 1982; Clarke, Cummins et al. 1987). Conversely, the anterior pituitary 
receives hormonal signals from the hypothalamus via the hypophyseal portal 
sinusoid vessels, regulating in situ pituitary hormone synthesis and secretion (Rizzoti 
and Lovell-Badge 2005). The anterior pituitary contains various trophic cell types 
which synthesize and secrete trophic hormones that act on target endocrine organs to 
elicit a physiological response detailed in Table 1.3 (Besser 1974a; Besser 1974b; 
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Table 1.3: Hormones released by the pituitary in response to hypothalamic paracrine 
signalling, their respective target organs and the main regulators of pituitary hormone 
release (Adapted using Amar and Weiss 2003). 





Target organ(s) Main regulators 
Anterior pituitary 
Corticotrophs ACTH CRH Adrenal gland Stress, glucocorticoids 
Gonadotrophs LH, FSH GnRH Ovary 
Estrogens, 
progesterone inhibin 
Lactotrophs Prolactin PRH Breast, uterus 
Light, stress, estrogens, 
glucocorticoids, 
suckling 
Somatotrophs GH GHRH Liver Estrogens, insulin 














Vasopressin (also known 




Blood volume, pressure 
and osmolality 
ACTH=adrenocorticotrophioc hormone; CNS=central nervous system; CRH=cortocotrophic releasing hormone; 
GH=growth hormone; FSH=follicle stimulating hormone; GHRH=growth hormone releasing hormone; 
GnRH=gonadotrophin releasing hormone; LH=luteinising hormone; TSH=thyroid stimulating hormone; 
TSH=thyrotrophin releasing hormone; MSH=melanocyte stimulating hormone; PVN=paraventricular nucleus; 
SoN=supraoptic nucleus; UV=ultraviolet  
 
One important feature of the hypophyseal portal system is a vascular 
arrangement allowing the precise conduction of undiluted hormonal signals from the 
hypothalamus directly to the cells of the anterior lobe, stimulating trophic cells to 
secrete hormone directly into the venous circulation (Amar and Weiss 2003). The 
hypophyseal artery divides into a selection of highly permeable sinusoid capillaries 
which contact the anterior pituitary allowing small macromolecules (such as GnRH) 
access to the trophic cell types (Amar and Weiss 2003). Both the anterior and 
posterior lobes contact venous sinusoid capillaries which empty into the hypophyseal 
vein (Besser 1974a; Besser 1974b). 
 
In pre-gonadotroph cells, the common α gonadotrophin subunit (αGSU) is the 
first gonadotrophin subunit to be expressed as Rathke‟s pouch forms during mouse 
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pituitary development at e10.5, six days later LHβ subunit expression follows at 
e16.5 and the FSHβ subunit is expressed seven days later at e17.5 (Rizzoti and 
Lovell-Badge 2005; Kelberman, Rizzoti et al. 2009). Across mammalian species 
there is consistent basal activation of the gonadotrophin subunit genes affected by 
various transcription factors present within the gonadotrophs. When GnRH binds to 
its cognate receptor at the gonadotroph cell surface PKC, MAPK and calcium 
signalling can each affect subunit expression at the promoter level (Brown and 
McNeilly 1999).  
 
At the endocrine level, steroid hormones also alter gonadotrophin subunit 
expression. E2 is known to decrease αGSU mRNA as well as LHβ mRNA via down-
regulation of the transcription factor SF-1 and in addition, E2 and P4 both negatively 
regulate FSHβ expression via activating protein-1 (AP-1) (Wang, Fortin et al. 2008; 
Fortin, Lamba et al. 2009). Additionally, GnRH pulse frequency affects 
gonadotrophin transcription. A higher frequency favours αGSU and LHβ synthesis 
while a lower pulse frequency favours synthesis of FSHβ mRNA (Haisenleder, 
Dalkin et al. 1991; Haisenleder, Yasin et al. 1997). 
 
1.6.2. The GnRH pulse generator 
 Gonadotrophin releasing hormone (GnRH) is a decapeptide, Glu-His-Trp-
Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, synthesized by the hypothalamus and released 
into the hypophyseal portal system in a pulsatile manner (Baba, Matsuo et al. 1971; 
Schally, Arimura et al. 1971).  During development, GnRH neurons migrate from the 
medial olfactory placode into the brain and are distributed throughout the basal 
forebrain, medial septum and the medio-basal hypothalamus (MBH). In the adult, 
GnRH neurons can be found in the hypothalamus, the medial pre-optic area (POA), 
the retrochiasmatic area and the arcuate nucleus (ARC) (Ebling 2005). Such 
extensive distribution of GnRH neurons allows signal reception from a wide variety 
of steroid hormones, growth factors, neurotransmitters and other signaling peptides. 
There exists a clear link between pulsatile GnRH release and LH release (Figure 
1.10), demonstrating that GnRH controls the female menstrual and estrus cycles in 
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two distinct fashions: (1) as a regulator of pulsatile LH secretion and (2) as an 
initiator of the pre-ovulatory LH surge (Clarke and Cummins 1982; Clarke and 
Cummins 1985; Clarke and Cummins 1987; Clarke, Thomas et al. 1987; Clarke, 
Cummins et al. 1989; Maeda, Tsukamura et al. 1995). However, GnRH neurons lack 
the necessary nuclear estrogen receptors (ER) which would mediate steroid hormone 
signals from the ovary back to the hypothalamus. 
 
 
Figure 1.10: The GnRH pulse generator during the female menstrual cycle: (A) In the 
follicular phase, GnRH pulses operate at a frequency of 1 pulse every 90 minutes; (B) Just 
before the LH surge, GnRH pulse frequency operates at one pulse per hour, priming GnRH 
neurons for continued GnRH release; (C) After ovulation during the luteal phase, negative 
feedback from E2 reduces GnRH pulse frequency to one pulse approximately every 3 to 4 
hours (Adapted from Clarke and Cummins 1982; Clarke and Cummins 1985; Clarke and 
Cummins 1987; Clarke, Thomas et al. 1987; Clarke, Cummins et al. 1989; Marshall and 
Griffin 1993). 
The arcuate nucleus (ARC) and anteroventral periventricular nucleus 
(AVPV) are both discrete neuronal regions, but both use kisspeptin (kiss) signaling 
via orphan G-protein coupled receptor 54 (GPCR54), to regulate the GnRH release 
from GnRH neurons (Lee, Miele et al. 1996; Muir, Chamberlain et al. 2001). Kiss 
neurons of the ARC are responsible for GnRH pusatility and those at the AVPV for 
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the GnRH surge (Maeda, Adachi et al. 2007). Within the AVPV, plasma E2 activates 
ERα and ERβ on kiss neurons, which at a certain threshold positively feeds forward 
the signal required for the LH surge (Haisenleder, Yasin et al. 1997). In contrast, E2 
feedback at the ARC is negative, modulating GnRH pulse frequency via ERα, with 
synchronized Kiss release by ARC neurons (Figure 1.11). This allows an episodic 
release of GnRH from the median eminence (Smith, Clifton et al. 2006). The precise 
mechanisms which govern E2 positive and negative feedback remain unclear. 
However experiments in female rats have shown that prior to the LH surge, both the 
number of Kiss expressing cells and amount of Kiss1 transcription increase within 
the AVPV and concomitantly decrease within the ARC (Lin, Li et al.). 
 
Figure 1.11: Estradiol (E2) feedback to kiss neurons in the anteroventral 
periventricular (AVPV) and arcuate nucleus (ARC) which synapse in the median 
eminence (ME) of the hypothalamus. Kisspeptin signals (k) are transmitted via GPCR54 to 
gonadotrophin releasing hormone (GnRH - blue hexagons) cells which release GnRH into 
the hypophyseal portal vessels: AHA=anterior hypothalamic area; SCN=suprachiasmatic 
nucleus; OC=optic chiasm; D/VMN=dorso/ventro-medial nucleus (Adapted from Smith, 
Clifton et al. 2006). 
 
Androgen receptor has been located to the female pituitary, hypothalamus 
and POA and may be involved in the regulation of hypothalamic sensitivity to 
catecholamines and other adrenal hormones (Barley, Ginsburg et al. 1975; Handa 
and Resko 1989; Miyamoto, Matsumoto et al. 2007). However, the role for this 
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1.6.3. Regulation of gonadotrophin secretion 
Gonadotrophin secretion varies over the course of the menstrual and estrus 
cycles as follicle development progresses towards ovulation (Chapter 1, Sections 3-
5) LH release is predominantly regulated by GnRH pulsatility, and FSH release is 
constitutive, being directly related to the rate of FSHβ mRNA synthesis (McNeilly, 
Crawford et al. 2003). During the follicular phase of the menstrual cycle in humans, 
and during diestrus in rats, GnRH pulse frequency is increased favouring regulated 
LH synthesis and storage before the pre-ovulatory LH surge. During the luteal phase 
of the menstrual cycle and proestrus/estrus in rodents, GnRH pulse frequency is 
slightly slower, favouring constitutive FSH synthesis and secretion (Haisenleder, 
Ortolano et al. 1993; Marshall, Dalkin et al. 1993; Adams, Taylor et al. 1994; Sisk, 
Richardson et al. 2001). Both gonadotrophins are secreted by the same bi-hormonal 
gonadotroph cells (Figure 1.12), although distinct populations of smaller „mono-
hormonal‟ gonadotroph cells have been identified in primates, ruminants and rodents 
(Childs, Hyde et al. 1983; Childs 1985). The proportions of these distinct mono- and 
bi-hormonal cell populations change over the course of the cycle in rodents in 
response to negative and positive feedback mechanisms, although ovine studies have 
proved conflicting and the cyclical changes observed have yet to be investigated 
thoroughly in primates (Thomas and Waring 1997; Thomas and Clarke 1997). 
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Figure 1.12: Mechanisms of regulated LH and constitutive FSH gonadotrophin storage 
and secretion (Adapted from McNeilly, Crawford et al. 2003; Naor 2009) 
 
LHβ is constitutively synthesized and just 5% is secreted in a pulsatile 
manner during the luteal and follicular phases. LH pulsatility directly mimics that of 
GnRH, and studies in ruminants have demonstrated that 95% of LH synthesized is 
stored in granules within gonadotrophs (McNeilly, Crawford et al. 2003). During the 
follicular phase of the cycle, and through the influence of E2 and GnRH upon actin 
cytoskeletal components, LH granules move from the cytoplasm towards the 
hypophyseal sinusoids, the optimal site for gonadotrophin exocytosis into the 
circulation. Indeed more than 90% of LH granules are located at the cellular 
periphery during the LH surge, and this number drops to less than 20% in the luteal 
phase of the cycle (Crawford, Currie et al. 2000; Crawford and McNeilly 2002). LH 
granular storage is exhausted after ovulation and is replenished in the subsequent 
days of the luteal phase; basal pulsatile LH secretion (again, in line with that of 
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FSHβ secretion, although constitutive and in line with FSHβ mRNA 
synthesis, is also related to GnRH pulsatility (McNeilly, Crawford et al. 2003). Up to 
two thirds of constitutive FSH release occurs in line with GnRH release. These 
studies noted that although distinguishing FSH protein isoforms together with the 
long half life of FSH mRNA, poses a significant problem when deducing the 
mechanism whereby FSH release occurs independently of GnRH (Padmanabhan and 
Sharma 2001). A specific FSH-releasing signal may yet exist since in the presence of 
GnRH antagonists a pulsatile element of FSH secretion remains. However, no 
protein or gene has been isolated to confer this function (Padmanabhan and McNeilly 
2001). The disparate packaging of FSH and LH into distinct granules may explain 
how differential secretion is achieved (Nicol, McNeilly et al. 2002). 
 
Investigations into protein packaging molecules, specifically secretagranins 
(Sg) and chromogranins (Cg) indicate that discrete gonadotrophin packaging 
mechanisms exist, even within the same cell, allowing the distinct secretory patterns 
of the gonadotrophins. SgII is one such granin associated with storage and secretion 
of hormones by endocrine cells (Courel, Soler-Jover et al. 2010). SgII is an electron 
dense secretagranin that binds calcium ions and has been localised to LH positive 
granules in pituitary gonadotrophs. Conversely CgA is an electron light 
chromogranin, localised to FSH positive granules. Such differential storage allows 
differential secretion, but does not account for the presence of basal LH secretion in 
the absence of GnRH receptor signalling (McNeilly, Crawford et al. 2003). Studies 
in sheep have demonstrated that SgII-negative granules containing LH exist, 
surrounded by FSH within the same granule, which may indicate one pathway of 
basal LH secretion (Crawford, Currie et al. 2000; Crawford and McNeilly 2002; 
Crawford, McNeilly et al. 2002; Crawford, McNeilly et al. 2004). 
 
Gonadotrophin secretion is regulated at the endocrine level through feedback 
of growth factors and steroid hormones. FSH secretion is negatively regulated by 
estradiol as well as inhibin B, both of which increase GnRH pulse generator 
frequency, leading to increased GnRH signalling to gonadotrophs causing exocytosis 
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of LH into the general circulation, thus inducing ovulation (Padmanabhan and 
McNeilly 2001). 
 
Furthermore, the actions of activin and inhibin feedback in the pituitary are 
antagonistic. Activin augments FSH synthesis and secretion while inhibin, follistatin 
and betaglycan bind available activin and type II activin receptors, lowering FSH 
synthesis. (Bilezikjian, Blount et al. 2006). Moreover, FSH synthesis and secretion 
may be further controlled by an activin/inhibin regulatory loop; recent in vitro 
studies have shown that activin-A also promotes synthesis of activin B, and to a 
lesser extent inhibin-B within pituitary LTβ2 gonadotroph cells. Activin-B then 
signals via smad2/3 phosphorylation to induce furin, a pro-convertase enzyme, which 
thus also promotes inhibin-B synthesis, and finally inhibin-B negatively regulates 
both furin production and FSH synthesis and secretion (Antenos, Zhu et al. 2008). 
Through these complex protein-protein interactions and phosphorylation signalling 
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1.7. Steroids in reproduction and metabolism 
Steroid hormones are vital for proper maintenance of mammalian endocrinology; 
synthesis and release of steroids is appropriately timed and regulated in order for 
reproduction, metabolism and growth to function correctly. Steroid hormones are 
large hydrophobic compounds synthesised from a parent molecule of cholesterol 
derived from acetyl-coA (Rang, Dale et al. 2003). Steroid hormones can therefore be 
categorised into five major steroidogenic groups according to how many carbon 
molecules they comprise and their modes of action within the mammalian system 
(Rang, Dale et al. 2003). Exposure or lack of proper exposure to various steroids 
during development and in adulthood can potentially lead to certain 
pathophysiologies; hypospadias, cryptorchidism (males), premature ovarian failure, 
polycystic ovarian syndrome (females), congenital adrenal hyperplasia (CAH), and 
hypothyroidism to name a few (Kopelman 1994; Barnes 1997; Welsh, Saunders et al. 
2008). 
 
The synthesis of steroid hormones is dependent on the activity of tissue specific 
enzymes which catalyse the addition or removal of various chemical groups, for 
example a 17α hydroxylase enzyme will catalyse the addition of a hydroxyl OH 
group connected to the 17
th
 carbon in the molecule. The nomenclature and classes of 
steroid hormones synthesized by various steroidogenic enzymes within endocrine 
tissues are detailed in Figure 1.13. The genes encoding these steroidogenic enzymes 
along with tissue specificity are shown in Figure 1.14. 
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Figure 1.13: Ovarian and adrenal steroidogenesis by steroid type: Synthesis of 
progestagens (green boxes), androgens (blue boxes), estrogens (pink boxes) 
glucocorticoids (grey boxes), and aldosterone (purple box) by various steroidogenic 
enzymes located in the endoplasmic reticulum (yellow boxes) and cytoplasm (orange boxes) 
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Figure 1.14: Ovarian and adrenal steroidogenesis by steroidogenic enzyme gene 
nomenclature: Progestagen, androgen, estrogen, glucocorticoid and aldosterone synthesis 
in various steroidogenic tissues including theca cells (blue box), granulosa cells (pink box) 
and adrenal cortex (grey box). Steroidogenic enzymes are shown by their gene names and 
correspond to the same enzymes detailed in Figure 1.13, these enzymes are expressed 
either in the ovary (orange boxes), the adrenal (yellow boxes) or both (orange and yellow 
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1.8. The role of androgens in reproduction 
Androgens are often referred to as male hormones since production of T in the 
testes is required for spermatogenesis and therefore fertility in males. As shown in 
Figure 1.13 and Figure 1.14, androgens are also produced by the adrenal and ovary in 
response to endocrine signals from the brain. Within the ovary the main function of 
A4 and T is that they are precursors to the estrogenic hormones which feedback to 
the pituitary. However the androgen receptor (AR) is nevertheless present throughout 
the ovary, particularly in stromal, thecal and granulosa cell types. Moreover, AR 
knockout (ARKO) female mice are infertile and therefore androgens must have their 
own functions with regards to the developing follicle (Yeh, Tsai et al. 2002). 
 
 
Figure 1.15: Molecular structures of endogenous androgens: DHT is the most potent 
androgen (against the androgen receptor) and is non-aromatisable, T and A4 are the second 
and third most potent androgens and are both aromatisable, while DHEA has the weakest 
potency and is also not aromatisable (Rang, Dale et al. 2003). 
 
Although androgens have many physiological roles, particularly in 
reproduction and metabolism, other compounds which mimic the actions of 
androgens (and estrogens) and could potentially disrupt mammalian endocrinology, 
have been studied extensively. Humans are exposed to many organic and inorganic 
compounds during their daily lives and the physiological consequences of 
transmission of environmental toxins, either through the food chain or environmental 
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1.8.1. The Androgen Receptor 
 The androgen receptor (AR), a member of the nuclear receptor (NR) 
superfamily, is present as two isoforms within humans, the second lacking a portion 
of the amino-terminal domain (ATD) that is involved in receptor transactivation 
(Wong, Burghoorn et al. 2004). In ruminants and rodents however, only one isoform 
of the AR is known. Across species, the AR gene, like that of other NRs, displays a 
high degree of homology and is located at chromosome position Xq11-q12 
(Reviewed in Zheng, Yang et al. 2010). Indeed, many X-linked fertility disorders in 
males are the result of defective AR signaling, passed down maternally as X 
chromosome mutations (Stouffs, Tournaye et al. 2009; Stouffs, Vandermaelen et al. 
2009; Zhang, Yang et al. 2010). 
 
The AR protein has a similar conformation to other NRs most importantly a 
carboxyl terminal ligand binding domain (LBD), which can bind an androgen 
molecule. All NR LBDs contain twelve α-helices which co-ordinate into a 
hydrophobic „pocket‟ and upon ligand binding helix 12 repositions to „lock in‟ the 
steroid molecule. Another key element to NRs is the presence of a DNA binding 
domain (DBD), containing two Zinc molecules which co-ordinate the cysteine 
residues involved in DNA binding as the NR effects transcription events (Ribeiro, 
Kushner et al. 1995). Activation function (AF) segments (which, in other NRs have 
their own distinct protein regions) exist within the DBD and LBD and are 
responsible for activating the receptor complex, leading to dimerization, 
translocation and/or degradation (Dennis, Haq et al. 2001; Whittle, Powell et al. 
2007). A more detailed exploration of AR gene and protein structure can be viewed 
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Figure 1.16: Structure of the AR coding sequences and protein: Key amino acid (aa) 
sequences are shown in boxes and single conserved aa in circles with colour coded 
functions. In the amino terminal domain (ATD) activation functions (AF) 1a and b serve to 
potentiate receptor activation of the ligand binding domain (LBD) in the presence of 
androgen ligand. Other nuclear receptors (NRs) however, possess specific AF domains. All 
NRs do contain a DNA binding domain (DBD), characterised by two conserved Zinc (Zn) 
fingers, the first of which includes a „P-box‟ sequence containing conserved aa which 
recognise androgen response elements. The second Zn finger contains a „D-box‟, necessary 
for DNA binding and dimerization. The hinge region may function as phosphate-acceptor to 
co-activators, in addition to playing a role in AR degradation. Finally, the ligand binding 
(LBD) or C-terminal domain (CTD) is similar to that of other NRs; 12 α-helices surround a 
ligand-binding cavity. Helix 12 acts as a second AF domain, repositioning upon ligand 
binding, closing the ligand cavity and allowing co activators to dock at the CTD before 
dimerization occurs (Adapted from Claessens, Denayer et al. 2008). 
 
Upon ligand binding, the AR acts as a transcription factor; two AR dimerize 
and translocate to the cell nucleus, where they bind various co-activators/repressors, 
subsequently affecting gene transcription events through the recognition of 
hexameric AR response elements (ARE) (Centenera, Harris et al. 2008). All steroid 
receptors, not just the AR, bind specific inverted hexameric repeat sequences. Indeed 
the glucocorticoid (GR),  mineralocorticoid (MR) and progestagen receptors (PR), in 
addition to the AR bind the consensus sequence 5`-TGTTCT-3`; conversely estrogen 
receptors ERα and ERβ bind the hexameric repeat 5`TGACCT-3`. More selective 
AREs exist that are not recognised by other NRs, and this together with tissue 
specific expression of steroid receptors, can alter disparate gene expression events 
across cell types (Claessens, Denayer et al. 2008). 
 
Nuclear receptor actions were initially documented as alterations in gene 
transcription events over the course of hours and days. However, research into the 
effects of NRs lacking DBDs demonstrated short-term alterations in cellular function 
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led scientists to postulate that NR actions could also be non-genomic in nature, 
effecting calcium release and even ion channel function(s) and over the last decade, 
such non-classical actions of the AR and other steroid receptors have now been 
documented (Clarke and Khosla 2009). 
 
Within the ovary, androgens act via the AR to promote GC proliferation as 
the follicle progresses from the primary to the early antral stage of follicular 
development. Furthermore androgens are precursors for mGC E2 biosynthesis 
(Hillier, Zeleznik et al. 1980; Hillier and De Zwart 1981; Hillier and Tetsuka 1997). 
In primary GC cultures DHT has been shown to inhibit aromatase activity and lead 
to follicular atresia, and so conversion of T by 5α-reductase to 5αDHT within the 
ovary may prevent follicles progressing to the pre-ovulatory stage (Hillier and De 
Zwart 1981). Thus modulation of androgen action via the activity and expression of 
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1.9. Developmental programming 
The concept of developmental programming relates to how changes in the in 
utero or early life environment during key windows of development can 
detrimentally affect adult animal physiology. This link between development and 
adult disease was identified using epidemiological studies, such as investigations into 
the 1940s Dutch famine and it‟s affects upon adults born during this period - these 
people developed features of the metabolic syndrome including obesity, type-2 
diabetes Mellitus (T2DM) and cardiovascular disease (CVD) (Roseboom, van der 
Meulen et al. 2001; Roseboom, van der Meulen et al. 2001; Painter, de Rooij et al. 
2007). In 1997, Dr David Barker published his hypothesis on the fetal origins of 
adult disease, observing in animal models that lack of proper nourishment during 
development in utero was not directly the cause of the coronary heart disease 
phenotype observed in adult animals (Barker 1997). Instead, Barker hypothesized 
that alterations to the in utero environment somehow affected fetal growth in a 
disproportionate manner, particularly during mid/late gestation in humans, 
predisposing the adult offspring to various metabolic pathophysiologies (Barker 
1997; Barker 1997). He also noted that different tissues have their critical periods of 
growth at different times of development (Barker 1997). Current research suggests a 
predictive adaptive response (PAR) of the fetus to the developing environment 
exists, whereby if nutrient restriction during development occurs offspring 
physiology compensates to account for nutrient restriction once outside of the womb 
(Reviewed in McMillen and Robinson 2005). 
 
 The mechanism(s) through which such developmental programming of adult 
disease occurs are thought to be epigenetic in nature i.e. alterations to gene 
expression without changes to the DNA sequence itself. Potential epigenetic 
alterations include changes to the methylation, phosphorylation or acetylation of 
histones in order to increase or decrease (silence) gene/promoter expression, in 
addition to changes in the expression of cofactors or enzymes involved in the 
transcription and modification of DNA coiling, RNA splicing and stability (Fowden 
and Forhead 2009). However, it should be noted that despite some research into the 
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mechanistic aspects of epigenetics, relatively little is known about epigenetic 
programming or the epigenome. 
 
 Mammalian development is mediated by the controlled expression of factors 
and hormones within the mother, placenta and fetus. Hormones expressed by the 
mother, placenta and fetus during development may respond to alterations in oxygen 
availability, temperature, photoperiod, nutrition and even maternal stress (Seckl, 
Cleasby et al. 2000; Fowden and Forhead 2004; Fowden, Giussani et al. 2005; 
Fowden, Forhead et al. 2008). Therefore, changes in the timing, duration and level of 
hormones or other signaling molecules secreted by the fetus, derived from the 
placenta or which cross from the mother through the placenta-fetal barrier, may alter 
the transcription or in/activation of other factors during development via epigenetic 
mechanisms (Figure 1.17). 
 
 
Figure 1.17: Hormones as epigenetic programmers of adult disease (Taken from 
Fowden, Giussani et al. 2005). 
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In terms of steroid hormones and their effects upon the developmental 
programming of mammalian development, estrogen is required in female mammals 
for the maintenance of primordial germ cell nests during development and 
testosterone is important for the proper progression of male sexual and behavioural 
development (Chapter 1, Sections 2 and 5). However, relatively little is known about 
the effects of these sex hormones when administered outside the critical windows of 
development. Some studies in male rodents have shown that exogenous testosterone 
exposure during periods of fetal and neonatal life leads to male reproductive 
dysfunction (Welsh, Saunders et al. 2008). Furthermore, exogenous androgens given 
during fetal life in primates and sheep has also been shown to produce a reproductive 
phenotype in the adult female animal (discussed in Section 11). 
 
The majority of research into the fetal programming of adult disease has 
focused upon the effects of corticosteroids and other synthetic glucocorticoids, for 
example dexamethasone (DEX), upon metabolic development Exposure of a 
pregnant rats to corticosteroids leads to a reduced pup birth weight and development 
of metabolic syndrome in the adult offspring demonstrating insulin resistance, 
glucose intolerance and hypertension (Cleasby, Kelly et al. 2003; Buhl, Neschen et 
al. 2007). The consequences of synthetic corticosteroid administration to the rat vary 
as they depend on which stage of development the animals have reached and what 
doses are used. It should also be noted that DEX is almost sixty times more potent 
than it‟s physiological rodent analogue, corticosterone (Baldwin and Sawyer 1974). 
Disturbed menstrual cycles are a common feature in women with Cushing‟s 
Syndrome, and so researchers sought to investigate the effects of DEX upon adult 
reproductive function. Daily exposure of 0.25-0.4μg DEX to mature female rats 
resulted in dose dependent pseudopregnancy, indicating that corticosteroids can 
modulate prolactin secretion, elevating it for prolonged periods of time (de Greef and 
van der Schoot 1987). The same studies also noted that in adult females treated with 
DEX, the ovulation rate was significantly increased. This was later confirmed to 
result from an initial early phase obstruction of ovarian inhibin secretion by DEX, 
leading to reduced anterior pituitary feedback, subsequently followed by a later 
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phase of increased FSH release and the ovulation of more follicles (Tohei, Sakamoto 
et al. 2000; Tohei, Sakamoto et al. 2001). Such observations support the notion that 
corticosteroid treatment in human anovulatory disorders might be beneficial in 
restoring ovulation. In contrast, a higher 1mg/kg bolus dose of DEX given in 
adulthood, has been found to completely disrupt ovulation in the rat, lowering 
ovarian volume and causing aberrant nuclear receptor expression in granulosa and 
thecal cell compartments (Illera, Silvan et al. 2005). This may be because 
glucocorticoids are known steroidal anti-inflammatory compounds, and since 
ovulation is largely an inflammatory process, large doses of glucocorticoid would be 
expected to inhibit ovulation. 
 
1.9.1. Endocrine tissues and development 
Given that much of this thesis will focus upon the effect of steroid 
administration during fetal and neonatal development of the rat (Chapters 4-7), this 
section will cover the relevant endocrine systems discussed. Although parallels 
between rodent and human metabolic development exist, research into mid and late 
gestational development of human endocrinology and metabolism is difficult given 
the sensitive nature of such research and paucity of tissue samples during later 
gestation. 
 
i. Adipose tissue 
Fibroblasts originating from blastocyst mesoderm form preadipocyte cells 
which differentiate into adipocytes during late embryonic development and shortly 
after birth in humans. In rodents preadipocytes differentiation occurs after birth only 
(Ailhaud, Grimaldi et al. 1992; MacDougald and Lane 1995). Differentiation of 
preadipocytes is stimulated by a variety of metabolic factors, including insulin, 
glucocorticoids, and cAMP elevating agents. During the course of around one week, 
preadipocyte differentiation follows a cycle of mitosis and growth arrest before they 
differentiate into adipocytes (Ntambi and Young-Cheul 2000). Initially growth 
factors and hormonal signals influence the expression of transcription factors, which 
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in turn effects the transcription of adipocyte specific genes (Rodriguez-Acebes, 
Palacios et al. 2010), e.g. peroxisome proliferator activating receptor-γ (PPARγ). 
Together CCAAT/enhancer binding protein (C/EBP) and PPARγ cross talk within 
the preadipocyte cell to direct the expression of genes characteristic of adipocyte 
function for example leptin, resistin and the insulin receptor (Gregoire, Smas et al. 
1998). As adipocyte-specific gene expression increases, fat droplet formation begins, 
marking the end of preadipocyte differentiation from a flat fibroblast-like cell into a 
spherical adipocyte. Most white adipose tissue (WAT) consists of differentiated 




Figure 1.18: Preadipocyte differentiation in vitro presented chronologically with gene 
expression as designated (Taken from Ntambi and Young-Cheul 2000):  LPL, 
lipoprotein lipase; C/EBP, CCAAT/enhancer binding protein, PPAR, peroxisome proliferator-
activated receptor; MIX, methylisobutylxanthine; DEX, dexamethasone. 
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Through regulation by adipogenic factors, adipocytes are able to safely store 
free fatty acids (FFA) in the form of triglycerides through a process termed 
lipogenesis. Triglycerides may be broken down and released as FFA and glycerol 
from the adipocyte, in a process termed lipolysis (Fonseca-Alaniz, Takada et al. 
2007). These processes protect the liver, pancreas and muscle organs from the 
lipotoxic effects associated with high circulating levels of FFA, as seen in clinical 
cases of lipodystrophy (Crandall, Quinet et al. 2006). Where lipogenesis is favoured 
over lipolysis, adipocytes become hypertrophied and obesity results (Buckle, 
Rubinstein et al. 1961; Caserta, Tchkonia et al. 2001). Obesity has far reaching 
systemic effects as adipocytes secrete hormones involved in the endocrine 
modulation of metabolism, called adipokines (Ahima 2008; Ahima and Antwi 2008). 
The adipokines include leptin, a hormone involved in the endocrine regulation of 
appetite and metabolism (Ahima 2008; Ahima and Antwi 2008), adiponectin, a 
hormone involved in the autocrine and paracrine regulation of FFA catabolism and 
glucose homeostasis (Ribot, Rodriguez et al. 2008) and resistin, a hormone involved 
in the inflammatory pathogenesis of obesity (McTernan, McTernan et al. 2002). 
 
ii. Liver 
Hepatocytes and biliary epithelial cells both originate from the endoderm, 
while the stromal cells, stellate cells, kuppfer cells and blood vessels, originate 
through the mesoderm (Zorn 2008). Although the liver is formed by embryonic day 
(e.) 8, hepatic maturation continues until birth in the rodent. During late gestation 
and early postnatal life, pre and postnatal androgen surges in male rats function to 
program liver enzyme activities to be low in presence of a highly androgenic 
environment (Gustafsson and Stenberg 1974; Gustafsson and Stenberg 1974). The 
adult testes release androgens and consequently inhibit the activity of 5α-reductases, 
allowing an androgenic hormonal milieu to be maintained. In female animals due to 
the absence of a postnatal androgen surge, 5α-reductase activity is between four and 
ten-fold higher than in males in the adult animal (Pak, Tsim et al. 1985). The 
hormonal milieu in the adult animal is thus programmed to remain in line with the 
requirements of the animal‟s physiology; high testosterone (a low level of hepatic 
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5α-reducion) in males, and low testosterone (a higher level of hepatic 5α-reducion) in 
females. 
 
In the adult female mammal, the liver has both anabolic and catabolic 
functions. Of particular relevance to this thesis, is the role of phosphoenolpyruvate 
carboxykinase (PEPCK). This protein is not only expressed in periportal hepatocytes, 
but is also found in adipose tissue, kidney proximal tubule epithelium and ileum 
villar epithelium. Gene expression within these organs is driven by tissue-specific cis 
acting elements, which allows PEPCK to function in different metabolic roles; in the 
liver, PEPCK is gluconeogenic, whereas in adipose it is glyceroneogenic in function 
(Beale, Clouthier et al. 1992). Regulation of blood glucose is mediated through the 
balance of insulin and glucagon release. PEPCK, is the rate-limiting enzyme in 
hepatic gluconeogenesis and is quickly and dominantly inhibited by insulin release, 
but it‟s expression is induced during periods of stress and/or fasting by glucagon 
(Quinn and Yeagley 2005).  
 
In type 2 diabetes mellitus, increased hepatic glucose production can lead to 
hyperglycaemia during fasting stages, thus insulin resistance can be reflected by 
increased hepatic PEPCK expression (Buhl, Neschen et al. 2007). Glucocorticoids 
also induce the expression of hepatic PEPCK, and so increased stress hormone 
output by the adrenal can contribute increase hepatic glucose production (Buhl, 
Neschen et al. 2007). Prenatal programming of PEPCK by steroid hormones has also 
been documented in the rat. In one study, administration of prenatal corticosteroid 
led to an increase in adult animals of hepatic PEPCK expression and activity, 
potentially contributing towards hyperglycaemia (Nyirenda and Seckl 1998). 
 
Hepatic glucocorticoid metabolism occurs through the balance of 11βHSD 
and 5α-/5β-reductase enzyme activities (Cleasby, Kelly et al. 2003; Buhl, Neschen et 
al. 2007). In human obesity and in rodent models of obesity, increased glucocorticoid 
activation by 11β-HSD type 1 and increased glucocorticoid clearance by 5β-
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reductase has been documented (Chin, Shackleton et al. 2000; Roelfsema, Kok et al. 
2010). In high fat diet (HFD) fed male Wistar rats, this increase in GC turnover has 
been postulated to occur as a consequence of acute changes in diet and nutrition, 
whilst animals on a long term HFD, although obese and insulin resistant, show no 
such changes in corticosteroid metabolism (Drake, Livingstone et al. 2005; Drake, 
Walker et al. 2005; Stimson, Lobley et al. 2010). In young lean women diagnosed 
with infertility due to PCOS, two studies have documented glucocorticoid clearance 
through urinary metabolite analysis, with results inferring an increase in 5α-reduction 
of glucocorticoids, with no effect on 11βHSD-1 (Chin, Shackleton et al. 2000; 
Tsilchorozidou, Honour et al. 2003). These molecules of glucocorticoid clearance are 
therefore of importance when investigating the development of obesity (Chapter 5). 
 
iii. Pancreas 
Progenitor pancreatic cells develop from two envaginations of the posterior 
foregut at e.8.5 in the rodent (Figure 1.19), from which the mature pancreatic ducts, 
acini and islets all arise by e.13.5 (Kopinke 2008). Maturation of pancreatic islet 
function occurs shortly after birth in the neonatal rodent, and may be modulated by 




Figure 1.19: Stages of pancreatic development in the rodent during late fetal and early 
neonatal life (Taken from Kopinke 2008). 
 
A. SPECIFICATION       B. BUD C. BUD OUT  D. SECONDARY E. MATURE
(E.8.5) THICKENING       -GROWTH TRANSITION (neonatal)
(E9.5) (E10.5-11.5) (E13.5-E14.5)
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Pancreatic function may be assessed by measuring blood insulin and glucose 
before and after glucose challenge. This allows for observation of any increases in 
fasting insulin and glucose, in addition to insulin resistance. 
 
iv. The hypothalamic-pituitary adrenal axis 
The adrenal is an endocrine organ responsible for the homeostatic regulation of 
blood volume, steroid hormone secretion and the release of adrenalines in response 
to external stressors; the „fight or flight‟ response (Lin and Achermann 2004). Two 
adrenals are located on top of each kidney in mammals and release of their 
secretagogues is directed via a negative feedback loop to the hypothalamic-pituitary 
axis in the brain (Figure 1.20).  
 
 
Figure 1.20: The hypothalamic-pituitary adrenal axis (HPAA); (A) The hypothalamus 
coordinates release of corticotrophin releasing hormone (CRH), which induces release of 
adrenocorticotrophioc hormone (ACTH). ACTH stimulates cortisol release from the adrenal 
zona glomerulosa which negatively feeds back to the brain (blue lines). (B) zonation of, and 
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At the level of the hypothalamus, paraventricular nuclei coordinate with 
noradrenergic neurons of the central sympathetic nervous system. It is changes in the 
signals between these neurons, along with any external stressor stimulus (emotional 
or physical), which lead to the release of neuroendocrine hormones into the 
hypophyseal portal vessels that connect to the pituitary (Seckl, Dow et al. 1993; 
Papadimitriou and Priftis 2009). Thus, corticotrophic releasing hormone (CRH) acts 
in synergy with arginine vasopressin (AVP) to promote the posttranslational 
processing of proopiomelanocortin (POMC) into adrenocorticotrophic hormone 
(ACTH) and other molecules at the level of the pituitary (Papadimitriou and Priftis 
2009). ACTH is the key regulatory hormone concerning the release of adrenal 
steroids and adrenalines and is secreted in a circadian pattern also adhered to by 
adrenal steroids. At the adrenal, ACTH stimulates the secretion of adrenal androgens, 
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1.10. Premature ovarian failure 
Premature ovarian failure (POF) (also known as primary ovarian insufficiency) is 
known to affect 0.1% of women under 30 and 1% of women under 40 with 
symptoms including amenorrhea and infertility. Women suffering from POF present 
with hypergonadotrophic hypogonadism, i.e. they exhibit high levels of 
gonadotrophins and low levels of steroid sex-hormones due to a deficit in ovarian 
inhibitory feedback at the level of the hypothalamus and pituitary. It is worth noting 
that although the symptoms of POF are menopausal in nature, POF itself is not 
considered an early menopause because in over half the women diagnosed, ovarian 
function remains unpredictable (Nelson 2009). Indeed, women with POF can still 
exhibit irregular patterns of estrogen secretion and thus may be able to ovulate and 
carry pregnancies to term after diagnosis, which currently occurs in roughly 10-15% 
of POI cases (Nelson 2009). Furthermore POF may be transient since treatment of 
any underlying causes can return the female endocrinology to its‟ normal state 
(Kalantaridou and Nelson 2000). 
 
1.10.1. Clinical observations and treatments of POF 
 POF is defined clinically as a woman under 40 years of age with 4 or more 
months of disordered menses during which time two blood samples of FSH (1 month 
apart) yield a value similar to those found post-menopause (greater than 40mIU/mL) 
(Nelson 2009). Patients are differentially diagnosed by physical examination, signs 
and symptoms of estrogen deficiency, investigation of karyotype and blood testing 
for the autoimmune disorders, such as myasthenia gravis. POF patients, like 
menopausal women, will often be treated with hormone replacement therapy (HRT) 
via trans-dermal E2 device alongside methoxyprogesterone therapy 12 days on 
followed by 12 days off, in order to mimic normal hormonal changes seen in women. 
HRT aims to counteract the detrimental health effects of sex hormone loss which 
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1.10.2. Idiopathic and acquired causes of POF 
 The aetiology of POF is complex given that various endocrine syndromes 
may underlie the disease, such as autoimmune diseases and mutations in genes 
involved in follicular development and steroid hormone synthesis. Each such 
disorder encompasses a distinct plethora of symptoms. To take two examples; 
myasthenia gravis is associated with chronic fatigue-like symptoms, while the 
galactose-1-phosphate uridyltransferase (GALT) mutation is associated with kidney 
failure, mental retardation and cateracts. In relation to immune function one common 
feature of POF regardless of aetiology is the infiltration of the theca interna with 
lymphatic cells which possibly contributes to increased atresia of developing 
follicles, sparing the remaining quiescent primordial follicles which have yet to 
activate. However, it should be noted that in more than 90% of POF cases, no cause 
can be identified (Nelson 2009). 
 
 A considerable proportion of POF cases are non-syndromic, exhibiting a 
genetic familial heritability. This has led researchers to focus upon the inheritance of 
specific gene mutations involved in follicular development. To date, rare mutations 
in genes involved in early follicular development have been found in patients with 
POF. Examples include BMP-15, NOBOX (Qin, Choi et al. 2007), steroidogenic 
factor 1 (SF-1) (Lourenco, Brauner et al. 2009; Martinerie, Bouvattier et al. 2009) 
POF gene (Lacombe, Lee et al. 2006), in addition to genes involved the 
gonadotrophic regulation of follicle development, such as LHr and FSHr and 
LH/FSHβ subunits (Simpson 2008). Furthermore, transgenic studies have 
documented that GC specific loss of retinoblastoma gene results in POF through 
increased follicular atresia, possibly via the dysregulation of pRb target genes 
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1.11. Polycystic Ovarian Syndrome 
Polycystic ovarian syndrome (PCOS) is the most widespread heterogeneous 
endocrinopathy of women and presents at reproductive age across a range of ethnic 
backgrounds. 
 
1.11.1. Features of PCOS 
Up to 22% of women may have polycystic ovaries (PCO) (Farquhar, Birdsall 
et al. 1994), but only around 5-10% of women develop the syndrome PCOS, 
associated with increased androgenisation, weight gain and infertility (Franks, 
McCarthy et al. 2006). Due to the heterogeneous nature of PCOS uniform diagnostic 
criteria were not firmly set out until 2004. PCOS is now clinically defined by the 
appearance of any two out of three diagnostic criteria, as set out by the Rotterdam 
consensus (Rotterdam Workshop, 2004); (1) the appearance of PCO on an ultrasound 
scan (2) biochemical or clinical evidence of hyperandrogenaemia (i.e. high levels of 
androgen hormones) which is not adrenal in origin, and (3) oligo- or anovulation. 
Studies in sheep (Steckler, Manikkam et al. 2007) and rhesus monkeys (Abbott, 
Dumesic et al. 1998) support the concept that PCOS develops as a consequence of 
overexposure during fetal life to androgens or potentially, estrogens (Abbott, 
Dumesic et al. 2002). 
 
Ovaries from women with PCOS show a characteristic pattern of up to 12 
follicles which are between two and nine millimetres in diameter, whereas a normal 
ovary would have between two and four follicles of this size (Balen, Laven et al. 
2003; Dewailly, Catteau-Jonard et al. 2007). In the diagnosis of PCO, transvaginal 
ultrasound examination is informative. FIGURE 1.21 REMOVED. PCO demonstrate 
an increased ovarian volume in addition to an increased stromal area when compared 
to normal ovaries or multi-follicular ovaries (MFO). This stromal area also correlates 
to the biochemical parameters indicative of PCOS; high LH, T and A4 (Fulghesu, 
Angioni et al. 2007). Indeed, by analysing a planar ovarian for the stromal/total area 
ratio in PCOS patients, clinicians can both diagnose and differentiate between 
women with PCO and those with MFO (Fulghesu, Ciampelli et al. 2001).  
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The high levels of androgen associated with PCOS are thought to originate 
from the stroma and theca cell compartments of the ovary. Stimulation of these 
steroidogenically active tissues by LH leads to an increased production of ovarian 
androgens (T and A4). This disruption of hormonal milieu is thought to be 
responsible for the anovulatory phenotype observed in women with PCOS, and 
appears to be augmented in women who also exhibit obesity. A diagnosis of PCOS 
does not require features of obesity to be present (Norman, Noakes et al. 2004). 
 
Due to the broad definition of PCOS, the affected female population is naturally 
heterogenic, and various types of the disorder exist under the umbrella term „PCOS‟ 
shown in Table 1.4. However, it is important to note that women with PCOS have an 
increased likelihood of type 2 diabetes Mellitus (T2DM) and cardiovascular 
problems later in life, and such health risks are likely caused by the association of 
PCOS with obesity (Svendsen, Nilas et al. 2008). Metformin, a known insulin-
sensitising agent, has shown some efficacy at improving menstrual frequency along 
with insulin resistance in PCOS subjects (Setji and Brown 2007). The full aetiology 
of PCOS remains unknown, however current hypotheses concur that the 
endocrinopathy likely results from a complex interplay between epigenetic 
programming by improper steroid exposure during development, genetic risk factors 
and environmental choices detailed in Figure 1.21 (Holte 1998; Abbott, Dumesic et 
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Table 1.4: The various types of PCOS found in women, their prevalence and features 
(Adapted from Abbott, Dumesic et al. 2002; Norman, Davies et al. 2002; Abbott 2010; 
Franks 2010; Wild, Carmina et al. 2010). 





Irregular Irregular Normal Irregular 
Ovary Polycystic Normal Polycystic Polycystic 
Androgens High High High Normal 
Percentage of 
women obese 




59% 10% 21% 10% 
 
1.11.2. PCOS origins 
 The initial cause of PCOS likely lies at some point along the hypothalamic-
pituitary-ovarian axis, and current evidence gathered from various animal models 
and cell cultures supports either an inherent ovarian or hypothalamic-pituitary defect, 
and are discussed in the next section. Developmentally timed exposure to androgens, 
may act as transcription factors directly via their cognate AR or indirectly via ER, 
and thus developmentally program various endocrine organs, including the ovary, 
pituitary, adrenal, hypothalamus, pancreas, fat and liver (Dumesic, Abbott et al. 
1997; Abbott, Dumesic et al. 1998; Dumesic, Schramm et al. 2005; Franks, 
McCarthy et al. 2006; Franks 2010). In addition to both genetic and environmental 
factors, the dose and the length of in utero androgen exposure may affect the 
resultant PCOS phenotype in the immature, adolescent and adult animal (Gorski and 
Barraclough 1963; Goy and Phoenix 1972; Hickey, Marrocco et al. 2005; 
Padmanabhan, Sarma et al. 2010). The potential causes of PCOS are laid out in 
Figure 1.21, which also depicts the clinical indicators in addition to the various 
outcomes and risk factors associated with this endocrinopathy. 
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Figure 1.21: Scheme summarising the origins of PCOS: Programming of organ systems 
by fetal adrenal or ovarian androgens during a sensitive period in development is augmented 
by both genetic and environmental risk factors. PCOS is characterised by high LH, excess 
androgens and the metabolic syndrome, insulin resistance of which further augments 
reproductive dysfunction (Adapted from Abbott, Dumesic et al. 2002). 
 
 The source of the androgens able to program a female fetus during 
development without causing virilization have been debated for some time and are 
unlikely to be maternal in origin, largely due to the presence of sex-hormone binding 
globulin (SHBG) in the mother and the steroid metabolizing enzymes of the placenta. 
Together, these molecules act as a guard against transfer of steroidal compounds to 
the fetus. One potential source of androgens is the developing fetus itself - androgens 



































Irregular menses Polycystic ovaries High circulating androgens
Risk Factors
Cardiovascular Disease Type2 Diabetes Endometrial cancer
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To compensate for the differences in gene product dosage between XX 
females and XY males, X chromosome inactivation (XCI) takes place during early 
female development. Either the maternal or paternal X chromosome may be 
inactivated in different cell lineages, resulting in a mosaic pattern of XCI in the adult 
(Heard, Chaumeil et al. 2004; Panning 2008). XCI initiates at a locus on the X-
chromosome, known as the X-inactivation center (Xic) (Borsani, Tonlorenzi et al. 
1991; Tsai, Rowntree et al. 2008). At the Xic locus is the Xist gene, which produces 
a non-coding RNA involved in initiation of XCI (Cantrell, Carstens et al. 2009; 
Senner and Brockdorff 2009; Chaumeil, Waters et al. 2011). The Xist RNA attaches 
to the chromosome designated for inactivation extending the length of the 
chromosome itself through an as yet unknown process (Kalantry 2011). 
Subsequently, processes of histone methylation, acetylation and further aspects of 
chromatin remodelling begin (Murakami, Ohhira et al. 2009). XCI is then maintained 
in the cell and all subsequent daughter cells (Morey and Avner 2010). Theoretically 
the pattern of XCI is random and highly regulated (Reviewed in Morey and Avner 
2010).  However, X-inactivation skewing may occur in order to selectively remove 
cells which may go on to express harmful mutations or display deregulated gene 
expression (Belmont 1996). 
 
PCOS displays familial clustering characteristic of a dominant gene with 
partial penetrance, yet standard genetic linkage analyses have struggled to find any 
causative genetic links, and few candidate genes or promoter repeat sequences have 
shown a correlation with PCOS. In one relatively recent study, epigenetic patterns of 
XCI and methylation around X-linked genes have been compared between sisters 
with varying degrees of PCOS across 40 families, the results of which suggest that 
XCI patterns, not just genetic sequences, dictate the reproductive phenotype, 
providing one explanation as to why studies on candidate susceptibility genes often 
yield negative results and leading to further research on the epigenetic status of X-
linked genes, such as the AR (Hickey, Legro et al. 2006). 
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 Sequencing of repeat polymorphisms within genes involved in 
steroidogenesis and folliculogenesis is the basis of many genetic association studies. 
Several studies have reported conflicting results when determining whether the 
number of CAG repeat polymorphisms within the AR gene is associated with factors 
of PCOS (Franks, Gharani et al. 1998; Hickey, Chandy et al. 2002; Jaaskelainen, 
Korhonen et al. 2005; Mohlig, Jurgens et al. 2006). The difficulty with such genetic 
association studies, and indeed with many of the theories surrounding the origin of 
PCOS, is that even if a correlation between gene expression/polymorphisms and 
PCOS exists, this does not necessarily imply causality. One problem with familial 
association PCOS studies is the lack of a corresponding male phenotype in brothers 
of women with PCOS. However, research into the metabolic phenotypes of the 
brothers and sons of women with PCOS has shown that these men are more likely to 
develop IR and central obesity, like many women with PCOS (Baillargeon and 
Carpentier 2007; Recabarren, Smith et al. 2008; Sam, Sung et al. 2008). 
 
1.11.3. Animal models of PCOS 
Several studies in rats have demonstrated that continuous exposure of post-
pubertal animals to steroid hormones, either via regular subcutaneous dosing or 
continuous release pellet implant, produce a PCOS phenotype in these animals. The 
most recent and relevant studies are summarised in Table 1.5. The models described 
in this table recapitulate various features of PCOS and thus become useful when 
testing potential treatments for the syndrome, as several studies have gone on to do 
using insulin sensitizing agents (Misugi, Ozaki et al. 2006), electroacupuncture, and 
exercise (Manneras, Jonsdottir et al. 2008). Models of PCOS using higher mammals, 
specifically sheep (Steckler, Herkimer et al. 2009) and non human primates (Faiman, 
Reyes et al. 1988; Abbott, Tarantal et al. 2009), focus upon the adult consequences 
of fetal programming by administering androgen (usually T) during fetal life at a 
time when germ cells first begin to form primordial follicles. In rodents this period of 
exposure corresponds to early postnatal life (Section 5). 
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Table 1.5: Recent rat investigations which involve fetal, neonatal and adult administration of steroidal hormones:  
Dose(s) Window Cull age Ovary 
Weight 
/ IR 
Hormones Key Features of Study Reference 
TP daily 
1mg 
e14 – 19 d 90 – 94 - ↓ weight n/a 
Fetal TP can induce dystocia, 
weight loss & infertility in females 
(Wolf CJ 2002) 
TP daily 
1mg/100g 
d 21 – 56 d 56 
Cystic; ↑ 
small antral 
IR ↑ T 
Ovarian homogenate showed 
↑Bcl-2; Glucose levels normal/low 
(Beloosesky, Gold 
et al. 2004) 
TP 3mg e16 – 19 
Daily 






↑ T, E2, P4 and LH 
Response to E2 after OVX at day 
60 
(Wu, Li et al. 
2010) DHT 3mg 
DHT pellet 
83µg/day 




and  IR 
Normal T and E2, ↑ P4 
↑ adipocyte size and ↑ leptin 
↑ mesenteric fat 
(Manneras, 
Cajander et al. 
2007) 
Letrozole 





↑ T and P4 
Normal adipocytes and leptin 
DHEA daily 
6mg/100g 
d 22 – 32 d 32 Cystic - 
↑ T, DHEA, A4, DHT 
Normal E1/E2, P4 FSH 
Initial ↑ in prolactin which fell 





d 22 – 29/37 d 30/38 GC atresia - - 
Follicle atresia contributed to by 
matrix remodelling 
(Honnma, Endo et 
al. 2006) 
EV 2mg d 14 d 71 PCO-like Normal ↑ E2 ↑ Norepinephrine 
(Rosa, Guimaraes 
et al. 2003) 
EV 2mg 
d 45 - 55 d 60 – 105 
PCO-like ↑ 
foll. diameter 
- ↓ T, cort. & LH 
Diestrus FSH 
↓ GC and thecal thickness (Baravalle, Salvetti 
et al. 2007) 24h Light - ↓ cort. 
Insulin pump 
0.04iU/day 
d 28 d 56 
Erratic, long 
estrus cycles 
IR ↑ T and DHEA(S), ↓P4 
↓GDF-9 and activin receptor 
expression in ovaries (by IHC) 
(Chakrabarty, 
Miller et al. 2006) 
e=embryonic day; d=postnatal day; CL=corpora lutea; IR=Insulin resistance; T=Testosterone; E2=estradiol; EV=estradiol valerate; P4=progesterone; 
PCO=Polycystic ovary; foll=follicle; cort=Corticosterone; PCO=polycystic ovary; GC=granulosa cell; ↓=decreased; ↑=increased.
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1.11.4. PCOS and metabolism 
 Since PCOS is associated with the development of obesity, patients 
frequently exhibit hyperinsulinaemia. Insulin and members of the IGF family are 
known to augment ovarian androgen production as well as promote weight gain; 
increased adiposity will not only increase insulin resistance (IR), but will reduce the 
amount of available SHBG, and hence may also increase the bioavailiblity of ovarian 
androgens, escalating PCOS severity (Botwood, Hamilton-Fairley et al. 1995; 
Panzer, Wise et al. 2006). 
 
 At the ovarian level, insulin and IGFs can impact ovarian functionality. 
Indeed in a mouse model of diabetes, gap junction communication in follicle COC 
was reduced in comparison with COC communication in non-diabetic mice. This 
implies a role for insulin in affecting oocyte quality and follicular dominance since 
bidirectional communication, as well as precisely timed gap junction disruption at 
the LH surge are both essential for ovulation (Ratchford, Esguerra et al. 2008). 
Ovarian theca and GCs are additionally responsive to insulin and IGFs, with both 
compounds shown to augment GC aromatase production in primary cell cultures 
(Hillier, Yong et al. 1991; Yong, Baird et al. 1992; Nahum, Thong et al. 1995). 
Insulin levels significantly increase during the pre-ovulatory period of cattle estrous 
cycles and may be stimulated by estrogen and insulin is also important in mediating 
nutrient uptake in cattle follicles (Webb, Garnsworthy et al. 2004). Other metabolic 
hormones have shown an association with female infertility and PCOS, for example, 
adiponectin impairs theca cell steroidogenesis and GC P4 production (Lagaly, Aad et 
al. 2008). 
 
Obesity and hepatic function are important components in the pathogenesis of 
PCOS with one to two-fifths of the lean PCOS cohort demonstrating the same level 
insulin resistance as two thirds of obese PCOS women (Ciampelli, Fulghesu et al. 
1997). In addition to these features, PCOS patients exhibit dyslipidemia, low grade 
chronic inflammation and an increased level of oxidative stress (Economou, Xyrafis 
et al. 2009). However, few studies have explored the role of the liver in the 
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pathogenesis of this syndrome. In one clinical study, all women with PCOS 
demonstrated reduced hepatic metabolism of insulin (inferred using plasma insulin:c-
peptide ratio at fasting) independent of their body-mass index (BMI), leading to the 
proposal that hyperinsulinemia is a primary feature of PCOS, with insulin resistance 
forming as a result of obesity (Ciampelli, Fulghesu et al. 1997). Obesity and IR are 
both associated with development of non-alcoholic fatty liver disease (NAFLD) and 
hepatic steatosis (HS), characterised by elevated liver enzymes (Setji, Holland et al. 
2006). 
 
Two investigations have so far established convincing evidence that a subset 
(around 30%) of women with PCOS have elevated aminotransferases, at an average 
age of 29 years, much earlier than many humans would develop NAFLD/HS 
(Schwimmer, Khorram et al. 2005; Setji, Holland et al. 2006). In addition, type 2 
diabetes and cardiovascular risk are both predicted by increased liver alanine 
transaminase (ALT) and γ-glutamyl transpeptidase (γGT) activities, which have 
recently been shown as elevated in highly obese PCOS women; but not in the lean 
PCOS cohort (Economou, Xyrafis et al. 2009). The clinical hope is that earlier liver 
screening may be used in conjunction with IR levels to asses PCOS patients who are 
at high risk of NAFLD. However, the aetiology of such liver dysfunction remains to 
be identified. 
 
1.11.5. Treatment of PCOS 
PCOS is a difficult endocrinopathy to treat clinically due to the heterogenic 
nature of this syndrome. Treatment usually relates to to one of two things; 1. The 
desire by the patient to become pregnant; 2. The impact of hirsutism or weight gain 
on the patient‟s quality of life. More often than not, these two aspects of PCOS 
treatment will go hand in hand, as physicians seek to improve a patient‟s weight in 
order to restore their fertility (ESHRE 2008). The easiest and primary treatment for 





 respectively) is weight loss through exercise and dietary 
caloric restriction (Moran, Brinkworth et al. 2006; Norman, Homan et al. 2006). 
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Frontline drug treatment for women with PCOS remains the anti-estrogen 
clomiphene citrate (CC) and insulin sensitizers such as metformin may also be used 
for PCOS patients with glucose intolerance (Moran and Norman 2004). For the 25-
27% of women who do not respond to ovulation induction with CC, gonadotrophin 
therapy may later be pursued (ESHRE 2008). In-vitro fertilization is usually only 
considered if a PCOS patient (or their partner) has associated reproductive 
pathologies (ESHRE 2008). 
 
In the clinic, vaginal ultrasonography is used to quantify the size of the 
largest ovarian follicle in each ovary and document endometrial and ovarian 
responses to therapy (Parsanezhad, Bagheri et al. 2003; Ozcimen, Uckuyu et al. 
2009). Furthermore, Doppler indices of blood flow within the stroma and follicle 
may be documented using this technique, particularly after laparoscopic ovarian 
drilling, a treatment known to successfully lessen PCOS symptoms, specifically 
ovarian blood flow velocity, along with vascular endothelial growth factor (VEGF), 
LH, and T levels (Amin, Abd el-Aal et al. 2003). Insulin-sensitising treatment of 
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1.12. Main objectives of this thesis 
The investigations described in this thesis use rodent models to examine the role 
of androgens in the pathogenesis of female infertility. An attempt to generate a 
granulosa cell specific androgen receptor knockout mouse model will first be 
described, followed by several studies into the developmental programming of 
female Wistar rat infertility and metabolism by steroid hormones.  
 
These later investigations focus in particular upon the effects of neonatal 
testosterone proprionate (TP) treatment during different time windows and at varying 
doses upon rat fertility and metabolism. The neonatally androgenised rat will be 
evaluated as a rodent model for PCOS. Furthermore these studies investigate whether 
neonatally TP treated animals become anovulatory, obese, insulin resistant, or 
glucose intolerant. Finally, to elucidate whether the effects of TP observed occur 
through androgenic pathways or through the aromatisation of TP into estrogens, 
animals will be treated with TP in addition to other steroid hormones. 
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Chapter 2. Materials and Methods 
2.1. General information 
Unless otherwise stated, all solutions were prepared with distilled MilliQ water 
(dH2O) and stored at room temperature. All liquid chemicals used were of analytical 
grade and were obtained from Fischer Scientific, while all solid chemicals were 
obtained from Sigma, unless otherwise stated.  
 
2.2. Animal experimentation 
All animal studies were carried out in accordance with the Animal (Scientific 
Procedures) act 1986 and were approved by the Home Office. Experimentation 
operated through personal licence number PIL 60/10682. Rodents were housed in 
clear solid-bottomed cages, containing bedding of wood shavings and corn cob. 
 
2.2.1. Welfare Conditions 
2.2.1.1. Transgenic mice 
Mice were housed and bred in an animal facility provided by the University 
of Edinburgh. Rooms were temperature (20-25°C) and light controlled (14 hour 
light, 10 hour dark photoperiod) with food (standard laboratory chow) and water 
provided ad libitum. Mice also had a cardboard tunnel for environmental enrichment 
(BS&S, Scotland). Experimentation was carried out under licence PPL 60/3544 held 
by Professor Philippa Saunders. Culls were carried out by the author on site. 
 
2.2.1.2. Rats 
Wistar rats were bred and maintained in the Little France animal facility. 
Here, daily animal husbandry was carried out by MRC technician Mr Mark Fisken. 
Mr Fisken supervised handling of animals, and assisted during certain licensed 
procedures, for example glucose tolerance testing. All rats were housed and bred in a 
temperature (20-25°C) and light controlled room (14-h light, 10-h dark photoperiod), 
with ad libitum access to fresh tap water and a soy-free breeding diet (Type 3, soy 
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free, rat; SDS diets; Dundee, UK). Up to six females were housed together after 
mating and stud male rats were housed individually before and after mating. 
Pregnant dams were housed individually just prior to parturition and kept with the 
pups until weaning at postnatal day (pnd) 21. Experimentation was carried out jointly 
under two project licences, PPL 60/3232 and PPL 60/3914 held by Professors Alan 
McNeilly and Richard Sharpe respectively. 
 
2.2.2. Injections 
 Immature rats were given subcutaneous (s.c.) injections of control oil or 
steroid hormone dissolved in oil (Table 2.1). For testosterone proprionate (TP) 
administration to pregnant dams during fetal life and dosing with 100mg/kg 
bromodeoxyuridine (BrdU), injections were administered intra-peritonealy (i.p.). 
Animals were treated and kept in the same experimental dose group. Pups were not 
mixed between litters since after injection, dams often groom pups around their 
injection sites and may ingest steroid hormone which has the potential to be absorbed 
and transmitted to other pups via suckling. 
 
Table 2.1 Summary of steroid hormone injection protocols and doses administered: 

















Estradiol Valerate (EV) 1mg/kg 5 0.5 9.5 
Dihydrotestosterone (DHT) 1mg/kg 5 0.5 9.5 
Dehydroepiandrosterone (DHEA) 1mg/kg 5 0.5 9.5 





 At maturity, rats were checked for the presence of vaginal openings and 
smeared gently to avoid triggering pseudopregnancy. Pseudopregnancy is caused by 
mechanical stimulation of the cervix, altering pituitary prolactin release. When 
taking a smear, water was dropped onto a slide, a wetted smear stick used to gently 
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scrub surface cells from the vagina, which were then scribbled onto the labelled 
slide. Smears were air dried briefly, fixed in methanol for 4 minutes, stained with 
giemsa diluted 1 in 20 with distilled water, for 15 minutes, washed gently with water 
and cover-slipped. Smears were viewed under a light microscope to check for regular 
estrus cycling and to time animal sacrifice at proestrus. 
 
2.2.4. Tail nick blood sampling 
Rats were wrapped in towels and handled by the author daily for at least two 
weeks to accustom them to the sampling environment. When taking tail bloods, each 
individual rat was wrapped in a towel on the author‟s knee, the tail extended and the 
end vein nicked with a size 10 scalpel. Blood was encouraged from the tail by 
massage; up to 200-250μl blood was sucked into pre-labelled capillary tubes 
(Sarstedt Microvette CB 300 with EDTA), which were cooled on ice until the end of 
the experiment. Samples were spun down at 6000 rpm for 10 minutes and the top 
plasma layer stored at -20°C. For glucose tolerance tests (GTTs), rats were fasted 
from 5.00pm the night before, and sampling began at 8.30am the next day. Tail nicks 
were taken from between 10 and 20 animals at a time, in the same order, over three 
time (t) points – t=0, t=30 and t=120 minutes. After the t=0 tail nick, animals were 
immediately gavaged with a 50% glucose solution (2g/kg) and returned to their cage. 
These samples were used for both glucose and insulin assays. 
 
2.3. Necropsy 
In all studies, female rodents were killed by cervical dislocation and a 
heparinised 25mm gauge needle attached to a 2ml syringe used to remove blood by 
cardiac puncture. The organs required were then located, removed, cleaned of 
surrounding fat, weighed and then fixed and/or frozen. Blood samples were kept on 
ice during necropsy and later spun down in a centrifuge for ten minutes at 10,000 
rotations per minute (rpm) to remove cellular debris. Supernatant plasma was 
removed stored at -20ºC for subsequent steroid and protein hormone analysis. 
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2.3.1. Reproductive organs 
 An initial longitudinal incision opened the abdominal cavity exposing the 
internal organs. The uterus was located and disconnected from the base of the vagina, 
any attached fat or blood vessels were then disconnected from the uterus and the 
ovaries located and removed from the end of each uterine horn.  
 
2.3.2. Hypothalamus and pituitary 
 The pituitary was located by removing the skin surrounding the skull and 
making an upward incision into the base of the skull. Flat scissor edges were then 
used to separate the skull bone into two pieces, allowing the brain to be lifted from 
the base of the cerebellum to expose the pituitary, subsequently removed by gently 
lifting it from the base of the skull with curved forceps. The hypothalamus was 
located by cutting the optic nerves and removing the triangular grey area located 
above the pituitary. 
 
2.3.3. Endocrine organs 
 The ribcage was raised using forceps and a 45° cut made next to the attached 
liver tissue. Mesenteric fat was removed by a snip incision at the pancreatic-stomach 
join, allowing the fat pad to be pulled away from the intestine and cut off at the 
colon. Retroperitoneal fat was removed by successive blunt snipping away from the 
animal‟s right side at the base of the knee joint up to the base of the rib cage; at this 
point the right adrenal could easily be located above the kidney and also removed. 
Muscle was removed from the animal‟s left knee by first a vertical and then a 45° 
incision into the quadricep; a sample of subcutaneous fat was also removed from 
behind the knee at this time. 
 
2.4. Histological analysis 
Organs to be fixed were placed in Bouins (Triangle Biomedical Sciences Ltd. 
Lancashire, UK.) or Neutral Buffered Formaldehyde (NBF) for 2-6 hours depending 
on size, before being transferred to 70% ethanol for paraffin embedding. Organs used 
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for mRNA and/or protein analysis were snap frozen on dry ice and stored at -70°C. 
Tissues were either fixed in Bouins (Triangle Biomedical Sciences, Lancashire, UK) 
for six hours or NBF overnight before processing. An automated Leica TP-1050 
processor (Leica Microsystems, Milton Keynes, UK) dehydrated the fixed tissue 
through a series of graded alcohol solutions over the course of 18 hours. After 
processing, the tissue was saturated and embedded in liquid paraffin wax and 
finished blocks left to cool. These were stored at room temperature until 
morphometric and histological analysis was required. Common solutions used in 
histological analysis are listed in Table 2.2. 
 
Table 2.2: Common fixatives and immunohistochemistry washing and staining 
solutions used in histological experiments. 
Solution type Protocol Quantity 
4% NBF 
- normal buffered 
formaldehyde 
- 1 litre 
40% formaldehyde 
Deionised H2O 
Sodium dihydrogen phosphate monohydrate 






- 1 litre 





- 10 X (1.0M) 
- 2 litres 
- Used at 0.1M for 
antigen retrieval 
Citric acid monohydrate (Sigma) 
Deionised H2O 
pH to 5.5 with NaOH 
Deionised H2O 






Eosin Triangle Biomedical Sciences Ltd. Lancashire, UK. 
Harris’ Haematoxylin (HH) 
 
Haematoxylin (Triangle Biomedical Sciences) 
Absolute alcohol 
Combine and boil with: 
Aluminium potassium sulphate 
Distilled water 
Add Mercury Oxide 
Cool solution in ice then filter 









Scott’s tap water 








- Tris-buffered saline 
- 10 X 
- 1 litre 




Adjust to pH 7.5 with HCl then make up to 1 






EtOH=ethanol; HCl=hydrochloric acid; H2O=water; g=grams; M=molar; ml=millilitres; 
g=grams; HCl=hydrochloric acid; H2O=water; ml=millilitres; NaCl=sodium chloride 
NaOH=sodium hydroxide; NBF=neutral buffered formaldehyde 
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2.4.1. Sectioning 
 Tissue sections were cut at 5μm widths using a microtome (Lecia RM, 2135, 
Germany) and laid onto paper ready for mounting. This allowed for serial sectioning 
and for section ribbons to be stored if needed. This also allowed sections from 
treatment and control groups to be matched onto the same slide. Sections were 
floated onto coated slides (Superfrost ® plus, BHD Laboratory Supplies, Poole, 
Dorset, UK) and dried in an oven at 50°C overnight. 
 
2.4.2. De-waxing and rehydrating 
 Slides were placed in racks of up to 25 and de-waxed in xylene (2 X 
5minutes). Tissue sections were then rehydrated through two absolute alcohol 
troughs followed by graded 95% and 70% alcohol. At this point slides could be taken 
for immunohistochemistry (IHC) or stained with haematoxylin (a purple nuclear 
stain) and eosin (a pink cytoplasmic stain) for basic morphological characterisation. 
Slides were dipped in acet-alcohol to remove any excess haematoxylin staining 
before being eosin stained. Sections were then dehydrated through troughs of 70, 80 
and 95% alcohol and two absolute alcohol troughs into xylene (2 X 5min) and finally 
mounted in pertex (Figure 2.1). 
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Figure 2.1: Schematic diagram of de-waxing, counterstaining and rehydrating slides 
during a typical staining run. Note, when performing DAB immunohistochemistry (IHC) the 
Eosin step was omitted. 
2.4.3. Antigen retrieval 
 After hydration, sections for IHC underwent antigen retrieval; 1 litre of 
citrate buffer (0.01M) per slide rack was heated in a pressure cooker until boiling, the 
slide racks were placed in, the lid secured and pressure turned up to full. After five 
minutes of full pressure, the pressure valve was opened and the cooker was allowed 
to cool for at least 20 minutes before proceeding with subsequent IHC steps. 
 
2.4.4. DAB-IHC 
After antigen retrieval, endogenous peroxidise activity was blocked by 
washing slides for 30 minutes in 3% (v/v) hydrogen peroxide (Sigma) in 300ml 
methanol   followed by a tap water rinse and two five minute washes in Tris-buffered 
saline (TBS). This was followed by a 15 minute block of endogenous avidin and 
biotin if required, according to the manufacturer‟s instructions (Vector Laboratories, 
Peterborough UK), with two TBS washes in after each block. Normal blocking 
serum was diluted 1:5 in TBS with 5% bovine serum albumin (BSA) and applied for 
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antibody was appropriately diluted in normal blocking serum and applied to the 
tissue for incubation in a humidity tray overnight at 4°C (Table 2.3). 
 
Table 2.3: Primary and secondary antibodies used for DAB immunohistochemistry: 
Subsequent to the addition of a biotinylated secondary antibody at 1 in 250µl, slides were 
incubated with tertiary ABC-HRP antibody at 1 in 1000µl, followed by DAB at 1 in 100µl. 
Primary Ab Raised in Block in Dilution (µm) Secondary AB Source 
PCNA Mouse NGS 1 in 1000 Goat anti mouse Novocastra 
VASA Rabbit NGS 1 in 200 Goat anti rabbit AbCam 
Caspase-3 Rabbit NGS 1 in 200 Goat anti rabbit 
Cell Signalling 
Technology 
AR Rabbit NGS 1 in 750 Goat anti rabbit Santa Cruz 
AMH Goat NRS 1 in 500 Rabbit anti goat Santa Cruz 
Aromatase Mouse NGS 1 in 50 Goat anti mouse 
Gift – Nigel 
Groome 
17α OH Rabbit NGS 1 in 500 Goat anti rabbit Gift – D. Hales 
3β-HSD Rabbit NGS 1 in 1000 Goat anti rabbit Gift – I. Mason 
BrdU Mouse NGS 1 in 50 Goat anti mouse 
Roche 
Diagnostics 
AB=antibody; PCNA=proliferating cell nuclear antigen; AMH=Anti-Müllerian Hormone; 
AR=Androgen Receptor; 17αOH=17α hydroxylase; 3β-HSD=3β-hydroxysteroid 
dehydrogenase; BrdU= Bromodeoxyuridine; NGS/NRS=normal goat/rabbit serum. 
Following at least 12 hours of incubation and two five minute TBS washes to 
remove excess primary antibody, an appropriate biotinylated secondary antibody in 
normal serum was incubated on sections for 30 minutes at a concentration of 
1:500μl. A second wash cycle was then followed by addition of an avidin-biotin 
horseradish peroixdase complex (ABC-HRP; DAKO, High Wycombe, UK) diluted 
1:1000μl TBS, which was applied for 30 minutes. After a final TBS wash, antibody 
localisation was determined by application of liquid diaminobenzidine (DAB)-
substrate chromogen system (DAKO, High Wycombe, UK) for 30 seconds until the 
brown positive staining in control sections was optimal. Haematoxylin was used as a 
counter-stain (Figure 2.1), followed by submergence in acet-alcohol (5 seconds) and 
Scott‟s tap water (20 seconds) with water washes in-between. Slides were then 
dehydrated back through graded alcohols and xylene before finally mounting in 
pertex. Figure 2.2 illustrates the principles of epitope binding and how IHC uses this 
to visualise a protein expressed by a tissue. 
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Figure 2.2: Antigen visualisation using DAB immunohistochemistry: (i) A primary 
antibody (AB), raised in mouse, recognises its complementary epitope AMH within the 
tissue; (ii) A secondary biotinylated AB specific for the mouse epitope is then added and 
binds to the primary AB; (iii) A third AB contains a complementary avidin molecule and 
conjugates to the biotin of the second AB; (iv) This tertiary AB contains a horseradish-
peroxidase (HRP) conjugate, which in the presence of diaminobenzidine (DAB) substrate, 
oxidises to a brown colour (v). 
2.4.5. Fluorescent IHC Protocol 
 Fluorescent IHC proceeded in much the same way as that of DAB-IHC, but 
washes were completed in phosphate buffer saline (PBS). The same primary 
antibodies could be used, but secondary/tertiary antibodies were conjugated to an 
alexa-fluorescent antibody (FAB) fragment; thus slide dishes were wrapped in foil to 
prevent bleaching of fluorescent fragments by light between stages. If HRP-linked or 
biotinylated complexes were not utilized, peroxidase or avidin-biotin blocking steps 
were not required. To enhance the fluorescence of some antibodies, red or green 
Tyramide was utilised at a dilution of 1:00μl after addition of secondary complexes 
for 10 minutes only. Slides were counterstained red with propidium iodide 
(1:1000μl), or blue toporo (1:500) and wet-mounted in permafluor for confocal laser 























Page | 70  
 
2.5. Follicle Counting 
Before commencing follicle counts, previous investigations into follicle numbers 
in rodents were assessed in order to decide the best method of quantifying the 
numbers and types of follicles present within the ovary. These methods are 
summarized in Table 2.4. The counting method used was that of Hirshfield and 
Midgley, since this method allows for a realistic estimate of follicle proportions, 
involves minimal data manipulation and is the study from which many others derive 
their follicle counting protocols, as shown in Table 2.4 (Hirshfield and Midgley 
1978). 
 
In this thesis, total follicle numbers are expressed alongside the proportions of 
follicles at each stage of follicle development; primordial, transitory, primary, 
secondary and antral, for analysis by two-way analysis of varience (ANOVA; see 
section 16 of this Chapter). Follicle numbers in these categories were also analysed 
by two-way ANOVA, but no further differences were seen between the number 
analysis compared to the percentage analysis and so these graphs are not reported.  
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Table 2.4: Summary of the various types of follicle counts performed on rodent ovaries: Follicle counts performed in this thesis were based 
on those of Hirshfield (1978). 









Follicle count Disadvantages Advantages Species Reference 
Serial 






























As in Hirshfield 
1978 
Using thickness 
correction factor is 
less accurate 


















present in one 
but not in other 
section 
As in Hirshfield 
1978 
Less likely to get 








Number of GC 
layers 




Whole ovary used Rat 
(Green, 
Mandl et al. 
1951) 





As in Hirshfield 
1978 
As in Hirshfield 
1978 




Takai et al. 
2003) 
Serial 8μm Every 5th Not stated 
GC 
morphology 
As in Hirshfield 
1978 
As in Hirshfield 
1978 




Perez et al. 
1999) 
Serial 7μm Every 4th 
Oocyte 









present in a 
fraction of the 




Alters original data 
Quick, 
overestimates 






et al. 2001) 
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Only follicles containing a visible oocyte nucleus were included in the count 
and follicles were classified on the basis of their granulosa cell (GC) layering. A 
layer of flat squamous GCs indicated a primordial follicle. Two or more cuboidal 
GCs indicated a transitory follicle. If two or less than two layers of cuboidal GCs 
were present around the oocyte, the follicle was primary and if more than two layers 
of cuboidal GCs were present around the oocyte, the follicle was secondary. Finally 
if there were more than two layers of cuboidal GCs and an antrum had formed, the 
follicle was antral (Figure 2.3). 
 
 
Figure 2.3: Follicle classifications exemplified as (A) Primordial; (B) Primary; (C) 
Secondary; (D) (i) Late pre-antral; (ii) Antral follicle: „sq‟ and „cu‟ designate squamous 
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2.6. Morphological and morphometric analysis 
The number cells/follicles expressing a specific stain in addition to staining 
intensity were be used to assess follicle morphology in a semi-quantitative fashion. 
Morphometric analyses were also completed using stereological equipment 
comprising an Olympus BH-2 microscope fitted with a Prior
 
automatic stage (Prior 
Scientific Instruments Ltd., Cambridge,
 
UK). Image-Pro Plus version 6.2 with 
Stereologer-Pro 5 plug-in
 
software (Media Cybernetics UK, Wokingham, Berkshire, 
UK) was used to count cells and measure areas in µm
2
. The histological features and 
DAB stains quantified using a Stereologer are detailed in Table 2.5. Representative 
images shown in each chapter were taken with a Provis AX70
 
(Olympus Optical, 
London, UK) microscope fitted to a Canon
 
DS6031 camera (Canon Europe, 
Amsterdam, The Netherlands). 
 
Table 2.5: Summary of morphometric analyses performed using a Stereologer: 




VASA Germ cells Germ cell count Germ cell stain/µm
2
 
Caspase-3 Apoptotic cells Apoptosis count - 
H&E stained 
sections 




Strong in stroma, weak in 
theca interna, CL & mGCs 
- 
Area measured minus 





Theca interna, weak in 
mGCs 
Follicle diameter 
Stained area measured 




BrdU Proliferating cells 
Positive GCs 
across follicles of 
different sizes 








Before starting any stereological analysis, the software was calibrated against 
the microscope objective so that all measurements were taken in µm or µm
2
 and 
remained accurate. The ovarian section or follicle of interest was put into focus and 
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an experiment set up using Image ProPlus 6.2 software; this software was then used 
to tile an image of choice at a specific magnification. The final image file was then 
saved and used for any subsequent morphometric analysis of that image, for 
example, the measurement of ovarian area, follicle area, or follicle diameter. The 
proportion of cells stained positively with DAB IHC could also be measured within a 
particular area of interest, for instance 3β-hydroxysteroid dehydrogenase (3βHSD) 
positive stromal area, or BrdU staining of proliferating GCs. Examples of these types 
of morphometric analyses are illustrated in Figure 2.4. To select a DAB stained area, 
a reference colour range was taken from the brown stained region and all pixels 
within the stated colour range highlighted. Stained area below 10µm
2
 was not 
included, in order to discount any background. 
 
Figure 2.4: Stereological analysis of a follicle using Image ProPlus; (A) Tiled image of a 
follicle calibrated to the X 40 objective with a manual area of interest (AOI) drawn around this 
follicle in green. (B) This AOI may be filled in black, which here is the follicle antrum. The 
black area is measured in µm
2
 and exported to an excel file. (C) Different cell types may be 
counted; here BrdU stained granulosa cells are counted in red and non-stained cells in blue. 
(D) DAB or haematoxylin staining may be specifically selected. In this case red staining to 
select the haematoxylin stained blue cells. Once again this stained area can be calculated in 
µm
2
 within the AOI and the data exported for analysis to Microsoft excel. 
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2.7. Nucleic acid extraction 
To guard against RNA degradation by ribonucleases, all solutions and 
instruments were autoclaved before use. The lab bench and all pipettes were wiped 
with 75% ethanol and RNase inhibitor before each RNA extraction run, and sterile 
plastic eppendorf tubes and pipette tips were used throughout. RNA was extracted 
using several different methods in this thesis, depending on the starting material 
(Table 2.6). For large amounts of easily homogenized or fatty starting material, for 
example Liver, a TRI-reagent protocol was used. For smaller amounts, for example 
pituitary tissue, a Qiagen RNA mini kit was used, and for all fat components a 
combination of the two was developed. Tissue was either homogenized using a rotor-
starter mini-homogenizer, or in 2ml tubes run on a Tissue Lyser (Qiagen) at 25Hz for 
2-3minutes. 
 
Table 2.6: Tissues from which RNA was extracted: Methods of homogenization and 






Mean RNA yield 
(ng/µl) 
Ovary Tissue lyser TRI reagent 241 
Pituitary Rotor Starter Qiagen mini kit 1149 
Liver Tissue lyser TRI reagent 3563 
Mesenteric fat Tissue lyser 
TRI reagent 
extraction followed 
by Qiagen mini kit 
883 
TRI reagent= guanidinium thiocyanate and sodium acetate 
  
The concentration of all eluted RNA was determined using a NanoDrop® 
ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). 
 
2.7.1. Tri-reagent method 
 This method uses the fact that RNA can be separated from DNA through 
tissue homogenization in 1ml of guanidinium thiocyanate and sodium acetate, 
otherwise known as TRI reagent (Chomczynski and Sacchi 2006). For each 1ml TRI 
reagent used, 0.2ml chloroform was added and mixed with the homogenate to 
complete the dissociation of nucleoprotein complexes. Upon centrifugation in these 
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acidic conditions, the RNA remained in an upper aqueous phase, leaving DNA in an 
interphase, and protein in an organic phase. Total RNA was then recovered by 
precipitation and centrifugation with 0.5ml isopropanol, which caused the RNA to 
form a pellet that was then washed with 75% ethanol solution. After air drying, the 
RNA was eluted at 60°C in an appropriate volume of water (30-50μl). 
 
 Contaminating genomic DNA was removed from TRI-extracted RNA using 
the Ambion
®
 TURBO DNA-free DNase Treatment and Removal kit (Applied 
Biosystems). The DNase is then removed by incubation with a patented „DNase 
Inactivation Reagent‟, which is then pelleted by centrifugation so that the supernatant 
containing DNA-free RNA can be removed to a fresh tube and stored at -70ºC for 
gene expression analysis. 
 
2.7.2. RNeasy® column RNA extraction 
 This method takes advantage of the ability of nucleic acids to pH dependently 
adsorb onto silica/other solid phase set within an RNeasy
®
 column (Qiagen) when 
tissue is homogenized in a buffer of high pH. For each 1ml of homogenization RLT 
buffer used, 10μl of β-Mecaptoethanol (β-ME) (Sigma) was added before starting. 
On-column DNase digestion was performed using a DNase digestion kit; for every 
column used, 70μl of Buffer RDD and 10μl of DNase stock solution were mixed 
gently. 
 
 Typically, 700μl RLT (+β-ME) was added to the tissue sample and 
homogenized before centrifugation at maximum speed to separate out the 
homogenate leaving a supernatant containing RNA (approximately 600-700μl 
depending on tissue). To this supernatant an equal volume of autoclaved 70% ethanol 
was added and the tubes mixed before adding 700μl of this lysate at a time to the 
RNeasy
® 
columns. The columns were then spun at 10,000 rpm for 15 seconds and 
the flow-through discarded. To each column, 350μl of buffer RDD was added and 
the columns spun again at 10,000 rpm for 15 seconds, discarding flow-through. At 
this point DNase digestion step could be performed by addition of 80μl (70μl Buffer 
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RDD + 10μl DNase) DNase digestion mixture directly onto the column membrane 
for a 15 minute incubation at room temperature. 
 
 A further 350μl RDD buffer was next added and the columns spun at 10,000 
rpm for 15 seconds, discarding flow-through and columns transferred to new 
collection tubes. Next, two 500μl loads of RNA wash buffer „RPE‟ were pipetted 
onto the column and flow-through discarded; the first spun for 10,000 rpm for 15 
seconds, the second for 2 minutes. Columns were next spun in a new collection tube 
(not supplied by the manufacturer) for 1 minute to thoroughly dry the membrane. 
RNA was then eluted by application of an appropriate volume of RNase free water, 
usually 30-50μl. This elute could then be passed through the column a second time to 
ensure the highest yield of RNA possible. 
 
2.7.3. RNA extraction from fat 
 When extracting RNA from fat, the TRI-Reagent method alone produced 
between 3 and 70ng/μl RNA when tested on practice fat samples. Equally when even 
a small amount of tissue was extracted using the Qiagen mini-kit method, the column 
became clogged with fat and RNA yield was minimal. As a result of this, a 
combination of both methods was used, yielding between 300 and 2000ng/μl RNA 
per sample, depending on the fat depot under extraction. Initial homogenization and 
dissociation was completed with 1ml TRI-reagent and 0.2ml chloroform, and the 
resulting aqueous RNA phase added to an equal volume of 75% ethanol (approx 
0.4ml). This solution was then applied to Qiagen mini-kit columns in 700μl aliquots, 
after which the Qiagen column protocol and DNase digestion steps were followed as 
detailed in Section 2.7.2 
 
2.8.  Reverse transcription, PCR and electrophoresis 
Reverse transcription of copy DNA (cDNA) from total RNA was performed 
using the SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen). The kit comprises 
a SuperScript® enzyme mix (the reverse transcriptase engineered from Moloney 
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murine leukaemia virus) and a 5 X VILO™ reaction buffer containing 
deoxyribonucleotides, random hexamer primers, and MgCl2. Template RNA was 
used consistently at a concentration of 200ng/μl to allow to precise quantification of 
gene expression in downstream quantitative PCR reactions. Single reaction 
components are listed in Table 2.7. After preparation, the cDNA synthesis reaction 
was incubated according to the manufacturer‟s instructions at 42°C and then 
terminated at 85°C using a PTC200 (Thermo Cycler) PCR block. cDNA was stored 
short term at 4°C and frozen long term at -70°C. 
 
Table 2.7: Single reaction components for SuperScript® VILO™ cDNA Synthesis Kit 
Component Volume (µl) 
5 X Vilo™ reaction buffer 4 
10 X SuperScript
®
 enzyme mix 2 
Nuclease free water 13 
RNA template at 200ng/µl 1 
 20 
 
The Polymerase Chain Reaction (PCR) is a well documented tool for the 
detection and quantification of gene expression (Deepak, Kottapalli et al. 2007). To 
determine the presence or absence of a particular gene, primers specific to the sense 
and antisense of an amplicon within the gene of interest were used in a standard PCR 
with the resulting product run on 1% agarose gel. For 50ml agarose gel 0.5g agarose 
was dissolved in 1 X TAE buffer (A 1 litre solution of 10 X TAE was made by 
dissolving 242g Tris base in 842.9ml dH2O with 57.1ml glacial acetic acid and 
100ml 0.5M EDTA). Safeview (NBS Biologicals) was then added to warm liquid gel 
at 5μl per 100μl gel to allow safe visualisation of each gel under a UV 
Transilluminator. Samples were run next to an appropriate ladder (100bp interval) 
for band identification. In each run using cDNA, two controls were included; an RT-
negative template control and a water control in place of cDNA template. When 
using extracted genomic DNA (Chapter 3) a water control only was included. All 
gels were run at 120 volts for at least half an hour before visualisation under a UV 
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transilluminator. All genes of interest were investigated in this way using 2 X 
Biomix Red PCR mix according to the manufacturer‟s instructions (Bioline, UK) as 
shown in Table 2.8.  
 
Table 2.8: Single reaction components for a Biomix Red PCR 
Component Volume (µl) 
Biomix Red 10 
Distilled Water 8.6 
Forward Primer 0.2 
Reverse Primer 0.2 
DNA template 1 
 20 
 
2.9. Quantitative PCR 
Quantitative PCR (hereafter qPCR) allows analysis of the relative abundance of 
PCR products during the exponential phase of PCR when reagents are not limited. 
Most qPCR was performed using Power SYBR
®
 Green PCR Master Mix (Applied 
Biosystems). Primers were designed using the online NCBI/Primer-BLAST tool. 
Specifications for primers used in qPCR included an amplicon length of 50 to 200 
bases, a %GC content below or equal to 65% at most and a melting temperature of 
between 58° and 61°C. Table 2.9 lists the primers used for quantitative PCR for each 
gene of interest and the tissue(s) they were used to investigate. 
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Table 2.9 List of genes analysed by quantitative PCR for each tissue with primer 
sequences and locations for Syber Green chemistry; Control genes are in bold. 






β-Actin Fwd+ CCTGTGCTGCTCACCGAGGC 122 103 161 
 
Rev- TGTGGGTGACCCCGTCTCCG 264 283  
αGSU Fwd+ TTGCTTCTCCAGGGCATATC 293 274 178 
 
Rev- GCGCTCAGAAGCTACGACTT 452 471  
FSHβ Fwd+ GGACCCAGCTAGACCAAACA 196 177 152 
 
Rev- TCTTACAGTGCAGTCGGTGC 329 348  
LHβ Fwd+ ACACTGGCTATGTCCCAGG 65 47 181 
 




β2-microglobuin Fwd+ TCGCTCGGTGACCGTGATCTTT 34 13 98 
 
Rev- AAGTTGGGCTTCCCATTCTCCGGT 109 132  
Adiponectin Fwd+ ACTGCAACCGAAGGGCCAGG 98 79 97 
 
Rev- TCTGCCATCACGGCCCGGTA 176 195  
Leptin Fwd+ TCATTCCCGGGCTTCACCCCA 234 214 181 
 
Rev- TCTGGCTTCTGCAGGCCACG 396 415  
Resistin Fwd+ TGCTGTACCCTGCGGGTTGG 418 399 119 
 
Rev- TTTCCTGCCCCCTGCGCTCT 518 537  
LPL Fwd+ ACGCCTCCGGCTCAACCCTT 113 94 145 
 
Rev- TCCGCGGAAGGCGGTCAAAC 239 258  
HSL Fwd+ GTTTCCACCCACGGCGCTCA 3070 3051 173 
 
Rev- TTCAGTCGCCGCGCGAACAT 3224 3243  
FAS Fwd+ TCCTGGTGTGGTGCCTGCCT 2005 1986 159 
 
Rev- GCAGCGTGGGGGCAATTCCT 2145 2164  
PPARγ Fwd+ ACCCAGAGCATGGTGCCTTCG 138 118 79 
 




β-Actin Fwd+ CCTGTGCTGCTCACCGAGGC 122 103 161 
 
Rev- TGTGGGTGACCCCGTCTCCG 264 283  
PPARα Fwd+ AGCGTGGTGCATTTGGGCGT 202 183 156 
 
Rev- GCGGGCCACAGAGCACCAAT 339 358  
PEPCK Fwd+ GCACCCCTGCCAGCCAATGT 1382 1363 171 
 
Rev- ATGCTCTGCAGCAGCGGTGG 1534 1553  
GC receptor Fwd+ TGGCCAAAGGCGATACCAGGC 1800 1780 128 
 
Rev- TCAGGAGCAAAGCAGAGCAGGT 1907 1928  
5β-reductase Fwd+ CGCCCAGCCCTGGAAAGGAC 351 332 144 
 
Rev- GCCTCCCACGTGGCACACAG 476 495  
αGSU=common α gonadotrophin subunit; FAS=fatty acid synthase; FSHβ=follicle 
stimulating hormone subunit β; GAPDH=glyceraldehydes-3 phosphate dehydrogenase; 
GC=glucocorticoid; HSL=hormone sensitive lipase; LHβ=luteinising hormone subunit β; 
LPL=lipoprotein lipase; PEPCK=Phosphoenolpyruvate carboxykinase; PPAR=peroxisome 
proliferator activator protein; Fwd=forward primer; Rev=reverse primer. 
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2.9.1. SYBR Green Signal Generation 
 Most genes were analysed using a Power SYBR
®
 Green PCR reaction 
according to the manufacturer‟s instructions. The chemistry of the SYBR
®
 Green 
reaction means that both specific and non-specific dsDNA products are detected and 
so it was important for all primers to amplify only one product specifically. For this 
reason, each primer set and corresponding amplicon sequences were BLAST 
searched before ordering. 
 
To validate primers for use with SYBR
®
 Green, primer pairs first underwent 
standard PCR and gel electrophoresis in each chosen tissue to assess for the presence 
of a single PCR product, as shown for GAPDH in Figure 2.5. To further validate 
primers for use in Power SYBR
®
 Green PCR, a set of standards was constructed by 
serially diluting a stock aliquot of cDNA from each tissue. Approximately six 
diluents were then run in triplicate for each target gene and a standard curve 
constructed using ABI7500 software (Version 2.0.1). RT Negative cDNA was 
diluted 1 in 10 and added to wells as a negative control for each target gene. For 
every PCR run, a master reaction mix was then made up for each gene under 
investigation and bulked up for the total number of individual well reactions. 9μl of 
master mix was pipetted into each well of a 96-well fast plate (Applied Biosystems) 
before adding 1μl of diluted cDNA template; individual reaction components are 
detailed in Table 2.10. 
 
Table 2.10: Single reaction components for the Power SYBR
®
 Green PCR reaction 
Component Volume (µl) 
SYBR master mix 2X 5 
Distilled Water 3 
Forward Primer 0.5 
Reverse Primer 0.5 
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 Primers were assessed using the criteria outlined by Figure 2.5. ABI7500 
software calculated reaction efficiency as well as fit (R
2
) and slope of a standard 
curve; a reaction efficiency of between 90-110% was considered acceptable, 
providing the R
2
 value was between 0.95 and 1 (in accordance with the 
manufacturer‟s instructions). A melt (dissociation) curve was run by gradually 
increasing the temperature beyond that of cDNA melting temperature, in order to 
assess for the presence of a single reaction product. ABI7500 software records a melt 
curve of reporter fluorescence against temperature. Twin peaks on this melt curve 
would indicate the presence of non-specific/impure PCR product or primer-dimer 
formation. During each PCR plate run, RT negative samples appeared as small peaks 
before the major melt curve peak, due to the absence of any template cDNA. 
 
For the amount of product to be doubling in the exponential phase, and 
assuming equal serial dilutions of cDNA were performed, the slope of a standard 
curve would be around -3.32. This was the main criterion used when evaluating and 
selecting primer sets for use in the quantification of gene expression. The primer 
validation criteria for each primer used in quantitative PCR throughout this thesis is 
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Figure 2.5: Gene expression validation: After initial validation using gel electrophoresis 
(A), serial diluents of a stock aliquot of cDNA at 1:4 nuclease free water were made up and 
run in triplicate on an ABI7500 machine. This generated (B) a dissociation (melt) curve to 
assess the purity of PCR product (C) an amplification plot with regular spacing between the 
CT value of the diluents which could be used to generate (D) a standard curve. The example 
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Table 2.11: Primer validation criteria for genes of interest in the designated tissues 
using SYBER Green PCR: Orange boxes denote control genes used; grey shading denotes 
use of Universal Probe Library (UPL) chemistry instead of SYBER green chemistry against 
the liver control gene cyclophillin (Chapter 5); *denotes further control genes validated but 
not used for that tissue. Melt curves with more than one peak () invalidated primers. 















0.993 95 -3.48 
GAPDH* 0.988 94 -3.45 
αGSU 0.972 99 -3.35 
FSHβ 0.984 105 -3.20 
LHβ 0.858 103 -3.26 
Estrogen receptor 0.858 101 -3.21 




0.993 102 -3.25 
GAPDH 0.929 106 -3.19 
18-S* 0.996 60 -4.89  
β2-microglobulin* 0.998 101 -3.28 
TATA box binding 
protein* 
0.977 102 -3.27  
PPARα 0.993 109 -3.12 
5β-reductase 0.999 98 -3.36 
PEPCK 0.999 100 -3.31 
PPARγ 0.947 86 -3.71  
Cyclophillin 0.997 104 -3.22  
5α reductase     




0.997 109 -3.12 
Cyclophillin* 0.971 107 -3.14  
Leptin 0.994 109 -3.13 
Resistin 0.984 107 -3.14 
Adiponectin 0.979 109 -3.13 
FAS 0.996 111 -3.08 
LPL 0.986 101 -3.21 
HSL 0.995 108 -3.13 
PPARγ 0.985 104 -3.02 
18-S=ribosome subunit 18; αGSU=common α gonadotrophin subunit; FAS=fatty acid 
synthase; FSHβ=follicle stimulating hormone subunit β; GAPDH=glyceraldehydes-3 
phosphate dehydrogenase; GR=glucocorticoid receptor; HSL=hormone sensitive lipase; 
11β-HSD=11β-hydroxysteroid dehydrogenase; LHβ=luteinising hormone subunit β; 
LPL=lipoprotein lipase; PEPCK=Phosphoenolpyruvate carboxykinase; PPAR=peroxisome 
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2.9.2. Relative quantification 
 Gene expression was analysed by relative abundance to a reference gene as 
well as to control tissue gene expression and so the 2^ΔΔCT method was used. 
Sample cDNA was diluted 1 in 10µl in nuclease free water (1 in 5µl for cDNA 
derived from fat) and this diluent used in each for the PCR reaction for that specific 
tissue. After each run, the threshold was reset to 0.103 amplification units if required, 
and the data analysed by the ABI7500 software and exported into an Excel 
spreadsheet. Equation 1 below was used to work out the relative expression of the 
gene of interest. These results were then graphed and statistically analysed to assess 
any differences in gene expression.  
 
(i) ΔCT = CT test gene (FSHβ) – CT reference gene (βActin) 
(ii) ΔΔCT = (Test tissue ΔCT) – (Mean control tissue ΔCT) 
(iii) Relative expression = 2^ΔΔCT 
Equation 1: 2^ΔΔCT method of analysis: (i) FSHβ analysed relative to βActin for the 
tissue of interest (ii) FSHβ expression analysed relative to mean control tissue ΔCT (iii) 
Assuming PCR is doubling the amount of the gene of interest every cycle, relative gene 
expression is calculated by taking 2 to the power of the ΔΔCT value. 
 
2.9.3. Roche Light Cycler PCR (liver) 
 For liver genes which could not be optimized using SYBR green, for example 
5α-Reductase, an alternative method of quantitative PCR was used. Primer-probe 
PCR involves addition of a fluorescent probe specific for the gene of interest which 
lies between the primer extension sites. Due to the presence of a probe 
complementary to the gene of interest, primer-probe PCR chemistry is highly 
specific at amplification and therefore measures no background primer-dimer 
formation. Analysis of the relative expression for each gene of interest in this 
instance was measured in relation to a control gene, using a standard curve method. 
For construction of a standard curve 1-2µl of cDNA from each sample were added 
together and serially diluted 1:3 in nuclease free water. These serial diluents were 
used to construct a standard curve for each gene, and were run on each 384 well plate 
(Roche, Welwyn, UK), in addition fluorescence was detected using a light cycler 
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(Roche, Welwyn, UK) and the data exported into Excel. CT values were then be used 
to calculate the expression of each gene in relation to the control gene cyclophillin 
using the ΔCT method. Details of universal probe library sequence designations are 
given in Chapter 5.  
 
2.10. Steroid hormone plasma-extraction 
To extract steroid hormone from plasma samples, 100-200μl rat 
plasma/qualitative plasma control was pipetted into large glass tubes, followed by 
2ml of diethyl ether and these substances mixed using a multi-tube clamp vortex 
(Baxter Scientific Products) for 3 minutes. Industrial methylated spirit (IMS) was 
then poured over dry ice in a metal bath and the tube racks placed in the resulting 
“slurry” mixture. This process snap-freezes the bottom of the tubes leaving a fraction 
of the mixture containing liquid steroid hormone dissolved in ether. The unfrozen 
fraction containing steroid was decanted into corresponding 12x75 glass tubes and 
left to evaporate overnight in a fume hood. Steroid hormone was re-solvated in an 
appropriate volume of assay buffer to allow for subsequent RIA analysis in duplicate. 
 
2.11. Radioimmunoassay 
2.11.1. Radioactive handling and iodination 
 Radioactive substances were handled at an in-house „hotlab‟ in accordance 
with local Health and Safety Rules and Radiation Protection Safety guidelines. 
Iodination of all tracers was carried out by Mr Ian Swanston. Tracers were stored in 
the hotlab and radioactive usage was documented in μCi. Before and after handling, 
a pre-iodination sweep check of the bench was carried out using a Geiger counter 
and any contamination reported to the Area Radiation Protection Officer. 
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2.11.2. RIA Protocol 
Unless otherwise stated, RIA antibody reagents were provided by the National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD, 
USA) and have been made available to researchers for many years. RIA is therefore 
a well established standard technique for measuring hormone concentrations. 
Radioimmunoassay (RIA) is based on competition between a hormone, for example 
estradiol (E2) and a trace amount of radioactive E2 for binding sites on a primary 
antibody specific to E2. 
 
In each assay a secondary antibody was added to binds the c-fragment epitope of 
the primary rabbit antibody. This formed a complex in the presence of normal rabbit 
serum γ-globulin (NRS). This complex precipitated upon addition of  wash buffer 
(9g NaCl, 40g PEG 6000, Triton-X 0.2% 1ml dissolved in 1 litre dH20) and was 
pelleted by centrifugation at 4ºC at 1400rpm for half an hour. Any “free” 
125
I-steroid 
was poured off, leaving a pelleted „bound‟ 
125
I-steroid fraction, which was measured 
using a γ-counter machine. Thus, the greater the amount of standard/unknown steroid 
competing with the 
125
I-steroid, the lower the resulting counts. 
 
The concentration of steroid in the unknown sample is interpolated from a 
standard curve using standard solutions with known concentrations of steroid. The 
typical standard curves obtained for each RIA described in this thesis are shown in 
Figure 2.6; a semi log plot where the y-axis is conferred by the ratio of bound to free 
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Figure 2.6: Standard curves from (A) Androstenedione (B) Estradiol and (C) 
Testosterone RIA experiments: Relative binding against known standard quantities for n=1 
curve per assay. 
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 Tubes were labelled in duplicate and set up with a standard curve followed by 
unknown samples for assay, as shown in Table 2.12.  








Total counts - - 100 - - 
NSB 100 - 100 100 100 
B0 100 100 100 100 100 
Standards/samples 100 100 100 100 100 
NRS=normal rabbit serum; NSB=non specific binding 
 
Tracer was defrosted inside a lead protector and then added to the required 
amount of assay buffer until 100μl of buffer/tracer mix was read at 10-15,000 counts 
on a mini-γ-counter. Primary antibody, tracer and secondary antibody/NRS were 
added over several time courses (between 1-3 days) depending on the sensitivity of 
the assay (Table 2.13). 
 
Table 2.13: Protocol and reagent summaries for RIAs performed: all tracers were made 
up to between 10-12,000 counts per minute for each assay. 

































Use at 1:600,000 
(AMS Biotech) 
Primary incubation Overnight n/a n/a 
Sample incubation Overnight in fridge 
Secondary AB 
serum 
Donkey α Rabbit 
Use at 1:1000 
(Diagnostic Scotland) 
Goat α Rabbit 
Use at 1:200 
(Diagnostic Scotland) 
Donkey α Rabbit 
Use at 1:60 
(Diagnostic Scotland) 
NRS Use at 1:200 Use at 1:200 Use at 1:600 
Secondary/NRS 
incubation 
1 hour on bench 4 hours on bench 
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Phosphate gelatinous buffered saline (PGBS) was used as an assay buffer. 
PGBS was made by dissolving 11.46g of Na2HPO4.2H2O, 2.61g of NaH2PO4, 9g 
NaCl, 1g of gelatine and 0.1g thiomersalate in 1 litre dH2O and altering the pH to 7.4 
using HCl. 
 
2.11.3. RIA Analysis 
 To analyse the raw γ-count data, a specialist software program, AssayZap 
(Biosoft, Cambridge, UK) was used. AssayZap allows the user to program in 
standard curve, quality control and unknown samples, which it then utilizes to 
construct standard curves; the B0 and NSB values are used to estimate the upper and 
lower curve limits. Each standard curve was saved to a „graveyard‟ for future 
reference. The programme then calculates the data for quality controls and quantities 
of hormone present in each unknown, and the resulting data can be exported into 
Microsoft Excel for statistical analysis. 
 
2.12. Enzyme Linked Immunosorbent Assay (ELISA) 
An ELISA operates using similar principles of antigen binding as RIA and is a 
well established technique for measuring hormone levels in small quantities of 
plasma or media. In the ELISA kits used for insulin and inhibin B analysis, 
microplate wells were pre-coated with a capture antibody for the protein of interest. 
Gonadotrophin ELISAs were developed my Mr Ian Swanson. These used adsorbent 
plastic plates (Nunc Biologicals) which were coated by incubating the adsorbent 
plates with 50µl capture antibody at a specified concentration overnight at 4ºC. 
Capture antibodies were diluted in coating buffer made by dissolving the contents of 
one carbonate-bicarbonate capsule (Sigma, code C3041) in 100ml deionised water. 
The plate was then washed the next day and blocked with assay buffer for at least 
one hour. After blocking and two consecutive washes, the standards, qualitative 
controls and unknown samples were added to the plate and again incubated overnight 
at 4ºC. ELISA protocols are summarised in Table 2.14. ELISA wash buffer was 
made as a X 25 concentrate by dissolving 302g tris base, 450g sodium chloride 
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(NaCl), 25ml tween20 in dH2O. The pH was adjusted to 7.5 using hydrochloric acid 
(HCl) and the volume made up to 2 litres. Gonadotrophin ELISA assay buffer, in 
which ELISA reagents were dissolved was made by dissolving 6g tris base, 9g NaCl, 
10g BSA (Sigma A3294), 1g bovine-γ globulin, 0.1ml tween20, 0.05g thiomersalate 
in dH2O. The pH was adjusted to 7.5 with HCl and buffer volume made up to 1 litre. 
 
Table 2.14: Protocol and reagent summaries for ELISAs performed: 




















0.78 to 50μg/ml 0.078 to 25μg/ml 






Anti-β chain Mab 
(Medix 6602)  
4μg/ml overnight 
Anti-β chain Mab 












Anti-rat α subunit 
IC1 (NIDDK 
AFP66P9986) 
0.5μg/ml 2 hours 
Anti-β chain Mab 

































H2O2 40 min 
Stop Solution 6% H3PO4 0.5M H3PO4 0.2M H3PO4 
Wash Solution ELISA wash buffer Provided by manufacturer 
FSH=follicle stimulating hormone; H3PO4= phosphoric acid; HRP=horseradish peroxidase; 
LH=luteinising hormone; RTP=at room temperature and pressure; Strep=streptavidin; 
TMB=tetramethylbenzidine chromogen reagent. 
 
After incubation with samples, ELISA plates were washed before addition of 
100µl/well antibody-biotin conjugate against the protein of interest, followed by a 
further wash and addition of 100µl/well streptavidin conjugated horseradish 
peroxidise (HRP) antibody, which attaches to the biotin conjugate. A further wash 
cycle removed unbound conjugate, after which 100µl/well TMB (3‟,5,5‟-
tetramethylbenzidine), was added and oxidised by the conjugated HRP, generating a 
blue coloured product. Oxidation was stopped by 100µl/well phosphoric acid 
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solution, turning each well yellow. The absorbance was read at λ 450nm and λ 600-
620nm. The second reading was subtracted from the first to eliminate any 
background from the results. For the gonadotrophins a standard curve was plotted 
using AssayZap standard values of absorbance (nm) against their known 
concentration (ng/ml), and the values of unknown samples interpolated (Figure 2.7).  
 
 
Figure 2.7: Standard curves for (A) FSH and (B) LH in-house ELISA plates (n=10 each): 
Typical curves are shown against a range (red) of other standard curves. Unknown values 
were interpolated using AssayZap.  
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For the insulin and inhibin ELISAs linear regression was performed according to 
the manufacturer‟s instructions and the values of any unknown samples interpolated 
from this standard curve. Inhibin B levels were interpolated using AssayZap (Figure 
2.8) and insulin levels using GraphPad Prism (Figure 2.9). 
 
Figure 2.8: Standard curve for n=4 Inhibin B ELISAs: Unknown values were interpolated 
using AsssayZap linear regression analysis. 
 
 
Figure 2.9: Standard curve for n=9 Insulin ELISAs: Unknown values were interpolated 
using GraphPad Prism linear regression analysis. Blue line is the mean linear relationship 
between insulin concentration and absorbance, with shading indicating the 95% confidence 
limit of the assay. 
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2.13. Glucose assay 
A glucose assay was used to determine the blood glucose levels of rats 
undergoing glucose tolerance testing. Unlike the ELISAs which rely on antibody 
binding, a glucose assay relies on a naturally redox reaction where addition of 
hexokinase enzyme, catalyses the phosphorylation of glucose, the product of which 
is further oxidized to 6-phosphogluconate, simultaneously reducing NAD+ to 
NADH. The amount of NADH formed is proportional to the concentration of glucose 
in the sample, and is then measured by an increase in absorbance at 340nm. 
 
 
Figure 2.10: Reactions occurring in the glucose assay system: Hexokinase catalyses 
the phosphorylation of glucose by ATP into glucose-6-phosphate (G6P) and ADP. G6P is 
subsequently oxidized to 6-phosphogluconate through the reduction of NAD+ to NADH by 
Glucose-6-Phosphate dehydrogenase. The amount of NADH formed is equimolar to the 
amount of glucose in the initial sample and is measured by spectrophotometer at 340nm. 
 
200mg/dl glucose standard (TR15923 Thermo Scientific) was used to make 
up the standards listed in Table 2.15. To each well 200µl of infinity glucose 
hexokinase liquid stable reagent (TR15421, Thermo Scientific) was added and 
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Table 2.15: Standard concentrations and volumes used for constructing glucose 
assay standard curves: 200mg/dl glucose standard was diluted in distilled water as shown 
for each standard up to 150mg/dl. 2µl of each standard was added in duplicate to the assay 






(µl) at 200mg/dl 
Blank 100 0 
25 87.5 12.5 
50 75 25 
100 50 50 
150 25 75 
200 - 2 
300 - 3 
400 - 4 
500 - 5 
 
Linear regression was used to form a straight line from which unknown samples 
and were be interpolated (Figure 2.11). 
 
 
Figure 2.11: Standard curve for n=9 glucose assay plates: Unknown values were 
interpolated using GraphPad Prism linear regression analysis. Blue line is the mean linear 
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2.14. Statistical analyses 
 All raw data was collated in a Microsoft Office Excel 2003 spreadsheet and 
exported to GraphPad Prism 5 for statistical analysis. Two-way analysis of variance 
(ANOVA) was performed between any grouped data, for example follicle counts, 
with a Bonferroni post-hoc to assess for specific in-group differences. Unless 
otherwise states, a two-tailed unpaired student‟s t-test was used to evaluate 
differences between rodent treatment groups in all other circumstances.  
 
Another analysis used was the Mann-Whitney test for non-parametric 
comparisons. A Kolmagorov-Smirnov test was also employed to assess the 
distribution of follicle percentage data (Chapters 4 and 7). This test showed that 
distribution of follicles in the ovary is not Guassian in control animals, likely due to 
large proportions of primordial follicles. However, the distribution of 
percentages/proportions between control and treated groups was similar in all 
experiments. However, it should be noted that higher n numbers than those employed 
in these experiments are usually required for distribution analysis and KS test to be 
robust. 
 
To measure correlation between two sets of data (X and Y), Pearson product-
moment correlation (PPMC) was used. A PPMC is a type of linear regression for 
normally distributed data. As shown in Equation 2 a correlation coefficient, „r‟ or 
„R
2
‟is calculated; a value close to 1 or -1 denotes a positive or negative correlation, 
and a value of 0 denotes no correlation. 
 
 
Equation 2: Pearson-product moment correlation (PPMC): the covariance of the two 
variables (X and Y) divided by the product of their standard deviations. r=correlation 
coefficient, n=number of measurements, S / δ=standard deviation, Ẋ=mean 
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To assess for differences between two correlation coefficients, a Fisher r-to-Z 
transformation was performed and applied to the sample correlation coefficients (r) 
calculated by a PPMC. A Fisher transformation is shown in Equation 3. In statistical 
packages like GraphPad, a P value for a Fisher transformation can also be calculated 
to test for the significant differences between two sets of overlapping correlative 
data. 
z = 0.5[ln{1+r} – ln{1-r}] 
σz1-z2=√ [{1/N1-3} + {1/N2-3}] 
Equation 3: Fisher r-to-Z transformation: A PPMC correlation coefficient „r‟ is transformed 
to a normally distributed Fisher coefficient, „z‟ for each PPMC, where ln is the natural 
logarithm. The next formula calculates the differences between each fisher coefficient (σz1-z2) 
for the number of data points from each sample group (N). 
Data is expressed in graph format where appropriate with control bars/lines in 
red and error bars denoting the standard error of the mean value (SEM) where 
possible. Data was considered significantly different if the resulting P value of a 
statistical test was ≤0.05 (denoting a 95% confidence of significance) and the levels 
of significance are expressed throughout this thesis as per the rules in Table 2.16. 
 
Table 2.16: Significance levels pertaining to all data analysis within this thesis. 
Significance Star Value P value 
Not significant (NS) n/a > 0.5 
95% significance * ≤ 0.5 
99% significance ** ≤ 0.1 
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2.15. General solutions 
Reagents for other solutions used in the lab are summarised in Table 2.17. 
Table 2.17: General solutions used: 




EDTA disodium salt 
Deionised H2O 














- Tris acetate EDTA 
- 1 litre 
- X 50 
Tris base 
Deionised H2O 
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Chapter 3. Generation of a Granulosa Cell specific 
Androgen Receptor Knockout (GCARKO) 
 
3.1. Introduction 
Over the past 20 years, genetic manipulation has been an invaluable tool when 
investigating physiological processes in vivo (Andersson and Skalhegg 1998). Global 
mouse knockouts of growth differentiation factor-9 (GDF-9KO), estrogen receptor β 
(ERβKO) and the androgen receptor (ARKO) to mention a few have illustrated the 
essential role of these genes and their protein products not only in female 
reproduction, but in many areas of mammalian physiology (Reviewed in Matzuk 
2000). Classical gene targeting has been refined, and now both tissue specific and 
developmentally timed knockouts are possible. Instead of disrupting the target gene 
in embryonic stem (ES) cells directly, a gene of interest is now flanked or „floxed‟ at 
introns by two loxP sites. A knockout is derived through Cre recombinase action at 
these sites when the loxP mouse line is bred with a second line which expresses the 
Cre recombinase gene (Figure 3.1). 
 
Within a Cre-loxP system, Cre recombinase can be driven by an upstream 
promoter of choice, which allows the researcher to direct Cre expression, and 
therefore the knockout, in a cell lineage specific manner. Furthermore, the Cre-loxP 
system overcomes embryonic and neonatal lethality problems which can arise from 
global knockouts, and recent generation of floxed fluorescent protein transgenes 
allows researchers to visualise Cre activity within live cells and organs in real-time. 
One disadvantage lies in the selection of a promoter able to drive Cre expression 
with sufficient precision and activity that it completely excises the target gene. In 
addition geneticists must rely on the loxP sites to be sufficiently accessible to the Cre 
recombinase protein (Davey and MacLean 2006).  
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Figure 3.1: The Cre-loxP system of transgenic derivation: In generation 1 Cre 
recombinase expression is driven by a cell/tissue specific promoter within the genome of a 
first mouse line. The genome of a second mouse line contains the target gene flanked by 
two 34 base pair loxP sites. When these two mouse lines are mated together, the resulting 
offspring (generation 2) contain both the tissue specific Cre recombinase and ubiquitously 
expressed loxP sites flanking the gene of interest. The cell specific Cre recombinase 
recognises the loxP sites, excises the DNA between them, so that they recombine, removing 
the gene of interest (Adapted from Davey and MacLean 2006). 
 
 Global AR knockout (ARKO) female mice exhibit reduced follicular 
maturation, and upon stimulation with hCG these ARKO females produce fewer CL 
and exhibit increased levels of GC apoptosis, thus the AR appears necessary for 
folliculogenesis (Hu, Wang et al. 2004). The use of Cre-loxP technology to ablate the 
AR in a cell or tissue specific manner would allow more informative conclusions to 
be drawn as to its role within the ovary. In male mice, generation of AR Cre-loxP 
knockouts is a straightforward process in comparison to female mice, since the AR 









) will theoretically produce a 
knockout in half of the male F1 offspring. Conversely generation of female ARKO 
animals, with the exception of the global knockout previously described, is 
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a second generation F2 derivation can potentially produce a knockout animal. The 
main issue that arises when knocking out a gene on the X-chromosome in female 
animals is that of dosage compensation and XCI (discussed in Chapter 1, Section 
11.2). In the derivation of male embryos with a floxed X-linked gene of interest, one 
Y chromosome and one X chromosome only are present, thus XCI does not take 
place and the floxed gene is expressed and can excised by Cre in the F1 generation 
when the male is bred with a Cre positive female. By comparison, in female embryos 
with a floxed gene of interest, dosage compensation processes inactivate one 
unaltered chromosome in 50% of cells, and the other floxed chromosome the other 
50% of cells of the P1 generation. The resultant female offspring of the F1 
generation will therefore, in theory, exhibit a mosaic pattern of floxed cells. In order 
to successfully flox 100% of cells in the next generation of female animals, this 
female must be bred with another male that also contains a floxed X-linked gene of 
interest. Recent research using AR-floxed mice has therefore yielded little insight 
regarding the involvement of the AR in female fertility with publications focused 
upon the more accessible effect of cell specific ARKO upon male fertility (Table 
3.1).  
 
Table 3.1: Summary of novel reproductively relevant ARKO publications to date: 
ARKO studies are either global knockouts or they target male tissues. 
Cre 
promoter 
Target cells Gender studied Reference(s) 
β-Actin Global ♂ and ♀ (Yeh, Tsai et al. 2002) 
hCMV Global ♂ and ♀ 
(Matsumoto, Takeyama et al. 
2003; Notini, Davey et al. 2005) 
PGK Global ♂ and ♀ (Venken, De Gendt et al. 2006) 
AMH Sertoli cells ♂ only 
(Chang, Chen et al. 2004; De 
Gendt, Swinnen et al. 2004) 
AMHR-II Leydig cells ♂ only (Xu, Lin et al. 2007) 
Transgelin Peritubular Myoid cells ♂ only (Zhang, Yeh et al. 2006) 
Scyp1 Germ cells ♂ only (Simanainen, Allan et al. 2007) 
♂=male physiology; ♀=female physiology; hCMV=human cytomegalovirus minimal 
promoter; PGK=phosphoglycerate kinase-1; AMH=Anti-Müllerian Hormone. 
 
 A successful SCARKO model has since been described using a Cre-loxP 
system, with Cre driven off the Sertoli-cell specific AMH promoter (Chang, Chen et 
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al. 2004; De Gendt, Swinnen et al. 2004). In the female mouse, AMH is produced by 
GCs of growing follicles and functions to inhibit the recruitment of primordial 
follicles into the activated follicle pool through an as yet unknown mechanism 
(Visser, Durlinger et al. 2007). For this reason, a granulosa cell specific androgen 
receptor knockout mouse (GCARKO) has been attempted in order to elucidate the 
specific role of AR in granulosa cell function more clearly. AR is expressed 
throughout the tissues of the mammalian ovary and non-aromatisable androgens such 
as DHT have been shown to augment GC FSH production in vitro (Hillier and De 
Zwart 1981). However, the molecular mechanisms by which AR affects GC function 
in vivo remain to be documented. This chapter will describe an attempt to generate a 
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3.2. Objectives 
 To derive a GC specific ARKO (GCARKO) mouse using the SCARKO breeding 
line as previously described (De Gendt, Swinnen et al. 2004). 
 
 To verify Cre activity by mating AMH-Cre positive males to females with a floxed 
enhanced yellow fluorescent protein (EYFP) transgene. 
 
 To verify AR knockout in the GCs of second generation AMH-Cre X ARflox crosses 
using IHC and IHF techniques. 
 
 Identify any differences in the estrus cycles and reproductive organs of knockout and 
mosaic knockout female animals. 
 
 Identify the role of AR in follicle development using this model, through ovarian, 
follicle and GC cultures. 
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3.3. Methods 
3.3.1. Transgenic Line Husbandry 
 Experiments were conducted at a University of Edinburgh animal house 
facility, Western General Site, Edinburgh. All animal studies were carried out in 
accordance with the Animal (Scientific Procedures) act 1986 and were approved by 
the Home Office. BRR staff were responsible for daily mouse husbandry and smears 
were performed by Ms Linda Baker on site, stored in a humidity box and couriered 
to the author for examination at the end of two weeks. Experimentation operated 
through personal licence PIL 60/10682 and project licence PPL 60/3544 held by 
Professor Philippa Saunders. Mice were housed in clear solid-bottomed cages, 
containing bedding of wood shavings, corn cob and cardboard tubing. 
 
3.3.2. ARflox and AMH-Cre transgenic mouse breeding 
 GCARKO line females were bred utilizing the same transgenics used when 
obtaining a Sertoli-cell ARKO (SCARKO); full details of transgenic mouse 
generation can be found in Figure 1 of the original paper (De Gendt, Swinnen et al. 
2004). Briefly, ES cells from a 129/SvJ BAC library were used to isolate a fragment 
containing the first two exons of the murine AR gene, the sequence of which was 
confirmed using Southern blot techniques. Next a targeting vector was constructed 
and electroporated into male R1 ES cells. Antibiotic cultures were used to isolate any 
recombined cells and successful homologous recombination was confirmed by 
further digestion and Southern blotting. In addition, an internal probe was used as a 
check against random vector integration. The recombined clones were subsequently 
transfected with a Cre-expressing plasmid and exon 2 excision verified by Southern 
blot. 
 
 ES cells containing the target vector were injected into blastocysts from 
Swiss-Webster (SW) females and implanted into pseudo-pregnant dams; chimeric 
male offspring were identified by agouti coat colour and mated to SW females as a 
test for germ line transmission. Germ line offspring were again identified by their 
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agouti phenotype and were subsequently genotyped using genomic DNA from tail-
tip biopsies. Two chimeric males demonstrating 100% germ line transmission were 
used as founders of the ARKO and SCARKO transgenic lines (De Gent et al. 2004). 




 from a 129/Swiss 




, shown in Figure 3.2. 
 
 
Figure 3.2: Schematic diagram showing the generation of the male F1 SCARKO 
transgenic line which were then used to derive the GCARKO second F2 generation: 
First (P1), second (G1) and third (G2) animals were genotyped at each stage to assess the 
allelic status of the floxed AR and for the presence or absence of Cre. Hemifloxed F2 
GCARKO mosaic animals could be used to continue GCARKO line generation (green 










 SCARKO males 
as the SCARKO mouse is infertile. 
 
3.3.3. AMH-Cre X EYFPflox 




 males were 
mated to females containing a floxed enhanced yellow fluorescent (EYFP) protein. 
This EYFP strain was derived as described for the ARKO line (Chapter 3, Section 
3.2), but here the EYFP transgene was inserted into the ubiquitously expressed 
ROSA26 locus on autosome 6, not AR exon 2 locus on the X chromosome (Srinivas, 
Watanabe et al. 2001). The ROSA26 locus is a commonly used and easily targeted 
location for transgene insertion. It highly expresses inserted genes and is not 
apparently subject to gene silencing events (Irion, Luche et al. 2007). The EYFP 
Cre-/- AR+/f Cre+/- AR+/f Cre-/- ARf/y Cre+/- ARf/y
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transgene was inserted downstream of a stop codon, that becomes excised by Cre 
recombinase, allowing expression of EYFP in the Cre positive cells EYFP floxed 
mice (Figure 3.3). 
 
 
Figure 3.3: Structure and function of the EYFP transgene: Cre activity excises at two 
loxP sites removing a transcriptional stop sequence (tpA) and allowing expression of EYFP 
within the target cell or tissue (Adapted from Srinivas, Watanabe et al. 2001). 
 
 Female offspring of AMH-Cre X EYFP crosses were killed at weaning by 
cervical dislocation and their ovaries removed and placed in PBS (as described in 
Chapter 2, Section 3). Whole ovaries were then viewed under a filter on a light 
microscope to see if GCs expressed EYFP. These ovaries were also fixed to be used 
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3.3.4. Genotyping 
 Mice were identified by ear clips which could then be used as a tissue sample 
for subsequent genotyping. F1 generation mice were genotyped for the allelic status 
of the AR (i.e. presence of a floxed transgene) and for the presence or absence of Cre 
using primer pairs (Table 3.2). Primers were designed to span exon 2 of the AR gene. 
Thus animals with one floxed allele and one non-floxed allele („hemifloxed‟) could 
be identified by two PCR products, and would in theory be mosaic GCARKO 
animals. 
 
Table 3.2: Details of primers used to genotype GCARKO line animals: Animals were 
genotyped for the presence/absence of Cre. The AR primers designated the allelic status of 
the floxed AR, with a band at 644bps in wild type animals, and a band at 675bp in floxed 
animals. Hemifloxed animals had both these bands. GAPDH was run as a positive control 
gene. 
Gene Target Primers used (5’  3’ sequence) Length (bp) Tm (°C) %GC 
AR Fwd+ AAGCAGGTAGCTCTGGGACA 20 54 55% 
 
Rev- CGTTTCTGCTGGCACATAGA 20 54 50% 
Cre Fwd+ GATCGCTGCCAGGATATACG 20 54 50% 
 
Rev- AGGCCAGGTATCTCTGACCA 20 54 60% 
GAPDH Fwd+ CTGCACCACCAACTGCTTAGC 20 54 55% 
 
Rev- ATGCCAGTGAGCTTCCGTTC 20 54 55% 
 
 F2 generation animals were genotyped in the same way. However, only the 
presence or absence of Cre could be used as a marker for potential GCARKO 
animals and was only fully assessed by ovarian immunohistochemistry for the AR to 
identify these animals after sacrifice.  
 
To genotype generation F1 and F2 animals, DNA extraction from ear clip 
samples was used. To extract, 25µl TE Tween solution (Method: 250µl TRIS-HCl, 
19µl 0.5M EDTA, plus 25µl Tween) and 2μl of a proteinase-K (pK) digestion 
enzyme were added tp each ear clip in a 0.2ml PCR tube. Samples, including pK 
negative controls, were then lysed at 55°C for two hours on a PTC200 (Thermo 
Cycler) PCR block, with a second step of 95°C for seven minutes to denature the pK. 
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Lysed samples were then vortexed and centrifuged at 4000 rpm for five minutes; 
10μl of DNA was then removed from the top aqueous layer and diluted in 90μl of 
autoclaved distilled water. Subsequent PCR was then performed for each gene using 
standard Biomix Red (Thermogenics) master mix (Table 3.3). 
 
Table 3.3: PCR master mix components used in genotyping. 
Component Volume (µl) 
Biomix Red 10 
Nuclease Free Water 7.6 
Forward Primer 0.2 
Reverse Primer 0.2 
DNA template 2 
TOTAL 20 
 
Samples were subsequently run on a cycle PCR program (Table 3.4) and 
visualised next to a 100 base pair interval ladder on 1% agarose TAE gel, examples 
of which are shown for each genotype (Figure 3.4). 
 
Table 3.4: Thermo Cycler PCR program used in genotyping: After step 1, steps 2 to 4 
are repeated 30 times before final extension of the PCR product 
Step Component Temperature (ºC) Time (min) 






















Figure 3.4: Image of a standard gel showing the results of a typical PCR performed 
when genotyping F1 and F2 generation GCARKO line: Panel (A) shows the presence or 
absence of Cre, panel (B) the allelic status of the floxed AR and (C) GAPDH control for the 





and thus were identified using IHC. In each PCR gel run, negative (water no-template (NT) 
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3.3.5. Immunohistochemistry and immunofluorescence 
 For histological analysis, colour co-immunolocalisation was performed using 
alexa-fluorophore antibodies (Table 3.5). Fluorescent staining was optimised for 
each individual antibody prior to dual staining optimisation. Dual staining took place 
over three days with relevant blocking steps between antibody additions as 
previously described (Chapter 2, Section 4). 
 
Table 3.5: Antibodies used in immunofluorescence (IHF): All tissues were blocked with 












Cre Rabbit NGS 
1 in 
2500 
Goat α Rabbit 
Peroxidase FAB 
- 1 in 10 Abcam 
GFP Mouse NGS 1 in 250 
Goat α Mouse 
Peroxidase FAB 
- 1 in 10 Abcam 
AMH Goat NRS 1 in 100 







AR Rabbit NGS 1 in 200 








 IHF runs were counterstained by either Toporo blue (at 1:500μl) or 
propidium iodide red (at 1:1000μl) and finally mounted wet (i.e. without dehydration 
through alcohols and xylene) using permafluor for laser confocal microscopy across 
three colour wavelengths; red at λ 546nm, green at λ 488nm and blue at λ 623nm. 
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3.4. Results 
3.4.1. Cre is driven off the AMH promoter in Cre-/+ EYFP-/+ F1 mice 
 To verify that the AMH promoter was driving Cre sufficiently, Cre positive 
females from AMH-Cre
-/+
 X EYFPflox crosses were culled and their ovaries 
examined in PBS under a fluorescent filter. Results showed that Cre successfully 




 animals, and no EYFP 




 (Figure 3.5). 
 
 
Figure 3.5: EYFP (green) is expressed by Cre recombinase activity, driven off the AMH 








 ovary. Whole 
ovaries were dissected out into PBS and examined under a fluorescent filtered microscope 
before fixing for use as Cre positive controls. Bar=100µm 
 
To determine more precisely where EYFP expression was occurring in the 




 animals, a GFP-antibody against the common fluorescent 
form of the GFP and YFP proteins was used to detect the location of EYFP 
expression (Figure 3.6). 
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 ovary. Sections were counterstained with propidium iodide red. Bar=50µm. 
 
To prove that AMH was driving Cre expression, the pattern of Cre expression 
was assessed using an antibody against Cre itself. This antibody exhibited extensive 
nonspecific staining using DAB IHC, and so IHF was employed to assess Cre 




 animals, Cre was expressed in the 
granulosa cells of developing follicles (Figure 3.7B-C).  
 
Additionally, both Cre and EYFP expression within individual follicles 
lacked uniformity and although present, varied between GCs (Figures 3.6 and 3.7). 
This uneven expression of EYFP and Cre is probably attributable to the uneven 
expression and subsequent transcription, translation and secretion of AMH by follicle 
GCs. 
                                                 
*
 Acknowledgement and thanks to Laura O‟Hara for supplying epididymus sections from EYFP male 
mice for use as positive controls in Cre IHF. 
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 epididymus Sections were counterstained with 
propidium iodide red. Bar=50µm. 
 
To assess for effects of Cre upon AMH or AR expression, dual IHF was 









 ovaries and ovaries 





 animals were also used (Figure 3.8).  
                                                 
†
 Acknowledgement and thanks to Laura O‟Hara for supplying epididymus sections from EYFP male 
mice for use as positive controls in Cre IHF. 
 
Page | 114 
 
 













 ovary and (D) ovary 
from a potential knockout animal. Sections were counterstained with toporo blue. Bar 
=50µm. 
 
AMH expression was evident in the GCs of developing follicles, and while 
AR expression was evident in all ovarian compartments, including GCs, stroma, 









 control animals. 
Moreover, IHF for AR (green) within hemifloxed ovaries and potential knockout 
ovaries remained uniform. The predicted mosaic pattern of AR expression in 
hemifloxed animals was not observed using IHF.  
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3.4.2. AMH-Cre X ARflox to produce a GCARKO 





expression of AR (Figure 3.9). 
 
 





Shown at (A) X 2 magnification, bar=200µm and (B) X 20 magnification, bar=50µm. 
 





females, the F1 generation exhibited normal expression of both AR and 








 females (Figure 3.10), 
presumably due to the presence of a single wild type AR allele. 
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ovaries: Shown at (i) X 2 magnification, bar=200µm and (ii) X 20 magnification, 
bar=50µm 
 
 Fixed ovaries from F2 animals (n=72) were collected for histological 
examination of AR and AMH expression. In theory 10% of total offspring should 
present with a granulosa cell knockout phenotype and 10% with a mosaic phenotype 
as predicted by the inheritance pattern of Mendelian genetics (Figure 3.2). Animals 





could be used to breed further generations and maintain the colony. Cre positive 
animals with a single PCR gel band for the AR gene were designated as potential 








). Their phenotype was only 
identified upon histological examination for the presence/absence of AR in ovarian 
GCs. If the ovarian phenotype did not match the designated genotype, the PCR was 
repeated at least twice. 
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 animals exhibited a mosaic pattern of AR expression in their ovaries (Figure 









, only one F2 exhibited some mosaic GCARKO, even though repeated 














generation F2 animals 
were further investigated for Cre expression using IHF (Figure 3.12). Cre expression 
appears sufficiently driven off the AMH promoter in both generations and thus does 
not account for the mosaic pattern of AR expression observed in one F2 animal. 
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. Uppercase lettered images bar=200µm, lowercase 
lettered images bar=50µm. Images D and d illustrate the only F2 animal to exhibit mosaic 
AR expression within GCs. 
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Sections were counterstained with propidium iodide red. Bar=50µm. 
 
 During the generation of the GCARKO transgenic line, Mendelian genetics 
were used to predict the likely proportions of each genotype observed with each 
generation. Table 3.6 illustrates the proportions expected alongside those observed, 
which were scored with each course of AR IHC for each animal. While a mosaic AR 




 F2 animals, none were seen except in one animal 
genotyped several times over as a potential F2 GCARKO (Table 3.6). 
 
Table 3.6: Expected proportions of female GCARKO animals across litters compared 





Experimental Outcomes Predicted 
Occurrence (%) 
Actual 




































One mosaic 18 (25%) 1 (<1%) 
TOTAL 
   
72 (100%) 72 (100%) 
AR=androgen receptor; Cre=cre recombinase; GCARKO=granulosa cell androgen receptor 
knockout. 
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 F1 mice, Cre recombinase activity drove EYFP expression 
sufficiently for detection under a fluorescent filter and through the use of IHF, 
although GC Cre expression was uneven. This irregular pattern of Cre expression 
was also observed by the laboratory where the AMH-Cre transgenic line was 
developed (Lecureuil, Fontaine et al. 2002). Furthermore despite confirmed Cre 













F2 animals as was 
predicted and therefore it is likely that Cre is not well driven off the AMH reporter in 
the female animal. 
 
 Several aims of this transgenic project have been met; Cre activity was 
verified by EYFP expression in rodent granulosa cells, AR expression in the 
GCARKO line was verified using IHC and IHF. However, the ultimate aim of this 
project was to derive a GCARKO animal in order to understand the role of AR 
within folliculogenesis through more novel means, and in this case the knockout was 
unsuccessful. 
 
 It is likely that the penetrance of Cre was not strong enough to fully excise 
the AR. Indeed, no other published studies have used the AMH-Cre line to drive a 
knockout in the female. Furthermore, the Cre recombinase protein itself may have 
had insufficient access to the floxed AR transgene in the female animal, although this 
is unlikely since a successful GCARKO has recently been generated using the 
AMHR2 driven Cre line. Preliminary results from a recently published GCARKO 
model indicate that AR is essential for proper primordial follicle activation, since in 
the absence of GC AR expression there is a reduction in the population of primordial 
follicles (Sen and Hammes 2010). GCARKO animals in this study exhibited a 
reduced proportion of primordial follicles in GCARKO animals, indicating that AR 
may be necessary for proper follicle recruitment in the rodent. In this study animals 
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remained fertile although they ovulated with fewer numbers of CL (Sen and Hammes 
2010).  
The AMH-type II receptor (AMHR2)-Cre reporter mouse line has since 
produced several GC specific knockout models to study the involvement of certain 
molecules in GC and ovarian development; for example the ribonuclease Dicer-1 
(Lei, Jin et al. 2010), the tumour suppressor Pten (Fan, Liu et al. 2009), and other key 
developmental proteins that include hedgehog signalling molecules (Ren, Cowan et 
al. 2009) and Wnt4 (Boyer, Paquet et al. 2009). To drive future GC knockout studies, 
the AMHR2 Cre line would therefore be a superior choice over the AMH-Cre 
reporter.  
 
In conclusion, an alternative avenue of identifying the role of androgens 
regarding the ovary must be pursued. 
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Chapter 4. Effects of fetal and postnatal testosterone 
exposure on the rat reproductive tract 
 
4.1. Introduction 
Clinical studies show that LH levels in PCOS women are frequently raised (Welt, 
Taylor et al. 2005), and an increased stromal compartment has been documented in 
the PCO (Fulghesu, Ciampelli et al. 2001). There is also evidence to suggest that 
developing follicles in ovaries from PCOS women have increased 17α-hydroxylase 
(17αOH) activity within the theca interna layer (Nelson, Legro et al. 1999). Together 
these steroidogenic ovarian cell types, under the influence of LH hypersecretion, may 
contribute to the ovarian hyperandrogenaemia observed in PCOS patients (Kaaijk, 
Sasano et al. 2000). However, it remains unclear whether these hormonal imbalances 
are due to defects at the ovarian, pituitary or even the hypothalamic level of the 
reproductive axis (Abbott, Dumesic et al. 2002). 
 
The hyperandrogenic status of many women with PCO is hypothesised to be 
one cause of the anovulation associated with the disorder, since the functional status 
of follicles within the PCO is altered; PCO are typified by the presence of an 
increased number of follicles (12 or more) which are between two and nine mm in 
diameter (Dewailly, Catteau-Jonard et al. 2007; Fulghesu, Angioni et al. 2007). 
These features could well be the result of suppression of pituitary FSH, below the 
levels required to stimulate adequate folliculogenesis (Franks, Stark et al. 2008). 
Thus an altered LH to FSH ratio impairs follicle selection and dominance, as a result 
of which few follicles rarely grow to greater than nine mm, reducing hormonal 
feedback to the hypothalamus/pituitary, and preventing the GnRH/LH surge that 
would normally induce ovulation (Taylor, McCourt et al. 1997). However, this does 
not rule out a defect in hypothalamic or pituitary sensitivity to hormonal feedback. 
Indeed the sheep model of PCOS has shown a reduction in feedback sensitivity to E2 
in fetally androgenised ewes (Veiga-Lopez, Astapova et al. 2009). The vicious cycle 
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of PCOS is one reason the source of the disorder has been difficult identify despite 
decades of research. 
 
Previous research into the fetal and neonatal programming of male rats by 
testosterone proprionate (TP) (Welsh, Saunders et al. 2008; Welsh, MacLeod et al. 
2010) has now been extended as this chapter investigates the consequences of fetal 
and neonatal exposure of female rats to TP, examining immature animals at postnatal 
day pnd 25 and adult animals at pnd 90. No rodent studies have performed in-depth 
validation of the neonatally androgenised animal as a model for PCOS, and few have 
documented the plethora of reproductive and metabolic consequences which result 
from fetal and/or neonatal androgen exposure (Chapter 1, Section 11). This chapter 
examines the effects of different windows of exposure to TP on ovarian development 
and aspects of metabolism, and seeks to determine if the alterations in ovarian, 
pituitary and metabolic function (that are a feature of PCOS in women), could occur 
independently at different times during fetal and/or neonatal life. Furthermore this 
chapter will focus upon the validation of the neonatal androgenised rat as a model for 
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4.2. Objectives 
 To determine which windows of neonatal TP treatment induce an altered 
reproductive phenotype in the adult animal and to what extent if any, the resulting 
phenotype mimics human reproductive pathophysiologies such as PCOS or POF. 
 
 To determine if the alterations in ovarian, pituitary and metabolic function (that are a 
feature of PCOS in women), could occur independently at different times during fetal 
and/or neonatal life. 
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4.3. Methods 
 Animals were housed and maintained as described in Chapter 2, Section 2. 
4.3.1. Study outline 
 In this study e.0.5 was defined by the presence of a vaginal plug and a 
minimum of four litters were used for each treatment group. For treatment during 
embryonic development, pregnant dams were injected with 20mg/kg TP in 0.4ml of 
corn oil. However, TP exposure during late fetal life has been shown to induce 
dystocia, significantly increasing the mortality of both pups and mother. To prevent 
this, animals from these treatment groups which received fetal TP were delivered by 
caesarean at e21.5 and cross-fostered to untreated dams that had delivered their own 
pups within six hours of caesarean. Animals treated during postnatal life received 
injections corresponding to pup weight every three days; those in the TP treatment 
group received a dose of 20mg/kg TP while those in the control litters received a 
comparable volume of corn oil (Welsh, Saunders et al. 2008; Welsh, MacLeod et al. 
2010). The windows of TP treatment are outlined in Figure 4.1 and are hereafter 
designated as fetal, late postnatal, fetal plus postnatal and postnatal windows. The 
numbers of animals used in each treatment group are outlined in Table 4.1. 
 
 
Figure 4.1: Schematic diagram to illustrate the windows of TP exposure in rats: 
Downward blue and orange arrows indicate the days of TP injection at 20mg/kg during fetal 
and postnatal life respectively. The downward red arrow indicates the day of birth, and 
purple arrows the days of sacrifice for immature (pnd 25) and adult (pnd 90) animals. 
Treatment groups are designated control, fetal, late postnatal, fetal plus postnatal, and 
postnatal TP hereafter. 
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Table 4.1: The number of animals in each experimental control and TP treatment 
group (outlined in Figure 4.1) in addition to their sampling ages. 
Group Name TP exposure Immature pnd 25 Adult pnd 90 
  
Male Female Male Female 
Control Oil: e14.5-pnd24 18 9 (20*) 21 9 (11*) 
Fetal e14.5-e21.5 8 5 (7*) 9 3 
Fetal plus 
postnatal 
e14.5-pnd24 8 4 (8*) 6 6 (9*) 
Late postnatal pnd15-24 9 5 7 5 
Postnatal pnd1-24 5 6 4 4 (6**) 
*red in brackets indicates the original sample number before litters were discounted due to 
suspected human error. **blue in brackets indicates the correct sample number but where 
three animals in the fetal plus postnatal group had dysgenic ovaries unsuited to follicle 
counting, and where two animals in the postnatal group developed large ovarian cysts and 
so were excluded from follicle analysis. 
 
Certain litters were excluded from this study, namely two control litters, one 
fetal TP litter and one fetal plus postnatal TP litter. These litters were discounted due 
to suspected human error when administering the TP doses and control vehicle. 
 
4.3.2. Necropsy 
 Two or more litters from each treatment window were culled and weighed at 
each time point for immature pnd 25 and adult pnd 90 (Chapter 2, Sections 2-3). 
Plasma was collected by cardiac puncture using heparinised syringes for 
gonadotrophin and estradiol analysis. The uterus and ovaries were subsequently 
dissected out and weighed before fixing in bouins, followed by paraffin embedding 
and serial sectioning (Chapter 2, Section 4). 
 
4.3.3. Follicle counts and IHC 
 One ovary from each animal was serial sectioned and every 10
th
 section H&E 
stained for follicle count analysis under a light microscope at X 20 magnification. 
The intervening sections were serially mounted onto the same slides, where possible 
with a control section, and DAB stained for various immunohistochemical markers 
used in morphometric analysis, described in Table 4.2. 
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Table 4.2: IHC markers used on cohorts of serial sections, every 10
th
 section: In the staining protocols requiring stereological measurements, 
weak staining was excluded by tracing round the area of interest as previously described in Section 2.5. 









Whole ovary Follicle count - All 
Day 25 & 
Day 90 
DAB VASA Germ cells Germ cell count Germ cell stain/µm
2
 Fetal TP e21.5 
DAB PCNA 
Nuclei of proliferating 
cells 
Qualitative - All Day 90 
DAB Caspase-3 Apoptotic cells Apoptosis count - Control & Fetal TP e21.5 
DAB AMH 
GCs of activated 
follicles up to the large 
antral stage 
Growing follicle counts - 
Control, Postnatal TP and 
Fetal plus Postnatal TP 
Day 90 
DAB Aromatase 
mGCs of large antral & 
dominant follicles 




Control, Postnatal TP and 
Fetal plus Postnatal TP 
Day 90 
DAB 3βHSD 
Strong in stroma, weak 
in theca interna, CL & 
mGCs 
- 
Measured as % 
ovarian area (-CL) 








Measured as % 
ovarian area; thecal 
thickness (μm) 
Control and Postnatal TP Day 90 
IHC=immunohistochemistry; H&E=Haematoxylin & Eosin; PCNA=Proliferating cell nuclear antigen; (m)GCs=(mural) granulosa cells; CL=Corpus 
Luteum; AMH=Anti-Müllerian Hormone; 3βHSD=3β-hydroxysteroid-dehydrogenase.
 




4.4.1. Effects of TP administered during late fetal life 
The effects of fetal TP were first assessed at e21.5 using serial DAB IHC for 
VASA, a germ cell secretagogue (Figure 4.2). Using the stereological methods 
described in Chapter 2 Section 6, germ cells were counted for ovaries from both 
control and fetal TP treated animals. Additionally, the ovarian area was measured to 
allow quantification of germ cell density. 
 
 
Figure 4.2: Germ cell clusters stained with VASA within the rat ovary at e21.5. Germ 
cells are shown at (A) X 20 and (B) X 40 magnification. 
 
 Morphometric analysis of germ cell populations, both the total numbers and 
proportion of germ cells per μm
2
 area, showed no significant differences between 
treatment groups (Figure 4.3). 
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Figure 4.3: (A) Total germ cell numbers per ovary and (B) number of germ cells per 
μm
2
 ovary at birth (e21.5/pnd0): Shown for control (n=4), and animals treated with 5mg/kg 
TP (n=4)  or 20mg/kg TP (n=4) during the fetal window. Values are expressed as the mean 
±SEM and were analysed by student‟s t-test. 
 
 Cleaved caspase-3 (CC3) protein was used to assess for the effects of fetal TP 
upon germ cell apoptosis within the ovary at e21.5 by using a further DAB stain for 
this apoptotic marker, illustrated in Figure 4.4. There were no differences in 




Figure 4.4: Cleaved caspase-3 staining showing germ cell apoptosis occurring in the 
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Figure 4.5: Quantitative analysis of apoptosis occurring in the rat ovary at birth (e21.5) 
with (A) number of cleaved caspase-3 positive germ cells and (B) number of cleaved 
caspase-3 positive germ cells per μm
2
 ovary: Shown for control (n=4), and animals 
treated with 5mg/kg TP (n=4)  or 20mg/kg TP (n=4) during the fetal window. Values are 
expressed as the mean ±SEM and were analysed by student‟s t-test. 
 
 Examination of gross ovarian morphology and was performed for both 
control and fetal TP treated animals at immature pnd 25 and adult pnd 90. No 
differences in ovarian morphology were observed in immature fetal TP animals or in 
adult animals (Figure 4.6). 
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Figure 4.6: Representative images of gross ovarian morphologies seen in (A) control 
and (B) fetal TP treated animals (i) at immature day 25 and (ii) at adult day 90; Normal 
morphology was observed at both ages; control animals and adult fetal TP animals both 
exhibit CL. Images were taken at X 2 magnification. 
 
Adult animals in the fetal TP treatment group developed a vaginal opening 
and ovulated with normal numbers of CL. In addition, there were no significant 
differences in follicle numbers and proportions between control and fetal TP 
treatment groups in both immature and adult animals (Figure 4.7). 
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Figure 4.7: Total follicle counts (A) and follicle proportion analysis (B) of control and 
fetal TP treated animal groups at (i) immature day 25 and (ii) adult day 90. Values are 
expressed as the mean ± SEM, (A-B) were analysed using a student‟s unpaired t-test and 




Page | 134  
 
4.4.2. Effects of TP administered during late postnatal life 
The ovarian morphologies of control and late postnatal TP treated animals 
were compared in immature animals (Figure 4.8) show follicle antra lined by 
pyknotic GCs, a sign of follicle atresia. 
 
 
Figure 4.8:  Representative images of gross ovarian morphologies seen in (A) control 
and (B) late postnatal TP treated animals (i) at immature day 25 and (ii) at adult day 90; 
Images were taken at (i-ii) X 2 and X 20 (iii) magnification. (iii) Illustrates follicle atresia 
evidenced by granulosa cells with pyknotic nuclei (arrowheads) at pnd 25 by TP in the late 
postnatal treatment group. Note the normal morphology observed at pnd 90 where like 
control animals, adult late postnatal TP animals exhibit CL. 
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Adult females treated with late postnatal TP developed a vaginal opening 
and, like fetal TP treated animals, exhibited morphologically normal ovaries which 
ovulated with normal numbers of CL. 
 
 
Figure 4.9: Total follicle counts (A) and follicle proportion analysis (B) of control and 
late postnatal TP treated animal groups at (i) immature day 25 and (ii) adult day 90: 
Values are expressed as the mean ± SEM. (A-B) were analysed using a student‟s unpaired 
t-test and (C-D) using two-way ANOVA with Bonferroni post-hoc test (* P≤0.05; ** P≤0.01). 
 
Examination of follicle numbers and proportions in immature and adult 
animals treated with late postnatal TP revealed no significant differences in total 
follicle numbers (Figure 4.9). However, immature animals treated with late postnatal 
TP exhibited an increase (P≤0.05) in the proportion of transitory follicles, and a 
decrease (P≤0.05) in the proportion of antral follicles. Furthermore adult animals 
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treated with late postnatal TP exhibited a significant increase (P≤0.01) in the 
proportions of primordial follicles. 
 
4.4.3. Effects of TP administered during both fetal and postnatal 
life 
 Animals treated with TP for the fetal plus the postnatal period displayed 
morphologically dysgenic ovaries at immature pnd 25. By contrast adult pnd 90 
animals treated with fetal plus postnatal TP lacked a vaginal opening and developed 
dysgenic “streak” ovaries (Figure 4.10). 
 
 
Figure 4.10: Representative images of gross ovarian morphologies seen in (A) control 
and (B) fetal plus postnatal TP treated animals (i) at immature day 25 (ii) at adult day 
90: Note the dysgenic morphology found in both immature and adult animals from the fetal 
plus postnatal TP treatment group. Images were taken at (A) X 2 and (B) X 10 magnification.  
 
Follicle population analyses of these ovaries (Figure 4.11) confirmed no 
differences in follicle numbers in the immature animal. However there existed a 
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greater proportion of transitory follicles (P≤0.001), and a lower proportion of antral 
follicles (P≤0.05) in comparison to controls at pnd 25. In adult animals treated with 
fetal plus postnatal TP there were significantly fewer ovarian follicles (P≤0.05) when 
compared to controls, and analysis of follicle proportions found a greater proportion 
of primordial follicles (P≤0.001) at this age. 
 
 
Figure 4.11: Total follicle counts (A) and follicle proportion analysis (B) of control and 
fetal plus postnatal TP treated animal groups at (i) immature day 25 and (ii) adult day 
90. Values are expressed as the mean ± SEM, (A-B) were analysed using a student‟s 
unpaired t-test and (C-D) were analysed by two-way ANOVA with Bonferroni post-hoc test 
(*P≤0.05; *** P≤0.001). 
 
  To investigate the effects of fetal plus postnatal TP treatment upon the adult 
ovary, 5μm ovary sections of ovaries from these animals were mounted on the same 
slide as a control ovary section and underwent IHC staining for various ovarian 
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markers of ovarian and follicular functional status. One marker included proliferating 
cell nuclear antigen (PCNA), a cell cycle protein involved in DNA replication and 
repair which is strongly expressed in the GC of growing follicles as they progress 
from small to medium size (El-Hefnawy and Zeleznik 2001). PCNA expression is 
reduced in atretic follicles irrespective of their size, and shows expression in the non-
proliferating corpus luteum (Baravalle, Salvetti et al. 2007).  PCNA expression in 
“streak” ovaries from adult animals treated with fetal plus postnatal TP was 
subjectively weaker when compared to PCNA expression in control ovaries (Figure 




Figure 4.12: PCNA expression in adult (A) control and (B) “streak” ovaries from 
animals treated with fetal and postnatal TP; expression is reduced in “streak” ovaries as 
there is a marked absence of larger proliferating follicles, like those depicted in A(ii). 
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To quantitatively assess the functional status of follicles within dysgenic 
“streak” ovaries and to compare them to controls, further IHC for AMH, a GC 
secretagogue known to inhibit further follicle recruitment was performed (Figure 
4.13). Subsequent analysis of the number of follicles expressing AMH illustrated that 
there were significantly fewer activated follicles (P≤0.05) within the dysgenic 
“streak” ovaries of fetal and postnatal TP animals (Figure 4.14). 
 
 
Figure 4.13: AMH expressing follicles in adult (A) control and (B) “streak” ovaries: 
Shown at (i) X 2 and (ii) X 20 magnification respectively. Note the absence of AMH 
expression in newly activated follicles within the “streak” ovary (B). 
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Figure 4.14: Follicle population analysis – the number of AMH positive follicles in 
control (n=5) and “streak” (n=4) ovaries: Values are expressed as the mean ± SEM, and 
were analysed using a student‟s unpaired t-test (* P≤0.05). 
 
Additionally, IHC for cleaved caspase-3 was performed on serial sections of 
ovaries. Very little staining was observed in both control ovaries and “streak” ovaries 
making semi-quantitative analysis of apoptosis in these sections unfeasible. 
 
4.4.4. Effects of TP administered during postnatal life 
Immature animals treated with TP for the postnatal period displayed 
morphologically normal ovaries while adult females of this treatment group lacked a 
vaginal opening and exhibited an anovulatory ovarian phenotype, as shown by the 
absence of CL (Figure 4.15). 
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Figure 4.15: Representative images of gross ovarian morphologies seen in (A) control 
and (B) postnatal TP treated animals (i) at immature day 25 (ii) at adult day 90; Note the 
relatively normal morphology of animals treated with postnatal TP at pnd 25 (Bi) and the 
anovulatory „cystic‟-like morphology found in adult animals of the same treatment group. 
Images were taken at X 2 magnification. 
 
It is of note that 2 out of 6 adult animals in the postnatal TP treatment group 
developed large fluid filled cysts around one of their ovaries. These large cysts were 
fixed in bouins for later microscopic examination (Figure 4.16). 
 
 
Figure 4.16: Postnatal TP produces large fluid filled cysts in the adult (pnd 90) animal: 
O=ovary and F=fluid filled cyst in panel (A) with an arrow indicating the capsule surrounding 
the cyst at X 2 magnification. (B) and (C) show this area further magnified area at X 20 and 
X 40 respectively. 
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Follicle population analysis of animals treated with postnatal TP revealed no 
significant differences in total follicle numbers at either pnd 25 or pnd 90, and no 
differences in follicle proportions at immature pnd 25. In adult animals treated with 
postnatal TP there was a significant increase in the proportion of primordial ovarian 
follicles (P≤0.01) when compared to controls (Figure 4.17). 
 
 
Figure 4.17: Total follicle counts (A) and follicle proportion analysis (B) of control and 
postnatal TP treated animal groups at (i) immature day 25 and (ii) adult day 90. Values 
are expressed as the mean ± SEM, (A-B) were analysed using a student‟s unpaired t-test 
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4.4.5. Effects of TP upon metabolic and hormonal parameters 
To investigate the effects of the various TP treatment windows upon 
hormonal parameters, E2 and gonadotrophin levels from animals at the time of 
sacrifice were measured (Figure 4.18). Although there is an apparent trend for higher 
LH levels in adult animals from the postnatal TP treatment group compared to 
controls, this was not significant. When gonadotrophin levels were below the 
detectable range of the assay (LH in pnd 25 late postnatal and postnatal TP and FSH 
in pnd 90 postnatal TP treated animals), non-parametric analysis found there to be a 
significant reduction in gonadotrophin levels (P≤0.05). Otherwise, no significant 
differences in LH or FSH levels across treatment groups were found, in either 
immature or adult animals. 
 
 
Figure 4.18: Plasma (A) FSH levels and (B) LH levels in (i) immature day 25 animals 
and (ii) adult day 90 animals, shown across treatment groups with n numbers as 
indicated. Values are expressed as the mean ± SEM and were analysed using a student‟s 
unpaired t-test. ND=not detectable levels <0.1ng/ml FSH and <0.2ng/ml LH; these groups 




Page | 144  
 
As previously detailed in Chapter 1, Sections 5 and 6, circulating E2 released 
by the ovary not only feeds back to the hypothalamic-pituitary axis to induce the 
GnRH/LH surge that stimulates ovulation, but it also acts to prepare the uterine 
endometrium for implantation of a potential embryo. Thus one biological marker of 
E2 levels in female mammals is uterine weight. Ovarian and uterine weights for each 




Figure 4.19: (A) Ovarian weights (B) uterine weights and (C) estradiol (E2) levels 
across treatment groups in adult animals with n numbers as indicated: Values are 
expressed as the mean ± SEM and were analysed using a student‟s unpaired t-test 
(*P≤0.05; ** P≤0.01; *** P≤0.001), ND=ovaries were not detectable in the gonadal fat pad, so 
the whole area was removed and fixed without weighing. 
 
 Ovaries from animals treated with postnatal TP weighed significantly less 
(P≤0.01) than those from control animals, presumably due to the absence of CL. 
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Ovaries from animals treated with fetal or late postnatal TP were not significantly 
different in weight compared to controls and had CL present (Figure 4.19). 
 
Due to the dysgenic nature of the ovaries from the fetal plus postnatal TP 
treatment group, these ovaries could not be located within the gonadal fat pad to be 
weighed. This data supports the fact that significantly lower E2 levels (P≤0.05) were 
found in this treatment group, in addition to significantly smaller uteri (P≤0.001). 
Furthermore, uteri from the postnatal and late postnatal treatment groups were also 
significantly lighter (P≤0.01) when compared to those of control animals. However 
these treatment groups exhibited no significant differences in plasma E2 levels when 
compared to controls. 
 
In addition to the reproductive phenotypes observed in animals exposed to TP 
during various windows of fetal and postnatal life, a metabolic phenotype was also 
seen in animals receiving TP postnatally. By day 25 of life, immature animals in the 
fetal plus postnatal TP, postnatal TP and late postnatal TP treatment groups were all 
significantly heavier compared to control animals (P≤0.05, P≤0.001 and P≤0.001 
respectively, Figure 4.20). 
 
 
Figure 4.20: Animal body weights at (A) immature day 25 and (B) adult day 90, shown 
across treatment groups, with n numbers as indicated: Values are expressed as the 
mean ± SEM and were analysed using a student‟s unpaired t-test (* P≤0.05; ***P≤0.001). 
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 At adult day 90 this weight gain was even more apparent, with fetal plus 
postnatal TP treated animals and postnatal TP treated animals growing to 
approximately 35% heavier than controls (P≤0.001). Furthermore at this age, late 
postnatal TP treated animals remained significantly heavier than controls, however 
only by a margin of around 8% (P≤0.05). There was no effect of fetal TP exposure 
upon weight gain in either immature or adult animals of this treatment group. 
 
 The significant weight gain induced by postnatal TP exposure in adult 
animals coupled with the cystic anovulatory phenotype of the ovaries within this 
treatment group led to further investigations into this window of postnatal TP 
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4.4.6. Validation of a PCOS model 
To investigate whether the cystic appearance of follicles observed in ovaries 
of animals treated with postnatal TP was due to the absence of CL and extra 
accumulation of follicle fluid into the antral space, antrum size of individual follicles 
with a nucleus was measured in every 10
th
 5μm section from the ovaries of both the 
control postnatal TP animals (Figure 4.21). 
 
 
Figure 4.21: Antrum size in follicles from control (n=6) and postnatal TP treated (n=4) 
animals: Values are shown for every antral follicle with a nucleus in every 10
th
 5μm section 
of each ovary. Black lines illustrate the mean ±SEM and differences were analysed using a 
student‟s unpaired t-test (*** P≤0.001). 
 
Given that ovaries from the postnatal TP group had on average significantly 
larger antra (P≤0.001) when compared to control ovaries, follicular functional status 
was investigated further using DAB IHC for AMH and aromatase on two additional 
cohorts of adjacent serial sections.  
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Figure 4.22: AMH staining in ovaries from (A) control and (B) postnatal TP treated 
animals. Images are shown at (i) X 2 and (ii) X 20 magnification. 
 
Ovaries of the postnatal TP group showed similar AMH staining to those of 
the control group (Figure 4.22); AMH is secreted from the GCs closest to the oocyte 
in activated growing follicles at the various levels of folliculogenesis. It was not 
secreted by any non-growing primordial follicles or by any very large antral follicles 
in either control or postnatal TP group ovaries. AMH positive follicles were counted 
and classified according to their size in order to perform a more quantitative 
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Figure 4.23: Follicular functional status through AMH serial staining to show (A) the 
number AMH positive follicles per ovary, and (B) AMH positive follicles classed and 
calculated as a percentage of AMH positive follicle numbers: Shown for control (n=5) 
and postnatal TP (n=4) ovaries. Values are expressed as the mean ± SEM and (A) was 
analysed using a student‟s unpaired t-test and (B) using two-way ANOVA with Bonferroni 
post-hoc test (** P≤0.01). 
 
 AMH staining was used to identify the number of activated follicles present 
in control and postnatal TP group ovaries. There was no significant difference in the 
total number of activated AMH positive follicles. However a significantly lower 
proportion of AMH positive small antral follicles (P≤0.01) in ovaries from postnatal 
TP treated animals were found, when compared to those from controls. During these 
experiments the number of GC layers secreting AMH was also documented and 
categorised by follicle type to determine if the level of AMH secretion was affected 
by postnatal TP. No significant differences between treatment groups were observed 
(data not shown). 
 
 Adjacent serial sections were stained for aromatase, the enzyme present in 
mGCs which, in large antral follicles, converts A4 and T produced by the theca cells 
of the follicle into estrogens (Figure 4.24). The number of aromatase positive 
follicles was counted in every 10
th
 section for each ovary, and these follicles were 
subsequently classified to have strong, weak or negative staining for aromatase 
(Figure 4.25). Despite significantly more aromatase positive follicles per ovary from 
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the postnatal TP treated group compared to controls (P≤0.05), no significant 




Figure 4.24: Aromatase staining in ovaries from (A) control and (B) postnatal TP 
treated animals: Images are shown at X 2 magnification. 
 
 
Figure 4.25: Follicular functional status inferred using aromatase serial staining in 
control (n=5) and postnatal TP (n=4) ovaries: (A) Number of aromatase positive follicles 
and (B) % large antral follicles classified on aromatase staining intensity; (C) i) strong, ii) 
weak, iii) negative aromatase staining. Values are expressed as the mean ± SEM with (A) 
analysed using a student‟s unpaired t-test and (B) using two-way ANOVA with Bonferroni 
post-hoc test (* P≤0.05). 
 
Page | 151  
 
Clinical studies have observed an increased stromal compartment and an 
increased thecal thickness in the ovaries of women with PCOS (Nelson, Legro et al. 
1999). These cellular compartments of the mammalian ovary are highly 
steroidogenic and may contribute towards hyperandrogenic status documented in 
many women with PCOS. To assess whether there was an increase in the stromal 
compartment and steroidogenic activity of theca interna in this rat model, serial DAB 
IHC using antibodies specific for these ovarian compartments was employed. 
Morphometric stereological analysis allowed the relative contribution of each of 
these ovarian compartments to be individually calculated.  
 
The stromal compartment was quantified using morphometric stereological 
analysis for 3β-hydroxysteroid-dehydrogenase (3βHSD), as previously described in 
Chapter 2, Section 6, illustrated in Figure 4.26. This enzyme is an isomerase that 
converts 5,3-βhydroxysteroids to 4,3-ketosteroids; notably (17-hydroxy) 
pregnenolone to (17-hydroxy) progesterone, androstenediol to T and 
dehydroepiandrosterone to A4 within both the adrenal and ovary. 
 
 
Figure 4.26: Stromal 3β-HSD staining in ovaries from (A) control and (B) postnatal TP 
treated animals. CL staining (controls) and mural GC staining was excluded from the area 
of interest before analysis. Images are shown at X 2 and X 4 magnification respectively. 
 
In a cohort of serial sections, the ovarian area was determined in each section 
for ovaries from postnatal TP treated animals and control oil animals (excluding CL). 
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The 3βHSD DAB stained area was determined in the same sections and taken as a 
percentage of ovarian area, again excluding CL and any mGC staining. When 
compared to controls, ovaries from postnatal TP treated animals presented a 
significantly greater area of 3β-HSD positive stroma (P≤0.05), and in addition these 




Figure 4.27: Stromal compartment measured as (A) overall 3β-HSD staining and (B) 
proportion of 3βHSD staining relative to ovarian area, in ovaries from control (n=5) 
and postnatal TP treated animals (n=4)
‡
. Control ovarian area excludes CL area. Values 
are expressed as the mean ± SEM and were analysed using a student‟s unpaired t-test 
(*P≤0.05; *** P≤0.001). 
 
 The thecal compartment was measured in a similar fashion, using serial 
staining for 17α-hydoxylase (17α-OH), an enzyme primarily localised to the theca 
interna of the rodent ovary (Figure 4.28). The enzyme 17α-OH is a cytochrome p450 
monooxygenase which, in the ovary converts pregnenolone and progesterone to their 
17-hydroxy counterparts. The enzyme subsequently acts as a lyase upon these two 
compounds to form dehydroepiandrosterone and androstenedione respectively, 
making 17α-OH an important enzyme in the generation of ovarian androgens. 
 
                                                 
‡
The measurement and analysis of data presented in Figure 4.27 was carried out by Marie Broyde, an 
honours student under the author‟s supervision. 
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Figure 4.28: Theca interna 17α-hydroxylase staining in ovaries from (A) control and 
(B) postnatal TP treated animals. CL staining (controls) and stromal background staining 
(D) was excluded from the area analysis by only including strong 17α-OH staining in the 
analysis, as exemplified by the follicle in panel C and indicated by arrowheads in panel D. 
 
 The 17αOH positive compartment was measured using the stereological 
methods described in Chapter 2, Section 6. The compartment was first selected and 
measured in µm
2
, and then taken as a % of ovarian area excluding the CL area, 
shown in Figure 4.29. There was a significantly reduced overall 17αOH area in 
ovaries from the postnatal TP treatment group compared to controls (P≤0.05), 
however this difference was absent when whole ovarian area (excluding CL) was 
accounted for. 
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Figure 4.29: Thecal compartment analysis using serial 17αOH staining in ovaries from 
control (n=5) and postnatal TP treated (n=4) animals
§
: (A) Total 17αOH stained area (B) 
17αOH staining as a % of ovarian area (excluding. CL). Values are expressed as the mean ± 
SEM and were analysed using a student‟s unpaired t-test (* P≤0.05). 
 
Additionally, follicles expressing 17αOH in their theca were classified and 
counted and their theca interna thickness measured individually during whole 
morphometric ovary analysis for 17αOH expression in each section. Again CL area 
and background stromal/mGC staining was excluded from this analysis, by only 
selecting the area with strong 17αOH staining, as indicated in Figure 4.28. As shown 
by Figure 4.30, there were no significant differences in the proportions of follicles 
expressing 17αOH in their theca interna between ovaries from control and postnatal 
TP treated animals. Furthermore there were no significant differences in mean theca 
interna thickness. There was however a direct correlation between thecal area and 
follicle size within ovaries from control animals as well those from postnatal TP 
treated ovaries. These two correlations were not significantly different from one 
another. 
  
                                                 
§
 The measurements and analysis for data in Figure 4.29 were carried out by Marie Broyde, an 
honours student under the author‟s supervision. 
 
Page | 155  
 
 
Figure 4.30: Further thecal compartment analysis using serial 17αOH staining in 
ovaries from control (n=5) and postnatal TP treated (n=4) animals: (A) Proportions of 
17α-OH positive follicles
**
; (B) Theca interna area for individual follicles; (C) Relationship 
between thecal area and follicle size. For (A-B) values are expressed as the mean ± SEM; 
(A) analysed by two-way ANOVA with Bonferroni post-hoc test; (B) analysed using a 





=0.883); a Fisher-Z transformation tested for differences between these two correlations - 
Control n=43 follicles and postnatal TP n=44 follicles yielded P=0.876.  
                                                 
**
 The measurements and analysis for data in Figure 4.30 part A only were carried out by Marie 
Broyde, an honours student under the author‟s supervision. 
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4.5. Discussion 
 Current rat models of PCOS employ the chronic administration of 
steroids/steroidogenic inhibitors during postnatal life to produce an altered 
reproductive phenotype in the adult. For example steroids used include T 
(Beloosesky, Gold et al. 2004), DHEA (Anderson and Lee 1997; Anderson, Lee et 
al. 1997), estradiol valerate (Brawer, Munoz et al. 1986; Rosa, Guimaraes et al. 
2003), DHT and letrozole (Manneras, Cajander et al. 2007). Other models use a 
single bolus injection of testosterone or estradiol on or just after the day of birth to 
produce a PCO-like phenotype in the adult animal (Barraclough 1961; Brawer, 
Naftolin et al. 1978; Ota, Wakizaka et al. 1986; Grossmann, Diez-Guerra et al. 1987; 
Alexanderson, Eriksson et al. 2007). In addition, relatively few rodent models have 
fully examined the reproductive phenotype in the adult animal and contrasted it with 
the clinical situation (Ota, Wakizaka et al. 1986; Manneras, Cajander et al. 2007). 
The main objective of these investigations was therefore to determine which 
windows of neonatal TP treatment induce an altered reproductive phenotype in the 
adult animal and to what extent if any, the resulting phenotype mimics human 
reproductive pathophysiologies such as PCOS or POF. 
 
4.5.1. Fetal TP has no discernable effects upon the female rat 
 Within the fetal TP treatment group, no effect was observed at any stage of 
measurement upon the formation and natural apoptosis of germ cells at birth. In 
addition in vitro cultures of fetal chicken ovaries have shown that androgens may act 
to promote germ cell proliferation rather than affect atresia (Anderiesz and Trounson 
1995). 
 
No effect of fetal TP exposure upon folliculogenesis or potential fertility 
occurred in adult life, as evidenced by the presence of healthy CL formation in 
addition to normal follicle numbers and proportions within the ovaries of these 
animals at both immature pnd 25 and pnd 90. Immature and adult body weights were 
normal, and gonadotrophin and E2 levels were comparable to those seen in controls 
at each stage of investigation for this TP treatment group. These findings corroborate 
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previous investigations into the effects of fetal TP upon female reproductive 
development (Smith 1970; Slob, den Hamer et al. 1983). It is worth noting that there 
may be species differences in the response to fetal androgen exposure as fetal TP 
administration in Sprague-Dawley (SD) rats in one study reduced both immature and 
adult animal body weight (Wolf, LeBlanc et al. 2004). Fetal TP treated female rats 
develop masculinised features of the urogenital tract, for example an increased ano-
genital distance (AGD), as described in the original paper upon which these studies 
were based (Welsh, Saunders et al. 2008; Welsh, MacLeod et al. 2010). 
 
4.5.2. Postnatal TP treatment leads to changes in ovarian follicle 
composition in the immature animal 
At pnd 25, in late postnatal TP and fetal plus postnatal TP (“streak” ovary) 
treatment groups, a higher proportion of activating transitory follicles and lower 
proportion of small antral follicles was observed, with no effect seen on total follicle 
numbers at this age. These results may demonstrate the mitogenic effects of 
testosterone upon folliculogenesis, whereby androgens stimulate GC proliferation of 
smaller newly activated transitory and primary follicles. These findings are supported 
by elegant experiments using ruminant follicles pre-exposed to testosterone then 
grafted into chick ovaries; the grafts were shown to selectively increase the 
proportion of growing primary follicles (Qureshi, Nussey et al. 2008). The same graft 
study found androgens to have a protective effect upon follicle survival, which is at 
odds with the reduced proportion of small antral follicles found in the late postnatal 
and fetal plus postnatal TP treatment groups of the current investigation. In the rat, 
ovarian AR expression is reduced in GCs of FSH responsive follicles (Tetsuka, 
Whitelaw et al. 1995) and previous studies involving exogenous administration of 
androgens to rats have shown that at the later stages of gonadotrophin-dependent 
folliculogenesis, exogenous androgens can facilitate follicular atresia (Drummond 
2006; Honnma, Endo et al. 2006). Indeed the small antral follicles present in the 
immature rat ovary will not express sufficient mGC aromatase for the production of 
estrogen (Mahesh, Mills et al. 1987). Thus in the current study TP likely acts to 
promote GC atresia in more advanced follicles, accounting for the reduction in small 
antral follicle proportions within these TP treatment groups at pnd 25. 
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A similar but insignificant trend was observed in the postnatal TP (PCO-like) 
treatment group at pnd 25. This lack of significance is most likely due to a 
reprogramming of the hypothalamic-pituitary-ovarian/adrenal (HPO/HPA) axes by 
early neonatal TP exposure, reducing the mitogenic actions of TP from exerting their 
influence. This explanation is the most plausible as animals in the late postnatal TP 
treatment group will have completed neonatal HPA and HPG organogenesis, while 
those in the fetal plus postnatal TP treatment group may have an increased sensitivity 
to postnatal TP exposure as a result of fetal TP treatments, as evidenced from other 
investigations (Hoepfner and Ward 1988). 
 
4.5.3. Fetal plus postnatal TP treatment leads to the formation of 
dysgenic “streak” ovaries 
TP administered during both fetal and postnatal life resulted in dysgenic 
“streak” ovaries within both immature and adult animals, which by pnd 90 of life had 
fewer follicles, fewer activated AMH expressing follicles and consequential lower 
circulating E2 levels with significantly reduced uterine weights. Secretion of AMH 
by GCs of growing follicles is known to inhibit further follicle activation (Rey, 
Lukas-Croisier et al. 2003). Following the ovulation of larger growing follicles, 
AMH levels dip and a further group of follicles activate, allowing regular follicular 
recruitment during the rodent estrus cycle (Rey, Lukas-Croisier et al. 2003). The 
deficit of AMH expressing follicles in these „“streak”‟ ovaries would indicate 
unimpeded follicular recruitment, which accounts for the reduction in follicle 
numbers within the adult animals at pnd 90. However, it remains unclear why these 
ovaries were dysgenic in immature animals. Changes to “streak” ovary tissue 
structure cannot be ruled out as one potential cause of the low levels of AMH/PCNA 
expression observed subjectively in these ovaries. Indeed, ovaries could not be 
properly located in the gonadal fat pad during dissection. Alterations in tissue 
structure might impede the breaking open of cross-linked proteins (such as collagens, 
biotins and fibrins) during IHC antigen retrieval and may subsequently affect IHC 
appearance. However, AMH expression, when it was observed in “streak” ovaries, 
was just as strong as that in control ovaries. This supports the notion that the changes 
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in AMH (and potentially PCNA) expression observed are due to differences in the 
tissue itself and are not an artefact of the IHC process. 
 
Formation of “streak” ovaries at both pnd 25 and pnd 90 implicates a 
combined effect of TP exposure during late fetal life together with the TP 
administered during early postnatal life, especially considering no effect was found 
in fetal TP treated animals and a different effect observed in postnatal TP treated 
animals. The TP dose administered during this study (20mg/kg) was designed to 
remain within the effective range for three days post-injection, minimizing the need 
for daily injections and thus reducing the number of stressful events pups and dams 
experienced. It is possible that the levels of circulating E2 (resulting from the 
placental aromatization of TP) and/or TP within animals of the fetal plus postnatal 
TP group at birth were high enough to persist into early neonatal life.  
 
It is known from other studies that neonatal E2 exposure in rodents prevents 
germ cell nest breakdown in the ovary (Kezele and Skinner 2003; Jefferson, 
Newbold et al. 2006). Since fetal E2/TP exposure was followed by TP administration 
the day after birth, the action of fetal TP may have increased the sensitivity of the 
postnatal animal to further androgen exposure. This notion is supported by another 
study in which TP administered to Sprague-Dawley rats during the late fetal period 
(e17-e18), had a priming effect upon female animals, leading to the masculinisation 
of female behaviour and physiology in animals which subsequently received a small 
postnatal dose of 5µg TP (Hoepfner and Ward 1988). Only one other study involving 
neonatal thymectomy at pnd 3 has resulted in the complete dysgenesis of ovarian 
function from such a young age in the rat, with ovaries histologically comparable to 
those observed in this study (Scalzo and Michael 1988). It is of course possible that 
combined fetal and neonatal TP treatment is able to reprogram thymocyte function, 
and further study into the effects of thymectomy upon ovarian development are 
therefore required (Deshpande, Chapman et al. 1997; Chapman, Min et al. 2009). 
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Further investigation into the reproductive consequences of combined late 
fetal and early neonatal testosterone, DHT or estradiol exposure in the rat is therefore 
warranted, as the effects of such treatments should be assessed at earlier time points 
in neonatal life, for example as germ cell nest breakdown completes on day one of 
life, after primordial follicles have finished forming on day five of life, and after 
formation of the first primary follicles by and ten of life, in addition to ex-vivo 
studies. 
 
One additional point of note is that fetal TP administration can lead to 
dystocia, associated with delayed littering and pup loss (Wolf CJ 2002). Animals in 
the fetal and fetal plus postnatal TP treatment group were cross-fostered to untreated 
dams that had recently littered. There is evidence to suggest that inadequate maternal 
care, in addition to differences litter size, during the rodent neonatal development 
period can affect hypothalamic-pituitary axis development (Champagne, Francis et 
al. 2003; Roma, Huntsberry et al. 2007). Cross fostering of certain litters (fetal and 
fetal plus postnatal TP) and not others (postnatal and late postnatal TP) may therefore 
have had an additional environmental effect upon endocrine development and 
function in animals from different litters, and could partially account for the 
differences in ovarian morphology and reproductive dysfunction observed between 
the postnatal and fetal plus postnatal treatment groups, although the mechanisms 
remain unknown. 
 
4.5.4. Postnatal TP treatment leads to weight gain in adult 
animals 
Significant weight gain was observed at immature pnd 25 and adult pnd 90 
within all treatment groups receiving TP postnatally. This indicates that the window 
of postnatal androgen exposure which can produce a metabolic phenotype extends 
further than two weeks of age. Furthermore, these findings are corroborated by other 
investigations, whereby regular neonatal administration of androgens (DHT) or 
aromatase inhibitors (Letrozole) have been shown to lead to weight gain and 
increased adiposity in adult animals (Manneras, Cajander et al. 2007; Manneras, 
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Jonsdottir et al. 2008). No studies have fully assessed the metabolic consequences of 
early neonatal programming of rat metabolism by testosterone, although rat models 
of the metabolic syndrome involve the fetal administration of the synthetic 
glucocorticoid, dexamethasone (Seckl 2001), since maternal stress is a known 
programming cause of adult disease (Cottrell and Seckl 2009). 
 
4.5.5. Postnatal TP treatment leads to changes in ovarian follicle 
composition in the adult animal 
One novel finding of these investigations was the increased primordial 
follicle proportion consistently observed in all animals that received TP postnatally. 
At present it is unclear clear how neonatal TP affects the rat follicle pool in this way, 
although recent research in mice has shown that estrogen acting via both ERα and 
ERβ can affect primordial follicle populations by inhibiting oocyte apoptosis and 
proper germ cell nest breakdown before birth, and after birth acting to prevent germ 
cell nest breakdown (Chen, Breen et al. 2009). Thus aromatisation of TP into E2 
within the neonate could account for the effects seen, as aromatase activity has been 
shown in the neonatal pituitary of female rats (Carretero, Vazquez et al. 2003). 
Additionally, reduced primordial follicle recruitment could play a part in the 
conservation of the primordial pool documented in these studies. These findings also 
corroborate with those of the primate model of PCOS, where increased proportions 
of primordial follicles were observed in infant animals following fetal exposure to 
TP (Abbott 2010). 
 
4.5.6. The postnatally androgenised rat as a PCOS model 
Postnatal TP administered between days 1-25 of life induced a PCOS-like 
phenotype in the adult rat by day 90. This potential PCOS model was subsequently 
evaluated by examining whether the ovarian and endocrine abnormalities associated 
with the clinical symptoms of the syndrome, namely a cystic ovarian phenotype, 
anovulation, high circulating levels of LH, low levels of E2, altered functional status 
of follicles and follicular persistence, increase in ovarian stromal compartment, 
increased theca interna 17αOH activity and finally obesity were present. 
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Animals from the postnatal TP group had reduced ovarian weights due to 
anovulation and lack of CL in addition to low uterine weights which, as a bioassay 
for estrogens in the rat, could have been due to low estrogen levels, although it 
should be noted that plasma E2 levels were comparable to controls in this group. 
Additionally, these animals exhibited a slight but insignificantly raised level of 
plasma LH, with no effect upon circulating FSH. One explanation for this is the fact 
that control animals were not culled at proestrus when E2 and FSH levels in the 
rodent are at their highest prior to the LH surge and ovulation. In addition other 
neonatally androgenised rat studies have shown E2 levels in the adult animal to be 
comparable to those at control proestrus with gonadotrophin levels comparable to 
met/diestrus (Ota, Wakizaka et al. 1986). 
 
Histological examination of ovaries from postnatal TP treated animals 
showed them to be anovulatory, with large fluid filled antral follicles apparent on 
subjective inspection. Alongside control ovaries, these PCO-like ovaries underwent 
serial section analysis for AMH and the results showed a reduction in the proportion 
of small antral AMH positive follicles. This may have contributed towards a larger 
mean number of antral follicles staining positive for aromatase found in adjacent 
sections, and supports the idea that the functional status of follicles within the rat 
PCO was altered. This argument is supported by the fact that follicles within the 
ovaries of adult postnatal TP treated animals had larger mean antrum sizes. Together, 
these observations add weight to the conclusion that although the postnatally TP 
treated female rat does not necessarily exhibit the hormonal aspects associated with 
PCOS such as raised LH and depressed FSH, some ovarian and metabolic aspects are 
recapitulated in the adult animal, namely weight gain, an anovulatory cystic 
phenotype, follicular persistence and altered follicular functional status. 
 
The effect of postnatal TP treatment upon the ovarian thecal and stromal 
compartments was also investigated. No difference was observed between ovaries 
from postnatal TP treated animals or control animals with regard to the status of the 
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theca; the thecal compartment was of a comparable size, enveloped a comparable 
number of follicles and the 17αOH stained area was similar between control and TP 
treated animals. A novel finding of this study was the increased amount and 
proportion of 3βHSD positive stroma found in postnatal TP treated animals, which 
further recapitulates clinical observations in women with PCOS (Fulghesu, Ciampelli 
et al. 2001; Fulghesu, Angioni et al. 2007). The increased stromal compartment 
observed may be a contributing factor to the resulting hyperandrogenism and 
anovulation seen in both this model and PCOS women. As no differences in 
circulating gonadotrophins were observed in adult postnatal TP treated animals, this 
would indicate that the increased stromal compartment could be due to epigenetic 
programming of the ovarian endocrinology, as hypothesized by other investigators 
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4.6. Conclusions 
The results from the fetal plus postnatal TP group, in addition to the findings of 
other studies (Hoepfner and Ward 1988),  demonstrate that fetal TP is able to reduce 
the threshold of sensitivity to neonatal testosterone exposure in female animals, 
providing one explanation for the ovarian dysgenesis observed in this treatment 
group. 
 
In the rodent, birth instigates a loss of maternal E2 for the offspring and 
subsequently oocyte apoptosis and nest breakdown occur (Chen, Breen et al. 2009). 
In rats that received fetal TP, oocyte apoptosis and nest breakdown could still occur 
subsequent to caesarean delivery. However animals which received postnatal TP in 
addition to fetal TP would have maintained their oocyte quotient and undergone 
disrupted cyst breakdown, which can account for their dysgenic phenotype. In 
animals receiving postnatal TP alone, TP (either as aromatised E2 or as TP) could 
only affect cyst breakdown resulting in a PCO-like ovarian phenotype. In late 
postnatal TP animals, cyst breakdown would already have initiated yet the level of 
TP exposure at this time point may still have been enough to conserve the proportion 
of primordial follicles. Exposure to TP during the first 25 days of rat life additionally 
led to a significant increase in both immature and adult body weight through an as 
yet unknown mechanism. 
 
 To conclude further, TP administration during the first 15 days of rat life leads to 
a valid PCOS-like phenotype in the female that is overweight, anovulatory, has 
„cystic‟ follicles, and an increased ovarian stromal compartment. Although this 
model does not recapitulate the hormonal abnormalities associated with PCOS. 
Neonatal exposure to TP has potent effects in the adult animal and thus warrants 
further investigation into the windows of exposure necessary to produce a PCOS-like 
phenotype, as well as a more detailed examination of the hormonal and metabolic 
consequences of this treatment. These aspects of the neonatally androgenised rat as a 
model of PCOS are further examined in Chapter 5. 
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Chapter 5. Windows of postnatal testosterone 
exposure which alter the rat HPG axis 
 
5.1. Introduction 
PCOS is significantly associated with obesity in both the clinical setting 
(Sathyapalan and Atkin 2010), as well as in primate (Abbott 2010), sheep 
(Padmanabhan, Veiga-Lopez et al. 2010), and rodent (Manneras, Cajander et al. 
2007) models of this reproductive endocrinopathy. Obesity is an increasing problem 
for Western society, and likely results through a combination of three factors (1) 
more sedentary lifestyles, (2) increases in calorific intake, and (3) a genetic 
background predisposed to energy storage (Patel, Srinivasan et al. 2009). 
Development of glucose intolerance and/or insulin resistance alongside obesity gives 
rise to a metabolic syndrome, which according to the World Health Organisation, 
carries with it an increased risk of CVD, certain cancer development, arthritis, stroke, 
and T2DM, in addition to placing huge logistical and financial strain on medical 
services (W.H.O. 2006). 
 
Women are increasingly likely to develop PCOS as the result of obesity, and 
weight reduction can serve to ameliorate symptoms and restore fertility (Reviewed in 
Norman, Noakes et al. 2004; Pasquali and Gambineri 2004). However, not all obese 
women will develop PCOS and not all PCOS patients gain weight (ESHRE Group 
2006). Although this discrepancy can be explained to some extent by the inherent 
heterogenic nature of PCOS, given that some women diagnosed with PCOS ovulate 
regularly (Chapter 1 Section 11), researchers are still left with the quandary as to 
why weight gain in some women negatively impacts fertility, while others remain 
unaffected. The heterogeneity of PCOS likely results from a combination of genetic 
risk factors, environmental factors and potentially developmental programming by 
nutrition or steroid hormones during fetal and/or infant life (Qi and Cho 2008; Lee 
2009; Patel, Srinivasan et al. 2009). It is therefore reasonable to hypothesize that 
more than one endocrine system may be programmed by aberrant hormonal exposure 
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simultaneously with the reproductive system. This chapter will examine the effects 
of various windows of postnatal (testosterone proprionate) TP exposure upon rat 
ovarian physiology, and in addition investigate further the metabolic aspects which 
are associated with infertility in the rat PCOS model, previously defined in Chapter 
4.  
5.1.1. Programming windows 
Previous investigations in neonatally androgenised rodents have not defined 
whether the reason for PCO-like formation and/or anovulation is due to a defect at 
the ovarian level, pituitary level, hypothalamic level or indeed is a combination of all 
three. However, it is known that a PCO-like ovary will result in the adult rat treated 
with TP between the day of birth (pnd 0) and pnd 5 (Barraclough 1961; Hoepfner 
and Ward 1988). To delineate which period of postnatal life in rats is the most 
sensitive to TP treatment and taking into account the ovulatory phenotype which 
results from TP exposure after pnd 15 (Chapter 4), the first 15 days of postnatal life 
were broken up into treatment windows corresponding to different windows of 
ovarian development. Firstly an early window of exposure, when primordial follicle 
formation completes between pnd one and six, secondly a late window of exposure 
after formation of primary follicles has begun between pnd seven and 15, finally a 
full window of exposure across both these time periods from pnd one to 15 (Kezele 
and Skinner 2003). 
 
Historic studies in rodents examined LH pulsatility in relation to hypothalamic 
GnRH release using bilateral pre-optic area stimulation (Barr and Barraclough 1978). 
The same scientists had documented lordosis behaviour and reported that neonatally 
androgenised female rats were unreceptive to male mating behaviours (Barraclough 
and Gorski 1962). In addition, they identified the hypothalamic POA as an area 
modulated by neonatal TP (Barraclough 1961; Barraclough and Gorski 1961; Gorski 
and Barraclough 1962; Gorski and Barraclough 1962). The investigations described 
in this chapter extend these findings by Barraclough, Gorski and colleagues to 
examine in greater detail the pituitary-ovarian axis of the sterilised female rat as a 
model of PCOS. Although the first five days of postnatal life have already been 
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identified as a key developmental time period in rodent endocrinology (Barraclough 
1961), no studies have examined the effects of various windows of neonatal TP upon 
multiple endocrine organ systems at a molecular level. 
 
 
During the designated early window of rodent postnatal life, it is not just ovarian 
primordial follicles which complete their development. Sexually dimorphic areas of 
the neuroendocrine system are also modulated by the circulating hormonal milieu at 
this time (Morris, Jordan et al. 2004), discussed in Chapter 1, Section 2. Furthermore, 
in rodents a postnatal leptin surge occurs after pnd seven, the role of which remains 
unclear, but this increase in leptin is known to occur independently of body fat mass 
and may well be involved in neuroendocrine development (Ahima, Prabakaran et al. 
1998). The HPAA has also shown sensitivity to neonatal steroid exposure, with one 
laboratory reporting that TP given to female rats at birth leads to hyperplasia and 
increased zona reticularis proliferation in the adult rat adrenal in addition to a lower 
„male-like‟ corticosteroid response to stress (Seale, Wood et al. 2005; Seale, Wood et 
al. 2005; da Silva, Lopes-Costa et al. 2007; da Silva, Lopes-Costa et al. 2009). 
Additionally, programming of liver reductase activity in the rat occurs in response to 
circulating steroid hormones, leading to differential expression of these enzymes 
between the sexes (Gustafsson and Stenberg 1974; Gustafsson and Stenberg 1974). 
In a more recent study, neonatally androgenised female rats developed indicators of 
NAFLD (Demissie, Lazic et al. 2008), a pathology frequently associated with 
prolonged obesity in women with PCOS (Chapter 1, Sections 9 and 11; Fassnacht, 
Schlenz et al. 2003; Setji and Brown 2007). 
 
Rat models of the metabolic syndrome have focussed upon early postnatal life as 
a key period of development, when both pancreatic islets and neurons are undergoing 
the final stages of development (Patel, Srinivasan et al. 2009). Such models range 
from fetal treatments with synthetic corticosteroids to investigate the effects of 
maternal stress (O'Regan, Kenyon et al. 2004; Seckl 2004; Drake, Livingstone et al. 
2005), to high fat/high carbohydrate diets administered to mother and/or pups 
(Srinivasan, Dodds et al. 2008; Srinivasan, Mitrani et al. 2008). Indeed many studies 
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in both rodent and human have shown that abnormal calorific intake during both fetal 
and early postnatal development can lead to the development of metabolic syndrome-
like features in the adult mammal (Patel, Srinivasan et al. 2009).  
 
Chapter 4 illustrated that TP given throughout the first 15 days of rat postnatal 
life produces a PCOS-like phenotype in the adult which is both anovulatory and 
overweight. However, it is unclear at which time during these 15 days TP can affect 
rodent physiology and to what extent TP is able to alter reproductive development. 
Moreover, the metabolic characteristics associated with the weight gain, observed in 
these animals still lack full definition in female animals, as do the precise effects 
upon the pituitary. This chapter will focus upon the effects of different windows of 
TP administration within the first 15 days of postnatal life, from pnd 1, the day after 
birth, to pnd 15. This study will examine not only the pituitary-ovarian axis, but also 
animal growth and fat distribution alongside mesenteric adipose adipokine 
expression, in addition to the programming effect of neonatal TP upon hepatic 
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5.2. Objectives 
 To investigate which windows of TP exposure within the first 15 days of postnatal 
life produce a PCOS-like phenotype in the female rat, by splitting TP exposure into 
three windows: full, from pnd one to 15; early, from pnd one to six; late, from pnd 
one to 15. 
 
 To further explore the effect that these windows of TP exposure have upon 
proportions of activated follicles within the ovaries of adult TP exposed animals and 
compare them to those of control oil treated animals.  
 
 To ascertain the effects of these windows of TP exposure upon the pituitary through 
assessment of both plasma and pituitary gonadotrophin content in addition to mRNA 
expression levels of the three gonadotrophin subunits. 
 
 To elucidate the effects of TP exposure upon endocrine organs such as liver, adrenal 
and fat depot weights. 
 
 To investigate the effect of TP exposure upon the liver by analysing mRNA 
expression levels of proteins involved in insulin/glucose homeostasis and 
glucocorticoid metabolism, and relate these findings to the metabolic status of the 
animals. 
 
 To further investigate the effect of TP exposure upon growth and adipogenesis by 
analysing mRNA expression levels of proteins involved in adipogenesis and lipolysis 
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5.3. Methods 
5.3.1. Treatment windows 
To elucidate which window of postnatal TP treatment would produce a 
PCOS-like phenotype, the first fifteen days of rat postnatal life were divided into 
three main treatment windows. For continuity between studies, the same dose of 
20mg/kg TP was used in this study as was used in the original study described in 
Chapter 4. The first treatment window was for the full fifteen days, with injections 
on days one, four, seven, ten and 13. A litter of control animals were correspondingly 
injected with the same volume of oil at these time points. Secondly an early window 
treatment for the first six days of life exposed animals to TP through injections on 
pnd one and four. Finally, a late window of treatment, for pnd seven to 15, exposed 
animals to TP through injections on pnd seven, ten and 13. These full, early and late 
windows of treatment are schemed in Figure 5.1 and the colours used in this figure 
will correspond to the same treatment groups throughout this chapter. 
 
 
Figure 5.1: Schematic diagram to illustrate the windows of postnatal TP exposure in 
rats: Downward purple arrows indicate the days of TP injection at 20mg/kg postnatal 
life. The downward red and yellow arrows indicate the days of birth and sacrifice 
respectively. Treatment groups are designated control, early, late and full TP treatment 
windows hereafter. 
 
One litter of animals was used for control full and early treatment groups and 
two smaller litters were amalgamated at weaning for the late window treatment 
group. Five dams underwent timed-mating overnight with stud males. After birth 
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(pnd 0) all litters were sacrificed down to an n=8 animals to prevent any differences 
in suckling litter size from masking/causing a metabolic phenotype in the adult 
female animals. At weaning (day 21) any male litter mates were sacrificed and as 
many females as possible kept in each treatment group (Table 5.1). 
 
Table 5.1: The number of animals in each experimental control and TP treatment 
group: These groups correspond to those outlined in Figure 5.1. Birth litter numbers are 
divided by sex, animals were sacrificed to an n=8 in each litter on the day of birth with males 
sacrificed at weaning (pnd21). 
Group name TP exposure 
Number of pups 
at birth 
Group n number 
  
Male Female (With animal designations) 
Control Oil: pnd 1 - 15 8 5 5 (A-E) 
Early pnd 1 – 6 4 6 6 (A-F) 
Full pnd 1 – 15 6 8 8 (A-H) 
Late (litter 1) pnd 7 – 15 8 4 
7 (A-G) 
Late (litter 2) pnd 7 – 15 5 3 
TP=testosterone proprionate; pnd=postnatal day. 
Animals were checked for a vaginal opening and underwent smears to assess 
both ovarian cyclicity and which cycle stage they were at. This allowed sacrifices to 
take place at proestrus when estrogen levels in the female rodent are at their highest 
(Chapter 1, Section 5). After weaning and vaginal opening formation, crude chow 
consumption was assessed in tandem with ovarian cyclicity for two weeks. Litters 
were split up into cages of two or three animals, depending on the group n number. 
Chow was weighed and topped up for each cage every two days and normalised for 
the number of animals in each cage, and the number of days. For example, the chow 
in a cage of three control animals weighed 96g less two days later and so the formula 
(96 X 0.5)/3 gave a result of 16g chow consumption per day for that period.  
 
5.3.2. Necropsy 
In this study additional tissues to those described in Chapter 4 were removed 
and weighed along with the ovary and uterus: Pituitary, liver, adrenal, retroperitoneal 
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adipose, and mesenteric adipose. The hypothalamic area, a portion of sub-cutaneous 
adipose and a portion of skeletal quadricep muscle were also removed but not 
weighed. Before sacrifice, animals underwent 8-13 days of smears to observe 
cyclicity and ensure that cycling animals were sacrificed at proestrus. Animals were 
sacrificed on or just after pnd 80 in week 10 of life, one week earlier than in the 
previous study (Chapter 4). 
 
5.3.3. Immunohistochemistry 
One ovary from each animal of each treatment group was fixed in Bouins and 
paraffin embedded. Standard IHC protocols were adhered to as previously described 
(Chapter 2 Section 4). Ovaries were embedded together to allow sectioning of 




Table 5.2: Ovaries from different treatment groups were embedded together and 
sectioned at the same time. The control ovary was always embedded at the base of the 
block and the others in an upwards clockwise direction to enable easy identification of which 
ovary came from which animal. Letters indicate animal designation (Table 5.2). 
Block designation Position in block (where 1=base of block) 
 
1 2 3 4 5 
090444 Control A Early A Full A Late A Early F 
09-0445 Control B Early B Full B Late B Full F 
09-0446 Control C Early C Full C Late C Late F 
09-0447 Control D Early D Full D Late D Full G & H 
09-0448 Control E Early E Full E Late E Late G 
 
Serial sections were taken from all blocks and every 10
th
 section mounted 
onto a clearly labelled slide for proliferating cell nuclear antigen (PCNA) DAB IHC 
(Chapter 2 Section 4). These sections were stained for PCNA in order to identify 
which follicles were activated. PCNA staining identifies proliferating GCs and so 
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only follicles from the primary to dominant stages of follicle development were 
considered for analysis. A follicle with 80% or more GCs surrounding it expressing 
PCNA was considered a primary; follicles with less than 80% of surrounding GCs 
expressing PCNA were designated transitory or primordial and for the purposes of 
these investigations were not counted (Chapter 2, Section 5). Secondary follicles 
were divided into groups of small (two to four layers of GCs) or large (five or more 
layers of GCs). Small antral follicles were classed as having an antrum which did not 
extend around most of the oocyte, and large antral follicles were classed as having an 
antrum which extended around most of the oocyte with clear cumulus and mural GC 
formation 
 
5.3.4. RIA and ELISA 
  Blood samples taken at the time of sacrifice were processed as described in 
Chapter 2, Section 2. Samples were defrosted and analysed in duplicate for LH, FSH, 
E2 and the ovarian androgens A4 and T. Gonadotrophins were measured by ELISA 
and steroid hormones measured by RIA (Chapter 2, Sections 11 and 12). Pituitaries 
were additionally quartered and homogenised in 500µl PBS to assess pituitary 
gonadotrophin content. This was normalised to pituitary protein content using a 
Bradford assay. 
 
5.3.5. Gene expression analysis 
RNA was extracted from samples of pituitary, liver and mesenteric fat taken 
from each animal. The RNA was measured using a Nanodrop, reverse transcribed 
into cDNA, which as then used to quantify the levels of mRNA present for each gene 
of interest using quantitative PCR (Chapter 2, Sections 7 and 8). The genes analysed, 
along with the PCR chemistry used and the tissues in which they were investigated 
are listed in Tables 5.3 and 4.4. Gene expression was calculated by the ΔΔCT 
method when using SYBER green chemistry (Chapter 2, Section 9). When using 
universal primer-probe library PCR, a standard curve for each gene was included on 
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every plate and for each sample, expression of gene of interest was subtracted from a 
validated control gene for that tissue. 
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Table 5.3: List of genes analysed by quantitative PCR for each tissue with primer 
sequences and locations for Syber Green chemistry. Control genes are in bold. 






β-Actin Fwd+ CCTGTGCTGCTCACCGAGGC 103 122 
161 
 
Rev- TGTGGGTGACCCCGTCTCCG 283 264 
αGSU Fwd+ TTGCTTCTCCAGGGCATATC 274 293 
178 
 
Rev- GCGCTCAGAAGCTACGACTT 471 452 
FSHβ Fwd+ GGACCCAGCTAGACCAAACA 177 196 
152 
 
Rev- TCTTACAGTGCAGTCGGTGC 348 329 
LHβ Fwd+ ACACTGGCTATGTCCCAGG 47 65 
179 
 




β2-microglobuin Fwd+ TCGCTCGGTGACCGTGATCTTT 13 34 
96 
 
Rev- AAGTTGGGCTTCCCATTCTCCGGT 132 109 
Adiponectin Fwd+ ACTGCAACCGAAGGGCCAGG 79 98 
97 
 
Rev- TCTGCCATCACGGCCCGGTA 195 176 
Leptin Fwd+ TCATTCCCGGGCTTCACCCCA 214 234 
182 
 
Rev- TCTGGCTTCTGCAGGCCACG 415 396 
Resistin Fwd+ TGCTGTACCCTGCGGGTTGG 399 418 
119 
 
Rev- TTTCCTGCCCCCTGCGCTCT 537 518 
LPL Fwd+ ACGCCTCCGGCTCAACCCTT 94 113 
145 
 
Rev- TCCGCGGAAGGCGGTCAAAC 258 239 
HSL Fwd+ GTTTCCACCCACGGCGCTCA 3051 3070 
173 
 
Rev- TTCAGTCGCCGCGCGAACAT 3243 3224 
FAS Fwd+ TCCTGGTGTGGTGCCTGCCT 1986 2005 
159 
 
Rev- GCAGCGTGGGGGCAATTCCT 2164 2145 
PPARγ Fwd+ ACCCAGAGCATGGTGCCTTCG 118 138 
77 
 




β-Actin Fwd+ CCTGTGCTGCTCACCGAGGC 103 122 
161 
 
Rev- TGTGGGTGACCCCGTCTCCG 283 264 
PPARα Fwd+ AGCGTGGTGCATTTGGGCGT 183 202 
156 
 
Rev- GCGGGCCACAGAGCACCAAT 358 339 
PEPCK Fwd+ GCACCCCTGCCAGCCAATGT 1363 1382 
171 
 
Rev- ATGCTCTGCAGCAGCGGTGG 1553 1534 
GC receptor Fwd+ TGGCCAAAGGCGATACCAGGC 1780 1800 
127 
 
Rev- TCAGGAGCAAAGCAGAGCAGGT 1928 1907 
5β-reductase Fwd+ CGCCCAGCCCTGGAAAGGAC 332 351 
144 
 
Rev- GCCTCCCACGTGGCACACAG 495 476 
αGSU=common α gonadotrophin subunit; bp=base pairs; FAS=fatty acid synthase; 
FSHβ=follicle stimulating hormone subunit β; GAPDH=glyceraldehydes-3 phosphate 
dehydrogenase; GC=glucocorticoid; HSL=hormone sensitive lipase; LHβ=luteinising 
hormone subunit β; LPL=lipoprotein lipase; PEPCK=Phosphoenolpyruvate carboxykinase; 
PPAR=peroxisome proliferator activator protein; Fwd=forward primer; Rev=reverse primer. 
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Table 5.4: List of genes analysed by quantitative PCR for liver tissue using Roche 
light cycler chemistry. Primers and probes were sourced from Applied Biosystems. 
Gene Target ABI primer/probe code 
Liver 
Cyclophillin A Rn00690933_m1 
PPARγ Rn00440945_m1 
5α-Reductase Rn00567064_m1 
11β-HSD Type 1 Rn01415034_m1 
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5.4. Results 
5.4.1. Effects of postnatal windows of TP exposure upon the rat 
ovary 
Full and early window TP treated animals did not develop vaginal openings, 
but in late window TP treated animals vaginal openings were present four days 
earlier than in the control group. Persistent estrus was observed in late window TP 
animals in contrast to the normal cycling controls. Furthermore, full, early and late 
TP treated animals all developed PCO- like ovaries (Figure 5.2). 
 
Figure 5.2: Ovarian morphologies (i) and estrus cyclicity (ii) shown where possible for 
(A) control (B) early (C) full and (D) late postnatal TP treated animals. Note, early and 
full postnatal testosterone treated animals developed pin hole vaginal openings and could 
not be smeared. Bar=500μm. 
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 With greater n numbers than the previous study (Chapter 4), the changes in 
activated follicle proportions were next investigated. Each ovary was serial sectioned 
and every 10
th
 section underwent DAB staining for PCNA (Figure 5.3). This enabled 




Figure 5.3: PCNA DAB staining in (A) control (B) early (C) full and (D) late postnatal TP 
treated animals: Follicle types are labelled; s2=small secondary; sA=small antral; LA=large 
antral follicle; CL=corpus luteum. Shown at X 4 magnification, bar=200µm. 
 
A follicle exhibiting more than 80% PCNA positive GCs surrounding the 
oocyte was considered a primary; follicles with less than 80% PCNA positive GCs 
were not counted. This follicle population analysis is illustrated in Figure 5.4. 
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Figure 5.4: Follicle population analyses across treatment window groups: (A) Total 
number of activated follicles alongside the percentage proportions of activated (growing non-
primordial) follicles in control (n=5) versus (B) early window (n=7) (C) full window (n=8) and 
(D) late window (n=6) TP treated animals. Values are expressed as the mean ±SEM with (A) 
analysed by student‟s unpaired t-test and (B-D) analysed by two-way ANOVA with 
Bonferroni post-hoc test (* P≤0.05; **P≤0.01). 
 
Animals treated with TP in the early, full and late windows had significantly 
fewer activated follicles when compared to control ovarian follicle counts (P≤0.05 
P≤0.01 and P≤0.05 respectively). In contrast, early window TP treated animals had 
ovaries with a significantly higher proportion of large secondary follicles (P≤0.05) 
and a significantly lower proportion of small antral follicles (P≤0.01) when 
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compared to controls. Similarly ovaries from the late window TP group had a 
significantly lower proportion of small antral follicles (P≤0.05); however none of 
these results were recapitulated in ovaries from full window TP treated animals. 
 
 
Figure 5.5: The effect of various windows of TP treatment upon (A) ovary and (B) 
uterine weight: Shown for control (n=5) versus early (n=6), full (n=8) and late (n=7) window 
TP treatment groups. Values are expressed as the mean ±SEM values and were analysed 
by student‟s unpaired t-test (* P≤0.05; **P≤0.01; *** P≤0.001). 
 
Uterine weights were significantly reduced in early, full and late TP treatment 
groups (P≤0.001, P≤0.01 and P≤0.05 respectively), as were ovarian weights 
(P≤0.001) again due to the absence of CL (Figure 5.5). Subsequent analysis of 
circulating ovarian feedback hormones (Figure 5.6) showed inhibin B feedback to be 
reduced in all TP treated animals (all at least P≤0.01). However, the interpretation of 
E2 levels is slightly more complex, as 2 of 5 control animals exhibited E2 levels 
below those seen at proestrus. Despite smearing the control animals in order to 
sacrifice at proestrus, it is possible they were sacrificed too late to catch the high 
levels of E2 and were instead sacrificed at the beginning of estrus. E2 levels across 
TP treatment window groups were significantly lower than proestrus controls 
(P≤0.01; Figure 5.6). 
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Figure 5.6: The effect of various windows of TP treatment upon ovarian feedback 
hormones: (A) Inhibin B (B) Estradiol (E2) shown for control (n=5) versus early (n=6), full 
(n=8) and late (n=7) window TP treatment groups. Control E2 results are broken down into 
red proestrus (control n=3) and striped estrus (control n=2) respectively. Values are 
expressed as the mean ±SEM values and were analysed by student‟s unpaired t-test against 
control proestrus values only (** P≤0.01; *** P≤0.001). 
 
No differences in circulating ovarian androgens T or A4 were found in either 
the early, full or late TP treatment groups when compared to controls (Figure 5.7). 
 
 
Figure 5.7: The effect of various windows of TP treatment upon (A) testosterone (T) 
and (B) androstenedione (A4): Shown for control (n=5) versus early (n=6), full (n=8) and 
late (n=7) window TP treatment groups. Values are expressed as the mean ±SEM values 
and were analysed by student‟s unpaired t-test. 
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5.4.2. Effects of postnatal windows of TP exposure upon the rat 
pituitary 
To assess whether the reduction in inhibin B/E2 feedback released from the 
ovary affected pituitary gonadotrophin secretion, rat pituitary weight and plasma and 
pituitary gonadotrophin contents were investigated. No differences in pituitary 
weight were observed across treatment groups although a larger range of pituitary 
weights were observed in the early window TP treatment group when compared with 
the other groups (Figure 5.8A). 
 
 
Figure 5.8: Effects of various windows of TP exposure upon the female rat pituitary 
weight and plasma gonadotrophin levels: (A) Pituitary weight (B) Plasma LH (C) Plasma 
FSH levels, for control (n=5) early (n=6), full (n=8) and late (n=7) window TP treatment 
groups. Values are expressed as (A) median range box plot and (B-C) a whisker dot plot and 
were analysed by student‟s unpaired t-test (* P≤0.05; ** P≤0.01; *** P≤0.001). 
 
Plasma gonadotrophin analysis yielded complex results; roughly half of 
animals across TP treatment groups had significantly raised FSH levels when 
compared to controls (P≤0.01) (Figure 5.8B), while others had circulating FSH levels 
comparable to controls. Animals from the early window TP treatment group had 
reduced levels of LH compared to controls (P≤0.001), while of the animals in the full 
window TP treatment group, two had significantly raised LH (P≤0.05) and six had 
reduced LH (P≤0.001). In the late window TP treatment group, five animals showed 
reduced LH (P≤0.001) and three animals had levels of LH comparable to controls. 
The differences in gonadotrophin levels are best shown as a scatter diagram (Figure 
5.8D), where unlike the gonadotrophin levels of TP treated animals, control animals 
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occupy a distinct area of the plot with relatively high LH and low FSH, typical of 
animals at proestrus. 
 
 To assess the effects of postnatal TP upon pituitary gonadotrophin storage, 
homogenised quartered pituitaries underwent gonadotrophin analysis at both the 
protein (Figure 5.9) and mRNA level (Figure 5.10). No significant differences in 
pituitary FSH or LH content were found in the early and full TP treatment groups 
when compared to controls. Animals in the late TP treatment group expressed a 
range of LH protein contents with three animals showing stored LH levels 
significantly higher than those of control animals (P≤0.001). 
 
 
Figure 5.9: Pituitary gonadotrophin protein content across treatment groups: (A) FSH 
(B) LH levels for control (n=5), early (n=6), full (n=8) and late (n=7) window TP treatment 
groups with the late window group broken up into high and low outliers (n numbers in white 
boxes). Values expressed are actual with the mean ±SEM and analysed by student‟s 
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The levels of pituitary mRNA expression for the common αGSU subunit 
were not significantly different between TP treated and control animals (Figure 
5.10), whilst early and full postnatal TP significantly increased FSHβ subunit mRNA 
with no effects upon LHβ subunit mRNA. There was a trend in pituitaries from the 




Figure 5.10: Expression of pituitary gland (A) αGSU (B) LHβ and (C) FSHβ 
gonadotrophin subunits: Shown for control (n=5) versus early (n=6), full (n=8) and late 
(n=7) window TP treatment groups. Values are expressed as the mean ±SEM and analysed 
by student‟s unpaired t-test (* P≤0.05). 
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5.4.3. Effects of postnatal testosterone upon growth and fat 
deposition 
By pnd 33 there was a significant increase in the body weight of animals 
from the early (P≤0.001), full (P≤0.01) and late (P≤0.001) postnatal TP treatment 
groups when compared to control animals (Figure 5.11). These differences in body 
weight remained constant until animals were sacrificed. 
 
 
Figure 5.11: Effects of postnatal testosterone upon pup growth for control versus (A) 
early (n=7), (B) full (n=8) and (C) late (n=6) window TP treated animals, with (D) adult 
weight at pnd 80. Note, each group of animals significantly gains weight after weaning 
around pnd 33 (arrows). Values are expressed as the mean ±SEM, analysed by student‟s 
unpaired t-test (** P≤0.01; *** P≤0.001). 
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At pnd 33 the food consumption of each litter was measured over two-day 
intervals for two weeks. Chow consumption fluctuated in the same way for each 
litter during these weeks of postnatal life and no differences in the daily chow 




Figure 5.12: Effects of postnatal TP on animal chow consumption: (A) Absolute values 
by day analysed by two way ANOVA with Bonferroni post-hoc test (B) Mean daily chow 
consumption ±SEM, analysed by student‟s unpaired t-test. Shown for control oil (n=5) early 
(n=7), full (n=8) and late (n=6) window TP treated animals during early adulthood. Chow was 
weighed every two days for two weeks. Differences in chow weight at each interval were 
divided by the number of animals per cage. 
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 To assess for the effects of postnatal TP upon fat deposition, mesenteric and 
retroperitoneal fat pads were dissected out and weighed at sacrifice. The mesenteric 
and retroperitoneal adipose depots were both significantly heavier in early window 
(P≤0.001), full window (P≤0.01 and P≤0.05 respectively) and late window (P≤0.001) 
TP exposed animals (Figure 5.13, A&C). These differences could not be normalised 
to body weight at the time of sacrifice (Figure 5.13, B&D).  
 
 
Figure 5.13: Fat deposition in adult female rats across treatment window groups: (A) 
Mesenteric fat weight (B) adjusted to body weight and (C) Retroperitoneal fat weight (D) 
adjusted to body weight for control oil (n=5), early (n=7), full (n=8) and late (n=6) window TP 
treated animals. Values are expressed as the mean ±SEM, analysed by student‟s unpaired t-
test (* P≤0.05; ** P≤0.01; *** P≤0.001). 
 
A sample of mesenteric adipose was underwent mRNA expression analysis 
for various adipogenic and lipolytic markers (Figure 5.14 and Figure 5.15 
respectively). Early postnatal TP had no effect upon leptin or adiponectin expression 
and led to a significant decrease (P≤0.05) in resistin expression. Likewise full 
window postnatal TP had no effect upon expression of these three adipokines. Late 
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window TP significantly increased mesenteric adipose leptin expression (P≤0.05) 




Figure 5.14: Expression of mesenteric fat adipokines (A) Leptin, (B) Adiponectin, and 
(C) Resistin: Shown for control oil (n=5), early (n=7), full (n=8) and late (n=6) window TP 
treated animals. Values are expressed as the mean ±SEM, analysed by student‟s unpaired t-
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Examination of genes involved in lipolysis showed late window TP to have 
no effect upon expression of lipoprotein lipase (LPL), hormone sensitive lipase 
(HSL), fatty acid synthase (FAS) or peroxisome proliferator activator protein-γ 
(PPARγ). Conversely early window TP exposure significantly reduced the 
expression of these molecules (P≤0.05), with the exception of LPL, for which only a 
trend reduction was seen. Full window TP led to a significant reduction in mesenteric 
FAS expression (P≤0.001), with only a trend reduction in LPL and PPARγ 
expression. For this treatment group HSL expression was comparable to that of 
control mesenteric adipose. 
 
 
Figure 5.15: Expression of mesenteric fat lipolytic factors (A) LPL, (B) HSL, (C) FAS, 
and (D) PPARγ: Shown for control oil (n=5), early (n=7), full (n=8) and late (n=6) window TP 
treated animals. Values are expressed as the mean ±SEM, analysed by student‟s unpaired t-
test (* P≤0.05; ** P≤0.01). 
 
 
Page | 190  
 
5.4.4. Effects of postnatal testosterone upon other endocrine 
organs 
Only early window postnatal TP significantly increased adrenal weight 
(P≤0.01, Figure 5.16), while early (P≤0.001), full and late (P≤0.01) window TP 
treatment led to significant increases in liver weight which normalised to body 
weight (Figure 5.17). 
 
 
Figure 5.16: The effect of various windows of TP treatment upon adrenal weight: 
Shown for control (n=5) versus early (n=6), full (n=8) and late (n=7) window TP treatment 
groups. Values are expressed as the mean ±SEM values and were analysed by student‟s 




Figure 5.17: The effect of various windows of TP treatment upon liver weight: (A) 
Gross liver weight (B) liver weight normalised to body weight for control (n=5) versus early 
(n=6), full (n=8) and late (n=7) window TP treatment groups. Values are expressed as the 
mean ±SEM values and were analysed by student‟s unpaired t-test (**P≤0.01; ***P≤0.001) 
 
Page | 191  
 
 
 Furthermore, livers from all TP treatment groups appeared fatty upon 
dissection and analysis of gene expression for molecules involved in insulin and 
glucose homeostasis (Figure 5.18), in addition to genes involved in glucocorticoid 
metabolism (Figure 5.19), was subsequently undertaken. Relative expression of liver 
PPARα was significantly increased in early window TP exposed animals (P≤0.05), 
with a non significant trend increase in expression for full window TP exposed 
animals. Liver PPARγ and PEPCK expression were not affected by postnatal TP 
exposure, although there appeared a trend increase in PEPCK expression within 
livers from the late window TP treatment group. 
 
 
Figure 5.18: Expression of liver (A) PPARα (B) PPARγ and (C) PEPCK genes involved 
in insulin/glucose homeostasis: Shown for Control oil (n=5), early (n=7), full (n=8) and late 
(n=6) window TP treated animals. Values are expressed as the mean ±SEM, analysed by 
student‟s unpaired t-test (* P≤0.05). 
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 Liver expression of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), 
5β-reductase and glucocorticoid receptor (GR) was significantly increased (P≤0.05) 
in all groups of TP exposed animals (with the exception of the late window TP group 
for GR expression, which showed only a non significant trend increase compared to 
controls). Expression of 5α-reductase was significantly reduced in the livers of both 
early and full window TP treated animals (P≤0.05), while 5α-reductase expression in 
the livers of late window TP treated animals was comparable to the expression in 
control animal liver. 
 
 
Figure 5.19: Expression of liver (A) 11β-HSD-1, (B) Glucocorticoid Receptor, (C) 5α-
Reductase (Type 1), and (D) 5β-Reductase genes involved in glucocorticoid 
metabolism: Shown for control oil (n=5), early (n=7), full (n=8) and late (n=6) window TP 
treated animals. Values are expressed as the mean ±SEM, analysed by student‟s unpaired t-
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5.5. Discussion 
It is known from these studies and others that exposure to TP during neonatal life 
in the rat leads to an anovulatory ovarian phenotype in the adult animal (Chapter 4). 
With the exception of experiments by Barraclough, Gorski and colleagues, few 
investigations have focused upon which key windows of postnatal life produce 
alterations in the various endocrine axes of the rodent; these studies demonstrated a 
hormone sensitive period of development in the rat occurring between birth and day 
10 of life (Barraclough and Leathem 1954; Barraclough 1955; Barraclough 1961).  
Specific examination of neonatal TP and the programming effects it exerts upon 
the rodent ovary, pituitary, adrenal, liver and adipose tissue has therefore been 
examined in this chapter. 
 
5.5.1. Windows of neonatal TP exposure, the ovary and 
hormones 
All windows of TP treatment in this study produced adult animals which had 
PCO-like ovaries, within which there was a reduction in activated follicle numbers. 
This may be due to the increases in secondary and small antral follicle proportions 
within early and late TP treatment groups; as with more follicles activated, so more 
may undergo atresia, although individual follicle proliferation and atresia were not 
measured in this study. 
 
As yet no other rodent models of PCOS have been examined at the level of 
follicle activation. Studies on ovaries from androgenised non-human primates and 
anovulatory PCOS women show a higher number of preantral and small antral 
follicles in these ovaries when compared to controls (Hughesdon 1982; Vendola, 
Zhou et al. 1998; Webber, Stubbs et al. 2003; Maciel, Baracat et al. 2004). To some 
extent these findings corroborate with the increased preantral and small antral follicle 
proportions described in the current study. However, although these types of follicles 
were more prevalent proportionately, they were fewer in number. Normal levels of 
circulating ovarian androgens T and A4 were also found in the current study, 
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whereas high levels have been found in some PCOS women and androgenised 
primates. An increase in circulating androgens could act to increase follicular 
recruitment, and would therefore account for the increased numbers of transitory and 
small preantral follicles observed in human and adult androgenised primate 
investigations (Vendola, Zhou et al. 1998; Jonard and Dewailly 2004; Maciel, 
Baracat et al. 2004). A primate model of PCOS in which animals received TP in 
utero showed a reduction in activated follicle numbers and an increase follicle 
proportions at the secondary and small antral level (Abbott 2010). The results of the 
activated follicle analysis in the rat could therefore be a direct consequence of 
androgen exposure during ovarian development, rather than a specific feature of 
PCOS itself. These changes in follicle populations could potentially result through 
disrupted germ cell nest breakdown/primary follicle formation by early postnatal TP 
exposure, though whether this is an effect mediated by androgens or estrogens 
through aromatisation remains to be seen (Pepling and Spradling 2001; Chen, 
Jefferson et al. 2007; Chen, Breen et al. 2009). 
 
No differences in circulating ovarian androgen levels (T and A4) were found 
between control and TP treated animals, and other studies contribute conflicting 
evidence regarding the neonatally androgenised rat as a PCOS model; with one study 
reporting a decrease in circulating T levels by pnd 100 after injection with 1mg TP at 
birth (Alexanderson, Eriksson et al. 2007), while another describes an increase in 
circulating T levels at pnd 63 after androgenisation between pnd one and five (vom 
Saal and Bronson 1978; vom Saal and Bronson 1980). Indeed normal circulating 
levels of ovarian androgens, in particular testosterone are found in ovulatory women 
diagnosed with PCOS, but are less frequently documented in anovulatory PCOS 
patients (Abbott, Tarantal et al. 2009; Guastella, Longo et al. 2010). 
 
Reduced E2 and inhibin B production by the ovary was also observed, which 
indicates insufficient hormonal feedback to induce FSH release in preparation for 
ovulation. This data was supported by a reduction in ovarian weights (due to absence 
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of CL) in addition to a reduction in uterine weights (a physiological marker of 
estrogen levels) across treatment groups. 
 
5.5.2. Windows of neonatal TP exposure and the pituitary 
Pituitary weight was comparable to controls across treatment window groups, 
although early TP treatment in contrast to that of full and late window treatment 
resulted in a greater range of pituitary weights. Despite reduced inhibin B and E2 
feedback to the pituitary gland in all TP treated animals, only some animals showed 
the significantly raised levels of FSH expected to result from this reduction in 
negative feedback. Other animals had FSH levels comparable to proestrus control 
animals. The plasma gonadotrophin profiles of each animal from each TP treatment 
group were highly variable in contrast to those of the control group. A high 
variability in gonadotrophin secretion patterns has also been found in women with 
PCOS, with LH pulse frequency increasing across all types of the syndrome, but LH 
pulse amplitude increasing in obese PCOS patients only (Arroyo, Laughlin et al. 
1997). Since neither LH pulse frequency, nor amplitude, was assessed in these 
experiments, the effect of neonatal TP upon LH pulsatility cannot currently be 
determined. 
 
In the late window TP treatment group a trend for higher pituitary FSHβ and 
LHβ expression, when taken together with the raised level of stored pituitary LH 
protein in some animals, indicates that the pituitary glands of the late window TP 
treatment group may have had some physiological response to the reduced 
circulating inhibin B and E2 – by synthesising and storing more FSH. This is further 
supported by the reduction in circulating LH levels and concomitant increase in 
gonadotrophin storage and transcription within the late window TP group. A recent 
pituitary specific insulin receptor knockout mouse model (PitIRKO) has shown that 
feeding a HFD to control animals led to normal serum LH with an increase in αGSU 
and LHβ pituitary expression. Conversely PitIRKO animals on a HFD had low 
serum LH and no transcriptional response to the diet induced obesity (Brothers, Wu 
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et al. 2010). This evidence supports a potential role for insulin in the pathogenesis of 
PCOS-like features in the rodent, especially since animals treated with TP during late 
window postnatal life gained significant weight. 
 
 Animals in early and full window TP treatment groups showed no 
differences in gonadotrophin storage when compared to controls, despite increases in 
FSH secretion and decreases in LH secretion in some animals. This paucity of 
pituitary response to low levels of inhibin B and E2 could indicate that early neonatal 
TP is able to reprogram the hypothalamic-pituitary axis and alter the pituitary 
response to steroid positive and negative feedback. Indeed, in male rats prenatal and 
postnatal androgen surges program the neuroendocrine axis, including the feedback 
loops which regulate gonadotrophin secretion in response to testicular androgens 
(Welsh, MacLeod et al. 2010; Scott, Hutchison et al. 2008). Since androgen levels in 
TP treated animals were comparable to those of control animals, this could explain 
why no apparent response was seen in gonadotrophin transcription, storage or 
secretion from the pituitary. 
 
It is worth noting that not all animals exhibited the patterns described. 
Research in sheep has shown that androgens can disrupt the negative feedback 
sensitivity of the pituitary through alterations in GnRH receptor and gonadotrophin 
subunit expression (Manikkam, Thompson et al. 2008; Veiga-Lopez, Astapova et al. 
2009). Future experiments could therefore assess the hypothalamic-pituitary 
gonadotrophin response to sex steroids T and E2. In addition to examining the 
expression of hypothalamic-pituitary genes involved in the regulation of 
gonadotrophin secretion. An increase in gonadotrophin secretion could be observed 
in response to exogenous T, if indeed the neuroendocrine axis had been 
reprogrammed to a male-like phenotype. 
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5.5.3. Windows of neonatal TP exposure and other endocrine 
organs 
Early neonatal TP has previously been shown to masculinise the HPAA 
(Seale, Wood et al. 2005), which could account for the heavier adrenals documented 
in animals from the early window TP treatment group, a consequence of neonatal TP 
also observed in a separate study (Barraclough 1961). Moreover developmental 
studies in male rats show that both estrogen and androgen action in the neonate are 
required for suitable adrenal function in the adult animal (Seale, Wood et al. 2005). 
Programming of the neonatal adrenal may occur at the level of the zona reticularis of 
the adrenal cortex, although no concurrent investigations into the hypothalamic-
pituitary component of the HPAA or hormonal milieu have been performed. 
Morphometric analyses of adult female rat adrenals show that a thicker, more 
proliferative zona reticularis compartment results from TP exposure shortly after 
birth (da Silva, Lopes-Costa et al. 2007; da Silva, Lopes-Costa et al. 2009). 
 
Certain clinical studies have shown that adrenal steroid production inferred 
by ACTH challenge in women with PCOS is slightly but significantly higher when 
compared to that of control women (Puurunen, Piltonen et al. 2009). Whether this is 
the result of increased adrenal sensitivity, a reduction in feedback sensitivity, or an 
increase in zona reticularis activity, remains to be elucidated, although the non 
human primate model of PCOS has shown some evidence in support of the latter 
(Zhou, Bird et al. 2005). It is worth noting that reduced adrenal activity in rats is 
secondary to a lack of circulating E2 (Seale, Wood et al. 2005), as was also observed 
across treatment window groups in this study, thus the effects of neonatal TP upon 
the rodent HPAA, particularly the rodent stress response, warrant further 
investigation. 
 
 Fatty livers were observed in animals treated with TP and liver weight was 
greater in all treatment window groups, although these values normalised to body 
weight, implying that hepatic mass may have grown larger in response to the 
metabolic requirements of the heavier animals. Characteristics of NAFLD, such as 
the fatty livers observed in this study at the time of sacrifice, can also be caused by a 
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HFD in rodents. These features result through neonatal androgen exposure, but are 
not compounded by the presence of a HFD (Demissie, Lazic et al. 2008). This 
suggests that NAFLD may be a consequence of increased adiposity rather than the 
result of hepatic programming by postnatal steroidal milieu, which potentially 
explains why NAFLD is associated with prolonged obesity in PCOS sufferers 
(Fassnacht, Schlenz et al. 2003; Setji and Brown 2007). 
 
From the patterns in hepatic gene expression observed, it is reasonable to 
deduce that early window TP exposure may act to program an increase in 
glucocorticoid turnover, through the increases in hepatic 11βHSD-1 and 5β-reductase 
expression observed. It should also be noted hepatic expression of these genes is 
heightened in other rodent models of obesity (Drake, Livingstone et al. 2005). 
Investigations into the effects of diet upon enzymes involved in glucocorticoid 
turnover have shown that male rats up-regulate both 11βHSD-1 and 5β-reductase 
expression in response to an acute high fat diet, although this response subsides after 
long term HFD feeding (Morton, Ramage et al. 2004; Drake, Livingstone et al. 
2005).Taken together with the results described in this study, these investigations 
support the hypothesis that increased glucocorticoid turnover (whether epigenetically 
programmed or raised in response to nutrition/diet) could play a role in the 
pathogenesis of female obesity, particularly since the animals described in the 
current study gained weight without consuming greater amounts of food. 
Investigation of steroid urinary metabolites in PCOS women has documented an 
increase in glucocorticoid clearance (Chin, Shackleton et al. 2000). However, a more 
recent study has also shown cortisol production to be elevated in obese women, 
independent of PCOS diagnosis (Roelfsema, Kok et al. 2010). Collectively these 
studies indicate that further investigations into the neonatal programming of obesity 
and glucocorticoid metabolism by androgens should include the measurement of 
corticosteroid hormones and 11βHSD enzyme expression in mesenteric adipose. 
 
The GR is known to undergo epigenetic modification and expression has 
been shown to increase in the presence of higher levels of corticosteroids, as 
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occurred in livers from animals that received late window TP treatment (Lillycrop, 
Slater-Jefferies et al. 2007). However, this was not the case in the early or full 
window TP treatment groups and therefore only neonatal TP administered before pnd 
six might act to reprogram liver GR expression. Furthermore, early window TP led to 
an apparent decrease in hepatic 5α-reductase expression in the adult. This is at odds 
with studies in human females which show 5α-reductase as well as 11β-HSD1 
expression to both be elevated in insulin resistant women (Tomlinson, Finney et al. 
2008). Moreover, neonatal TP has been shown to masculinise hepatic function in 
female rats and reduce 5α-reductase activity in female animals (Pak, Tsim et al. 
1985). In PCOS although 5α-reductase activity within the liver may be reduced, one 
investigation has demonstrated an up-regulation of activity within peripheral tissues 
(Fassnacht, Schlenz et al. 2003). Other studies have shown PCOS to correlate with 
high levels of 5α-reduced metabolites, in addition to up-regulated 5α-reductase 
activity within the PCO itself (Jakimiuk, Weitsman et al. 1999). 
 
At this point it is worth remembering that neonatally androgenised animals in 
this study did not exhibit raised levels of either T or A4, and so full analysis of 
steroid metabolites in the plasma/urine of neonatally androgenised females could in 
future prove useful when assessing rodent models of PCOS, particularly when 
differentiating between ovarian and adrenal hyperandrogenism.  
 
 The expression profile of genes involved in liver catabolism of fatty acids 
under the regulation of nutrition and gluconeogenic hormones showed that early 
window TP exposure led to raised PPARα transcription factor expression in the adult 
liver. Regulation of PPARα and PEPCK genes by gluconeogenic hormones and 
glucocorticoids is well described (Panadero, Herrera et al. 2000; Panadero, Vidal et 
al. 2001). Thus the increase in PPARα expression may be secondary to the increases 
in glucocorticoid turnover observed. A similar trend was shown in PEPCK 
expression but was not significant. As only diminutive differences are apparent in 
catabolic gene expression profiles between postnatal TP exposed rats and their 
control counterparts, further investigation into the nutritional status of the neonatally 
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androgenised rodent is warranted, potentially through glucose tolerance and insulin 
resistance testing. 
 
In human metabolic syndrome and in the Zucker rat model of obesity, a 
reduction in liver 11βHSD-1 expression and a concomitant increase in expression of 
both 5α and 5β reductase occurs (Stimson, Lobley et al. 2010). Such discordances 
may be explained through differences between species and experimental design. 
However, to some extent these findings support the notion that a different obese 
pathophysiology may develop in women with PCOS, as well as in rodent models 
where steroid programming is at work during development. 
 
5.5.4. Windows of neonatal TP exposure, growth and adipose 
tissue 
By 12 days post-weaning, animals from all TP treatment windows were 
significantly heavier than controls, with early TP treatment having the strongest 
impact by pnd 80. These animals became approximately 50% heavier than controls. 
Despite such weight increases, there were no differences in crude chow consumption 
after weaning between animals in the control litter and those of the TP treatment 
groups. The weight gain observed could therefore be due to a combination of several 
factors; a decrease in physical activity and thus calorie expenditure or an increase in 
calorie absorption, either of which may result through programming by neonatal TP 
exposure. Onset of weight gain occurred after weaning in all groups, suggesting that 
either a change in diet at puberty may result in the metabolic changes documented, or 
that activation of the GnRH pulse generator may be involved in the pathogenesis of 
adult onset obesity in neonatal TP treated rats.  
 
Steroid treatments and altered nutrition can lead to HPAA abnormalities in 
conjunction with obesity; fetal administration of corticosteroids or a high fat neonatal 
diet have previously been used to model metabolic syndrome in the rodent 
(Plagemann, Heidrich et al. 1992; Armitage, Taylor et al. 2005; Drake, Livingstone 
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et al. 2005). Only one study has thus far investigated in detail the effects of 
exogenous corticosteroid during the neonatal period upon the ovary, where fetal 
dexamethasone in the five days before birth reduced follicle numbers by pnd five 
(Ristic, Nestorovic et al. 2008). Evaluation of the effects of corticosteroids upon 
female reproductive axis development have yet to be undertaken, although some 
investigations have shown that dexamethasone administered to adult rodents can 
increase the number of eggs ovulated (Tohei, Sakamoto et al. 2000; Rockwell and 
Koos 2009). In current studies postnatal TP led to significant weight gain in line with 
that of rodent models of the metabolic syndrome (Armitage, Taylor et al. 2005). 
 
At sacrifice, all TP window treatment groups showed significantly greater 
mesenteric and retroperitoneal fat masses, which did not normalise to body weights. 
This indicates that the weight gain observed in animals which received TP was due 
to increased adiposity. While several rodent studies into the developmental 
programming of female reproduction by both androgens and estrogens have 
documented weight gain in the adult animals (Barraclough 1961; vom Saal and 
Bronson 1978; Alexanderson, Eriksson et al. 2007), none have related this adult 
obesity to increases in fat deposition at specific sites. However, rat models where a 
PCOS-like phenotype is induced by chronic steroid administration, have 
demonstrated that androgens or estrogens can lead to increased central obesity 
(Beloosesky, Gold et al. 2004; Wang, Sun et al. 2004; Alexanderson, Eriksson et al. 
2007). One study went on to show that high circulating androgens led to an increase 
in adipocyte size and reduction in insulin sensitivity in adult animals receiving long 
term DHT treatment (Manneras, Cajander et al. 2007). 
 
It may well be that the changes adipose distribution documented are an 
adaptive response to neonatal TP and its influence upon the developing metabolic 
axes. It is well documented that animals over-nourished during early postnatal life 
have shown steeper growth trajectories, potentially as an adaptive response to over 
nutrition (Gluckman and Hanson 2004). This predictive adaptive response is 
hypothesised to occur where a mismatch exists between the „expected‟ post-
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developmental nutritional environment and the actual one (Chapter 1, Section 9; 
Gluckman and Hanson 2004; Gluckman, Cutfield et al. 2005; Ikenasio-Thorpe, 
Breier et al. 2007). Further investigation is therefore warranted into the 
spatiotemporal expression and secretion of lipolytic factors and adipokines across 
female rodent development within the various adipose tissue depots. Other endocrine 
influences upon adipokine expression also need to be taken into account, given that a 
change in postnatal environment in rodents has been shown to induce alterations in 
adult metabolism, including both central and peripheral insulin and leptin 
sensitivities (Krechowec, Vickers et al. 2006). 
 
As a known predictor of insulin resistance and metabolic syndrome in 
humans, the mesenteric (central) fat mass was chosen to assess expression of various 
adipokines and lipolytic factors involved in adipogenesis and the pathogenesis of 
obesity (Stevens 1995; Liu, Chan et al. 2006). During the early window of rodent 
postnatal life, organ development is still occurring (Armitage, Taylor et al. 2005). 
Given the differences between treatment groups in the expression of some adipogens 
and adipokines, it is reasonable to speculate that administration of TP prior to the 
postnatal leptin surge (early window) may to some extent program the metabolic 
response to obesity in a different way to TP administered after the postnatal leptin 
surge (late window). 
 
The reduction in expression levels of lipolytic factors (FAS, HSL, LPL, 
PPARγ) and adiponectin in animals receiving TP during the early window may be 
due to a reduction in lipolysis. FAS is known to be involved in the synthesis of fatty 
acids and is transcriptionally regulated by insulin/feeding via a sterol regulatory 
element binding protein (SREBP) pathway (Gosmain, Dif et al. 2005). A reduction in 
FAS expression might therefore indicate the development of insulin resistance. The 
involvement of HSL and LPL in lipolysis indicates that a reduction in HSL and LPL 
expression may lead to increased adipogenesis, triglyceride storage and as a result, 
adiposity. Low HSL expression has also been documented in obese women with 
PCOS which may partly explain the association of PCOS with increased 
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atherosclerotic risk (Seow, Tsai et al. 2009). Furthermore, adiponectin has been 
shown to inversely correlate with insulin resistance in studies of human obesity, 
therefore the lower levels observed here could indicate the development of insulin 
resistance in early window TP treated animals. In addition, low adiponectin levels 
have been documented in NAFLD models (Pagano, Soardo et al. 2005), as well as in 
PCOS patients, independently of their body mass index (Toulis, Goulis et al. 2009). 
Future investigations into the metabolic status of rats receiving neonatal TP could 
therefore examine plasma, liver and adipose triglyceride levels to further evaluate 
changes in adipogenesis and metabolism. 
 
Late window TP exposure led to increased leptin and trend increases in 
resistin and adiponectin levels, as may be expected in animals with increased 
adiposity, shown by other studies aiming to recapitulate features of the metabolic 
syndrome in rodents (Cleasby, Kelly et al. 2003). However, no differences in 
lipolytic factor expression were observed. In other investigations, leptin has been 
shown to reduce adipose FAS and LPL expression (Cleasby, Kelly et al. 2003; 
Gallardo, Bonzon-Kulichenko et al. 2007). Thus it can be deduced that an increase in 
leptin activity could function to restrict lipolysis in already overweight animals. 
Plasma and adipocyte leptin protein levels were not analysed in this study and so 
cannot currently be related to lipolytic factor expression. 
 
Few models of PCOS have performed analysis of genes involved in 
adipogenesis, although one recent study in fetally androgenised sheep has shown that 
the adult animals have reduced hepatic HSL and PPARγ expression, but increased 
adipose PPARγ expression (Padmanabhan, Veiga-Lopez et al. 2010). While these 
findings are distinct to those documented in this study, they provide support to the 
notion that transcriptional function in adipose tissue can be altered in adult animals 
as a result of neonatal steroid exposure. Whether these effects are directly the result 
of epigenetic programming by steroids, or occur indirectly through an alternate 
mechanism remains to be seen. 
 




The investigations described herein show that the first 15 days of postnatal 
life in the rat is a steroid-sensitive period of development, and this finding is 
supported by the prior work of others (Barraclough and Leathem 1954; Barraclough 
1961). Moreover the results of this chapter show that TP exposure between pnd 1 and 
6 is potentially able to reprogram the female neuroendocrine axis so that there is 
reduced negative feedback from the ovary to hypothalamic-pituitary centres. 
 
Taken together, these results allow further evaluation of the neonatally 
androgenised rat PCOS model which although anovulatory and overweight, does not 
exhibit high levels of circulating androgen, nor an increased number of activated 
follicles. Furthermore the results demonstrate that neonatal TP exposure may 
reprogram hepatic glucocorticoid turnover, in addition to adipose lipolysis, 
potentiating an obese phenotype. Whether the changes in gene expression observed 
result through an epigenetic mechanism or via changes in calorie absorption or 
nutrition/diet remains to be seen, although the early window of postnatal 
development (pnd 1-6) before the postnatal leptin surge appears to be the key 
window during which the programming of both the hypothalamic-pituitary 
neuroendocrine and metabolic axes occurs. 
 
Collectively these results indicate that the PCOS-like phenotype which 
develops in the rat as a consequence of neonatal TP exposure may be a useful model 
for non-ovulatory PCOS with normal androgen levels and impaired hypothalamic-
pituitary ovarian feedback mechanisms, in addition to features of the metabolic 
syndrome. Furthermore, examination of the metabolic changes which result from 
early neonatal steroid treatment warrant further investigation. 
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Chapter 6. Dose of postnatal TP required to alter the 
rat hypothalamic-pituitary gonadal axis 
6.1. Introduction 
In early rat postnatal development there exists a time period between pnd one 
(the day after birth) and pnd six, during which the HPG and metabolic axes can be 
developmentally reprogrammed by aromatisable androgens such as TP (Barraclough 
1961; Beloosesky, Gold et al. 2004; Alexanderson, Eriksson et al. 2007). This results 
in anovulatory infertility and a metabolic syndrome-like phenotype in adult animals 
(Chapter 5). In addition to rodents, this key window of reproductive and metabolic 
development also exists at corresponding time periods in sheep (Clarke, Scaramuzzi 
et al. 1976; Wood and Foster 1998; Steckler, Herkimer et al. 2009; Veiga-Lopez, 
Astapova et al. 2009) and non human primate fetal life (Dumesic, Abbott et al. 2007; 
Abbott, Tarantal et al. 2009; Abbott 2010). Studies in rats suggest that a single dose 
above 0.5mg/kg TP is required for effective reprogramming at both the reproductive 
and metabolic levels (Gorski and Barraclough 1963). However, it remains unknown 
whether the dose of TP administered during this key period of development affects 
the resulting severity of reproductive and metabolic disorders in the adult animal. 
 
Investigations into the aetiology of PCOS, the most common cause of infertility 
in women, indicate that PCOS may result from epigenetic programming by abnormal 
steroid exposure during development, in addition to environmental and genetic 
influences (Chapter 1, Section 11; Abbott, Dumesic et al. 2002). Mono-ovulatory 
PCOS animal models use fetal androgen treatment to induce a reproductive and 
metabolic phenotype in the adult. These animals become anovulatory, show 
increased LH pulse amplitude and develop features of the metabolic syndrome which 
include an increased central fat mass that correlates with insulin resistance and 
glucose intolerance (Abbott, Dumesic et al. 1998; Manikkam, Thompson et al. 2008; 
Abbott 2010). Furthermore, granulosa cells (GCs) taken from women with PCOS 
show increased in proliferation rates when in culture (Stubbs, Stark et al. 2007; Das, 
Djahanbakhch et al. 2008). Bidirectional communication operates between the 
oocyte and surrounding GCs throughout follicle development (Eppig 2001; Knight 
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and Glister 2003; Edson, Nagaraja et al. 2009). Disruption of GC proliferation by a 
mitogenic factor, such as androgens, may help explain why follicle development 
appears dysregulated in PCOS; the PCO typically presents on an ultrasound scan 
with an increased number of follicles (12 or more) that are between two and nine mm 
in diameter (Dewailly, Catteau-Jonard et al. 2007; Fulghesu, Angioni et al. 2007). 
Furthermore, culture studies have shown androgens may induce GC atresia in larger 
antral follicles (Hagen, McNatty et al. 1976; Harlow, Hillier et al. 1986; Harlow, 
Shaw et al. 1988; Honnma, Endo et al. 2006). It is therefore reasonable to deduce 
that the high levels of ovarian androgens seen in many women with PCOS may 
impact follicle development through their mitogenic and/or atretic actions upon GCs. 
 
A potential rat model of polycystic ovarian syndrome (PCOS) has previously 
been described (Chapters 4 and 5), in which the neonatally androgenised animal 
developed follicles with larger antra, as well as ovaries with a greater proportion of 
stroma in comparison to control ovaries, like those observed in PCOS (Fulghesu, 
Ciampelli et al. 2001; Fulghesu, Angioni et al. 2007). However, whether these 
abnormalities are due to the effects of neonatal TP upon GC atresia or proliferation 
remain to be seen. Thus in this chapter the functional status of GCs within the 
various ovarian follicle types will be investigated by examining BrdU incorporation 
in GCs and through this the level of GC proliferation. Metabolic abnormalities 
resulting from neonatal TP exposure have also been documented at the transcription 
level (Chapter 5), although glucose intolerance and insulin resistance have yet to be 
demonstrated in this particular PCOS model. 
 
The current study expands previous investigations into the window of neonatal 
TP exposure required to induce a PCOS-like phenotype in the adult animal (Chapter 
5), and aims to assess whether TP dose affects the severity of the reproductive and/or 
metabolic phenotype seen in adult animals. In addition, administration of a single 
dose of TP on pnd one of life will further delineate the window of steroid exposure 
necessary to produce a PCOS-like phenotype in the adult animal. 
 




 To investigate which doses of TP administered during the early window of postnatal 
life produce a PCOS-like phenotype in the female rat; 1, 5 or 20mg/kg. 
 
 To ascertain the effects of these doses of TP exposure upon reprogramming of the 
hypothalamic-pituitary axis through measurement of both plasma and pituitary 
gonadotrophin content in addition to mRNA expression levels of the three 
gonadotrophin subunits. 
 
 To further explore the effect of each TP dose upon GC proliferation in the ovaries of 
the neonatally androgenised rat using IHC for BrdU incorporation. 
 
 To elucidate the effects of different TP doses upon other endocrine organs such as 
liver, adrenal and fat depot weights. 
 
 To further investigate the effect of TP exposure upon the pancreas through glucose 
tolerance testing and subsequent analysis of insulin and glucose plasma levels.  
 
 To investigate whether the effects of a single injection of TP on the day after birth 
produces a PCOS-like phenotype in the female rat, and if this treatment results in any 
significant differences in reproductive or metabolic abnormalities when compared to 
those observed in early window TP exposed animals. 
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6.3. Methods 
6.3.1. Experimental outline 
To elucidate which dose of postnatal TP treatment would produce a PCOS-
like phenotype, two litters of rats per treatment group were given either 1, 5 or 
20mg/kg TP. The same dose of 20mg/kg as well as the same timing of TP exposure 
during the early window of postnatal life (with TP injections on pnd 1 and 4) were 
used in this study in accordance with previous studies (Chapters 4 and 5). In addition 
to investigate the effects of TP dose, one extra litter was used to further delineate the 
window of steroid exposure necessary to produce a reproductive phenotype in the 
adult animal by administering a single dose of 20mg/kg TP on the day after birth 
(pnd 1). Two control litters were correspondingly injected with the same volume of 
oil during the early window time point. The varying doses and windows of treatment 
are schemed in Figure 6.1 and the colours used in this figure will correspond to the 
same treatment groups throughout this chapter. 
 
 
Figure 6.1: Schematic diagram to illustrate the windows of postnatal TP exposure in 
rats: Downward purple arrows indicate the days of TP injection postnatal life. The downward 
red and yellow arrows indicate the days of birth and sacrifice respectively.  
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Two litters of Wistar rats were used for each treatment dose group, except for 
the 20mg/kg single group which used only one litter. Initially, ten dams underwent 
timed-mating overnight with stud males. After birth (pnd 0) one newborn litter was 
killed by the dam (this litter was originally designated to the 20mg/kg single group), 
bringing the total number of litters used in this study down to nine with n numbers 
detailed in Table 6.1. Subsequently all litters were sacrificed down to an n=8 animals 
at pnd 1 to prevent any differences in suckling and litter size from masking/causing a 
metabolic phenotype in the adult female animals (Champagne, Francis et al. 2003; 
Roma, Huntsberry et al. 2007). At weaning (pnd 21) any male litter mates were 
sacrificed and as many females as possible kept in each treatment group. 
 
Table 6.1: The number of animals in each experimental control and TP treatment dose 
group: These groups correspond to those outlined in Figure 6.1. Birth litter numbers are 
divided by sex, animals were sacrificed to an n=8 in each litter on the day of birth with males 
sacrificed at weaning (pnd21);  







Control Oil: pnd 1 - 6 
8 7 06 A – G  
n=15 
6 8 07 A – H  
1mg/kg pnd 1 - 6 
8 7 08 A – G  
n=14 
8 7 10 A – G  
5mg/kg pnd 1 - 6 
10 7 11 A – G  
n=14 
6 7 12 A – G  
20mg/kg pnd 1 - 6 
7 4 09 A – D  
n=10 
10 6 13 A – F  
20mg/kg single pnd 1 - 3 6 7 06 A – G  n=7 
TP=testosterone proprionate; pnd=postnatal day. 
 
Crude chow consumption was assessed in tandem with smears for ovarian 
cyclicity for two weeks after puberty although it should be noted that only control 
litters developed vaginal openings. Litters were split up into cages of two or three 
animals, depending on the group n number. Chow was weighed and topped up for 
each cage every two days and normalised for the number of animals in each cage and 
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the number of days. For example, the chow in a cage of three control animals 
weighed 96g less two days later and so the formula (96 X 0.5)/3 gave a result of 16g 
chow consumption per day for that period. 
 
6.3.2. Insulin resistance and glucose tolerance 
Insulin resistance and glucose tolerance were assessed after chow 
consumption measurements during this study. In week eight of life, animals 
underwent glucose tolerance testing (GTT). Briefly, rats were fasted overnight from 
6pm, tail nick blood samples were taken over three time (t) points (t=0, t=30 and 
t=120 minutes) with the t=0 sample taken before gavage
††
 with a 50% (2g/kg) 
glucose solution. These blood samples were used for both insulin and glucose assays 
(Chapter 2, Sections 12 and 13). 
 
6.3.3. Necropsy 
Animals were injected intra-peritonealy with 100mg/kg of the synthetic 
nucleoside BrdU at 6pm the evening before sacrifice. BrdU is a thymidine analogue 
and incorporates into the DNA of replicating cells during the mitotic S-phase. An 
antibody against the BrdU epitope was therefore used to assess cell proliferation 
using IHC. 
 
The same tissues as in the previous study (Chapter 5) were removed and 
weighed along with the ovary and uterus: Pituitary, liver, adrenal, retroperitoneal 
adipose, and mesenteric adipose tissue. The hypothalamic area, a portion of 
subcutaneous adipose tissue and a portion of skeletal quadricep muscle were also 
removed but not weighed. One ovary and adrenal was frozen and the second was 
fixed in 4% NBF before processing and embedding (Chapters 2, Section 4). Animals 
were sacrificed on or just after pnd 60 in week eight of life. Blood samples taken at 
                                                 
††
 Special thanks to Mr Mark Fisken for performing glucose gavages. 
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sacrifice by cardiac puncture were spun down and plasma stored at -20ºC for future 
investigation of plasma gonadotrophin and hormone levels (Chapters 2, Sections 11 
and 12). 
 
6.3.4. Immunohistochemistry and stereological analysis 
Ovaries from each litter were embedded together and serial sectioned at 5µm 
intervals. H&E staining was performed on some mounted sections to examine 
ovarian morphology. Every 10
th
 section from each treatment group underwent DAB 
staining for BrdU. Briefly, BrdU antibody (Roche) was diluted in NGS at 1:50µl and 
slides incubated overnight at 4ºC in a humidity tray before standard DAB 
visualisation (Chapter 2, Section 4) 
Measuring the proportion of BrdU staining occurring in the GCs of various 
follicles, the number of GCs present within a follicle would in theory relate to follicle 
area. For this reason follicles of different classes in the control group had both area 
and the number of visible GCs measured; a correlation between these two factors 
was performed for follicles both with and without an antrum to ensure the presence 
of a linear relationship (Figure 6.2).  
 
Figure 6.2: The number of granulosa cells (GCs) within a follicle is directly 
proportional to the follicle area. This linear relationship remains even when antrum area is 
excluded from the follicle area measured, analysed by linear regression. 
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BrdU staining in individual follicles from each treatment group was subsequently 
assessed using Image ProPlus 6.2 software connected to a stereological microscope. 
Follicles were tiled individually at X 40 magnification. The basement membrane of 
each follicle assessed was drawn around using Image ProPlus allowing only the GC 
and oocyte (and an antrum if present) to be selected as an area of interest (AOI), 
described in detail in Chapter 2, Section 6. Within the selected AOI, the overall 
brown stained GC area (BrdU positive) or blue stained GC area (BrdU negative) area 
could be selected and taken as a proportion of the AOI. In antral follicles the antrum 
area was additionally measured so that it could be excluded from the AOI. The 
proportion of BrdU incorporation within GCs increased in line with follicle size, 
although no significant differences between the levels of proliferation in follicles of 
various sizes were observed. As the largest range in levels of GC proliferation 
measured by BrdU incorporation were observed in antral follicles, this group of 
follicles was split into small and large antral follicles (Figure 6.3).  
 
 
Figure 6.3: Granulosa cell BrdU proliferation index in different sized follicles from 
ovaries of control animals. A=antral. Values are expressed as the mean ±SEM and were 
analysed by student‟s unpaired t-test. 
 
Small antral follicles were classed as having an antrum which did not extend 
around most of the oocyte, and large antral follicles were classed as having an 
antrum which extended around most of the oocyte with clear cumulus and mural GC 
formation (Figure 6.4). 
 





Figure 6.4: Images typical of (A) small antral follicles and (B) large antral follicles 
stained with BrdU: Small antral follicles were classed as having an antrum which did not 
extend around most of the oocyte, and large antral follicles were classed as having an 
antrum which extended around the oocyte with clear cumulus and mural GC formation. 
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6.4. Results 
6.4.1. Effects of TP dose upon reproductive tract and hormones 
Control animals demonstrated regular estrus cycles, whilst all animals that 
received TP did not develop vaginal openings and thus their estrus cyclicity could 
not be assessed. Ovaries from all animals that received TP were anovulatory and had 
no CL (Figure 6.5). 
 
 
Figure 6.5: H&E stained ovaries and estrus cyclicity documented where possible in 
(Ai) Control (B) 1mg/kg TP (C) 5mg/kg TP (D) 20mg/kg and (E) single dose 20mg/kg TP 
dosage groups. Note the cystic phenotype seen across all TP treatment doses and that no 
animals other than controls (Aii) developed vaginal openings. Images at X 2 magnification. 
 




 section from each ovary underwent DAB staining for BrdU 
incorporation (Figure 6.6) followed by stereological analysis to assess the proportion 
of GCs which incorporated BrdU (stained brown) relative to the proportion of GCs 
which did not (Figure 6.7).  
 
 
Figure 6.6: DAB immunohistochemistry for BrdU in follicles of (Ai) Control (B) 1mg/kg 
TP (C) 5mg/kg TP (D) 20mg/kg and (E) single dose 20mg/kg TP dosage groups: Images 
are shown at X 10 magnification. 
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No difference in the incorporation of BrdU into GCs during proliferation was 




Figure 6.7: Granulosa cell BrdU proliferation index for (A) primary (B) secondary (C) 
small antral and (D) large antral follicles: BrdU staining is taken as a percentage of 
granulosa cell area. Counts were performed in every 10
th
 5µm section for ovaries from 
control (n=15), 1mg/kg TP (n=14), 5mg/kg TP (n=13), 20mg/kg TP (n=10), and single dose 
20mg/kg TP (n=7) treated animals. Values are expressed as the mean ±SEM and were 
analysed by student‟s unpaired t-test.  
 
Uterine and ovarian weights were significantly reduced in animals from all 
TP treated dose groups when compared to controls (P≤0.05 and P≤0.001 
respectively), most likely due to the absence of CL (Figure 6.8).  
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Figure 6.8: Effects of various doses of TP upon (A) uterine and (B) ovarian weight: 
Shown for control (n=15), 1mg/kg TP (n=14), 5mg/kg TP (n=13), 20mg/kg TP (n=10), and 
single dose 20mg/kg TP (n=7) treated animals. Values are expressed as the mean ±SEM 
and were analysed by student‟s unpaired t-test (* P≤0.05; ** P≤0.01 *** P≤0.001). 
 
Subsequent analysis of circulating ovarian feedback hormones (Figure 6.9) 
showed both inhibin B and E2 feedback to be reduced in all TP treated animals 
(P≤0.01 and P≤0.05 respectively) compared to control proestrus levels, except for 
animals from the single 20mg/kg TP dose group, which despite low levels of 
circulating inhibin (P≤0.01), had E2 levels comparable to those of control animals. 
 
 
Figure 6.9: Effects of various doses of TP upon ovarian feedback hormones (A) 
Inhibin B and (B) Estradiol (E2): Shown for control (n=15), 1mg/kg TP (n=14), 5mg/kg TP 
(n=13), 20mg/kg TP (n=10), and single dose 20mg/kg TP (n=7) treated animals. Values are 
expressed as the mean ±SEM and were analysed by student‟s unpaired t-test (* P≤0.05; 
**P≤0.01 *** P≤0.001). 
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No differences in circulating ovarian androgen levels T or A4 were found 
between TP treated animals of any dose group, except for the single injection 
20mg/kg dose group which had significantly greater levels of T (P≤0.01) when 
compared to controls (Figure 6.10). 
 
 
Figure 6.10: Effects of various doses of TP upon plasma (A) testosterone (T) and (B) 
Androstenedione (A4) levels: Shown for control (n=15), 1mg/kg TP (n=14), 5mg/kg TP 
(n=13), 20mg/kg TP (n=10), and single dose 20mg/kg TP (n=7) treated animals. Values are 
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6.4.2. Effects of TP dose upon the pituitary 
Pituitary weights (Figure 6.11) were significantly greater in animals treated 
with single 20mg/kg and 5mg/kg TP doses (P≤0.05), while animals in the 20mg/kg 
TP dose group showed a significant reduction in pituitary weight (P≤0.05). Plasma 
FSH levels were not significantly different between dose groups, and LH levels were 
significantly reduced in the 5mg/kg and 20mg/kg dosage groups (P≤0.001). There 
were no significant differences in pituitary gonadotrophin protein levels between 
treatment groups, although a trend increase in pituitary FSH and LH levels was 
observed in the 5mg/kg TP treatment group (Figure 6.12) 
 
 
Figure 6.11: Effects of various doses of TP exposure upon plasma gonadotrophin 
levels: (A) Pituitary weight (B) Plasma FSH (C) Plasma LH levels, shown for control (n=15), 
1mg/kg TP (n=14), 5mg/kg TP (n=13), 20mg/kg TP (n=10), and single dose 20mg/kg TP 
(n=7) treated animals. Values are expressed as (A) the mean ±SEM and (B-C) dot plot, and 
were analysed by student‟s unpaired t-test (* P≤0.05; *** P≤0.001). 
 
 
Figure 6.12: Pituitary gonadotrophin protein levels across dosage groups (A) FSH 
levels (B) LH levels: Shown for control (n=15), 1mg/kg TP (n=14), 5mg/kg TP (n=13), 
20mg/kg TP (n=10), and single dose 20mg/kg TP (n=7) treated animals. Values are 
expressed as the mean ±SEM and were analysed by student‟s unpaired t-test. 
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Pituitary gland expression of gonadotrophin subunits αGSU, FSHβ and LHβ 
was not significantly different to controls across TP dosage groups (Figure 6.13). 
However, a trend of increased LHβ expression was observed in the 5mg/kg and 
single 20mg/kg dose groups. 
 
 
Figure 6.13: Expression of pituitary (A) αGSU (B) FSHβ and (C) LHβ gonadotrophin 
subunits: Shown for control (n=15), 1mg/kg TP (n=14), 5mg/kg TP (n=13), 20mg/kg TP 
(n=10), and single dose 20mg/kg TP (n=7) treated animals. Values are expressed as the 
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6.4.3. Effects of postnatal TP doses upon other endocrine organs 
No effect of neonatal TP exposure upon adrenal weight was observed across 
TP dose groups (Figure 6.14). 
 
Figure 6.14: Effects of various TP doses upon adrenal weight: (A) Shown for control 
(n=15), 1mg/kg TP (n=14), 5mg/kg TP (n=13), 20mg/kg TP (n=10), and single dose 20mg/kg 
TP (n=7) treated animals. Values are expressed as the mean ±SEM and were analysed by 
student‟s unpaired t-test. 
 
Liver weight at sacrifice was significantly raised in the 5mg/kg TP dose 
group (P≤0.001) when compared to control liver weight, this difference was removed 
when liver weight was divided by body weight (Figure 6.15). 
 
 
Figure 6.15: Effects of various TP doses upon liver weight: (A) Gross liver weights (B) 
liver weights normalised to body weight for control (n=15), 1mg/kg TP (n=14), 5mg/kg TP 
(n=13), 20mg/kg TP (n=10), and single dose 20mg/kg TP (n=7) treated animals. Values are 
expressed as the mean ±SEM and were analysed by student‟s unpaired t-test (* P≤0.05; 
***P≤0.001). 
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6.4.4. Effects of early window TP dose upon fat deposition 
Animals which received different doses of TP during the early window of 
postnatal development became significantly heavier after pnd 47 (P≤0.01). At 
sacrifice (pnd 60) these animals remained significantly heavier in each dose group; 
1mg/kg (P≤0.01), 5mg/kg (P≤0.001) and 20mg/kg (P≤0.05). In contrast, animals 
which received a single dose of 20mg/kg on pnd one of life had significantly gained 
weight shortly after weaning by pnd 26 (P≤0.001). However, from pnd 32 up until 
the point of sacrifice at pnd 60, these animals had body weights comparable to those 



















Page | 223  
 
 
Figure 6.16: Effects of postnatal testosterone doses upon pup growth: Growth curves 
for control (n=15) versus (A) 1mg/kg TP (n=14), (B) 5mg/kg TP (n=13), (C) 20mg/kg TP 
(n=10), and (D) single dose 20mg/kg TP (n=7) treated animals. (E) Adult weight at cull. 
Values are expressed as the mean ±SEM and were analysed using a student‟s unpaired t-
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Gross chow consumption was measured during weeks six and seven of life 
before glucose tolerance tests took place (Chapter 6.3.1). No differences in chow 
consumption between control litters and those from TP treatment groups were 
observed (Figure 6.17).  
 
 
Figure 6.17: (A) Chow was weighed at two day intervals for two weeks with (B) mean 
±SEM chow consumption: Shown for Control (n=15), 1mg/kg TP (n=14), 5mg/kg TP 
(n=13), (D) 20mg/kg TP (n=10), and single dose 20mg/kg TP (n=7) treated animals. Chow 
weight differences between intervals were divided by the number of animals per litter for 
each dosage group. Values in B represent the mean ±SEM, analysed by student‟s unpaired 
t-test. 
 
At sacrifice both the mesenteric and retroperitoneal adipose depot were 
dissected and weighed to assess for differences in fat distribution (Figure 6.18). A 
significantly heavier mesenteric adipose depot was observed in 1mg/kg (P≤0.001), 
5mg/kg (P≤0.001), 20mg/kg (P≤0.01) and single dose 20mg/kg (P≤0.01) TP dose 
groups, and these differences were not normalised by adjusting for body weight. In 
contrast, the retroperitoneal adipose depots across treatment groups were not 
significantly heavier than that those of control animals. 
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Figure 6.18: Fat deposition in adult female rats across dosage groups: (A) Mesenteric 
fat weight (B) adjusted by body weight with (C) Retroperitoneal fat weight (D) adjusted for 
body weight for (A) Control (n=15) (B) 1mg/kg TP (n=14), (C) 5mg/kg TP (n=13), (D) 
20mg/kg TP (n=10), and (E) single dose 20mg/kg TP (n=7) treated animals. Values 
represent the mean ±SEM, analysed by student‟s unpaired t-test (**P≤0.01; *** P≤0.001). 
 
6.4.5. Effects of TP dose upon insulin and glucose metabolism 
Plasma samples taken at t=0, 30 and 120 minutes after glucose gavage were 
used to analyse insulin and glucose levels. The mean insulin response to glucose over 
two hours is shown for each TP treatment group in Figure 6.19. Analysis of plasma 
insulin t=0 was used to determine the fasting insulin levels, whilst area under the 
curve analysis of the insulin response to glucose was undertaken to determine if 
animals were insulin resistant (Figure 6.20). All animals which received TP had 
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Figure 6.19: Rat insulin responses to glucose gavage over time: Measured at t=0, 30 
and 120 minutes with mean ±SEM values shown for control (n=15), 1mg/kg TP (n=14), 
5mg/kg TP (n=13), 20mg/kg TP (n=10), and single dose 20mg/kg TP (n=7) treated animals. 
 
 
Figure 6.20: (A) Fasting insulin levels at t=0 minutes and (B) Area under the curve 
(AUC) analysis of insulin response to glucose gavage after overnight fast: Shown 
across dosage groups for control (n=15), 1mg/kg TP (n=14), 5mg/kg TP (n=13), 20mg/kg TP 
(n=10), and single dose 20mg/kg TP (n=7) treated animals. Values are expressed as the 
mean ±SEM, and were analysed by student‟s unpaired t-test (**P≤0.01; *** P≤0.001). 
 
The mean blood glucose levels after glucose gavage are shown for each 
treatment group in Figure 6.21. Analysis of plasma glucose at t=0 was used to 
determine fasting glucose levels, whilst area under the curve analyses of the blood 
glucose levels after gavage were undertaken to determine if animals were glucose 
tolerant (Figure 6.22). Animals in the 5mg/kg, 20mg/kg and single dose 20mg/kg TP 
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treatment groups all had raised fasting AM glucose levels (P≤0.01). Area under the 
curve analysis of blood glucose levels however showed no glucose intolerance in 
these groups. Fasting glucose levels in the 1mg/kg TP treatment group were 
comparable to those of controls and area under the curve analysis of blood glucose 
levels in this treatment group showed these TP treated animals to have significantly 
better clearance of glucose than control oil treated animals (P≤0.05) 
 
Figure 6.21: Mean blood glucose levels after glucose gavage over time: Measured at 
t=0, 30 and120 minutes with absolute values shown for control (n=15), 1mg/kg TP (n=14), 
5mg/kg TP (n=13), 20mg/kg TP (n=10) and single dose 20mg/kg TP (n=7) treated animals. 
Lines show the mean ±SEM insulin response values for each treatment group. 
 
 
Figure 6.22: (A) Fasting blood glucose levels and (B) area under curve (AUC) analysis 
of glucose tolerance response after overnight fast: Shown across dosage groups at t=0 
minutes. Shown for control (n=15), 1mg/kg TP (n=14), 5mg/kg TP (n=13), 20mg/kg TP 
(n=10), and single dose 20mg/kg TP (n=7). Values are expressed as mean ±SEM, analysed 
by student‟s unpaired t-test (* P≤0.05; ** P≤0.01; *** P≤0.001). 
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6.5. Discussion 
This chapter sought to investigate whether the dose of TP administered during 
early postnatal development in the rat affects the resulting severity of reproductive 
and metabolic dysfunction in the adult animal. To expand previous investigations 
into the neonatally androgenised rat as a model for PCOS, effects of TP dose upon 
ovarian GC proliferation, the HPG axis and insulin resistant aspects of the metabolic 
syndrome were studied. 
 
6.5.1. Effects of TP dose upon HPG axis and infertility 
In line with previous investigations (Chapters 4 and 5), ovaries from all 
animals which received neonatal TP were PCO-like and had reduced ovarian weights 
due to a lack of ovulation and formation of CL. Furthermore, there was no apparent 
effect of TP dose upon the severity of PCO formation. These results are in line with 
previous reports that a TP dose above 0.5mg/kg (10μg of TP on the day of birth) is 
required for anovulation to result in the adult animal (Gorski and Barraclough 1963).  
 
No differences in GC proliferation between controls or TP treated animals 
were documented at any stage of follicular development for any TP dosage group. 
This finding is at odds with those of human studies using cultured GCs which found 
that GCs of preantral follicles from PCOS women had increased levels of 
proliferation. In one study, a concurrent reduction in cleaved caspase-3 mediated 
atresia was also observed (Stubbs, Stark et al. 2007; Das, Djahanbakhch et al. 2008). 
However, it should be noted that there are both experimental (in vivo vs. in vitro) and 
species differences between these investigations. In addition, the GC cultures in the 
described studies were from women with high levels of circulating androgens. This 
may partly explain why increased levels of GC proliferation were observed, as 
androgens have shown mitogenic properties when added to GC cultures (Harlow, 
Shaw et al. 1988; Drummond 2006; Stubbs, Stark et al. 2007; Das, Djahanbakhch et 
al. 2008; Qureshi, Nussey et al. 2008). This could further explain why no effect upon 
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GC proliferation was observed in the current study, since no TP dose treatment group 
had high levels of circulating T or A4. 
 
 However, raised circulating levels of T were found in the single 20mg/kg 
dose group of this study and no differences in GC proliferation were seen through the 
assessment of BrdU incorporation. Although, it may be that these raised levels of T 
were not sufficiently high for an effect upon GC proliferation to be observed. 
 
All animals which received TP neonatally had reduced inhibin B and E2 
feedback levels from the ovary to the hypothalamic-pituitary axis by pnd 60, with the 
exception of animals in the single 20mg/kg dose group, who had E2 levels 
comparable to those of controls. There were no significant changes in pituitary 
gonadotrophin transcription or storage. In animals with reduced ovarian negative 
feedback, increases in gonadotrophin secretion would be expected, since a reduction 
in feedback in the female both directly and indirectly (via the hypothalamus and 
preoptic area) modulates pituitary gland gonadotrophin transcription, storage and 
secretion (McNeilly, Crawford et al. 2003). 
 
Both animals in the 5mg/kg and single 20mg/kg TP dose groups showed a 
significant increase in mean pituitary weight, whilst the 20mg/kg TP dose group 
showed a reduction in pituitary weight. These findings may relate to those of 
gonadotrophin gene expression and protein levels, as trend increases in pituitary 
gonadotrophin proteins and pituitary LH protein were apparent in the 5mg/kg TP 
dose group and single 20mg/kg TP treated groups respectively. Additionally, both 
these TP dosage groups showed trend increases in pituitary LHβ mRNA levels. The 
20mg/kg TP dose group also showed a trend reduction in αGSU and FSHβ 
transcription which could potentially explain the reduced pituitary weight observed 
in this dose group. 
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The apparent lack of pituitary response to reduced E2 and inhibin B feedback 
is in line with earlier findings (Chapter 5) and supports the notion that early neonatal 
TP is able to reprogram the hypothalamic-pituitary axis and alter the pituitary 
response to hormone positive and negative feedback in one of two ways: Either the 
female pituitary is masculinised by TP action during early postnatal life, or the 
pituitary becomes highly sensitive to ovarian feedback hormones, secreting normal 
levels of gonadotrophins in response to low levels of inhibin and E2 released from 
the ovary. 
 
Indeed, in male rats prenatal and postnatal androgen surges program the 
neuroendocrine axis, including the feedback loops which regulate gonadotrophin 
secretion in response to testicular androgens (Scott, Hutchison et al. 2007; Scott, 
Hutchison et al. 2008; Welsh, Saunders et al. 2008; Macleod, Sharpe et al. 2010). 
Since androgen levels in TP treated animals were comparable to those of control 
animals in 1, 5 and 20mg/kg dosage groups, this may explain why no apparent 
response was seen in gonadotrophin transcription, storage or secretion from the 
pituitary. A reduction in plasma LH levels were also observed in the 5mg/kg and 
20mg/kg dose groups could potentially be due to a lack of positive androgen 
feedback, which in the male would induce LH release to facilitate spermatogenesis. 
 
Further investigations into the HPG axis feedback mechanisms operating in 
the neonatally androgenised female rat are therefore warranted, potentially using ex-
vivo pituitary and ovary cultures, or cross transplantation of control ovaries into 
neonatally androgenised animals to observe whether ovarian cyclicity is altered. 
Such studies would help to elucidate whether it is the ovary or hypothalamic-
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6.5.2. Effects of TP dose upon severity of metabolic syndrome 
features 
As in previous studies (Chapter 5), no change in adrenal weight was 
documented in female rats treated with TP. Unlike previous studies however, liver 
weight was greater only in the 5mg/kg treatment group, which is potentially due to 
differences between investigations in the age of sacrifice (pnd 60 as opposed to pnd 
80) and the number of litters used for each treatment group; litter size was controlled 
for in the current study in order to minimise the effects of suckling litter size upon 
the developing metabolism of the pups (Champagne, Francis et al. 2003; Roma, 
Huntsberry et al. 2007). 
 
Significant weight gain was apparent by pnd 60 only in animals which 
received two doses of TP during the early window of postnatal life (pnd 1-6). 
Animals in the single injection 20mg/kg dose group were not significantly heavier 
than controls. These findings support the notion that the window of TP exposure 
required for significant weight gain by pnd 60 extends past pnd three. It may be that 
animals in the single 20mg/kg treatment group were culled too early for an effect 
upon body weight to be observed. However, it is worth noting that differentiation of 
adipocytes from preadipocytes probably occurs in the week after birth in the rodent 
(MacDougald and Lane 1995), thus a single dose of TP on pnd 1 may be insufficient 
to epigenetically reprogram changes in preadipocyte differentiation and thus whole 
body weight in the adult animal. 
 
The increases in body weight resulting from early window TP exposure were 
relatively small, but all TP treatment groups developed a significant increase in 
mesenteric fat, despite no differences in calorie consumption. This increase in central 
adiposity occurred alongside an increase in fasting insulin and insulin resistance in 
all TP treated animals. Although a single dose of TP on pnd 1 of life is insufficient to 
program significant changes in whole body weight in the adult animal, this period of 
steroid exposure still elicits changes in body fat distribution and insulin resistance in 
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the adult animal. Sex differences in body fat distribution and insulin resistance have 
been documented in many species including humans (Priego, Sanchez et al. 2008; 
Ribot, Rodriguez et al. 2008). Prenatal and neonatal androgen surges in males and an 
estrogenic hormonal milieu in females are postulated to be just two reasons for 
differences in adipocyte size and number between sexes across species (Geer and 
Shen 2009).  
 
Increased central obesity results from neonatal steroid exposure in other 
rodent models of PCOS (Beloosesky, Gold et al. 2004; Wang, Sun et al. 2004; 
Alexanderson, Eriksson et al. 2007). In addition, chronic treatment with androgens is 
known to lead to adipocyte hyperplasia in female rats (Manneras, Cajander et al. 
2007), further supporting the role of high circulating androgens in the pathogenesis 
of central obesity in animal models and women with PCOS. The raised T levels 
documented in the single 20mg/kg dose group may therefore be a contributing factor 
in the development of central obesity and insulin resistance in the absence of 
significant weight gain in this treatment group. 
 
The development of insulin resistance in these animals may be the result of 
epigenetic programming of pancreatic islet function. Other rodent, sheep and primate 
studies into the aetiology of PCOS and the metabolic syndrome have documented 
similar metabolic abnormalities resulting from fetal/neonatal androgen treatment 
(Bruns, Baum et al. 2007; Demissie, Lazic et al. 2008; Padmanabhan, Veiga-Lopez 
et al. 2010). These findings may well be consequences of pancreatic islet dysfunction 
and the programming of adipocyte hyperplasia (Roland, Nunemaker et al. 2010). 
Such programmed differences in pancreatic function could also contribute to the 
changes in body weight and fat deposition documented in neonatally androgenised 
female rats. Future studies should therefore target the pancreas, for example using 
histology as well as functional assays of insulin response, in order to further 
understand how neonatal steroids can affect pancreatic islet development. 
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6.6. Conclusions 
To conclude, relatively small doses of TP of 1mg/kg or greater are required to 
induce anovulation in the adult animal; increasing the dose of TP does not appear to 
impact the severity of reproductive dysfunction in the adult female rat at either the 
pituitary or the ovarian level. There also appears to be no effect of neonatal TP upon 
adult GC proliferation in follicles of various sizes and at various stages of follicular 
development. Furthermore a single dose of TP on pnd 1 of life is sufficient to induce 
anovulation in the adult animal. 
 
Historical investigations have shown that 0.5mg/kg TP is sufficient to induce 
anovulatory sterility in around 70% of female animals (Gorski and Barraclough 
1963). Of these sterile animals, around half could be induced into ovulation through 
electrical stimulation of the median eminence, not the POA. Their resultant finding 
was that the degree of neurological remodelling brought about by neonatal TP is 
dose-dependent (Barraclough and Leathem 1954; Gorski and Barraclough 1963).  
 
By contrast the aim of the current study was to determine if the severity of 
infertility or metabolic abnormalities which results from neonatal TP exposure are 
dose dependent. Indeed, a dose of 5mg/kg TP or higher appears required to induce 
glucose intolerance, whilst a smaller dose of 1mg/kg is sufficient to program insulin 
resistance and central obesity in the adult animal, with no apparent increases in 
calorie consumption. Moreover a single dose of 20mg/kg TP on pnd 1 of life is 
sufficient to induce glucose intolerance, IR, and central obesity potentially 
augmented by raised levels of plasma T. However, this single injection of TP appears 
insufficient to induce significant weight gain in the adult animal. These features of 
metabolic syndrome are likely mediated through the epigenetic programming of 
preadipocytes (MacDougald and Lane 1995; Ntambi and Young-Cheul 2000) and 
potentially pancreatic islet function, as has been documented in studies of neonatally 
androgenised mice and fetally androgenised sheep and primates (Bruns, Baum et al. 
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2007; Demissie, Lazic et al. 2008; Padmanabhan, Veiga-Lopez et al. 2010; Roland, 
Nunemaker et al. 2010). 
  
As a PCOS model, the neonatally androgenised rat that receives TP during the 
early window of postnatal life (pnd one to six) gains weight after weaning, is 
anovulatory, centrally obese, insulin resistant and potentially glucose intolerant. This 
further recapitulates the reproductive and metabolic pathophysiological aspects of the 
syndrome. However, only animals which receive TP on the day after birth (pnd one) 
develop high circulating levels of T by pnd 60, and this group of animals do not gain 
weight as they mature. Therefore, potentially two anovulatory models of PCOS have 
been described in this chapter; one recapitulating the metabolic characteristics of the 
syndrome and the other recapitulating the high levels of circulating androgens 
observed in some women with PCOS devoid of the weight gain which occurs after 
puberty in adolescent PCOS patients. 
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Chapter 7. Exposure of the female rat to different 
steroids during early postnatal life 
 
7.1. Introduction 
Previous study has identified that early postnatal life in the rat is a critical period 
of reproductive and endocrine development, during which treatment with 
aromatisable androgen (TP) between pnd 1-6 leads to a PCOS-like phenotype 
(Chapters 4-6). As adults, these animals are anovulatory and have ovarian follicles 
with larger antra. In addition the ovaries from TP treated animals develop a greater 
stromal compartment in comparison to controls, like those observed in PCO studies 
(Fulghesu, Ciampelli et al. 2001; Fulghesu, Angioni et al. 2007). Furthermore these 
animals develop central obesity and gain weight after weaning, with a significant 
proportion of this weight gain attributable to increases in the mesenteric (central) 
adipose tissue depot, as often also occurs women with PCOS at adolescence (Rossi, 
Sukalich et al. 2008). Insulin resistance and glucose intolerance also results from 
neonatal TP exposure with raised levels of both fasting insulin and glucose (Chapter 
6). 
 
These findings are in concordance with other rodent studies into 
neuroendocrine development, in which neonatal steroid treatment in the rat can lead 
to reproductive and metabolic dysfunctions in the adult animal. Such effects on 
reproduction and metabolism have been reported after administration of TP 
(McDonald and Doughty 1972; Sheridan, Zarrow et al. 1973; Alexanderson, 
Eriksson et al. 2007), free T (Alklint and Norgren 1971), estradiol valerate (Brawer, 
Naftolin et al. 1978; Brawer, Munoz et al. 1986; Rosa, Guimaraes et al. 2003), and in 
some studies high doses of DHT (Iguchi and Takasugi 1981; Mizukami, 
Yamanouchi et al. 1982). Additionally, rodent investigations into metabolic 
syndrome development have used synthetic glucocorticoids like DEX, administered 
during the end of fetal life to program glucose intolerance, insulin resistance and 
increased adiposity in both male and female adult animals (O'Regan, Kenyon et al. 
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2004; Seckl 2004; Drake, Livingstone et al. 2005). In the male neonatal rat 
aromatase expressed in the brain converts testosterone into estrogen, which 
masculinises the HPG and neuroendocrine axes. Thus, the effects of TP which we 
see in studies that investigate developmental programming of the mammalian 
endocrinology may be due to either the actions of androgens, estrogens, or indeed a 
combination of both.  
 
Early investigations into the developmental origin of sexual behaviour and 
preference in monkeys used in utero testosterone treatment and noted that 
androgenised primate females did not exhibit regular menstrual cycles (Goy and 
Phoenix 1972; Pomerantz, Goy et al. 1986; Goy, Bercovitch et al. 1988; Pomerantz, 
Roy et al. 1988). Researchers then postulated that abnormal androgen exposure 
during a key window of development could potentially explain the origin of PCOS. 
However, androgens may also be converted to estrogens by placental aromatase 
during mammalian fetal development (Means, Mahendroo et al. 1989; Corbin, Khalil 
et al. 1995). Recent studies in sheep and non-human primates have attempted to 
address this by comparing the effects of TP to those of a non-aromatisable androgen, 
DHT (Goy, Bercovitch et al. 1988; Masek, Wood et al. 1999; Steckler, Manikkam et 
al. 2007; Ortega, Salvetti et al. 2009; Smith, Steckler et al. 2009; Ortega, Rey et al. 
2010). However, such research is highly costly and time consuming to perform due 
to the long gestational length of the animals. Another major caveat of using in utero 
steroid administration to induce a PCOS-like phenotype in an adult mammal is that 
high doses of steroid must be used in order for the drug to cross the placental barrier.  
 
Given that rodent neuroendocrine development mostly occurs after birth, the 
rat therefore provides an ideal model to elucidate which aspects of endocrine 
dysfunction result from developmentally timed exposure to aromatisable androgens. 
Whether these characteristics are a consequence of androgenic, estrogenic or stress 
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7.2. Objectives 
 To investigate which steroids administered during the early window of postnatal life 
produce a PCOS-like phenotype in the female rat; EV, TP, DHT, DHEA and DEX. 
 
 To ascertain the effects of these steroids upon reprogramming of the hypothalamic-
pituitary axis through measurement of both plasma and pituitary gonadotrophin 
content in addition to mRNA expression levels of the three gonadotrophin subunits.  
 
 To ascertain the effects of these steroids upon reprogramming of the pituitary 
feedback through measurement of pituitary ER and GR expression.  
 
 To further explore the effect that each steroid treatment has upon the numbers and 
proportions of ovarian follicles in the adult ovary at pnd 60 in line with previous 
investigations (Chapter 4). 
 
 To elucidate the effects of different neonatal steroid treatments upon other endocrine 
organs such as liver, adrenal and fat depot weights. 
 
 To further investigate the effect of neonatal steroid treatments upon the pancreas 
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7.3. Methods 
Two litters of Wistar rats were used for each treatment group and 12 dams 
underwent timed-mating overnight with stud males. After birth all litters were 
sacrificed down to an n=8 animals at pnd 1 to prevent any differences in suckling and 
litter size from masking/causing a metabolic phenotype in the adult female animals 
(Champagne, Francis et al. 2003; Roma, Huntsberry et al. 2007). At weaning (pnd 
21) any male litter mates were sacrificed and six females kept in each treatment 
group. Table 7.1 shows the n numbers and designations of each steroid treatment 
group. 
 
Table 7.1 The number of animals in each experimental control and steroid treatment 
group: These groups correspond to those outlined in Figure 7.1. Birth litter numbers are 
divided by sex, animals were sacrificed to an n=8 in each litter on the day of birth and then 
sacrificed to an n=6 at weaning on pnd 21, except for C24 and DHEA22 which had an n=5. 
Steroid given Number of pups Final group n number 
Pnd 1 – 6 Male Female 
Animal / litter 
designations 
Group n 
Control 5 9 C20 A – F 
n=11 
Control 3 5 C24 A – E 
Estradiol Valerate 7 11 EV 15 A – F 
n=12 
Estradiol Valerate 4 6 EV 26 A – F 
Testosterone Proprionate 5 8 TP 19 A – F 
n=12 
Testosterone Proprionate 4 6 TP 25 A – F 
Dihydrotestosterone 4 6 DHT 16 A – F 
n=12 
Dihydrotestosterone 0 8 DHT23 A – F 
Dehydroepiandrosterone 7 7 DHEA 18 A – F 
n=11 
Dehydroepiandrosterone 8 6 DHEA 22 A – E 
Dexamethasone 5 7 DEX 17 A – F 
n=12 
Dexamethasone 8 8 DEX 21 A – F 
 
7.3.1. Experimental outline 
To elucidate which steroid treatment would produce a PCOS-like phenotype 
female rats were given a dose of each steroid or control oil during the early window 
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of postnatal life (with injections on pnd 1 and 4), in accordance with previous studies 
(Chapters 5 and 6). The steroid treatments are detailed in Table 7.2.  
 
Table 7.2: Summary of steroid hormone injection protocols and doses administered: 









Testosterone proprionate (TP) 1mg/kg 100 0.5 9.5 
Estradiol Valerate (EV) 1mg/kg 5 0.5 9.5 
Dihydrotestosterone (DHT) 1mg/kg 5 0.5 9.5 
Dehydroepiandrosterone (DHEA) 1mg/kg 5 0.5 9.5 
Dexamethasone (DEX) 0.8mg/kg 4 0.5 9.5 (saline) 
 
The treatment window and experimental outline are depicted in Figure 7.1 
and the colours used in this figure will correspond to the same steroid treatment 
groups throughout this chapter. 
 
 
Figure 7.1 Schematic diagram to illustrate the windows of postnatal TP exposure in 
rats: Downward purple arrows indicate the days of steroid injection during postnatal life. The 
downward red and yellow arrows indicate the days of birth and sacrifice respectively. 
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7.3.2. Assessing insulin resistance and glucose tolerance 
Insulin resistance and glucose tolerance were assessed after chow 
consumption measurements during this study. In week eight of life, animals 
underwent glucose tolerance testing (GTT). Briefly, rats were fasted overnight from 
6pm, tail nick blood samples were taken over three time (t) points (t=0, t=30 and 
t=120 minutes) with the t=0 sample taken before gavage
‡‡
 with a 50% (2g/kg) 
glucose solution. These blood samples were used for both insulin and glucose assays 
(Chapter 2, Sections 12 and 13). 
 
7.3.3. Necropsy 
The same tissues as in the previous studies (Chapters 5 and 6) were removed 
and weighed along with the ovary and uterus: Pituitary, liver, adrenal, retroperitoneal 
adipose, and mesenteric adipose. The hypothalamic area, a portion of subcutaneous 
adipose and a portion of skeletal quadriceps muscle were also removed but not 
weighed. One ovary and adrenal was frozen and the second was fixed in Bouins‟ 
solution before processing and embedding (Chapter 2, Section 4). Animals were 
sacrificed on or just after pnd 60 in week eight of life. Blood samples taken at 
sacrifice by cardiac puncture were spun down and plasma stored at -20ºC for future 
investigation of plasma gonadotrophin and hormone levels (Chapter 2, Sections 11 
and 12). 
 
7.3.4. Ovarian follicle counts 
Ovaries from each litter were embedded together and serial sectioned at 5µm 
intervals. H&E staining was performed on every 10
th
 section for follicle population 
analysis. Follicle counts were performed as before, with only follicles containing an 
oocyte nucleus counted and follicles classed based on their GC layering (Chapter 2, 
Section 6). 
  
                                                 
‡‡
 Special thanks to Mr Mark Fisken for performing glucose gavages. 
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7.4. Results 
7.4.1. Effects of exposure to various steroids on vaginal opening, 
oestrus cyclicity and ovarian morphology in the female rat 
Smears were used to assess ovarian cyclicity in animals which developed a 
vaginal opening. Animals were subsequently grouped into ovulatory and non-
ovulatory treatment groups based on assessments of smear cyclicity (Figure 7.2) and 
ovarian histology (Figure 7.3) after sacrifice.  
 
Figure 7.2: Typical estrus cyclicity of animals treated with (A) Control oil (B) EV (C) 
DHT (D) DHEA and (E) DEX treated animals. Estrus cycles monitored through 
Proestrus(P), Estrus(E), Metestrus(M) and Diestrus(D). TP treated animals and 5 of 12 DHT 
treated animals did not develop a vaginal opening. 
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Vaginal opening was again sensitive to androgen treatment, with all animals 
in TP treatment group and five of 12 animals in the DHT treatment group failing to 
develop vaginal openings also. Interestingly, although a vaginal opening did develop 
in all EV treated animals, in eight animals the opening was small and „pin-hole‟ like. 
Animals treated with EV or TP were anovulatory as evidenced by a lack of CL upon 
histological examination, unlike ovaries from control, DHT, DHEA and DEX treated 
animals (Figure 7.3). 
 
Figure 7.3: Ovarian morphology exemplary of animals treated with neonatal steroids 
compared to controls, shown for (A) control (B) EV and (C) DHT (D) TP (E) DHEA and 
(F) DEX treated animals. Images are of H&E stained sections shown at X 2 magnification. 
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Six ovaries from the control, TP, EV and DHT treatment groups were 
randomly selected for follicle analysis. Total follicle counts (Figure 7.4) showed that 
ovaries from animals treated with EV and TP had significantly fewer ovarian 
follicles (P≤0.001 and P≤0.01 respectively). 
 
 
Figure 7.4: Total follicle count of ovaries from animals treated with EV, TP and DHT 
compared to controls. Values are shown for n=6 animals per treatment group and are 
expressed as the mean ±SEM. Results were analysed by student‟s unpaired t-test (**P≤0.01 
*** P≤0.001). 
 
To delineate which types of follicles were reduced in ovaries from animals at 
pnd 60 that received neonatal EV and TP, follicle populations were first assessed 
based on non growing follicle numbers and proportions i.e. primordial follicles 
(Figure 7.5). Ovaries from animals in the EV treatment group showed a significant 
reduction in primordial follicle numbers (P≤0.05). However, proportional analysis of 
primordial follicles showed that the EV and TP treatment groups had significantly 
greater proportions of primordial follicles (P≤0.05 and P≤0.001 respectively). 
Ovaries from animals in the DHT treated group showed no differences in primordial 
follicle numbers or proportions. 
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Figure 7.5: Primordial follicle (A) numbers and (B) proportions in ovaries from animals 
treated with EV, TP and DHT compared to controls. Values are shown for n=6 animals 
per treatment group and are expressed as the mean ±SEM. Results were analysed by 
student‟s unpaired t-test (* P≤0.05; *** P≤0.001). 
 
 Next, growing follicle numbers i.e. those between the primary and antral 
stages of follicular development were also assessed (Figure 7.6). Ovaries from 
animals in the EV and TP treatment groups both showed a significant reduction in 
growing follicle numbers (P≤0.001 and P≤0.01 respectively), whereas ovaries from 
animals in the DHT treated group showed no changes. Proportional analysis of 
growing follicles in the EV and TP treatment groups also showed them to be 
significantly reduced (P≤0.05 and P≤0.01 respectively), again with no differences in 
follicle proportions in ovaries from DHT treated animals. 
 
 
Figure 7.6: Developing follicle (A) numbers and (B) proportions in ovaries from 
animals treated with EV, TP and DHT compared to controls. Values are shown for n=6 
animals per treatment group and are expressed as the mean ±SEM. Results were analysed 
by two-way ANOVA with Bonferroni post-hoc test (* P≤0.05; ** P≤0.01; *** P≤0.001). 
 
Page | 245  
 
 
 To ascertain which types of growing follicles in ovaries from the EV and TP 
treatment groups were reduced, further follicle population classifications and 
proportional analysis was performed (Figure 7.7). Ovaries from animals which 
received neonatal EV and TP had significantly greater primordial follicle numbers 
and proportions (P≤0.001), with a significantly lower proportion of growing antral 
(P≤0.001) follicles. Additionally, ovaries in the EV treated group also had a reduced 
proportion of growing secondary (P≤0.05) follicles. Ovaries from animals in the 
DHT treated group once again had no differences in follicle numbers or proportions. 
 
 
Figure 7.7: Follicle proportion analysis in ovaries from animals treated with EV, TP 
and DHT compared to controls. Values are shown for n=6 animals per treatment group 
and are expressed as the mean ±SEM. Results were analysed by two-way ANOVA with 
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7.4.2. Effects of exposure to various steroids upon the HPG axis 
Results presented in this chapter were also analysed in relation to estrus cycle 
stages between control and ovulatory animals. Such analyses are presented based on 
estrus cycle stage when significant differences between proestrus and met/diestrus 
animals occurred. 
 
Uterine and ovarian weights were significantly reduced in animals treated 
with EV (P≤0.001) and TP (P≤0.05 and P≤0.001 respectively). In addition, the 
uterine weights of animals treated with DHEA were significantly lighter than those 
of control animals (P≤0.01), even when accounting for the different estrus cycle 
stages between treatment groups (data not shown). 
 
 
Figure 7.8: (A) Uterine weights and (B) Ovarian weights across treatment groups: 
Shown for control (n=11), EV (n=12), TP (n=12), DHT (n=12), DHEA (n=11) and DEX (n=12) 
treated animals. Values are expressed as the mean ±SEM and were analysed by student‟s 
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Animals in the EV, TP and DEX treatment groups did not exhibit significant 
changes in plasma ovarian androgen levels (Figure 7.9). However animals treated 
with DHEA showed reduced levels of plasma T (P≤0.05), and animals treated with 




Figure 7.9: (A) Testosterone-T and (B) Androstenedione-A4 steroid hormone levels 
across treatment groups: Shown for control (n=11), EV (n=12), TP (n=12), DHT (n=12), 
DHEA (n=11) and DEX (n=12) treated animals. Values are expressed as the mean ±SEM 
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Analysis of circulating ovarian feedback hormone levels (E2 and inhibin B) 
showed no significant differences between ovulatory treatment groups when 
analysed by estrus cycle stage (Figure 7.10). However, in non-ovulatory EV and TP 
treatment groups, E2 and inhibin B levels were significantly lower when compared to 
both control proestrus and di/metestrus levels (P≤0.001). 
 
 
Figure 7.10: (i) Estradiol-E2 and (ii) Inhibin B hormone levels for (A) ovulatory 
treatment groups and (B) non ovulatory treatment groups: Shown for control (n=11), 
DHT (n=12), DHEA (n=11), DEX (n=12), EV (n=12) and TP (n=12) treated animals. Values 
are split based on the time of estrus cycle sacrifice for control and ovulatory treatment 
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To investigate whether neonatal androgen or EV treatment affected pituitary 
gonadotrophin secretion, circulating gonadotrophin levels were measured (Figure 
7.11). No differences in FSH levels were observed across treatment groups although 
LH levels were significantly raised in animals from the DHEA treatment group 
(P≤0.05). No further differences were observed when gonadotrophin levels were 
analysed by estrus cycle stage in any treatment group (data not shown). 
 
 
Figure 7.11: (A) Plasma FSH and (B) plasma LH levels across treatment groups: 
Shown for control (n=11), DHT (n=12), DHEA (n=11), DEX (n=12), EV (n=12) and TP 
(n=12). Values expressed are actual with the mean ±SEM shown in black. Results were 
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To assess the effects of postnatal steroids upon pituitary gonadotrophin storage, 
homogenised quartered pituitaries underwent gonadotrophin analysis at both the protein 
(Figure 7.12) and mRNA level (Figure 7.13). No significant differences in pituitary 




Figure 7.12: (A) Pituitary FSH (B) pituitary LH protein levels across steroid treatment 
groups: Shown for control (n=11), EV (n=12), TP (n=12), DHT (n=12), DHEA (n=11) and 
DEX (n=12) treated animals. Values expressed are actual with the mean ±SEM shown in 
black, and were analysed by student‟s unpaired t-test. 
 
Pituitary weight was significantly lower in EV treated animals (P≤0.001) and 
significantly heavier (P≤0.01) in TP treated animals (Figure 7.13). No changes in 
αGSU, LHβ or FSHβ subunit gene expression were observed across steroid treatment 
groups, except for in EV treated animals, which had significantly raised levels of 
αGSU and FSHβ expression (P≤0.05). Pituitary AR and GR expression was also 
analysed by PCR (Figure 7.14). No changes in AR expression were observed across 
steroid treatment groups, but pituitary GR expression was greater in animals from the 
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Figure 7.13: (A) Pituitary weight and expression of (B) αGSU (C) FSHβ subunit and (D) 
LHβ subunit across steroid treatment groups: Shown for control (n=11), EV (n=12), TP 
(n=12), DHT (n=12), DHEA (n=11) and DEX (n=12) treated animals. Values are expressed 
as (A) the median and data spread using a box plot and (B-D) the mean ±SEM. Results were 
analysed by student‟s unpaired t-test (* P≤0.05; ** P≤0.01; ***P≤0.001). 
 
 
Figure 7.14: Expression of pituitary (A) Androgen receptor-AR and (B) Glucocorticoid 
receptor-GR, across steroid treatment groups: Shown for control (n=11), EV (n=12), TP 
(n=12), DHT (n=12), DHEA (n=11) and DEX (n=12) treated animals. Values are expressed 
as the mean ±SEM and were analysed by student‟s unpaired t-test (* P≤0.05; ** P≤0.01; *** 
P≤0.001). 
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7.4.3. Effects of exposure to various steroids growth, fat and the 
liver 
Animals from the EV, TP and DHT steroid treatment groups were 
significantly heavier by pnd 65 when compared to control animals (P≤0.001, P≤0.05 
and P≤0.01 respectively). These differences in body weight did not occur at weaning 
(Figure 7.15), as was the case in previous studies (Chapters 5 and 6). 
 
Figure 7.15: Effects of steroid hormones upon pup growth: Control versus (A) TP (B) EV 
(C) DHT (D) DHEA and (E) DEX treated animals with (F) adult body weight at day 65 with n 
numbers as shown. Values are expressed as the mean ±SEM and were analysed by 
student‟s unpaired t-test (* P≤0.05; ** P≤0.01; *** P≤0.001).  
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 To assess for any changes in anabolism, in addition to measuring body weight 
at the time of sacrifice, animal length was also measured from snout to anus and to 
tail tip (Figure 7.16). Animals from the EV and DHT steroid treated groups were 
significantly longer than control animals (P≤0.01), while animals treated with DHEA 
were significantly shorter when compared to controls (P≤0.05).  
 
 
Figure 7.16: Anabolic measurements of body length from (A) snout to anus and (B) 
snout to tail tip across steroid treatment groups: Shown for control (n=11), EV (n=12), 
TP (n=12), DHT (n=12), DHEA (n=11) and DEX (n=12) treated animals. Values are 
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At sacrifice, mesenteric and retroperitoneal fat pads were dissected out and 
weighed to assess for any differences in fat deposition between steroid treated groups 
(Figure 7.17). Mesenteric fat weight was significantly greater in animals from the EV 
and TP treatment groups (P≤0.05 and P≤0.01 respectively) and significantly lighter 
in animals from the DEX treatment group (P≤0.05). However, although this 
difference was removed by dividing the fat depot weight by body weight in the EV 
and DEX treated animals, this was not the case in animals from the TP treated group 
(P≤0.01). DEX treated animals also had a reduced retroperitoneal fat depot weight in 
comparison to control animals, and this difference was not removed by adjusting for 




Figure 7.17: (A) Gross weight of (i) mesenteric and (ii) retroperitoneal fat depots (B) 
shown per g body weight across steroid treatment groups: Shown for control (n=11), EV 
(n=12), TP (n=12), DHT (n=12), DHEA (n=11) and DEX (n=12) treated animals. Values are 
expressed as the mean ±SEM and were analysed by student‟s unpaired t-test (* P≤0.05; 
**P≤0.01). 
 
Page | 255  
 
Liver weight (Figure 7.18) at sacrifice was significantly greater in EV, TP 
and DHT treated animals when compared to controls (P≤0.001, P≤0.05 and P≤0.05 
respectively). These differences remained when liver weight was divided by animal 
body weight (P≤0.01, P≤0.001 and P≤0.01 respectively). Neonatal EV and DHT 
treatment significantly increased animal adrenal weight in these treatment groups 
(P≤0.001), whilst TP treatment significantly reduced it (P≤0.01), when compared to 
that of control animals (Figure 7.19). 
 
 
Figure 7.18: (A) Liver weights (B) expressed per g body weight across steroid 
treatment groups: Shown for control (n=11), EV (n=12), TP (n=12), DHT (n=12), DHEA 
(n=11) and DEX (n=12) treated animals. Values are expressed as the mean ±SEM and were 
analysed by student‟s unpaired t-test (* P≤0.05; ** P≤0.01; *** P≤0.001). 
 
 
Figure 7.19: Adrenal weight across steroid treatment groups: Shown for control (n=11), 
EV (n=12), TP (n=12), DHT (n=12), DHEA (n=11) and DEX (n=12) treated animals. Values 
are expressed as the median and data spread using a box plot and were analysed by 
student‟s unpaired t-test (**P≤0.01; *** P≤0.001). 
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7.4.4. Effects of exposure to various steroids upon insulin and 
glucose metabolism 
Plasma samples taken at t=0, 30 and 120 minutes after glucose gavage were 
used to analyse insulin and glucose levels. The mean insulin response to glucose over 
two hours is shown for each TP treatment group in Figure 7.20. Analysis of plasma 
insulin t=0 was used to determine the fasting insulin levels, whilst area under the 
curve analysis of the insulin response to glucose was undertaken to determine if 
animals were insulin resistant (Figure 7.21).  
 
Figure 7.20: Insulin response to glucose gavage: Shown for control (n=11), EV (n=12), 
TP (n=12), DHT (n=12), DHEA (n=11) and DEX (n=12) treated animals. Values are 
expressed as the mean ±SEM and were analysed for the area under the curve. 
 
Animals in the EV, DHT and DHEA treatment groups had significantly 
higher fasting insulin levels than controls (P≤0.001, P≤0.01 and P≤0.05 respectively) 
and TP treated animals showed a trend for high fasting insulin levels (P≤0.057). 
These four treatment groups also showed significantly greater insulin response to 
glucose than control animals (P≤0.001). Animals treated with DEX showed fasting 
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Figure 7.21: (A) Fasting insulin levels and (B) area under the curve analysis of insulin 
response to glucose: Shown for control (n=11), EV (n=12), TP (n=12), DHT (n=12), DHEA 
(n=11) and DEX (n=12) treated animals. Values are expressed as the mean ±SEM and were 
analysed by student‟s unpaired t-test (* P≤0.05; ** P≤0.01; *** P≤0.001). 
 
The mean blood glucose levels after glucose gavage are shown for each 
treatment group in Figure 7.22.  
 
Figure 7.22: Blood glucose levels after to glucose gavage: Shown for control (n=11), EV 
(n=12), TP (n=12), DHT (n=12), DHEA (n=11) and DEX (n=12) treated animals. Values are 
expressed as the mean ±SEM and were analysed for the area under the curve. 
 
Analysis of plasma glucose at t=0 was used to determine fasting glucose 
levels, whilst area under the curve analyses of the blood glucose levels after gavage 
were undertaken to determine if animals were glucose tolerant. 
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All steroid treatment groups showed no differences in fasting glucose or glucose 
tolerance when compared to control animal values (Figure 7.23). 
 
 
Figure 7.23: (A) Fasting glucose levels and (B) area under the curve analysis of blood 
glucose after glucose gavage: Shown for control (n=11), EV (n=12), TP (n=12), DHT 
(n=12), DHEA (n=11) and DEX (n=12) treated animals. Values are expressed as the mean 
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7.5. Discussion 
The experiments described in this chapter have shown that a combination of 
androgenic and estrogenic action may be responsible for the reproductive and 
metabolic dysfunction observed in the neonatally androgenised rat model of PCOS 
previously described (Chapters 4-6). 
 
7.5.1. Effects of postnatal steroid exposure upon the ovary and 
ovarian hormones 
Both early postnatal EV and TP treatment led to a loss of ovarian cyclicity in 
adult animals by pnd 65, leading to reduced ovarian weight in these treatment 
groups. The reduction in uterine weight observed in the DHEA treatment group, 
although potentially accounted for by differences in estrus cycle stage, may also 
point towards the developmental programming of the uterus by an abnormal steroid 
milieu during early postnatal life in the rodent. Studies into the effects of postnatal 
androgens upon the uterus have shown that neonatal TP, in addition to neonatal 
clomifene treatment in rats, leads to a reduced uterine response to exogenous E2 in 
the adult animal, with a thinner myometrial membrane sand reduced number of 
glandular cells (White, Moore et al. 1981; Mena, Arriaza et al. 1992). Although the 
low uterine weights found in TP and EV treated animals can potentially be attributed 
to the reduced levels of E2 and inhibin B, further investigation into the effects of 
neonatal steroid treatment upon the development of rat uterine morphology and 
function are required. 
 
At the hormonal level, circulating E2 and inhibin B levels were significantly 
reduced even when compared to those of control metestrus animals. These results are 
in line with those found in previous investigations (Chapters 5 and 6) and other 
studies in neonatally androgenised rodents (Barraclough 1961; Barraclough and 
Haller 1970). In the current study, non-ovulatory treatment groups (TP and EV) 
showed no differences in circulating ovarian androgens levels (T or A4). Normal 
androgen levels were observed in another model of PCOS where rats received EV or 
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DHT within three hours of birth. However, in this same study animals treated with 
TP had reduced plasma levels of T (Alexanderson, Eriksson et al. 2007). 
Additionally, a separate investigation reported that early window TP led to an 
increase in circulating T levels in female offspring (vom Saal and Bronson 1980). 
Thus, whether neonatally androgenised or estrogenised rodents develop 
hyperandrogenaemia remains a moot point due to the variability of findings from 
other published rodent PCOS models. 
 
Animals treated with DHT and DHEA had reduced levels of plasma A4 and 
T respectively. These differences could be attributed to the androgenic programming 
of the rodent adrenal or liver since these organs are responsible for endocrine 
androgen production and steroid hormone catabolism respectively. Moreover 
differences in SHBG or other hormone binding proteins may exist. The regulation by 
steroid hormones upon hormone binding proteins have been shown across several 
species including humans; corticosteroid binding globulin is reduced in the offspring 
of sows stimulated with ACTH during late gestation, and SHBG is elevated in 
women who use oral contraceptives and remains elevated after discontinuation of 
long term use (Kanitz, Otten et al. 2006; Panzer, Wise et al. 2006). SHBG binds 
around 66% of free T in humans and decreases in association with several factors, 
including reduced circulating estrogens (also found in this study), 
hyperandrogenaemia, high glucocorticoids, growth hormone and prolactin, in 
addition to insulin and obesity – many of which are also features of PCOS (Botwood, 
Hamilton-Fairley et al. 1995). Additional investigations into intra- and extra-ovarian 
androgen levels in relation to the amount of free or bound sex-hormone binding 
globulin could therefore be pursued. This would help to elucidate whether any 
changes in bound or local ovarian hormone concentrations exist and provide further 
evaluation of the neonatally androgenised rat as a PCOS model. 
 
Postnatal EV and TP exposure produced similar results with regard to ovarian 
follicle populations in the adult rat; reduced follicle numbers with greater primordial 
follicle proportions, reduced activated follicle numbers and reduced activated follicle 
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proportions at the secondary and antral level. DHT treatment did not have any effect 
upon ovarian follicle numbers or proportions. Similar changes have been reported in 
another study where rats were exposed to TP on pnd 1 of life (Ulloa-Aguirre, 
Damian-Matsumura et al. 1990). A loss of follicles was also reported in the TP 
exposed ovine mode of PCOS and greater proportions of primordial follicles were 
observed in the infant females of the non-human primate PCOS model (Smith, 
Steckler et al. 2009; Abbott 2010). Taken together these investigations indicate that 
neonatal estrogen, acting via either/both ERα and ERβ, may be responsible for the 
differences in follicle populations in the EV and TP treatment groups. Aromatase 
activity in the female rat pituitary and ovary during neonatal life may additionally be 
responsible for converting TP into estrogens (Picon, Pelloux et al. 1985; Carson and 
Smith 1986; Carretero, Vazquez et al. 2003; Johnson 2007). This notion is further 
supported by investigations into mouse germ cell nest breakdown and oocyte 
apoptosis, where loss of the maternal estrogenic milieu after birth in rodents leads to 
germ cell nest breakdown (Chen, Breen et al. 2009).  
 
7.5.2. Effects of postnatal steroid exposure upon the 
hypothalamic-pituitary axis 
The apparent lack of pituitary response to reduced E2 and inhibin B feedback 
in the TP treatment group is in line with earlier findings (Chapters 5 and 6) and may 
be due to a reprogramming of the hypothalamic-pituitary response to ovarian 
hormonal feedback. Since no changes in ovarian feedback hormones or pituitary 
gonadotrophin secretion were observed in DHT treated animals, but were observed 
in both EV and TP treatment groups, programming of the neonatal hypothalamic-
pituitary axis by TP probably occurs via estrogenic hormonal action. It is possible 
that the pituitaries in EV and TP treated animals are more sensitive to ovarian 
feedback hormones and secrete normal levels of gonadotrophins in response to low 
levels of inhibin B and E2. Alternatively, the female pituitary may be masculinised 
by TP action in the same way that early postnatal T released from the immature testis 
acts to program to neuroendocrine axis in male rats (Carretero, Vazquez et al. 2003; 
Johnson 2007). 
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No differences in circulating or stored pituitary gonadotrophin levels were 
observed across steroid treatment groups, with the exception of DHEA treated which 
had raised levels of circulating LH. While this may be due to early morning sacrifice 
at precisely the LH surge in some animals of the DHEA treatment group, it could 
also be due to androgenic programming of the hypothalamic-pituitary axis. Indeed, 
an increased sensitivity of LH secretion in response to GnRH challenge has been 
reported in the fetally androgenised sheep PCOS model and high circulating levels of 
LH are one feature of PCOS (Manikkam, Thompson et al. 2008).  Furthermore, the 
estrogenic effects of DHEA treatment must be considered in tandem with those 
found in the EV treatment group, since DHEA is a precursor steroid in estrogen 
biosynthesis (Chapter 1, Section 7). 
 
Pituitary weight was reduced in EV treated animals. Data on pituitary weight 
has not been reported in other rodent studies of PCOS. It may be that the differences 
in pituitary weight observed in this study are the result of a trend reduction in stored 
LH and FSH protein. This data is supported by other investigations into the effects of 
specific ER modulators (for example raloxifene), administered neonatally to female 
rats, which show a reduction in pituitary gonadotrophin content, reduced LH release 
and alterations in the LH response to exogenous GnRH (Sanchez-Criado, Guelmes et 
al. 2002). TP treatment led to an increase in pituitary weight, as was reported in 
Chapters 5 and 6 and may again relate to levels of gonadotrophin protein storage and 
gene expression. At this point it is worth noting that the effects of neonatal steroids 
upon the hypothalamic-pituitary axis are not exclusive to GnRH and the 
gonadotrophs. Indeed other investigations have noted a disruptive effect of neonatal 
sex steroid administration upon lactotrophs, somatotrophs and the HPA axis 
(Gonzazalez-Parra, Argente et al. 2000; Bellido, Martin de las Mulas et al. 2003; 
Seale, Wood et al. 2005a; Seale, Wood et al. 2005b). Whilst these endocrine features 
were not examined here, future investigations into the effect of neonatal steroids 
upon trophic cell proportions, GnRH and GHRH would be useful in determining 
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which other aspects of the hypothalamic-pituitary axis are disrupted and/or 
masculinised by various steroid hormones. 
 
 One novel finding in relation to animals treated with EV is the presence of 
increased gene expression for αGSU, FSHβ and GR. The androgenic actions of TP 
(as well as DHT and DHEA) may act to reprogram pituitary gonadotrophin gene 
expression, protein storage and secretion – where EV treatment alone is insufficient 
to reprogram certain genes at the transcriptional level. One study has examined the 
effects of neonatal leptin treatment upon the HPAA and showed that adult 
hippocampal and hypothalamic GR content increased after neonatal leptin 
administration (Proulx, Clavel et al. 2001). 
 
Moreover, animals in the DEX steroid treatment group also showed an 
increased level of pituitary GR expression. This result corroborates other findings 
which have shown programming of GR expression in the paraventricular nucleus 
through glucocorticoid action (Kapoor and Matthews 2008). In addition, DEX 
treatment has been shown to affect development of the HPAA (Seckl 2004). Thus 
investigations into the effects of early window postnatal DEX and other steroid 
hormones upon the HPAA are warranted, specifically to elucidate the effects of these 
hormones upon the development of the mammalian stress response by measuring 
plasma corticosteroid levels.  
 
7.5.3. Effects of postnatal steroid exposure upon features of 
metabolism 
Animals treated with EV, TP and DHT had all gained significant weight by 
pnd 65. These treatment groups also showed a significant increase in central 
mesenteric fat depot weight. In the EV and DHT treatment groups, this difference 
was removed adjusting for body weight. Further anabolic changes were noted in the 
EV, DHT and DHEA treatment groups, all of which had greater body lengths when 
compared to those of controls. In contrast, TP treated animals, despite showing a 
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greater body weight and mesenteric adipose depot at pnd 65, were no longer than 
controls. Similar increases in body weight have been reported in other rodent studies 
which use neonatal TP, DHT or EV steroid hormone treatment (Barraclough 1961; 
vom Saal and Bronson 1980; Alexanderson, Eriksson et al. 2007). In addition, sheep 
and non-human primate models of PCOS have demonstrated that fetal TP exposure 
leads to insulin resistance and visceral (central) fat accumulation (Bruns, Baum et al. 
2007; Nada, Thompson et al. 2010; Padmanabhan, Veiga-Lopez et al. 2010; Veiga-
Lopez, Lee et al. 2010). 
 
The adrenal weights of TP treated animals were reduced (and yet increased in 
EV and DHT treatment groups). It may be that adrenal weight and anabolism 
(measured by body length) are related. Such differences in adrenal weight are thus a 
further indication that the effects of neonatal sex steroids upon the HPAA and growth 
hormone require further elucidation. One recent study into the effects of 
antimicrobial parabens upon endocrine organ development have shown that neonatal 
exposure to these estrogenic compounds increases adult adrenal weight, and has 
negative effects upon uterine and ovarian development similar to those observed in 
the current study (Vo, Yoo et al. 2010). The increased adrenal weights in the EV and 
DHT treatment groups, in addition to the greater body length observed in the DV, 
DHT and DHEA treatment groups may therefore be due to the actions of these 
steroids via ERβ, since non-aromatisable androgens can be converted to 3β-diols by 
the neonatal liver. Furthermore, the changes in adrenal weight could relate to 
changes in prolactin secretion. Previous investigations have shown adrenal weight to 
increase in response to exogenous prolactin in rats (Schlein, Zarrow et al. 1974; 
Vasquez and Kitay 1978). Future investigation into plasma and pituitary prolactin 
levels and receptor expression content in addition to adrenalectomy studies of the 
neonatally estrogenised rat might therefore prove useful. 
 
Raised fasting insulin levels and insulin resistance were present in animals 
treated with EV and TP, and in animals treated with DHT and DHEA to a lesser 
extent. This insulin resistance may therefore be a consequence of both the androgenic 
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and estrogenic actions of aromatisable androgens. However, the aforementioned ERβ 
effects of non-aromatisable androgens through their conversion to 3β-diols would 
still need to be excluded. 
 
Insulin resistance may also result through the epigenetic programming of 
pancreatic islet function. Other rodent, sheep and primate studies into the aetiology 
of PCOS and the metabolic syndrome have documented similar metabolic 
abnormalities resulting from fetal/neonatal androgen treatment (Bruns, Baum et al. 
2007; Demissie, Lazic et al. 2008; Padmanabhan, Veiga-Lopez et al.). Such 
programmed differences in pancreatic function could contribute to the changes in 
body weight and fat deposition documented in the EV, TP and DHT treatment 
groups. Future studies might therefore use AR specific antagonists (flutamide) or 
SERMs (raloxifene, tamoxifen, ICI-182780) in order to further elucidate which 
metabolic changes result through the actions of which specific steroids/receptors.  
 
Neonatal animals showed a decrease in neonatal body weight after DEX 
treatment (data not shown). This is in line with previous studies which have shown 
corticosteroids to negatively affect animal growth during development (Cleasby, 
Kelly et al. 2003). Body weight was comparable to that of control animals by pnd 65, 
although DEX treated animals showed a reduction in retroperitoneal and mesenteric 
adipose tissue weight, the latter of which became comparable to controls by dividing 
by body weight. In addition, DEX treated animals showed no changes in insulin 
resistance or glucose tolerance when compared to controls. 
 
The majority of rodent studies investigating the effects of DEX upon HPAA and 
metabolic development have used DEX administration during late fetal life in order 
to model the effects of maternal stress upon development and examine the 
epigenetics involved. By six months of age, animals treated with DEX during late 
gestation are significantly obese, insulin resistant and glucose intolerant (Levitt, 
 
Page | 266  
 
Lindsay et al. 1996; Nyirenda, Lindsay et al. 1998; Cleasby, Kelly et al. 2003; 
O'Regan, Kenyon et al. 2004; Drake, Walker et al. 2005; Mairesse, Lesage et al. 
2007), whilst similar findings have been reported in sheep (Fletcher, Ma et al. 2004; 
De Blasio, Dodic et al. 2007). There are several caveats to the current investigations 
which may in part account for these differences; the animals used in other studies of 
maternal stress and metabolic epigenetics are often male, sacrificed at a later age, and 
are treated with DEX during late foetal development. It may be that were the animals 
in the current study sacrificed several months later, effects of postnatal DEX upon 
metabolism might be observed, although this is purely speculative. 
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7.6. Conclusions 
To conclude, the anovulation, changes in ovarian follicle populations, reduced 
ovarian hormonal feedback, weight gain and insulin resistance which are observed to 
result in the adult rat after neonatal exposure to TP, are most likely the result of the 
estrogenic actions of TP after aromatisation in the newborn rat. However, a role for 
androgens in the programming of the abnormal development of the hypothalamic-
pituitary and metabolic axes cannot be completely excluded. Furthermore, neonatal 
DEX exposure does not appear to effect female fertility, but may yet have effects 
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Chapter 8. General Discussion 
 
The studies described in this thesis used rodent models to examine the role of 
androgens in the pathogenesis of female infertility. An unsuccessful attempt to 
generate a granulosa cell specific androgen receptor knockout mouse model was first 
described, thus an alternative avenue of examining the role of androgens in the ovary 
was pursued (Chapter 3). Subsequent studies investigated the developmental 
programming of female rat infertility and various aspects of metabolism by steroid 
hormones, in particular aromatisable androgens (Chapters 4-7). The core objective of 
these later studies was to use the rat as a model for exploring the role of androgens in 
the aetiology of female infertility, with particular reference to PCOS. In addition, 
these investigations sought to evaluate the use of the neonatally androgenised rat as a 
model for this reproductive endocrinopathy. 
 
Weight gain was consistently apparent in animals which received neonatal TP 
(Chapters 5-7). If comparisons are to be made across these different studies and 
conclusions drawn, changes in control animal weights must be compared between 
studies (Figure 8.1). Despite differences in the number of control animals and litter 
sizes, the growth trajectories of control animals were similar across the studies 
shown. 
 
Figure 8.1: Growth trajectories of control group animals in Chapter 5 (n=5), Chapter 6 
(n=15) and Chapter 7 (n=11): Litter sizes were kept to an n of 8 until weaning (pnd 21) for 
all three studies. Note, control groups in Chapters 6 and 7 were divided across two litters 
each. Values are expressed as the mean± SEM and were analysed by one way ANOVA. 
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The main androgen administered to animals during neonatal life was 
testosterone conjugated with proprionate (Chapters 4-7). In addition, estradiol 
conjugated to valerate and non-conjugated forms of DHT, DHEA and DEX were 
used in Chapter 7. The conjugation of steroid hormones to acidic molecules such as 
proprionate and valerate reduces peripheral steroid metabolism within the body, 
hence increasing steroid bioavailability (Chard 1990). This reduces the need to inject 
animals daily at extremely high doses, maintaining the steroid dose within an 
effective range. Such conjugation molecules are widely used as food additives, in 
medical drugs, and may also be produced in vivo through fatty acid metabolism 
(Rang, Dale et al. 2003). As yet, there is no evidence to suggest that they may 
negatively impact mammalian development. Early studies into rodent programming 
by neonatal androgens compared conjugated with non-conjugated steroids and found 
relatively few differences, save that conjugated androgens were more effective in 
altering development (Alklint and Norgren 1971; McDonald and Doughty 1974). In 
light of these studies, the results presented in Chapter 7 retain their validity and the 
doses of steroid chosen throughout this thesis were in line with those of the published 
literature and studies in male animals (Welsh, Saunders et al. 2008). 
 
Rodents possess differences in estrus cycle length, hormonal feedback and 
uterine morphology when compared to their ovine, bovine and primate counterparts. 
In addition they are a poly-ovulatory species and lack a menstrual cycle (Johnson 
2007). Nevertheless, rodent models of reproductive dysfunction still provide an 
excellent and well-established animal model to elucidate the features and 
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8.1. The neonatally androgenised rat as a model for PCOS 
Approximately 22% of women have PCO, but only around 5-10% of women 
develop PCOS, thus studies into the aetiology of this complex endocrinopathy are 
vital in order to understand the pathogenesis of infertility associated with this 
disorder. Studies into the origin of PCOS have long focused upon the role of 
abnormal androgen exposure during a key window of developmental life to produce 
a PCOS-like phenotype in the adult animal (Abbott, Dumesic et al. 1998; 
Beloosesky, Gold et al. 2004; Manneras, Cajander et al. 2007; Padmanabhan, Veiga-
Lopez et al. 2010). The investigations described in this thesis have shown that TP 
administration during the first 15 days of rat life leads to a valid PCOS-like 
phenotype in the female that is overweight, anovulatory, has „cystic‟ follicles, and an 
increased ovarian stromal compartment (Chapter 4). 
 
This thesis has described more than one rat model of PCOS; for instance if a 
single dose of TP is given on the day after birth (Chapter 6), raised levels of T are 
found in the adult animal, which to some extent recapitulates the abnormal androgen 
status of many women with PCOS (Rotterdam Consensus 2004). Similarly 
administration of TP between either pnd 1-6 or 7-15 both result in an anovulatory, 
overweight phenotype (Chapter 5). These findings are corroborated by other studies 
in rodents (Dissen, Lara et al. 2000; Alexanderson, Eriksson et al. 2007), in addition 
to studies in sheep (Steckler, Wang et al. 2005; Veiga-Lopez, Astapova et al. 2009; 
Nada, Thompson et al. 2010; Padmanabhan, Veiga-Lopez et al. 2010) and non-
human primates (Abbott, Dumesic et al. 1998; Abbott, Tarantal et al. 2009; 
Padmanabhan, Veiga-Lopez et al. 2010). However, the neonatally androgenised rat 
PCOS model fails to recapitulate circulating gonadotrophin abnormalities associated 
with the disorder; raised LH and an increased LH:FSH ratio. LH secretion has been 
shown to be altered in some PCOS models but not others (Manikkam, Thompson et 
al. 2008; Veiga-Lopez, Ye et al. 2008). Interpretation of the neonatally androgenised 
rat as a PCOS model should therefore take into consideration the findings of other 
animal models. Other rodent, sheep and non-human primate PCOS models using 
developmentally timed steroid hormone treatment have shown similar results, 
detailed comparatively in Table 8.1. 
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Table 8.1 : Features of PCOS recapitulated by Chapters 4-7 and other recent animal models referenced in this thesis. 
Human PCOS This study Other Rodent Studies Sheep Studies Primate Studies 
Reproductive features 
Irregular menses / 
anovulation / PCO 




(Dissen, Lara et al. 2000; 
Alexanderson, Eriksson et al. 
2007; Manneras, Cajander et 
al. 2007) 
(Steckler, Wang et al. 2005; 
Smith, Steckler et al. 2009) 
(Abbott, Dumesic et al. 1998; 
Dumesic, Damario et al. 2001) 
↑ stromal / thecal area 
Chapter 4; increased 
stromal compartment 
- (Ortega, Rey et al. 2010) (Vendola, Zhou et al. 1998) 
Hormonal features 
↑ ovarian androgens 
Chapter 6; high T in 
single TP dose group 
(vom Saal and Bronson 
1980; Dissen, Lara et al. 
2000; Wu, Li et al. 2010) 
- (Vendola, Zhou et al. 1998) 
↑ LH - (Wu, Li et al. 2010) 
(Manikkam, Thompson et al. 
2008) 
(Dumesic, Abbott et al. 1997; 
Dumesic, Damario et al. 2001) 
↓ hormonal feedback / 
ovarian response to 
exogenous stimulation 
Chapters 5-7; 
reduced E2 and 
Inhibin B feedback 
- 
(Sarma, Manikkam et al. 
2005; Steckler, Manikkam et 
al. 2007; Veiga-Lopez, Ye et 
al. 2008; Veiga-Lopez, 
Astapova et al. 2009) 
(Steiner, Clifton et al. 1976; 
Abbott, Tarantal et al. 2009) 
Metabolic features 
Insulin resistance / 
glucose intolerance 
Chapters 6-7; ↑ 
fasting insulin & 
glucose; Chapter 6; ↓ 
glucose clearance 
(Alexanderson, Eriksson et 
al. 2007; Manneras, 
Jonsdottir et al. 2008; Wu, Li 
et al. 2010) 
(Nada, Thompson et al. 
2010; Padmanabhan, Sarma 
et al. 2010) 
(Dumesic, Nielsen et al. 1999; 
Bruns, Baum et al. 2004; 
Abbott, Tarantal et al. 2009) 





(vom Saal and Bronson 
1980; Alexanderson, 
Eriksson et al. 2007; 
Manneras, Cajander et al. 
2007) 
(Steckler, Herkimer et al. 
2009) 
(Bruns, Baum et al. 2007) 
↑ lipids / features of 
NAFLD 
Chapter 5 
(Manneras, Cajander et al. 
2007) 
- - 
↑=increased; ↓=decreased; PCO=polycystic ovary; T=testosterone; LH=luteinising hormone; E2=estradiol; NAFLD=non-alcoholic fatty liver disease
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In terms of recapitulating PCOS, chronic treatment of adult rats with DHT 
has shown that females will gain weight and stop ovulating as a result of this 
disturbed hormonal milieu (Manneras, Cajander et al. 2007). Whilst such 
investigations are useful in determining the potential effectiveness of novel PCOS 
treatments, for example electroacupuncture (Manneras, Jonsdottir et al. 2008), they 
provide little insight into the aetiology of the disorder and have not been thoroughly 
examined at the ovarian level for abnormalities or changes in ovarian follicle 
composition which may result from such treatment. 
 
As a model of PCOS the neonatally androgenised rat provides a valid in vivo 
system for the study of reproductive dysfunction in the female animal. However, the 
findings shown using this model should be considered in context with other culture 
and in vivo model systems taken into account. The data presented in this thesis does 
not categorically prove that PCOS results through an abnormal hormonal milieu 
during a critical window of development and further investigation is required. Early 
studies into TP exposure during neonatal development showed that cross 
transplantation of an anovulatory ovary from a neonatally androgenised animal into a 
control animal allows the ovary to resume ovulation (Barraclough and Leathem 
1954; Barraclough 1961; Smith and Peng 1966; Barraclough and Haller 1970). 
However, in these studies no detailed morphometric analysis of the ovary was 
performed and animals were only hemi-ovariectomized. Therefore the effects of 
estrogen through the transplantation of a control ovary cannot be excluded, as this 
estrogen may act to stimulate ovulation, as was observed in hemi-ovariectomized 
animals in a similar study (Simard, Brawer et al. 1987). Further investigations should 
therefore involve complete ovariectomy and cross-transplantation, alongside full 
investigation into the follicle populations and stromal compartment of the 
transplanted ovaries; control to neonatally androgenised animals and vice versa, with 
the inclusion of sham operated animals. 
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The endocrine response of the neonatally androgenised rat to exogenous 
estrogen, hCG or even PMSG also have yet to be investigated and such studies 
would provide valuable insight into HPG axis function. The late window of postnatal 
life (TP exposure between pnd 7-15; Chapter 5) could also be used in order to 
investigate estrus cycle function in these animals through vaginal smears. Future 
investigations into the timing of anovulation and the ovarian ageing (loss of oocytes) 
which occurs in postnatally androgenised animals might also be undertaken. 
Particularly since in the current studies, neonatally androgenised animals had fewer 
total and activated follicles at pnd 65 (Chapter 7), but not at pnd 90 (Chapter 4) when 
compared with controls. 
 
8.2. Developmental programming of multiple endocrine 
systems: a role for epigenetics 
This thesis has shown that steroid administration during the first 25 days of rat 
life (Chapters 4, 5 and 7) may reprogram the function of multiple endocrine systems. 
Ovarian follicle populations are altered (Chapters 4 and 7), and the weight of many 
endocrine organs increased/decreased in the adult animal (Chapters 4-7); the uterus, 
pituitary gland, adrenal gland, liver, as well as growth, body length and mesenteric 
and retroperitoneal adipose tissue depots. Such changes implicate that neonatal TP 
(and by inference other steroid hormones) can impact not just the reproductive axis 
but also the metabolic and stress response axes during this key window of 
development in rats.  
 
In this thesis ovarian follicle populations were altered by neonatal TP/EV 
treatment with no apparent change in GC apoptosis (Chapters 4, 6 and 7). The 
molecular mechanism(s) through which neonatal estrogens/aromatisable androgens 
affect rodent germ cell nest breakdown require further investigation. One way to 
document whether rat germ cell nest breakdown is affected by neonatal steroid 
administration would be to assess the changes in germ cell populations on a daily 
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basis during the course of early postnatal life following TP/EV injections. 
Furthermore, terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) staining might also be a useful way of assessing the effects of neonatal 
steroids upon follicle/germ cell death which has so far only been indirectly measured 
(Chapter 6) through GC proliferation (Gavrieli, Sherman et al. 1992).  
 
Uterine weight was also consistently reduced in animals which received neonatal 
steroid hormones. As discussed in Chapter 7, this may be due to low levels of plasma 
estradiol or differences in estrus cycle stage. The uterus may also be another target 
organ for developmental programming by neonatally administered steroids (White, 
Moore et al. 1981; Mena, Arriaza et al. 1992). Further investigations into the how the 
endometrium, myometrium and glandular cells of the uterus are affected by the 
hormonal milieu during development might prove necessary. This is particularly 
relevant, since clomiphene citrate, an ER SERM is used to induce ovulation in 
women with PCOS. Although 70% of women treated with clomiphene citrate do 
ovulate, only 40% go on to maintain a successful pregnancy. The causes of this 
discrepancy are unknown but it may in part be due to a non-receptive uterine 
environment (Amin, Abd el-Aal et al. 2003).  
 
The impact of neonatal hormones upon the HPA axis is well documented and a 
dichotomy of adrenal function exists between the sexes, since adrenal cortisol output 
may be affected by the circulating hormonal milieu (Barraclough and Gorski 1961; 
Seale, Wood et al. 2005). As discussed in Chapters 5-7, investigations into the rodent 
stress response is warranted since the HPAA is altered by fetal DEX administration 
in other studies (Seckl 2004; Drake, Livingstone et al. 2005; Drake, Walker et al. 
2005). Hypothalamic and pituitary mRNA, protein and plasma CRH, corticosterone 
and ACTH also require further investigation, as does characterisation of the changes 
in zona reticularis function which result from neonatal TP treatment, to corroborate 
the findings of other studies (da Silva, Lopes-Costa et al. 2007; da Silva, Lopes-
Costa et al. 2009). 
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Of the tissues investigated in this thesis, Figure 8.2A details those that undergo 
maturation during early postnatal development in the rat while Figure 8.2B shows the 
windows of TP treatment which have affected these tissues. Such stark effects upon 
reproduction and metabolism may therefore indicate that environmental estrogens, 
androgens and other steroidal compounds may be partly responsible for epigenetic 




Figure 8.2: Mirror diagram: Top panel (A) shows the tissue processes which undergo 
maturation/formation during early postnatal life in the rat. Formation of these tissues 
may be modulated by neonatal TP treatment. Bottom panel (B) shows the ways in 
which TP treatment has been shown to alter tissue function, and the Chapter(s) in 
which these changes were reported. 
 
Central (mesenteric) weight gain and IR were documented across several studies 
(Chapters 5-7). Recently a connection between pituitary insulin receptor and ovarian 
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function using a pituitary insulin receptor knockout mouse (PitIrKO), where wild 
type obese animals were infertile, but obese PitIrKO animals had normal 
reproductive function (Brothers, Wu et al. 2010). These investigations, together with 
those described in this thesis, point towards a role for peripheral tissue IR in the 
development of female infertility and should be investigated further. Gene expression 
analysis of the insulin receptor, IGFs and IGFBPs should ideally be addressed in 
future investigations at the level of the pituitary, liver, and muscle, in addition to the 
various adipose tissue depots. This is particularly relevant since even non-obese 
women with PCOS display a degree of insulin resistance (Shumak 2009). The 
epigenetic regulation of metabolism, specifically the IGF family of genes may 
provide a clue as to how obesity and PCOS are interlinked (Chao and D'Amore 2008; 
Fu, Yu et al. 2009; Guilloteau, Zabielski et al. 2009). 
 
Due to the heterogeneous nature of PCOS, many studies have focused upon the 
individual gene variants or developing environments which might cause this disorder 
(Franks, Gharani et al. 1998; Abbott, Barnett et al. 2005; Fratantonio, Vicari et al. 
2005; Franks, McCarthy et al. 2006). In recent years, the idea that epigenetic changes 
are responsible for the development of PCOS has received a lot of attention (Abbott, 
Dumesic et al. 2002; Norman 2002; Abbott, Zhou et al. 2008; Padmanabhan, Veiga-
Lopez et al. 2010). However, few studies into the global/single gene methylation, 
phosphorylation or acetylation states of PCOS women when compared to normal 
subjects have been completed (Chapter 1, Section 9; Hickey, Chandy et al. 2002; 
Hickey, Legro et al. 2006). One small study of 40 women found no differences 
between age and BMI matched subjects in terms of global methylation status (Xu, 
Azziz et al.). Recently, bisulphite sequencing of key genes in a mouse model PCOS 
showed that DHEA treatment of pnd 25 mice led to hypomethylation of the LHr 
(Zhu, Zhu et al.), although this study so far represents the only PCOS model to 
undergo epigenome analysis at the individual gene level. Epigenetic changes of 
genes involved in follicle development might also help explain the alterations to 
follicle proportions which resulted from TP treatment (Chapters 4 and 7). In a recent 
study, treatment of mice with diethylstilbestrol, a known estrogenic compound, led to 
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hypermethylation of NOBOX gene A10; a gene known to be expressed in primordial 
follicles (Chapter 1, Section 3 Huntriss, Hinkins et al. 2006) 
 
Studies into the epigenetic programming of obesity and the metabolic syndrome 
have demonstrated for many years the link between in utero environment, birth 
weight and the development of adult disease (Law, Barker et al. 1992; Barker 1995; 
McCowan, Harding et al. 2000; Barker 2001). Investigations into the developmental 
programming of mammalian physiology by steroid hormones have noted that various 
genes involved in the development of endocrine systems and metabolism, 
particularly that of the IGF gene family, may be epigenetically regulated (Chao and 
D'Amore 2008; Fu, Yu et al. 2009; Guilloteau, Zabielski et al. 2009). One hypothesis 
which may explain the heritable nature of PCOS and the metabolic syndrome is that 
of transgenerational epigenetics. In this hypothesis, improper exposure to endocrine 
disruptors such as steroidal compounds/poor nutritional diet alters the epigenome of 
the developing fetus (generation one), and also affects the germ cells within this fetus 
(generation two) (Skinner, Manikkam et al. ; Anway, Cupp et al. 2005; Anway and 
Skinner 2006; Nilsson, Anway et al. 2008; Skinner 2008). Although useful as a 
hypothesis for the aetiology of a disorder such as PCOS, epigenetics poses a 
relatively novel area of research and the links between epigenetic modifications and 
disease prevalence remain unclear. 
 
There are other tissues not investigated in this thesis which may also be 
modulated by the developing hormonal milieu. For example, the thymus is one 
endocrine organ which is regulated by sex hormones in addition to possessing the 
enzymatic capacity for androgen metabolism, even in fetal life (Borlak, Schulte et al. 
2004). The thymus is known to undergo its final stages of maturation during 
postnatal life (up to pnd 10) in rodents, known as the „immune adaptive period‟ 
(West 2002). Thymectomy during early life results in ovarian dysgenesis like that 
observed in fetal plus postnatal TP treated animals (Chapter 4; Scalzo and Michael 
1988). Recent investigations in mice have shown that neonatal estradiol treatment 
(pnd 4-7) not only leads to anovulation, but also defective thymocyte function 
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(Deshpande, Chapman et al. 1997; Chapman, Min et al. 2009). Thymectomy of 
estradiol treated animals (pnd 3) before estradiol treatment was able to prevent 
anovulation in most animals (Chapman, Min et al. 2009). Corticosterone treatment 
during this time period has also been shown to alter thymus function (Chapman, Min 
et al. 2002). However, associations between PCOS diagnosis and defective thymus 
function have yet to be clinically reported. Further investigations into the effects of 
neonatal steroid treatments upon the thymus and innate immune system should 
therefore be pursued. It is worth noting that steroid hormone action upon other 
organs during neonatal development are likely to exist, since thymectomy alone 
results in complete ovarian dysgenesis, but can be rescued by neonatal estradiol 
treatment (Chapman, Griffin et al. 1995). 
 
In addition to the role of the innate immune system in endocrine development, 
other PCOS models have documented changes of the sympathetic and nervous 
systems, which were not investigated in this thesis (Stener-Victorin, Lundeberg et al. 
2000; Stener-Victorin and Lindholm 2004; Manni, Holmang et al. 2005; Stener-
Victorin, Ploj et al. 2005). If the peripheral nervous system is reprogrammed either 
directly or indirectly by steroid hormones, it may be that increased sympathetic tone 
to the ovary is partly responsible for the changes in follicle proportions and increased 
stromal compartment measured in the current model (Chapters 4 and 7; Lara, Ferruz 
et al. 1993). Increased vascularisation within the ovarian cortex has also been 
documented in PCOS women (Loverro, Vicino et al. 2001; Ferrara, Frantz et al. 
2003). This could affect follicular blood supply and impact upon follicle 
development and maturation leading to atresia (Jarvela, Sladkevicius et al. 2004). 
Future investigations might therefore include the measurement of follicle osmolality, 
ovarian neurotransmitters (such as adrenaline or noradrenaline), and histological 
assessment of angiogenesis in the ovary of the neonatally androgenised rat. 
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8.3. Final conclusions 
Investigations into the aetiology of PCOS, in addition to those described in this 
thesis, have provided valuable insight into the developmental programming of 
endocrine function in mammalian physiology. This thesis has demonstrated not only 
that neonatal estrogen or aromatisable androgen treatment of the neonatal rat leads to 
a PCOS like phenotype, but also that even if PCOS does not result from 
inappropriate steroid exposure during a critical window of endocrine development, 
the action of steroids during this window still have a detrimental effect upon adult 
mammalian fertility and metabolism. Further research into the characterisation, 
development and inheritance of PCOS and the associated metabolic syndrome in 
women is therefore required in order to properly match the scientific model with the 
clinical situation. 
 
Taken collectively, the results described in this thesis demonstrate that the 
PCOS-like phenotype observed in the neonatally androgenised female rat is likely to 
be due to the estrogenic actions of testosterone, potentially through epigenetic 
actions, the precise mechanisms of which remain unclear. The programming of the 
metabolic components described may additionally be due to the actions of 
androgens, which is to be expected since many nuclear receptors share common 
binding motifs. Furthermore, these studies demonstrate a novel estrogenic effect of 
neonatal steroids upon primordial follicle populations and show that the neonatally 







Page | 281  
 
Chapter 9. References 
(2004). "Revised 2003 consensus on diagnostic criteria and long-term health risks 
related to polycystic ovary syndrome." Fertil Steril 81(1): 19-25. 
 
Abbott, D. H. (2010). Prenatally Androgenised Female Rhesus Monkeys: A model 
for Polycystic Ovarian Syndrome. Society for Reproduction and Fertility, 
Nottingham. 
 
Abbott, D. H., D. K. Barnett, et al. (2005). "Androgen excess fetal programming of 
female reproduction: a developmental aetiology for polycystic ovary syndrome?" 
Hum Reprod Update 11(4): 357-374. 
 
Abbott, D. H., D. A. Dumesic, et al. (1998). "Insights into the Development of 
Polycystic Ovary Syndrome (PCOS) from Studies of Prenatally Androgenized 
Female Rhesus Monkeys." Trends Endocrinol Metab 9(2): 62-67. 
 
Abbott, D. H., D. A. Dumesic, et al. (2002). "Developmental origin of polycystic 
ovary syndrome - a hypothesis." J Endocrinol 174(1): 1-5. 
 
Abbott, D. H., A. F. Tarantal, et al. (2009). "Fetal, infant, adolescent and adult 
phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus 
monkeys." Am J Primatol 71(9): 776-784. 
 
Abbott, D. H., R. Zhou, et al. (2008). "Fetal programming of adrenal androgen 
excess: lessons from a nonhuman primate model of polycystic ovary syndrome." 
Endocr Dev 13: 145-158. 
 
Adams, J. M., A. E. Taylor, et al. (1994). "The midcycle gonadotropin surge in 
normal women occurs in the face of an unchanging gonadotropin-releasing hormone 
pulse frequency." J Clin Endocrinol Metab 79(3): 858-864. 
 
Ahima, R. S. (2008). "Revisiting leptin's role in obesity and weight loss." J Clin 
Invest 118(7): 2380-2383. 
 
Ahima, R. S. and D. A. Antwi (2008). "Brain regulation of appetite and satiety." 
Endocrinol Metab Clin North Am 37(4): 811-823. 
 
 
Page | 282  
 
Ahima, R. S., D. Prabakaran, et al. (1998). "Postnatal leptin surge and regulation of 
circadian rhythm of leptin by feeding. Implications for energy homeostasis and 
neuroendocrine function." J Clin Invest 101(5): 1020-1027. 
 
Ahmed, E. I., J. L. Zehr, et al. (2008). "Pubertal hormones modulate the addition of 
new cells to sexually dimorphic brain regions." Nat Neurosci 11(9): 995-997. 
 
Ailhaud, G., P. Grimaldi, et al. (1992). "Cellular and molecular aspects of adipose 
tissue development." Annu Rev Nutr 12: 207-233. 
 
Alexanderson, C., E. Eriksson, et al. (2007). "Postnatal testosterone exposure results 
in insulin resistance, enlarged mesenteric adipocytes, and an atherogenic lipid profile 
in adult female rats: comparisons with estradiol and dihydrotestosterone." 
Endocrinology 148(11): 5369-5376. 
 
Alklint, T. and A. Norgren (1971). "Effects of neonatally injected non-esterified 
testosterone on reproductive functions in female rats." Acta Endocrinol (Copenh) 
66(4): 720-726. 
 
Amar, A. P. and M. H. Weiss (2003). "Pituitary anatomy and physiology." 
Neurosurg Clin N Am 14(1): 11-23, v. 
 
Amin, A. F., D. E. Abd el-Aal, et al. (2003). "Evaluation of the impact of 
laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, 
serum vascular endothelial growth factor, and insulin-like growth factor-1 in women 
with polycystic ovary syndrome." Fertil Steril 79(4): 938-941. 
 
Anderiesz, C. and A. O. Trounson (1995). "The effect of testosterone on the 
maturation and developmental capacity of murine oocytes in vitro." Hum Reprod 
10(9): 2377-2381. 
 
Anderson, E. and G. Y. Lee (1997). "The polycystic ovarian (PCO) condition: 
apoptosis and epithelialization of the ovarian antral follicles are aspects of 
cystogenesis in the dehydroepiandrosterone (DHEA)-treated rat model." Tissue Cell 
29(2): 171-189. 
 
Anderson, E., G. Y. Lee, et al. (1997). "Polycystic ovarian condition in the 
dehydroepiandrosterone-treated rat model: hyperandrogenism and the resumption of 
meiosis are major initial events associated with cystogenesis of antral follicles." Anat 
Rec 249(1): 44-53. 
 
Page | 283  
 
 
Andersson, K. B. and B. S. Skalhegg (1998). "[Genetic modification of the mouse]." 
Tidsskr Nor Laegeforen 118(25): 3952-3957. 
 
Andreu-Vieyra, C., R. Chen, et al. (2008). "Conditional deletion of the 
retinoblastoma (Rb) gene in ovarian granulosa cells leads to premature ovarian 
failure." Mol Endocrinol 22(9): 2141-2161. 
 
Antenos, M., J. Zhu, et al. (2008). "An activin/furin regulatory loop modulates the 
processing and secretion of inhibin alpha- and betaB-subunit dimers in pituitary 
gonadotrope cells." J Biol Chem 283(48): 33059-33068. 
 
Anway, M. D., A. S. Cupp, et al. (2005). "Epigenetic transgenerational actions of 
endocrine disruptors and male fertility." Science 308(5727): 1466-1469. 
 
Anway, M. D. and M. K. Skinner (2006). "Epigenetic transgenerational actions of 
endocrine disruptors." Endocrinology 147(6 Suppl): S43-49. 
 
Armitage, J. A., P. D. Taylor, et al. (2005). "Experimental models of developmental 
programming: consequences of exposure to an energy rich diet during development." 
J Physiol 565(Pt 1): 3-8. 
 
Arroyo, A., G. A. Laughlin, et al. (1997). "Inappropriate gonadotropin secretion in 
polycystic ovary syndrome: influence of adiposity." J Clin Endocrinol Metab 82(11): 
3728-3733. 
 
Baba, Y., H. Matsuo, et al. (1971). "Structure of the porcine LH- and FSH-releasing 
hormone. II. Confirmation of the proposed structure by conventional sequential 
analyses." Biochem Biophys Res Commun 44(2): 459-463. 
 
Baillargeon, J. P. and A. C. Carpentier (2007). "Brothers of women with polycystic 
ovary syndrome are characterised by impaired glucose tolerance, reduced insulin 
sensitivity and related metabolic defects." Diabetologia 50(12): 2424-2432. 
 
Baird, D. T., T. G. Baker, et al. (1975). "Relationship between the secretion of the 
corpus luteum and the length of the follicular phase of the ovarian cycle." J Reprod 
Fertil 45(3): 611-619. 
 
 
Page | 284  
 
Baird, D. T., A. Brown, et al. (2003). "Effect of long-term treatment with low-dose 
mifepristone on the endometrium." Hum Reprod 18(1): 61-68. 
 
Baird, D. T. and I. S. Fraser (1974). "Blood production and ovarian secretion rates of 
estradiol-17 beta and estrone in women throughout the menstrual cycle." J Clin 
Endocrinol Metab 38(6): 1009-1017. 
 
Baird, D. T. and I. S. Fraser (1975). "Concentration of oestrone and oestradiol in 
follicular fluid and ovarian venous blood of women." Clin Endocrinol (Oxf) 4(3): 
259-266. 
 
Baldwin, D. M. and C. H. Sawyer (1974). "Effects of dexamethasone on LH release 
and ovulation in the cyclic rat." Endocrinology 94(5): 1397-1403. 
 
Balen, A. H., J. S. Laven, et al. (2003). "Ultrasound assessment of the polycystic 
ovary: international consensus definitions." Hum Reprod Update 9(6): 505-514. 
 
Baravalle, C., N. R. Salvetti, et al. (2007). "The role of ACTH in the pathogenesis of 
polycystic ovarian syndrome in rats: hormonal profiles and ovarian morphology." 
Physiol Res 56(1): 67-78. 
 
Barker, D. J. (1995). "Fetal origins of coronary heart disease." Bmj 311(6998): 171-
174. 
 
Barker, D. J. (1997). "Fetal nutrition and cardiovascular disease in later life." Br Med 
Bull 53(1): 96-108. 
 
Barker, D. J. (1997). "Maternal nutrition, fetal nutrition, and disease in later life." 
Nutrition 13(9): 807-813. 
 
Barker, D. J. (2001). "The malnourished baby and infant." Br Med Bull 60: 69-88. 
 
Barley, J., M. Ginsburg, et al. (1975). "An androgen receptor in rat brain and 
pituitary." Brain Res 100(2): 383-393. 
 
Barnes, R. B. (1997). "Diagnosis and therapy of hyperandrogenism." Baillieres Clin 
Obstet Gynaecol 11(2): 369-396. 
 
 
Page | 285  
 
Barr, G. D. and C. A. Barraclough (1978). "Temporal changes in medial basal 
hypothalamic LH-RH correlated with plasma LH during the rat estrous cycle and 
following electrochemical stimulation of the medial preoptic area in pentobarbital-
treated proestrous rats." Brain Res 148(2): 413-423. 
 
Barraclough, C. A. (1955). "Influence of age on the response of preweaning female 
mice to testosterone propionate." Am J Anat 97(3): 493-521. 
 
Barraclough, C. A. (1961). "Production of anovulatory, sterile rats by single 
injections of testosterone propionate." Endocrinology 68: 62-67. 
 
Barraclough, C. A. and R. A. Gorski (1961). "Evidence that the hypothalamus is 
responsible for androgen-induced sterility in the female rat." Endocrinology 68: 68-
79. 
 
Barraclough, C. A. and R. A. Gorski (1962). "Studies on mating behavior in the 
androgen-sterilized female rat in relation to the hypothalamic regulation of sexual 
behaviour." J Endocrinol 25: 175-182. 
 
Barraclough, C. A. and E. W. Haller (1970). "Positive and negative feedback effects 
of estrogen on pituitary LH synthesis and release in normal and androgen-sterilized 
rats." Endocrinology 86(3): 542-551. 
 
Barraclough, C. A. and J. H. Leathem (1954). "Infertility induced in mice by a single 
injection of testosterone propionate." Proc Soc Exp Biol Med 85(4): 673-674. 
 
Beale, E. G., D. E. Clouthier, et al. (1992). "Cell-specific expression of cytosolic 
phosphoenolpyruvate carboxykinase in transgenic mice." Faseb J 6(15): 3330-3337. 
 
Bellido, C., J. Martin de las Mulas, et al. (2003). "Tamoxifen induces gonadotropin-
releasing hormone self-priming through an estrogen-dependent progesterone receptor 
expression in the gonadotrope of the rat." Neuroendocrinology 77(6): 425-435. 
 
Belmont, J. W. (1996). "Genetic control of X inactivation and processes leading to 
X-inactivation skewing." Am J Hum Genet 58(6): 1101-1108. 
 
Beloosesky, R., R. Gold, et al. (2004). "Induction of polycystic ovary by testosterone 
in immature female rats: Modulation of apoptosis and attenuation of glucose/insulin 
ratio." Int J Mol Med 14(2): 207-215. 
 
Page | 286  
 
 
Berta, P., J. R. Hawkins, et al. (1990). "Genetic evidence equating SRY and the 
testis-determining factor." Nature 348(6300): 448-450. 
 
Besser, G. M. (1974). "Hypothalamus as an endocrine organ--I." Br Med J 3(5930): 
560-564. 
 
Besser, G. M. (1974). "Hypothalamus as an endocrine organ. II." Br Med J 3(5931): 
613-615. 
 
Besser, G. M. and C. H. Mortimer (1974). "Hypothalamic regulatory hormones: a 
review." J Clin Pathol 27(3): 173-184. 
 
Bilezikjian, L. M., A. L. Blount, et al. (2006). "Pituitary actions of ligands of the 
TGF-beta family: activins and inhibins." Reproduction 132(2): 207-215. 
 
Borlak, J., I. Schulte, et al. (2004). "Androgen metabolism in thymus of fetal and 
adult rats." Drug Metab Dispos 32(6): 675-679. 
 
Borsani, G., R. Tonlorenzi, et al. (1991). "Characterization of a murine gene 
expressed from the inactive X chromosome." Nature 351(6324): 325-329. 
 
Botwood, N., D. Hamilton-Fairley, et al. (1995). "Sex hormone-binding globulin and 
female reproductive function." J Steroid Biochem Mol Biol 53(1-6): 529-531. 
 
Boyer, A., M. Paquet, et al. (2009). "Dysregulation of WNT/CTNNB1 and 
PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the 
testis." Carcinogenesis 30(5): 869-878. 
 
Brawer, J. R., M. Munoz, et al. (1986). "Development of the polycystic ovarian 
condition (PCO) in the estradiol valerate-treated rat." Biol Reprod 35(3): 647-655. 
 
Brawer, J. R., F. Naftolin, et al. (1978). "Effects of a single injection of estradiol 
valerate on the hypothalamic arcuate nucleus and on reproductive function in the 
female rat." Endocrinology 103(2): 501-512. 
 
Bridges, C. B. (1916). "Non-Disjunction as Proof of the Chromosome Theory of 
Heredity (Concluded)." Genetics 1(2): 107-163. 
 
Page | 287  
 
 
Britt, K. L., A. E. Drummond, et al. (2001). "The ovarian phenotype of the aromatase 
knockout (ArKO) mouse." J Steroid Biochem Mol Biol 79(1-5): 181-185. 
 
Brothers, K. J., S. Wu, et al. (2010). "Rescue of obesity-induced infertility in female 
mice due to a pituitary-specific knockout of the insulin receptor." Cell Metab 12(3): 
295-305. 
 
Brown, P. and A. S. McNeilly (1999). "Transcriptional regulation of pituitary 
gonadotrophin subunit genes." Rev Reprod 4(2): 117-124. 
 
Bruns, C. M., S. T. Baum, et al. (2007). "Prenatal androgen excess negatively 
impacts body fat distribution in a nonhuman primate model of polycystic ovary 
syndrome." Int J Obes (Lond) 31(10): 1579-1585. 
 
Bruns, C. M., S. T. Baum, et al. (2004). "Insulin resistance and impaired insulin 
secretion in prenatally androgenized male rhesus monkeys." J Clin Endocrinol 
Metab 89(12): 6218-6223. 
 
Bucher, J. R. (2009). "Bisphenol A: where to now?" Environ Health Perspect 
117(3): A96-97. 
 
Buckle, R. M., D. Rubinstein, et al. (1961). "Factors influencing the release of free 
fatty acids from rat adipose tissue." Endocrinology 69: 1009-1015. 
 
Buckle, V. J., Y. Boyd, et al. (1987). "Localisation of Y chromosome sequences in 
normal and 'XX' males." J Med Genet 24(4): 197-203. 
 
Buhl, E. S., S. Neschen, et al. (2007). "Increased hypothalamic-pituitary-adrenal axis 
activity and hepatic insulin resistance in low-birth-weight rats." Am J Physiol 
Endocrinol Metab 293(5): E1451-1458. 
 
Bukovsky, A., M. R. Caudle, et al. (2004). "Origin of germ cells and formation of 
new primary follicles in adult human ovaries." Reprod Biol Endocrinol 2: 20. 
 
Bukovsky, A., M. R. Caudle, et al. (2005). "Oogenesis in adult mammals, including 
humans: a review." Endocrine 26(3): 301-316. 
 
 
Page | 288  
 
Canning, J., Y. Takai, et al. (2003). "Evidence for genetic modifiers of ovarian 
follicular endowment and development from studies of five inbred mouse strains." 
Endocrinology 144(1): 9-12. 
 
Cantrell, M. A., B. C. Carstens, et al. (2009). "X chromosome inactivation and Xist 
evolution in a rodent lacking LINE-1 activity." PLoS One 4(7): e6252. 
 
Carabatsos, M. J., J. Elvin, et al. (1998). "Characterization of oocyte and follicle 
development in growth differentiation factor-9-deficient mice." Dev Biol 204(2): 
373-384. 
 
Carretero, J., G. Vazquez, et al. (2003). "Postnatal differentiation of the 
immunohistochemical expression of aromatase P450 in the rat pituitary gland." 
Histol Histopathol 18(2): 419-423. 
 
Carson, R. and J. Smith (1986). "Development and steroidogenic activity of preantral 
follicles in the neonatal rat ovary." J Endocrinol 110(1): 87-92. 
 
Case, A. M. (2003). "Infertility evaluation and management. Strategies for family 
physicians." Can Fam Physician 49: 1465-1472. 
 
Caserta, F., T. Tchkonia, et al. (2001). "Fat depot origin affects fatty acid handling in 
cultured rat and human preadipocytes." Am J Physiol Endocrinol Metab 280(2): 
E238-247. 
 
Castrillon, D. H., L. Miao, et al. (2003). "Suppression of ovarian follicle activation in 
mice by the transcription factor Foxo3a." Science 301(5630): 215-218. 
 
Centenera, M. M., J. M. Harris, et al. (2008). "The contribution of different androgen 
receptor domains to receptor dimerization and signaling." Mol Endocrinol 22(11): 
2373-2382. 
 
Chakrabarty, S., B. T. Miller, et al. (2006). "Ovarian dysfunction in peripubertal 
hyperinsulinemia." J Soc Gynecol Investig 13(2): 122-129. 
 
Champagne, F. A., D. D. Francis, et al. (2003). "Variations in maternal care in the rat 
as a mediating influence for the effects of environment on development." Physiol 
Behav 79(3): 359-371. 
 
 
Page | 289  
 
Chang, C., Y. T. Chen, et al. (2004). "Infertility with defective spermatogenesis and 
hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells." 
Proc Natl Acad Sci U S A 101(18): 6876-6881. 
 
Chao, W. and P. A. D'Amore (2008). "IGF2: epigenetic regulation and role in 
development and disease." Cytokine Growth Factor Rev 19(2): 111-120. 
 
Chapman, J. C., W. J. Griffin, et al. (1995). "The ovarian dysgenesis normally 
induced by neonatal thymectomy is prevented by the prior administration of 
estrogen." Am J Reprod Immunol 34(3): 195-199. 
 
Chapman, J. C., S. Min, et al. (2002). "The administration of cortisone to female 
B6A mice during their immune adaptive period causes anovulation and the formation 
of ovarian cysts." Am J Reprod Immunol 48(3): 184-189. 
 
Chapman, J. C., S. H. Min, et al. (2009). "The estrogen-injected female mouse: new 
insight into the etiology of PCOS." Reprod Biol Endocrinol 7: 47. 
 
Chard, T., Ed. (1990). Laboratory techniques in biochemistry and molecular biology, 
ELSEVIER. 
 
Chassot, A. A., E. P. Gregoire, et al. (2008). "Genetics of ovarian differentiation: 
Rspo1, a major player." Sex Dev 2(4-5): 219-227. 
 
Chassot, A. A., F. Ranc, et al. (2008). "Activation of beta-catenin signaling by Rspo1 
controls differentiation of the mammalian ovary." Hum Mol Genet 17(9): 1264-1277. 
 
Chaumeil, J., P. D. Waters, et al. (2011). "Evolution from XIST-Independent to 
XIST-Controlled X-Chromosome Inactivation: Epigenetic Modifications in Distantly 
Related Mammals." PLoS One 6(4): e19040. 
 
Chen, Y., K. Breen, et al. (2009). "Estrogen can signal through multiple pathways to 
regulate oocyte cyst breakdown and primordial follicle assembly in the neonatal 
mouse ovary." J Endocrinol 202(3): 407-417. 
 
Chen, Y., W. N. Jefferson, et al. (2007). "Estradiol, progesterone, and genistein 
inhibit oocyte nest breakdown and primordial follicle assembly in the neonatal 
mouse ovary in vitro and in vivo." Endocrinology 148(8): 3580-3590. 
 
 
Page | 290  
 
Childs, G. V. (1985). "Shifts in gonadotropin storage in cultured gonadotropes 
following GnRH stimulation, in vitro." Peptides 6(1): 103-107. 
 
Childs, G. V., C. Hyde, et al. (1983). "Heterogeneous luteinizing hormone and 
follicle-stimulating hormone storage patterns in subtypes of gonadotropes separated 
by centrifugal elutriation." Endocrinology 113(6): 2120-2128. 
 
Chin, D., C. Shackleton, et al. (2000). "Increased 5alpha-reductase and normal 
11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a 
young population with polycystic ovarian syndrome." J Pediatr Endocrinol Metab 
13(3): 253-259. 
 
Chomczynski, P. and N. Sacchi (2006). "The single-step method of RNA isolation by 
acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years 
on." Nat Protoc 1(2): 581-585. 
 
Ciampelli, M., A. M. Fulghesu, et al. (1997). "Heterogeneity in beta cell activity, 
hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic 
ovary syndrome." Hum Reprod 12(9): 1897-1901. 
 
Claessens, F., S. Denayer, et al. (2008). "Diverse roles of androgen receptor (AR) 
domains in AR-mediated signaling." Nucl Recept Signal 6: e008. 
 
Clarke, B. L. and S. Khosla (2009). "New selective estrogen and androgen receptor 
modulators." Curr Opin Rheumatol 21(4): 374-379. 
 
Clarke, H. G., S. A. Hope, et al. (2006). "Formation of ovarian follicular fluid may 
be due to the osmotic potential of large glycosaminoglycans and proteoglycans." 
Reproduction 132(1): 119-131. 
 
Clarke, I. J. and J. T. Cummins (1982). "The temporal relationship between 
gonadotropin releasing hormone (GnRH) and luteinizing hormone (LH) secretion in 
ovariectomized ewes." Endocrinology 111(5): 1737-1739. 
 
Clarke, I. J. and J. T. Cummins (1985). "GnRH pulse frequency determines LH pulse 
amplitude by altering the amount of releasable LH in the pituitary glands of ewes." J 
Reprod Fertil 73(2): 425-431. 
 
 
Page | 291  
 
Clarke, I. J. and J. T. Cummins (1987). "The significance of small pulses of 
gonadotrophin-releasing hormone." J Endocrinol 113(3): 413-418. 
 
Clarke, I. J., J. T. Cummins, et al. (1987). "Pituitary receptors for gonadotropin-
releasing hormone in relation to changes in pituitary and plasma luteinizing hormone 
in ovariectomized-hypothalamo pituitary disconnected ewes. I. Effect of changing 
frequency of gonadotropin-releasing hormone pulses." Biol Reprod 37(4): 749-754. 
 
Clarke, I. J., J. T. Cummins, et al. (1989). "The oestrogen-induced surge of LH 
requires a 'signal' pattern of gonadotrophin-releasing hormone input to the pituitary 
gland in the ewe." J Endocrinol 122(1): 127-134. 
 
Clarke, I. J., R. J. Scaramuzzi, et al. (1976). "Effects of testosterone implants in 
pregnant ewes on their female offspring." J Embryol Exp Morphol 36(1): 87-99. 
 
Clarke, I. J., G. B. Thomas, et al. (1987). "GnRH secretion throughout the ovine 
estrous cycle." Neuroendocrinology 46(1): 82-88. 
 
Cleasby, M. E., P. A. Kelly, et al. (2003). "Programming of rat muscle and fat 
metabolism by in utero overexposure to glucocorticoids." Endocrinology 144(3): 
999-1007. 
 
Corbin, C. J., M. W. Khalil, et al. (1995). "Functional ovarian and placental isoforms 
of porcine aromatase." Mol Cell Endocrinol 113(1): 29-37. 
 
Cottrell, E. C. and J. R. Seckl (2009). "Prenatal stress, glucocorticoids and the 
programming of adult disease." Front Behav Neurosci 3: 19. 
 
Courel, M., A. Soler-Jover, et al. (2010). "Pro-hormone secretogranin II regulates 
dense core secretory granule biogenesis in catecholaminergic cells." J Biol Chem 
285(13): 10030-10043. 
 
Crandall, D. L., E. M. Quinet, et al. (2006). "Modulation of adipose tissue 
development by pharmacological inhibition of PAI-1." Arterioscler Thromb Vasc 
Biol 26(10): 2209-2215. 
 
Crawford, J. L., R. J. Currie, et al. (2000). "Replenishment of LH stores of 
gonadotrophs in relation to gene expression, synthesis and secretion of LH after the 
preovulatory phase of the sheep oestrous cycle." J Endocrinol 167(3): 453-463. 
 
Page | 292  
 
 
Crawford, J. L. and A. S. McNeilly (2002). "Co-localisation of gonadotrophins and 
granins in gonadotrophs at different stages of the oestrous cycle in sheep." J 
Endocrinol 174(2): 179-194. 
 
Crawford, J. L., J. R. McNeilly, et al. (2004). "No evidence for pituitary priming to 
gonadotropin-releasing hormone in relation to luteinizing hormone (LH) secretion 
prior to the preovulatory LH surge in ewes." Biol Reprod 71(1): 224-235. 
 
Crawford, J. L., J. R. McNeilly, et al. (2002). "Promotion of intragranular co-
aggregation with LH by enhancement of secretogranin II storage resulted in 
increased intracellular granule storage in gonadotrophs of GnRH-deprived male 
mice." Reproduction 124(2): 267-277. 
 
Critchley, H. O., R. W. Kelly, et al. (2006). "Regulation of human endometrial 
function: mechanisms relevant to uterine bleeding." Reprod Biol Endocrinol 4 Suppl 
1: S5. 
 
Da Silva-Buttkus, P., G. S. Jayasooriya, et al. (2008). "Effect of cell shape and 
packing density on granulosa cell proliferation and formation of multiple layers 
during early follicle development in the ovary." J Cell Sci 121(Pt 23): 3890-3900. 
 
Da Silva-Buttkus, P., G. Marcelli, et al. (2009). "Inferring biological mechanisms 
from spatial analysis: prediction of a local inhibitor in the ovary." Proc Natl Acad Sci 
U S A 106(2): 456-461. 
 
da Silva, B. B., P. V. Lopes-Costa, et al. (2009). "Evaluation of Ki-67 antigen 
expression in the zona reticularis of the adrenal cortex of female rats in persistent 
estrus." Hum Reprod 24(3): 705-709. 
 
da Silva, B. B., P. V. Lopes-Costa, et al. (2007). "Morphological and morphometric 
analysis of the adrenal cortex of androgenized female rats." Gynecol Obstet Invest 
64(1): 44-48. 
 
Daniel, S. A. and D. T. Armstrong (1980). "Enhancement of follicle-stimulating 
hormone-induced aromatase activity by androgens in cultured rat granulosa cells." 
Endocrinology 107(4): 1027-1033. 
 
 
Page | 293  
 
Das, M., O. Djahanbakhch, et al. (2008). "Granulosa cell survival and proliferation 
are altered in polycystic ovary syndrome." J Clin Endocrinol Metab 93(3): 881-887. 
 
Davey, R. A. and H. E. MacLean (2006). "Current and future approaches using 
genetically modified mice in endocrine research." Am J Physiol Endocrinol Metab 
291(3): E429-438. 
 
De Blasio, M. J., M. Dodic, et al. (2007). "Maternal exposure to dexamethasone or 
cortisol in early pregnancy differentially alters insulin secretion and glucose 
homeostasis in adult male sheep offspring." Am J Physiol Endocrinol Metab 293(1): 
E75-82. 
 
De Gendt, K., J. V. Swinnen, et al. (2004). "A Sertoli cell-selective knockout of the 
androgen receptor causes spermatogenic arrest in meiosis." Proc Natl Acad Sci U S A 
101(5): 1327-1332. 
 
de Greef, W. J. and P. van der Schoot (1987). "Effects of dexamethasone on ovarian 
activity in rats." Acta Endocrinol (Copenh) 116(3): 350-356. 
 
Deepak, S., K. Kottapalli, et al. (2007). "Real-Time PCR: Revolutionizing Detection 
and Expression Analysis of Genes." Curr Genomics 8(4): 234-251. 
 
Demeestere, I., C. Gervy, et al. (2004). "Effect of insulin-like growth factor-I during 
preantral follicular culture on steroidogenesis, in vitro oocyte maturation, and 
embryo development in mice." Biol Reprod 70(6): 1664-1669. 
 
Demissie, M., M. Lazic, et al. (2008). "Transient Prenatal Androgen Exposure 
Produces Metabolic Syndrome in Adult Female Rats." Am J Physiol Endocrinol 
Metab. 
 
Dennis, A. P., R. U. Haq, et al. (2001). "Importance of the regulation of nuclear 
receptor degradation." Front Biosci 6: D954-959. 
 
Deshpande, R. R., J. C. Chapman, et al. (1997). "The anovulation in female mice 
resulting from postnatal injections of estrogen is correlated with altered levels of 
CD8+ lymphocytes." Am J Reprod Immunol 38(2): 114-120. 
 
 
Page | 294  
 
Dewailly, D., S. Catteau-Jonard, et al. (2007). "The excess in 2-5 mm follicles seen 
at ovarian ultrasonography is tightly associated to the follicular arrest of the 
polycystic ovary syndrome." Hum Reprod 22(6): 1562-1566. 
 
Diaz, F. J., K. Sugiura, et al. (2008). "Regulation of Pcsk6 expression during the 
preantral to antral follicle transition in mice: opposing roles of FSH and oocytes." 
Biol Reprod 78(1): 176-183. 
 
Diaz, F. J., K. Wigglesworth, et al. (2007). "Oocytes determine cumulus cell lineage 
in mouse ovarian follicles." J Cell Sci 120(Pt 8): 1330-1340. 
 
Dissen, G. A., H. E. Lara, et al. (2000). "Intraovarian excess of nerve growth factor 
increases androgen secretion and disrupts estrous cyclicity in the rat." Endocrinology 
141(3): 1073-1082. 
 
Dohler, K. D., A. Coquelin, et al. (1986). "Pre- and postnatal influence of an estrogen 
antagonist and an androgen antagonist on differentiation of the sexually dimorphic 
nucleus of the preoptic area in male and female rats." Neuroendocrinology 42(5): 
443-448. 
 
Dohler, K. D., S. S. Srivastava, et al. (1984). "Differentiation of the sexually 
dimorphic nucleus in the preoptic area of the rat brain is inhibited by postnatal 
treatment with an estrogen antagonist." Neuroendocrinology 38(4): 297-301. 
 
Dong, J., D. F. Albertini, et al. (1996). "Growth differentiation factor-9 is required 
during early ovarian folliculogenesis." Nature 383(6600): 531-535. 
 
Drake, A. J., D. E. Livingstone, et al. (2005). "Reduced adipose glucocorticoid 
reactivation and increased hepatic glucocorticoid clearance as an early adaptation to 
high-fat feeding in Wistar rats." Endocrinology 146(2): 913-919. 
 
Drake, A. J., B. R. Walker, et al. (2005). "Intergenerational consequences of fetal 
programming by in utero exposure to glucocorticoids in rats." Am J Physiol Regul 
Integr Comp Physiol 288(1): R34-38. 
 
Drummond, A. E. (2006). "The role of steroids in follicular growth." Reprod Biol 
Endocrinol 4: 16. 
 
 
Page | 295  
 
Dumesic, D. A., D. H. Abbott, et al. (1997). "Prenatal exposure of female rhesus 
monkeys to testosterone propionate increases serum luteinizing hormone levels in 
adulthood." Fertil Steril 67(1): 155-163. 
 
Dumesic, D. A., D. H. Abbott, et al. (2007). "Polycystic ovary syndrome and its 
developmental origins." Rev Endocr Metab Disord 8(2): 127-141. 
 
Dumesic, D. A., M. A. Damario, et al. (2001). "Ovarian morphology and serum 
hormone markers as predictors of ovarian follicle recruitment by gonadotropins for 
in vitro fertilization." J Clin Endocrinol Metab 86(6): 2538-2543. 
 
Dumesic, D. A., M. F. Nielsen, et al. (1999). "Insulin action during variable 
hyperglycemic-hyperinsulinemic infusions in hyperandrogenic anovulatory patients 
and healthy women." Fertil Steril 72(3): 458-466. 
 
Dumesic, D. A., R. D. Schramm, et al. (2005). "Early origins of polycystic ovary 
syndrome." Reprod Fertil Dev 17(3): 349-360. 
 
Ebling, F. J. (2005). "The neuroendocrine timing of puberty." Reproduction 129(6): 
675-683. 
 
Economou, F., X. Xyrafis, et al. (2009). "In overweight/obese but not in normal-
weight women, polycystic ovary syndrome is associated with elevated liver enzymes 
compared to controls." Hormones (Athens) 8(3): 199-206. 
 
Edson, M. A., A. K. Nagaraja, et al. (2009). "The mammalian ovary from genesis to 
revelation." Endocr Rev 30(6): 624-712. 
 
El-Hefnawy, T. and A. J. Zeleznik (2001). "Synergism between FSH and activin in 
the regulation of proliferating cell nuclear antigen (PCNA) and cyclin D2 expression 
in rat granulosa cells." Endocrinology 142(10): 4357-4362. 
 
Elvin, J. A., A. T. Clark, et al. (1999). "Paracrine actions of growth differentiation 
factor-9 in the mammalian ovary." Mol Endocrinol 13(6): 1035-1048. 
 
Elvin, J. A., C. Yan, et al. (1999). "Molecular characterization of the follicle defects 




Page | 296  
 
Eppig, J. J. (2001). "Oocyte control of ovarian follicular development and function in 
mammals." Reproduction 122(6): 829-838. 
 
ESHRE (2008). "Consensus on infertility treatment related to polycystic ovary 
syndrome." Hum Reprod 23(3): 462-477. 
 
Evuarherhe, O., J. D. Leggett, et al. (2009). "Organizational role for pubertal 
androgens on adult hypothalamic-pituitary-adrenal sensitivity to testosterone in the 
male rat." J Physiol 587(Pt 12): 2977-2985. 
 
Faiman, C., F. I. Reyes, et al. (1988). "Effects of long-term testosterone exposure on 
ovarian function and morphology in the rhesus monkey." Anat Rec 222(3): 245-251. 
 
Fan, H. Y., Z. Liu, et al. (2009). "Cell type-specific targeted mutations of Kras and 
Pten document proliferation arrest in granulosa cells versus oncogenic insult to 
ovarian surface epithelial cells." Cancer Res 69(16): 6463-6472. 
 
Farquhar, C. M., M. Birdsall, et al. (1994). "The prevalence of polycystic ovaries on 
ultrasound scanning in a population of randomly selected women." Aust N Z J Obstet 
Gynaecol 34(1): 67-72. 
 
Fassnacht, M., N. Schlenz, et al. (2003). "Beyond adrenal and ovarian androgen 
generation: Increased peripheral 5 alpha-reductase activity in women with polycystic 
ovary syndrome." J Clin Endocrinol Metab 88(6): 2760-2766. 
 
Ferrara, N., G. Frantz, et al. (2003). "Differential expression of the angiogenic factor 
genes vascular endothelial growth factor (VEGF) and endocrine gland-derived 
VEGF in normal and polycystic human ovaries." Am J Pathol 162(6): 1881-1893. 
 
Flaws, J. A., A. N. Hirshfield, et al. (2001). "Effect of bcl-2 on the primordial follicle 
endowment in the mouse ovary." Biol Reprod 64(4): 1153-1159. 
 
Fletcher, A. J., X. H. Ma, et al. (2004). "Antenatal glucocorticoids reset the level of 
baseline and hypoxemia-induced pituitary-adrenal activity in the sheep fetus during 
late gestation." Am J Physiol Endocrinol Metab 286(2): E311-319. 
 
Fonseca-Alaniz, M. H., J. Takada, et al. (2007). "Adipose tissue as an endocrine 
organ: from theory to practice." J Pediatr (Rio J) 83(5 Suppl): S192-203. 
 
 
Page | 297  
 
Forabosco, A., C. Sforza, et al. (1991). "Morphometric study of the human neonatal 
ovary." Anat Rec 231(2): 201-208. 
 
Ford, C. E., K. W. Jones, et al. (1959). "A sex-chromosome anomaly in a case of 
gonadal dysgenesis (Turner's syndrome)." Lancet 1(7075): 711-713. 
 
Fortin, J., P. Lamba, et al. (2009). "Conservation of mechanisms mediating 
gonadotrophin-releasing hormone 1 stimulation of human luteinizing hormone beta 
subunit transcription." Mol Hum Reprod 15(2): 77-87. 
 
Fowden, A. L. and A. J. Forhead (2004). "Endocrine mechanisms of intrauterine 
programming." Reproduction 127(5): 515-526. 
 
Fowden, A. L. and A. J. Forhead (2009). "Hormones as epigenetic signals in 
developmental programming." Exp Physiol 94(6): 607-625. 
 
Fowden, A. L., A. J. Forhead, et al. (2008). "The placenta and intrauterine 
programming." J Neuroendocrinol 20(4): 439-450. 
 
Fowden, A. L., D. A. Giussani, et al. (2005). "Endocrine and metabolic programming 
during intrauterine development." Early Hum Dev 81(9): 723-734. 
 
Franks, R. (2010). Polycystic Ovary Syndrome - SRF Distinguished Scientist 2010. 
Society for Reproduction and Fertility, Nottingham. 
 
Franks, S., N. Gharani, et al. (1998). "Genetics of polycystic ovary syndrome." Mol 
Cell Endocrinol 145(1-2): 123-128. 
 
Franks, S., M. I. McCarthy, et al. (2006). "Development of polycystic ovary 
syndrome: involvement of genetic and environmental factors." Int J Androl 29(1): 
278-285; discussion 286-290. 
 
Franks, S., J. Stark, et al. (2008). "Follicle dynamics and anovulation in polycystic 
ovary syndrome." Hum Reprod Update 14(4): 367-378. 
 
Fratantonio, E., E. Vicari, et al. (2005). "Genetics of polycystic ovarian syndrome." 
Reprod Biomed Online 10(6): 713-720. 
 
 
Page | 298  
 
Fu, Q., X. Yu, et al. (2009). "Epigenetics: intrauterine growth retardation (IUGR) 
modifies the histone code along the rat hepatic IGF-1 gene." Faseb J 23(8): 2438-
2449. 
 
Fulghesu, A. M., S. Angioni, et al. (2007). "Ultrasound in polycystic ovary 
syndrome--the measuring of ovarian stroma and relationship with circulating 
androgens: results of a multicentric study." Hum Reprod 22(9): 2501-2508. 
 
Fulghesu, A. M., M. Ciampelli, et al. (2001). "A new ultrasound criterion for the 
diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio." Fertil 
Steril 76(2): 326-331. 
 
Gallardo, N., E. Bonzon-Kulichenko, et al. (2007). "Tissue-specific effects of central 
leptin on the expression of genes involved in lipid metabolism in liver and white 
adipose tissue." Endocrinology 148(12): 5604-5610. 
 
Gavrieli, Y., Y. Sherman, et al. (1992). "Identification of programmed cell death in 
situ via specific labeling of nuclear DNA fragmentation." J Cell Biol 119(3): 493-
501. 
 
Gaytan, F., C. Bellido, et al. (1998). "Both prolactin and progesterone in proestrus 
are necessary for the induction of apoptosis in the regressing corpus luteum of the 
rat." Biol Reprod 59(5): 1200-1206. 
 
Gaytan, F., C. Morales, et al. (1998). "Ovarian follicle macrophages: is follicular 
atresia in the immature rat a macrophage-mediated event?" Biol Reprod 58(1): 52-59. 
 
Gaytan, F., C. Morales, et al. (1998). "Macrophages, cell proliferation, and cell death 
in the human menstrual corpus luteum." Biol Reprod 59(2): 417-425. 
 
Geer, E. B. and W. Shen (2009). "Gender differences in insulin resistance, body 
composition, and energy balance." Gend Med 6 Suppl 1: 60-75. 
 
Gluckman, P. D., W. Cutfield, et al. (2005). "The fetal, neonatal, and infant 
environments-the long-term consequences for disease risk." Early Hum Dev 81(1): 
51-59. 
 
Gluckman, P. D. and M. A. Hanson (2004). "The developmental origins of the 
metabolic syndrome." Trends Endocrinol Metab 15(4): 183-187. 
 
Page | 299  
 
 
Gonzazalez-Parra, S., J. Argente, et al. (2000). "Effect of neonatal and adult 
testosterone treatment on the cellular composition of the adult female rat anterior 
pituitary." J Endocrinol 164(3): 265-276. 
 
Gorski, R. A. and C. A. Barraclough (1962). "Adenohypophyseal LH content in 
normal androgen-sterilized and progesteroneprimed sterile female rats." Acta 
Endocrinol (Copenh) 39: 13-21. 
 
Gorski, R. A. and C. A. Barraclough (1962). "Studies on hypothalamic regulation of 
FSH secretion in the androgen-sterilized female rat." Proc Soc Exp Biol Med 110: 
298-300. 
 
Gorski, R. A. and C. A. Barraclough (1963). "Effects of Low Dosages of Androgen 
on the Differentiation of Hypothalamic Regulatory Control of Ovulation in the Rat." 
Endocrinology 73: 210-216. 
 
Gosmain, Y., N. Dif, et al. (2005). "Regulation of SREBP-1 expression and 
transcriptional action on HKII and FAS genes during fasting and refeeding in rat 
tissues." J Lipid Res 46(4): 697-705. 
 
Goy, R. W., F. B. Bercovitch, et al. (1988). "Behavioral masculinization is 
independent of genital masculinization in prenatally androgenized female rhesus 
macaques." Horm Behav 22(4): 552-571. 
 
Goy, R. W. and C. H. Phoenix (1972). "The effects of testosterone propionate 
administered before birth on the development of behavior in genetic female rhesus 
monkeys." UCLA Forum Med Sci 15: 193-201. 
 
Green, S. H., A. M. Mandl, et al. (1951). "The proportion of ovarian follicles in 
different stages of development in rats and monkeys." J Anat 85(4): 325-329. 
 
Greenfeld, C. R., M. E. Pepling, et al. (2007). "BAX regulates follicular endowment 
in mice." Reproduction 133(5): 865-876. 
 
Gregoire, F. M., C. M. Smas, et al. (1998). "Understanding adipocyte 
differentiation." Physiol Rev 78(3): 783-809. 
 
 
Page | 300  
 
Grossmann, R., F. J. Diez-Guerra, et al. (1987). "Neonatal testosterone modifies LH 
secretion in the adult female rat by altering the opioid-noradrenergic interaction in 
the medial preoptic area." Brain Res 415(2): 205-210. 
 
Group, E. C. W. (2006). "Nutrition and reproduction in women." Hum Reprod 
Update 12(3): 193-207. 
 
Guastella, E., R. A. Longo, et al. (2010). "Clinical and endocrine characteristics of 
the main polycystic ovary syndrome phenotypes." Fertil Steril. 
 
Guilloteau, P., R. Zabielski, et al. (2009). "Adverse effects of nutritional 
programming during prenatal and early postnatal life, some aspects of regulation and 
potential prevention and treatments." J Physiol Pharmacol 60 Suppl 3: 17-35. 
 
Gustafsson, J. A. and A. Stenberg (1974). "Irreversible androgenic programming at 
birth of microsomal and soluble rat liver enzymes active on androstene-3,17-dione 
and 5alpha-androstane-3alpha,17beta-diol." J Biol Chem 249(3): 711-718. 
 
Gustafsson, J. A. and A. Stenberg (1974). "Neonatal programming of androgen 
responsiveness of liver of adult rats." J Biol Chem 249(3): 719-723. 
 
Hagen, C., K. P. McNatty, et al. (1976). "Immunoreactive alpha- and beta-subunits 
of luteinizing hormone in human peripheral blood and follicular fluid throughout the 
menstrual cycle, and their effect on the secretion rate of progesterone by human 
granulosa cells in tissue culture." J Endocrinol 69(1): 33-46. 
 
Haisenleder, D. J., A. C. Dalkin, et al. (1991). "A pulsatile gonadotropin-releasing 
hormone stimulus is required to increase transcription of the gonadotropin subunit 
genes: evidence for differential regulation of transcription by pulse frequency in 
vivo." Endocrinology 128(1): 509-517. 
 
Haisenleder, D. J., G. A. Ortolano, et al. (1993). "Regulation of gonadotropin subunit 
messenger ribonucleic acid expression by gonadotropin-releasing hormone pulse 
amplitude in vitro." Endocrinology 132(3): 1292-1296. 
 
Haisenleder, D. J., M. Yasin, et al. (1997). "Gonadotropin subunit and gonadotropin-
releasing hormone receptor gene expression are regulated by alterations in the 
frequency of calcium pulsatile signals." Endocrinology 138(12): 5227-5230. 
 
 
Page | 301  
 
Han, Y. K., Y. G. Kim, et al. (2010). "Hyperosmotic stress induces autophagy and 
apoptosis in recombinant Chinese hamster ovary cell culture." Biotechnol Bioeng 
105(6): 1187-1192. 
 
Handa, R. J. and J. A. Resko (1989). "Alpha-adrenergic regulation of androgen 
receptor concentration in the preoptic area of the rat." Brain Res 483(2): 312-320. 
 
Harlow, C. R., S. G. Hillier, et al. (1986). "Androgen modulation of follicle-
stimulating hormone-induced granulosa cell steroidogenesis in the primate ovary." 
Endocrinology 119(3): 1403-1405. 
 
Harlow, C. R., H. J. Shaw, et al. (1988). "Factors influencing follicle-stimulating 
hormone-responsive steroidogenesis in marmoset granulosa cells: effects of 
androgens and the stage of follicular maturity." Endocrinology 122(6): 2780-2787. 
 
Heard, E., J. Chaumeil, et al. (2004). "Mammalian X-chromosome inactivation: an 
epigenetics paradigm." Cold Spring Harb Symp Quant Biol 69: 89-102. 
 
Hickey, T., A. Chandy, et al. (2002). "The androgen receptor CAG repeat 
polymorphism and X-chromosome inactivation in Australian Caucasian women with 
infertility related to polycystic ovary syndrome." J Clin Endocrinol Metab 87(1): 
161-165. 
 
Hickey, T. E., R. S. Legro, et al. (2006). "Epigenetic modification of the X 
chromosome influences susceptibility to polycystic ovary syndrome." J Clin 
Endocrinol Metab 91(7): 2789-2791. 
 
Hickey, T. E., D. L. Marrocco, et al. (2005). "Androgens augment the mitogenic 
effects of oocyte-secreted factors and growth differentiation factor 9 on porcine 
granulosa cells." Biol Reprod 73(4): 825-832. 
 
Hillier, S. G. and F. A. De Zwart (1981). "Evidence that granulosa cell aromatase 
induction/activation by follicle-stimulating hormone is an androgen receptor-
regulated process in-vitro." Endocrinology 109(4): 1303-1305. 
 
Hillier, S. G., R. A. Knazek, et al. (1977). "Androgenic stimulation of progesterone 
production by granulosa cells from preantral ovarian follicles: further in vitro studies 
using replicate cell cultures." Endocrinology 100(6): 1539-1549. 
 
 
Page | 302  
 
Hillier, S. G. and M. Tetsuka (1997). "Role of androgens in follicle maturation and 
atresia." Baillieres Clin Obstet Gynaecol 11(2): 249-260. 
 
Hillier, S. G., E. L. Yong, et al. (1991). "Effect of recombinant inhibin on androgen 
synthesis in cultured human thecal cells." Mol Cell Endocrinol 75(2): R1-6. 
 
Hillier, S. G., A. J. Zeleznik, et al. (1980). "Hormonal regulation of preovulatory 
follicle maturation in the rat." J Reprod Fertil 60(1): 219-229. 
 
Hirshfield, A. N. and A. R. Midgley, Jr. (1978). "Morphometric analysis of follicular 
development in the rat." Biol Reprod 19(3): 597-605. 
 
Hoepfner, B. A. and I. L. Ward (1988). "Prenatal and neonatal androgen exposure 
interact to affect sexual differentiation in female rats." Behav Neurosci 102(1): 61-
65. 
 
Holte, J. (1998). "Polycystic ovary syndrome and insulin resistance: thrifty genes 
struggling with over-feeding and sedentary life style?" J Endocrinol Invest 21(9): 
589-601. 
 
Honnma, H., T. Endo, et al. (2006). "Altered expression of Fas/Fas ligand/caspase 8 
and membrane type 1-matrix metalloproteinase in atretic follicles within 
dehydroepiandrosterone-induced polycystic ovaries in rats." Apoptosis 11(9): 1525-
1533. 
 
Hu, Y. C., P. H. Wang, et al. (2004). "Subfertility and defective folliculogenesis in 
female mice lacking androgen receptor." Proc Natl Acad Sci U S A 101(31): 11209-
11214. 
 
Hughesdon, P. E. (1982). "Morphology and morphogenesis of the Stein-Leventhal 
ovary and of so-called "hyperthecosis"." Obstet Gynecol Surv 37(2): 59-77. 
 
Huhtaniemi, I. and A. Bartke (2001). "Perspective: male reproduction." 
Endocrinology 142(6): 2178-2183. 
 
Huntriss, J., M. Hinkins, et al. (2006). "cDNA cloning and expression of the human 
NOBOX gene in oocytes and ovarian follicles." Mol Hum Reprod 12(5): 283-289. 
 
 
Page | 303  
 
Hwang, S. O. and G. M. Lee (2008). "Nutrient deprivation induces autophagy as well 
as apoptosis in Chinese hamster ovary cell culture." Biotechnol Bioeng 99(3): 678-
685. 
 
Iguchi, T. and N. Takasugi (1981). "Occurrence of permanent anovulation in mouse 
ovaries and permanent changes in the vaginal and uterine epithelia following 
neonatal treatment with large doses of 5 alpha-dihydrotestosterone." Endocrinol Jpn 
28(2): 207-213. 
 
Ikenasio-Thorpe, B. A., B. H. Breier, et al. (2007). "Prenatal influences on 
susceptibility to diet-induced obesity are mediated by altered neuroendocrine gene 
expression." J Endocrinol 193(1): 31-37. 
 
Illera, J. C., G. Silvan, et al. (2005). "The effect of dexamethasone on disruption of 
ovarian steroid levels and receptors in female rats." J Physiol Biochem 61(3): 429-
438. 
 
Irion, S., H. Luche, et al. (2007). "Identification and targeting of the ROSA26 locus 
in human embryonic stem cells." Nat Biotechnol 25(12): 1477-1482. 
 
Irving-Rodgers, H. F., M. Krupa, et al. (2003). "Cholesterol side-chain cleavage 
cytochrome P450 and 3beta-hydroxysteroid dehydrogenase expression and the 
concentrations of steroid hormones in the follicular fluids of different phenotypes of 
healthy and atretic bovine ovarian follicles." Biol Reprod 69(6): 2022-2028. 
 
Jaaskelainen, J., S. Korhonen, et al. (2005). "Androgen receptor gene CAG length 
polymorphism in women with polycystic ovary syndrome." Fertil Steril 83(6): 1724-
1728. 
 
Jabbour, H. N., R. W. Kelly, et al. (2006). "Endocrine regulation of menstruation." 
Endocr Rev 27(1): 17-46. 
 
Jacobs, P. A. and J. A. Strong (1959). "A case of human intersexuality having a 
possible XXY sex-determining mechanism." Nature 183(4657): 302-303. 
 
Jakimiuk, A. J., S. R. Weitsman, et al. (1999). "5alpha-reductase activity in women 
with polycystic ovary syndrome." J Clin Endocrinol Metab 84(7): 2414-2418. 
 
 
Page | 304  
 
Jarvela, I. Y., P. Sladkevicius, et al. (2004). "Comparison of follicular 
vascularization in normal versus polycystic ovaries during in vitro fertilization as 
measured using 3-dimensional power Doppler ultrasonography." Fertil Steril 82(5): 
1358-1363. 
 
Jefferson, W., R. Newbold, et al. (2006). "Neonatal genistein treatment alters ovarian 
differentiation in the mouse: inhibition of oocyte nest breakdown and increased 
oocyte survival." Biol Reprod 74(1): 161-168. 
 
Jia, X. C., B. Kessel, et al. (1985). "Androgen inhibition of follicle-stimulating 
hormone-stimulated luteinizing hormone receptor formation in cultured rat granulosa 
cells." Endocrinology 117(1): 13-22. 
 
Johnson, M. H. (2007). Essential Reproduction, Blackwell Publishing. 
 
Jonard, S. and D. Dewailly (2004). "The follicular excess in polycystic ovaries, due 
to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest." 
Hum Reprod Update 10(2): 107-117. 
 
Kaaijk, E. M., H. Sasano, et al. (2000). "Distribution of steroidogenic enzymes 
involved in androgen synthesis in polycystic ovaries: an immunohistochemical 
study." Mol Hum Reprod 6(5): 443-447. 
 
Kalantaridou, S. N. and L. M. Nelson (2000). "Premature ovarian failure is not 
premature menopause." Ann N Y Acad Sci 900: 393-402. 
 
Kalantry, S. (2011). "Recent advances in X-chromosome inactivation." J Cell 
Physiol 226(7): 1714-1718. 
 
Kanitz, E., W. Otten, et al. (2006). "Changes in endocrine and neurochemical 
profiles in neonatal pigs prenatally exposed to increased maternal cortisol." J 
Endocrinol 191(1): 207-220. 
 
Kapoor, A. and S. G. Matthews (2008). "Prenatal stress modifies behavior and 
hypothalamic-pituitary-adrenal function in female guinea pig offspring: effects of 




Page | 305  
 
Kelberman, D., K. Rizzoti, et al. (2009). "Genetic regulation of pituitary gland 
development in human and mouse." Endocr Rev 30(7): 790-829. 
 
Kelly, R. W. and H. O. Critchley (1997). "Immunomodulation by human seminal 
plasma: a benefit for spermatozoon and pathogen?" Hum Reprod 12(10): 2200-2207. 
 
Kezele, P. and M. K. Skinner (2003). "Regulation of ovarian primordial follicle 
assembly and development by estrogen and progesterone: endocrine model of follicle 
assembly." Endocrinology 144(8): 3329-3337. 
 
Knight, P. G. and C. Glister (2003). "Local roles of TGF-beta superfamily members 
in the control of ovarian follicle development." Anim Reprod Sci 78(3-4): 165-183. 
 
Knobil, E. (1974). "On the control of gonadotropin secretion in the rhesus monkey." 
Recent Prog Horm Res 30(0): 1-46. 
 
Kopelman, P. G. (1994). "Hormones and obesity." Baillieres Clin Endocrinol Metab 
8(3): 549-575. 
 
Kopinke, L. C. M. a. D. (2008). Pancreatic stem cells. StemBook: Harvard Stem Cell 
Institute. L. G. H. S. C. Institute). 
 
Krechowec, S. O., M. Vickers, et al. (2006). "Prenatal influences on leptin sensitivity 
and susceptibility to diet-induced obesity." J Endocrinol 189(2): 355-363. 
 
Lacombe, A., H. Lee, et al. (2006). "Disruption of POF1B binding to nonmuscle 
actin filaments is associated with premature ovarian failure." Am J Hum Genet 79(1): 
113-119. 
 
Lagaly, D. V., P. Y. Aad, et al. (2008). "Role of adiponectin in regulating ovarian 
theca and granulosa cell function." Mol Cell Endocrinol 284(1-2): 38-45. 
 
Lara, H. E., J. L. Ferruz, et al. (1993). "Activation of ovarian sympathetic nerves in 
polycystic ovary syndrome." Endocrinology 133(6): 2690-2695. 
 
Larsen, B., A. J. Markovetz, et al. (1977). "Relationship of vaginal cytology to 
alterations of the vaginal microflora of rats during the estrous cycle." Appl Environ 
Microbiol 33(3): 556-562. 
 
Page | 306  
 
 
Lau, Y. F. and Y. Li (2009). "The human and mouse sex-determining SRY genes 
repress the Rspol/beta-catenin signaling." J Genet Genomics 36(4): 193-202. 
 
Law, C. M., D. J. Barker, et al. (1992). "Early growth and abdominal fatness in adult 
life." J Epidemiol Community Health 46(3): 184-186. 
 
Lecureuil, C., I. Fontaine, et al. (2002). "Sertoli and granulosa cell-specific Cre 
recombinase activity in transgenic mice." Genesis 33(3): 114-118. 
 
Lee, J. H., M. E. Miele, et al. (1996). "KiSS-1, a novel human malignant melanoma 
metastasis-suppressor gene." J Natl Cancer Inst 88(23): 1731-1737. 
 
Lee, Y. S. (2009). "The role of genes in the current obesity epidemic." Ann Acad 
Med Singapore 38(1): 45-43. 
 
Lei, L., S. Jin, et al. (2010). "The regulatory role of Dicer in folliculogenesis in 
mice." Mol Cell Endocrinol 315(1-2): 63-73. 
 
Lephart, E. D., S. B. Call, et al. (2001). "Neuroendocrine regulation of sexually 
dimorphic brain structure and associated sexual behavior in male rats is genetically 
controlled." Biol Reprod 64(2): 571-578. 
 
Levitt, N. S., R. S. Lindsay, et al. (1996). "Dexamethasone in the last week of 
pregnancy attenuates hippocampal glucocorticoid receptor gene expression and 
elevates blood pressure in the adult offspring in the rat." Neuroendocrinology 64(6): 
412-418. 
 
Lillycrop, K. A., J. L. Slater-Jefferies, et al. (2007). "Induction of altered epigenetic 
regulation of the hepatic glucocorticoid receptor in the offspring of rats fed a protein-
restricted diet during pregnancy suggests that reduced DNA methyltransferase-1 
expression is involved in impaired DNA methylation and changes in histone 
modifications." Br J Nutr 97(6): 1064-1073. 
 
Lin, L. and J. C. Achermann (2004). "The adrenal." Horm Res 62 Suppl 3: 22-29. 
 
Lin, Y., X. Li, et al. "The Role of the Medial and Central Amygdala in Stress-
Induced Suppression of Pulsatile LH Secretion in Female Rats." Endocrinology. 
 
Page | 307  
 
 
Liu, K. H., Y. L. Chan, et al. (2006). "Mesenteric fat thickness is an independent 
determinant of metabolic syndrome and identifies subjects with increased carotid 
intima-media thickness." Diabetes Care 29(2): 379-384. 
 
Liu, L., S. Rajareddy, et al. (2007). "Infertility caused by retardation of follicular 
development in mice with oocyte-specific expression of Foxo3a." Development 
134(1): 199-209. 
 
Lourenco, D., R. Brauner, et al. (2009). "Mutations in NR5A1 associated with 
ovarian insufficiency." N Engl J Med 360(12): 1200-1210. 
 
Loverro, G., M. Vicino, et al. (2001). "Polycystic ovary syndrome: relationship 
between insulin sensitivity, sex hormone levels and ovarian stromal blood flow." 
Gynecol Endocrinol 15(2): 142-149. 
 
Luo, W. and M. C. Wiltbank (2006). "Distinct regulation by steroids of messenger 
RNAs for FSHR and CYP19A1 in bovine granulosa cells." Biol Reprod 75(2): 217-
225. 
 
MacDougald, O. A. and M. D. Lane (1995). "Transcriptional regulation of gene 
expression during adipocyte differentiation." Annu Rev Biochem 64: 345-373. 
 
Maciel, G. A., E. C. Baracat, et al. (2004). "Stockpiling of transitional and classic 
primary follicles in ovaries of women with polycystic ovary syndrome." J Clin 
Endocrinol Metab 89(11): 5321-5327. 
 
Macleod, D. J., R. M. Sharpe, et al. (2010). "Androgen action in the masculinization 
programming window and development of male reproductive organs." Int J Androl 
33(2): 279-287. 
 
Maeda, K., S. Adachi, et al. (2007). "Metastin/kisspeptin and control of estrous cycle 
in rats." Rev Endocr Metab Disord 8(1): 21-29. 
 
Maeda, K., H. Tsukamura, et al. (1995). "The LHRH pulse generator: a mediobasal 
hypothalamic location." Neurosci Biobehav Rev 19(3): 427-437. 
 
Magoffin, D. A. (2005). "Ovarian theca cell." Int J Biochem Cell Biol 37(7): 1344-
1349. 
 
Page | 308  
 
 
Mahesh, V. B., T. M. Mills, et al. (1987). "Animal models for study of polycystic 
ovaries and ovarian atresia." Adv Exp Med Biol 219: 237-257. 
 
Mairesse, J., J. Lesage, et al. (2007). "Maternal stress alters endocrine function of the 
feto-placental unit in rats." Am J Physiol Endocrinol Metab 292(6): E1526-1533. 
 
Manikkam, M., R. C. Thompson, et al. (2008). "Developmental programming: 
impact of prenatal testosterone excess on pre- and postnatal gonadotropin regulation 
in sheep." Biol Reprod 78(4): 648-660. 
 
Manneras, L., S. Cajander, et al. (2007). "A new rat model exhibiting both ovarian 
and metabolic characteristics of polycystic ovary syndrome." Endocrinology 148(8): 
3781-3791. 
 
Manneras, L., I. H. Jonsdottir, et al. (2008). "Low Frequency Electro-Acupuncture 
and Physical Exercise Improve Metabolic Disturbances and Modulate Gene 
Expression in Adipose Tissue in Rats with Dihydrotestosterone-Induced Polycystic 
Ovary Syndrome." Endocrinology. 
 
Manni, L., A. Holmang, et al. (2005). "Ovarian expression of alpha (1)- and beta (2)-
adrenoceptors and p75 neurotrophin receptors in rats with steroid-induced polycystic 
ovaries." Auton Neurosci 118(1-2): 79-87. 
 
Marshall, J. C., A. C. Dalkin, et al. (1993). "GnRH pulses--the regulators of human 
reproduction." Trans Am Clin Climatol Assoc 104: 31-46. 
 
Marshall, J. C. and M. L. Griffin (1993). "The role of changing pulse frequency in 
the regulation of ovulation." Hum Reprod 8 Suppl 2: 57-61. 
 
Marteil, G., L. Richard-Parpaillon, et al. (2009). "Role of oocyte quality in meiotic 
maturation and embryonic development." Reprod Biol 9(3): 203-224. 
 
Martinerie, L., C. Bouvattier, et al. (2009). "[SF-1, a key player in adrenal and 
gonadal differentiation: implications in gonadal dysgenesis and primary ovarian 
insufficiency]." Ann Endocrinol (Paris) 70 Suppl 1: S26-32. 
 
 
Page | 309  
 
Masek, K. S., R. I. Wood, et al. (1999). "Prenatal dihydrotestosterone differentially 
masculinizes tonic and surge modes of luteinizing hormone secretion in sheep." 
Endocrinology 140(8): 3459-3466. 
 
Matsuda-Minehata, F., N. Inoue, et al. (2006). "The regulation of ovarian granulosa 
cell death by pro- and anti-apoptotic molecules." J Reprod Dev 52(6): 695-705. 
 
Matsumoto, T., K. Takeyama, et al. (2003). "Androgen receptor functions from 
reverse genetic models." J Steroid Biochem Mol Biol 85(2-5): 95-99. 
 
Matzuk, M. M. (2000). "Revelations of ovarian follicle biology from gene knockout 
mice." Mol Cell Endocrinol 163(1-2): 61-66. 
 
Matzuk, M. M., K. H. Burns, et al. (2002). "Intercellular communication in the 
mammalian ovary: oocytes carry the conversation." Science 296(5576): 2178-2180. 
 
McConnell, N. A., R. S. Yunus, et al. (2002). "Water permeability of an ovarian 
antral follicle is predominantly transcellular and mediated by aquaporins." 
Endocrinology 143(8): 2905-2912. 
 
McCowan, L. M., J. E. Harding, et al. (2000). "A pilot randomized controlled trial of 
two regimens of fetal surveillance for small-for-gestational-age fetuses with normal 
results of umbilical artery doppler velocimetry." Am J Obstet Gynecol 182(1 Pt 1): 
81-86. 
 
McDonald, P. G. and C. Doughty (1972). "Comparison of the effect of neonatal 
administration of testosterone and dihydrotestosterone in the female rat." J Reprod 
Fertil 30(1): 55-62. 
 
McDonald, P. G. and C. Doughty (1974). "Effect of neonatal administration of 
different androgens in the female rat: correlation between aromatization and the 
induction of sterilization." J Endocrinol 61(1): 95-103. 
 
McMillen, I. C. and J. S. Robinson (2005). "Developmental origins of the metabolic 
syndrome: prediction, plasticity, and programming." Physiol Rev 85(2): 571-633. 
 
McNatty, K. P., Quirke, L.D., Fidler, A., Smith, P., Heath, D.A. & Tisdall, D. 
(2000). Ovarian Development: Fetus to Puberty. Hormones and Women's Heath. H. 
A. P. Ed. L.A. Salamonsen, The Netherlands.: pp9-22. 
 
Page | 310  
 
 
McNeilly, A. S., J. L. Crawford, et al. (2003). "The differential secretion of FSH and 
LH: regulation through genes, feedback and packaging." Reprod Suppl 61: 463-476. 
 
McTernan, C. L., P. G. McTernan, et al. (2002). "Resistin, central obesity, and type 2 
diabetes." Lancet 359(9300): 46-47. 
 
Meachem, S. J., E. Nieschlag, et al. (2001). "Inhibin B in male reproduction: 
pathophysiology and clinical relevance." Eur J Endocrinol 145(5): 561-571. 
 
Means, G. D., M. S. Mahendroo, et al. (1989). "Structural analysis of the gene 
encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen 
biosynthesis." J Biol Chem 264(32): 19385-19391. 
 
Mena, M. A., C. A. Arriaza, et al. (1992). "Early postnatal androgenization imprints 
selective changes in the action of estrogens in the rat uterus." Biol Reprod 46(6): 
1080-1085. 
 
Midgley, A. R., Jr. and R. B. Jaffe (1968). "Regulation of human gonadotropins. IV. 
Correlation of serum concentrations of follicle stimulating and luteinizing hormones 
during the menstrual cycle." J Clin Endocrinol Metab 28(12): 1699-1703. 
 
Midgley, A. R., Jr. and R. B. Jaffe (1971). "Regulation of human gonadotropins. X. 
Episodic fluctuation of LH during the menstrual cycle." J Clin Endocrinol Metab 
33(6): 962-969. 
 
Misugi, T., K. Ozaki, et al. (2006). "Insulin-lowering agents inhibit synthesis of 
testosterone in ovaries of DHEA-induced PCOS rats." Gynecol Obstet Invest 61(4): 
208-215. 
 
Miyamoto, J., T. Matsumoto, et al. (2007). "The pituitary function of androgen 
receptor constitutes a glucocorticoid production circuit." Mol Cell Biol 27(13): 4807-
4814. 
 
Mizukami, S., K. Yamanouchi, et al. (1982). "Failure of ovulation after neonatal 




Page | 311  
 
Mohlig, M., A. Jurgens, et al. (2006). "The androgen receptor CAG repeat modifies 
the impact of testosterone on insulin resistance in women with polycystic ovary 
syndrome." Eur J Endocrinol 155(1): 127-130. 
 
Moran, L. and R. J. Norman (2004). "Understanding and managing disturbances in 
insulin metabolism and body weight in women with polycystic ovary syndrome." 
Best Pract Res Clin Obstet Gynaecol 18(5): 719-736. 
 
Moran, L. J., G. Brinkworth, et al. (2006). "Effects of lifestyle modification in 
polycystic ovarian syndrome." Reprod Biomed Online 12(5): 569-578. 
 
Morey, C. and P. Avner (2010). "Genetics and epigenetics of the X chromosome." 
Ann N Y Acad Sci 1214: E18-33. 
 
Morita, Y., G. I. Perez, et al. (1999). "Targeted expression of Bcl-2 in mouse oocytes 
inhibits ovarian follicle atresia and prevents spontaneous and chemotherapy-induced 
oocyte apoptosis in vitro." Mol Endocrinol 13(6): 841-850. 
 
Morris, J. A., C. L. Jordan, et al. (2004). "Sexual differentiation of the vertebrate 
nervous system." Nat Neurosci 7(10): 1034-1039. 
 
Morton, N. M., L. Ramage, et al. (2004). "Down-regulation of adipose 11beta-
hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential 
adaptive mechanism counteracting metabolic disease." Endocrinology 145(6): 2707-
2712. 
 
Muir, A. I., L. Chamberlain, et al. (2001). "AXOR12, a novel human G protein-
coupled receptor, activated by the peptide KiSS-1." J Biol Chem 276(31): 28969-
28975. 
 
Murakami, K., T. Ohhira, et al. (2009). "Identification of the chromatin regions 
coated by non-coding Xist RNA." Cytogenet Genome Res 125(1): 19-25. 
 
Murray, A. A., A. K. Swales, et al. (2008). "Follicular growth and oocyte 
competence in the in vitro cultured mouse follicle: effects of gonadotrophins and 
steroids." Mol Hum Reprod 14(2): 75-83. 
 
Myers, M., K. L. Britt, et al. (2004). "Methods for quantifying follicular numbers 
within the mouse ovary." Reproduction 127(5): 569-580. 
 
Page | 312  
 
 
Myers, M., E. Gay, et al. (2007). "In vitro evidence suggests activin-A may promote 
tissue remodeling associated with human luteolysis." Endocrinology 148(8): 3730-
3739. 
 
Myers, M., S. van den Driesche, et al. (2008). "Activin A reduces luteinisation of 
human luteinised granulosa cells and has opposing effects to human chorionic 
gonadotropin in vitro." J Endocrinol 199(2): 201-212. 
 
Nada, S. E., R. C. Thompson, et al. (2010). "Developmental programming: 
differential effects of prenatal testosterone excess on insulin target tissues." 
Endocrinology 151(11): 5165-5173. 
 
Nahum, R., K. J. Thong, et al. (1995). "Metabolic regulation of androgen production 
by human thecal cells in vitro." Hum Reprod 10(1): 75-81. 
 
Naor, Z. (2009). "Signaling by G-protein-coupled receptor (GPCR): studies on the 
GnRH receptor." Front Neuroendocrinol 30(1): 10-29. 
 
Nelson, L. M. (2009). "Clinical practice. Primary ovarian insufficiency." N Engl J 
Med 360(6): 606-614. 
 
Nelson, V. L., R. S. Legro, et al. (1999). "Augmented androgen production is a stable 
steroidogenic phenotype of propagated theca cells from polycystic ovaries." Mol 
Endocrinol 13(6): 946-957. 
 
Nicol, L., S. C. Bishop, et al. (2009). "Homozygosity for a single base-pair mutation 
in the oocyte-specific GDF9 gene results in sterility in Thoka sheep." Reproduction 
138(6): 921-933. 
 
Nicol, L., J. R. McNeilly, et al. (2002). "Influence of steroids and GnRH on 
biosynthesis and secretion of secretogranin II and chromogranin A in relation to LH 
release in LbetaT2 gonadotroph cells." J Endocrinol 174(3): 473-483. 
 
Nilsson, E. E., M. D. Anway, et al. (2008). "Transgenerational epigenetic effects of 
the endocrine disruptor vinclozolin on pregnancies and female adult onset disease." 
Reproduction 135(5): 713-721. 
 
 
Page | 313  
 
Norman, R. J. (2002). "Hyperandrogenaemia and the ovary." Mol Cell Endocrinol 
191(1): 113-119. 
 
Norman, R. J., M. J. Davies, et al. (2002). "The role of lifestyle modification in 
polycystic ovary syndrome." Trends Endocrinol Metab 13(6): 251-257. 
 
Norman, R. J., G. Homan, et al. (2006). "Lifestyle choices, diet, and insulin 
sensitizers in polycystic ovary syndrome." Endocrine 30(1): 35-43. 
 
Norman, R. J., M. Noakes, et al. (2004). "Improving reproductive performance in 
overweight/obese women with effective weight management." Hum Reprod Update 
10(3): 267-280. 
 
Notini, A. J., R. A. Davey, et al. (2005). "Genomic actions of the androgen receptor 
are required for normal male sexual differentiation in a mouse model." J Mol 
Endocrinol 35(3): 547-555. 
 
Ntambi, J. M. and K. Young-Cheul (2000). "Adipocyte differentiation and gene 
expression." J Nutr 130(12): 3122S-3126S. 
 
Nyirenda, M. J., R. S. Lindsay, et al. (1998). "Glucocorticoid exposure in late 
gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and 
glucocorticoid receptor expression and causes glucose intolerance in adult offspring." 
J Clin Invest 101(10): 2174-2181. 
 
Nyirenda, M. J. and J. R. Seckl (1998). "Intrauterine events and the programming of 
adulthood disease: the role of fetal glucocorticoid exposure (Review)." Int J Mol 
Med 2(5): 607-614. 
 
O'Regan, D., C. J. Kenyon, et al. (2004). "Glucocorticoid exposure in late gestation 
in the rat permanently programs gender-specific differences in adult cardiovascular 
and metabolic physiology." Am J Physiol Endocrinol Metab 287(5): E863-870. 
 
Orisaka, M., K. Tajima, et al. (2009). "Oocyte-granulosa-theca cell interactions 
during preantral follicular development." J Ovarian Res 2(1): 9. 
 
Ortega, H. H., F. Rey, et al. (2010). "Developmental programming: effect of prenatal 
steroid excess on intraovarian components of insulin signaling pathway and related 
proteins in sheep." Biol Reprod 82(6): 1065-1075. 
 
Page | 314  
 
 
Ortega, H. H., N. R. Salvetti, et al. (2009). "Developmental programming: prenatal 
androgen excess disrupts ovarian steroid receptor balance." Reproduction 137(5): 
865-877. 
 
Ota, H., A. Wakizaka, et al. (1986). "Enhanced ovarian gonadotropin receptors in the 
testosterone-induced polycystic ovary in rats." Tohoku J Exp Med 148(3): 313-325. 
 
Ozcimen, E. E., A. Uckuyu, et al. (2009). "The effect of metformin treatment on 
ovarian stromal blood flow in women with polycystic ovary syndrome." Arch 
Gynecol Obstet 280(2): 263-269. 
 
Padmanabhan, V. and A. S. McNeilly (2001). "Is there an FSH-releasing factor?" 
Reproduction 121(1): 21-30. 
 
Padmanabhan, V., H. N. Sarma, et al. (2010). "Developmental reprogramming of 
reproductive and metabolic dysfunction in sheep: native steroids vs. environmental 
steroid receptor modulators." Int J Androl 33(2): 394-404. 
 
Padmanabhan, V. and T. P. Sharma (2001). "Neuroendocrine vs. paracrine control of 
follicle-stimulating hormone." Arch Med Res 32(6): 533-543. 
 
Padmanabhan, V., A. Veiga-Lopez, et al. (2010). "Developmental programming: 
impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity 
index and transfer of traits to offspring of overweight females." Endocrinology 
151(2): 595-605. 
 
Pagano, C., G. Soardo, et al. (2005). "Plasma adiponectin is decreased in 
nonalcoholic fatty liver disease." Eur J Endocrinol 152(1): 113-118. 
 
Painter, R. C., S. R. de Rooij, et al. (2007). "Maternal nutrition during gestation and 
carotid arterial compliance in the adult offspring: the Dutch famine birth cohort." J 
Hypertens 25(3): 533-540. 
 
Pak, R. C., K. W. Tsim, et al. (1985). "The role of neonatal and pubertal gonadal 
hormones in regulating the sex dependence of the hepatic microsomal testosterone 5-
reductase activity in the rat." J Endocrinol 106(1): 71-79. 
 
 
Page | 315  
 
Pakarainen, T., F. P. Zhang, et al. (2005). "Knockout of luteinizing hormone receptor 
abolishes the effects of follicle-stimulating hormone on preovulatory maturation and 
ovulation of mouse graafian follicles." Mol Endocrinol 19(10): 2591-2602. 
 
Panadero, M., E. Herrera, et al. (2000). "Peroxisome proliferator-activated receptor-
alpha expression in rat liver during postnatal development." Biochimie 82(8): 723-
726. 
 
Panadero, M., H. Vidal, et al. (2001). "Nutritionally induced changes in the 
peroxisome proliferator-activated receptor-alpha gene expression in liver of suckling 
rats are dependent on insulinaemia." Arch Biochem Biophys 394(2): 182-188. 
 
Panning, B. (2008). "X-chromosome inactivation: the molecular basis of silencing." 
J Biol 7(8): 30. 
 
Panzer, C., S. Wise, et al. (2006). "Impact of oral contraceptives on sex hormone-
binding globulin and androgen levels: a retrospective study in women with sexual 
dysfunction." J Sex Med 3(1): 104-113. 
 
Papadimitriou, A. and K. N. Priftis (2009). "Regulation of the hypothalamic-
pituitary-adrenal axis." Neuroimmunomodulation 16(5): 265-271. 
 
Parsanezhad, M. E., M. H. Bagheri, et al. (2003). "Ovarian stromal blood flow 
changes after laparoscopic ovarian cauterization in women with polycystic ovary 
syndrome." Hum Reprod 18(7): 1432-1437. 
 
Pasquali, R. and A. Gambineri (2004). "Role of changes in dietary habits in 
polycystic ovary syndrome." Reprod Biomed Online 8(4): 431-439. 
 
Patel, M. S., M. Srinivasan, et al. (2009). "Metabolic programming: Role of nutrition 
in the immediate postnatal life." J Inherit Metab Dis 32(2): 218-228. 
 
Payne, A. H. and D. B. Hales (2004). "Overview of steroidogenic enzymes in the 
pathway from cholesterol to active steroid hormones." Endocr Rev 25(6): 947-970. 
 
Pepling, M. E. (2006). "From primordial germ cell to primordial follicle: mammalian 
female germ cell development." Genesis 44(12): 622-632. 
 
 
Page | 316  
 
Pepling, M. E. and A. C. Spradling (2001). "Mouse ovarian germ cell cysts undergo 
programmed breakdown to form primordial follicles." Dev Biol 234(2): 339-351. 
 
Picon, R., M. C. Pelloux, et al. (1985). "Conversion of androgen to estrogen by the 
rat fetal and neonatal female gonad: effects of dcAMP and FSH." J Steroid Biochem 
23(6A): 995-1000. 
 
Plagemann, A., I. Heidrich, et al. (1992). "Lifelong enhanced diabetes susceptibility 
and obesity after temporary intrahypothalamic hyperinsulinism during brain 
organization." Exp Clin Endocrinol 99(2): 91-95. 
 
Pomerantz, S. M., R. W. Goy, et al. (1986). "Expression of male-typical behavior in 
adult female pseudohermaphroditic rhesus: comparisons with normal males and 
neonatally gonadectomized males and females." Horm Behav 20(4): 483-500. 
 
Pomerantz, S. M., M. M. Roy, et al. (1988). "Social and hormonal influences on 
behavior of adult male, female, and pseudohermaphroditic rhesus monkeys." Horm 
Behav 22(2): 219-230. 
 
Priego, T., J. Sanchez, et al. (2008). "Sex-differential expression of metabolism-
related genes in response to a high-fat diet." Obesity (Silver Spring) 16(4): 819-826. 
 
Proulx, K., S. Clavel, et al. (2001). "High neonatal leptin exposure enhances brain 
GR expression and feedback efficacy on the adrenocortical axis of developing rats." 
Endocrinology 142(11): 4607-4616. 
 
Puurunen, J., T. Piltonen, et al. (2009). "Adrenal androgen production capacity 
remains high up to menopause in women with polycystic ovary syndrome." J Clin 
Endocrinol Metab 94(6): 1973-1978. 
 
Qi, L. and Y. A. Cho (2008). "Gene-environment interaction and obesity." Nutr Rev 
66(12): 684-694. 
 
Qin, Y., Y. Choi, et al. (2007). "NOBOX homeobox mutation causes premature 
ovarian failure." Am J Hum Genet 81(3): 576-581. 
 
Quinn, P. G. and D. Yeagley (2005). "Insulin regulation of PEPCK gene expression: 
a model for rapid and reversible modulation." Curr Drug Targets Immune Endocr 
Metabol Disord 5(4): 423-437. 
 
Page | 317  
 
 
Quirk, S. M., R. G. Cowan, et al. (2004). "Ovarian follicular growth and atresia: the 
relationship between cell proliferation and survival." J Anim Sci 82 E-Suppl: E40-
52. 
 
Qureshi, A. I., S. S. Nussey, et al. (2008). "Testosterone selectively increases 
primary follicles in ovarian cortex grafted onto embryonic chick membranes: 
relevance to polycystic ovaries." Reproduction 136(2): 187-194. 
 
Rang, H. P., M. M. Dale, et al. (2003). Pharmacology, Elsevier Science. 
 
Ratchford, A. M., C. R. Esguerra, et al. (2008). "Decreased oocyte-granulosa cell gap 
junction communication and connexin expression in a type 1 diabetic mouse model." 
Mol Endocrinol 22(12): 2643-2654. 
 
Recabarren, S. E., R. Smith, et al. (2008). "Metabolic profile in sons of women with 
polycystic ovary syndrome." J Clin Endocrinol Metab 93(5): 1820-1826. 
 
Reddy, P., L. Liu, et al. (2008). "Oocyte-specific deletion of Pten causes premature 
activation of the primordial follicle pool." Science 319(5863): 611-613. 
 
Reddy, P., L. Shen, et al. (2005). "Activation of Akt (PKB) and suppression of 
FKHRL1 in mouse and rat oocytes by stem cell factor during follicular activation 
and development." Dev Biol 281(2): 160-170. 
 
Ren, Y., R. G. Cowan, et al. (2009). "Dominant activation of the hedgehog signaling 
pathway in the ovary alters theca development and prevents ovulation." Mol 
Endocrinol 23(5): 711-723. 
 
Rey, R., C. Lukas-Croisier, et al. (2003). "AMH/MIS: what we know already about 
the gene, the protein and its regulation." Mol Cell Endocrinol 211(1-2): 21-31. 
 
Ribeiro, R. C., P. J. Kushner, et al. (1995). "The nuclear hormone receptor gene 
superfamily." Annu Rev Med 46: 443-453. 
 
Ribot, J., A. M. Rodriguez, et al. (2008). "Adiponectin and resistin response in the 
onset of obesity in male and female rats." Obesity (Silver Spring) 16(4): 723-730. 
 
 
Page | 318  
 
Ristic, N., N. Nestorovic, et al. (2008). "Maternal dexamethasone treatment reduces 
ovarian follicle number in neonatal rat offspring." J Microsc 232(3): 549-557. 
 
Rizzoti, K. and R. Lovell-Badge (2005). "Early development of the pituitary gland: 
induction and shaping of Rathke's pouch." Rev Endocr Metab Disord 6(3): 161-172. 
 
Rockwell, L. C. and R. D. Koos (2009). "Dexamethasone enhances fertility and 
preovulatory serum prolactin levels in eCG/hCG primed immature rats." J Reprod 
Dev 55(3): 247-251. 
 
Rodgers, R. J., H. F. Irving-Rodgers, et al. (2003). "Extracellular matrix of the 
developing ovarian follicle." Reproduction 126(4): 415-424. 
 
Rodriguez-Acebes, S., N. Palacios, et al. (2010). "Gene expression profiling of 
subcutaneous adipose tissue in morbid obesity using a focused microarray: Distinct 
expression of cell-cycle- and differentiation-related genes." BMC Med Genomics 
3(1): 61. 
 
Roelfsema, F., P. Kok, et al. (2010). "Cortisol production rate is similarly elevated in 
obese women with or without the polycystic ovary syndrome." J Clin Endocrinol 
Metab 95(7): 3318-3324. 
 
Roland, A. V., C. S. Nunemaker, et al. (2010). "Prenatal androgen exposure 
programs metabolic dysfunction in female mice." J Endocrinol 207(2): 213-223. 
 
Roma, P. G., M. E. Huntsberry, et al. (2007). "Separation stress, litter size, and the 
rewarding effects of low-dose morphine in the dams of maternally separated rats." 
Prog Neuropsychopharmacol Biol Psychiatry 31(2): 429-433. 
 
Rosa, E. S. A., M. A. Guimaraes, et al. (2003). "Prepubertal administration of 
estradiol valerate disrupts cyclicity and leads to cystic ovarian morphology during 
adult life in the rat: role of sympathetic innervation." Endocrinology 144(10): 4289-
4297. 
 
Roseboom, T. J., J. H. van der Meulen, et al. (2001). "Adult survival after prenatal 




Page | 319  
 
Roseboom, T. J., J. H. van der Meulen, et al. (2001). "Maternal nutrition during 
gestation and blood pressure in later life." J Hypertens 19(1): 29-34. 
 
Rossi, B., S. Sukalich, et al. (2008). "Prevalence of metabolic syndrome and related 
characteristics in obese adolescents with and without polycystic ovary syndrome." J 
Clin Endocrinol Metab 93(12): 4780-4786. 
 
S.S. Nussey, S. A. W. (2001). Endocrinology: An Integrated Approach, Oxford: 
BIOS Scientific Publishers. 
 
Sam, S., Y. A. Sung, et al. (2008). "Evidence for pancreatic beta-cell dysfunction in 
brothers of women with polycystic ovary syndrome." Metabolism 57(1): 84-89. 
 
Sanchez-Criado, J. E., P. Guelmes, et al. (2002). "Tamoxifen but not other selective 
estrogen receptor modulators antagonizes estrogen actions on luteinizing hormone 
secretion while inducing gonadotropin-releasing hormone self-priming in the rat." 
Neuroendocrinology 76(4): 203-213. 
 
Sanchez-Criado, J. E., A. Ruiz, et al. (1996). "Follicular and luteal progesterone 
synergize to maintain 5-day cyclicity in rats." Rev Esp Fisiol 52(4): 223-229. 
 
Sarma, H. N., M. Manikkam, et al. (2005). "Fetal programming: excess prenatal 
testosterone reduces postnatal luteinizing hormone, but not follicle-stimulating 
hormone responsiveness, to estradiol negative feedback in the female." 
Endocrinology 146(10): 4281-4291. 
 
Sathyapalan, T. and S. L. Atkin (2010). "Mediators of inflammation in polycystic 
ovary syndrome in relation to adiposity." Mediators Inflamm 2010: 758656. 
 
Scalzo, C. M. and S. D. Michael (1988). "Source of high testosterone levels 
associated with autoimmune ovarian dysgenesis in neonatally thymectomized B6A 
mice." Biol Reprod 38(5): 1115-1121. 
 
Schally, A. V., A. Arimura, et al. (1971). "Gonadotropin-releasing hormone: one 
polypeptide regulates secretion of luteinizing and follicle-stimulating hormones." 
Science 173(4001): 1036-1038. 
 
Schlein, P. A., M. X. Zarrow, et al. (1974). "The role of prolactin in the depressed or 
'buffered' adrenocorticosteroid response of the rat." J Endocrinol 62(1): 93-99. 
 
Page | 320  
 
 
Schulz, K. M., H. A. Molenda-Figueira, et al. (2009). "Back to the future: The 
organizational-activational hypothesis adapted to puberty and adolescence." Horm 
Behav 55(5): 597-604. 
 
Schwimmer, J. B., O. Khorram, et al. (2005). "Abnormal aminotransferase activity in 
women with polycystic ovary syndrome." Fertil Steril 83(2): 494-497. 
 
Scott, H. M., G. R. Hutchison, et al. (2008). "Relationship between androgen action 
in the "male programming window," fetal sertoli cell number, and adult testis size in 
the rat." Endocrinology 149(10): 5280-5287. 
 
Scott, H. M., G. R. Hutchison, et al. (2007). "Role of androgens in fetal testis 
development and dysgenesis." Endocrinology 148(5): 2027-2036. 
 
Seale, J. V., S. A. Wood, et al. (2005). "Postnatal masculinization alters the HPA 
axis phenotype in the adult female rat." J Physiol 563(Pt 1): 265-274. 
 
Seale, J. V., S. A. Wood, et al. (2005). "Organizational role for testosterone and 
estrogen on adult hypothalamic-pituitary-adrenal axis activity in the male rat." 
Endocrinology 146(4): 1973-1982. 
 
Seckl, J. R. (2001). "Glucocorticoid programming of the fetus; adult phenotypes and 
molecular mechanisms." Mol Cell Endocrinol 185(1-2): 61-71. 
 
Seckl, J. R. (2004). "Prenatal glucocorticoids and long-term programming." Eur J 
Endocrinol 151 Suppl 3: U49-62. 
 
Seckl, J. R., M. Cleasby, et al. (2000). "Glucocorticoids, 11beta-hydroxysteroid 
dehydrogenase, and fetal programming." Kidney Int 57(4): 1412-1417. 
 
Seckl, J. R., R. C. Dow, et al. (1993). "The 11 beta-hydroxysteroid dehydrogenase 
inhibitor glycyrrhetinic acid affects corticosteroid feedback regulation of 
hypothalamic corticotrophin-releasing peptides in rats." J Endocrinol 136(3): 471-
477. 
 
Sekido, R., I. Bar, et al. (2004). "SOX9 is up-regulated by the transient expression of 
SRY specifically in Sertoli cell precursors." Dev Biol 274(2): 271-279. 
 
Page | 321  
 
 
Sen, A. and S. R. Hammes (2010). "Granulosa cell-specific androgen receptors are 
critical regulators of ovarian development and function." Mol Endocrinol 24(7): 
1393-1403. 
 
Senner, C. E. and N. Brockdorff (2009). "Xist gene regulation at the onset of X 
inactivation." Curr Opin Genet Dev 19(2): 122-126. 
 
Seow, K. M., Y. L. Tsai, et al. (2009). "Omental adipose tissue overexpression of 
fatty acid transporter CD36 and decreased expression of hormone-sensitive lipase in 
insulin-resistant women with polycystic ovary syndrome." Hum Reprod 24(8): 1982-
1988. 
 
Setji, T. L. and A. J. Brown (2007). "Comprehensive clinical management of 
polycystic ovary syndrome." Minerva Med 98(3): 175-189. 
 
Setji, T. L., N. D. Holland, et al. (2006). "Nonalcoholic steatohepatitis and 
nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome." J 
Clin Endocrinol Metab 91(5): 1741-1747. 
 
Sharpe, R. M. "Bisphenol A exposure and sexual dysfunction in men: editorial 
commentary on the article 'Occupational exposure to bisphenol-A (BPA) and the risk 
of self-reported male sexual dysfunction' Li et al., 2009." Hum Reprod 25(2): 292-
294. 
 
Sharpe, R. M., A. Rivas, et al. (2003). "Effect of neonatal treatment of rats with 
potent or weak (environmental) oestrogens, or with a GnRH antagonist, on Leydig 
cell development and function through puberty into adulthood." Int J Androl 26(1): 
26-36. 
 
Sheridan, P. J., M. X. Zarrow, et al. (1973). "Androgenization of the neonatal female 
rat with very low doses of androgen." J Endocrinol 57(1): 33-45. 
 
Short, R. V. (1964). "Ovarian Steroid Snnthesis and Secretion in Vivo." Recent Prog 
Horm Res 20: 303-340. 
 




Page | 322  
 
Simanainen, U., C. M. Allan, et al. (2007). "Disruption of prostate epithelial 
androgen receptor impedes prostate lobe-specific growth and function." 
Endocrinology 148(5): 2264-2272. 
 
Simard, M., J. R. Brawer, et al. (1987). "An intractable, ovary-independent 
impairment in hypothalamo-pituitary function in the estradiol-valerate-induced 
polycystic ovarian condition in the rat." Biol Reprod 36(5): 1229-1237. 
 
Simpson, J. L. (2008). "Genetic and phenotypic heterogeneity in ovarian failure: 
overview of selected candidate genes." Ann N Y Acad Sci 1135: 146-154. 
 
Sinclair, A. H., P. Berta, et al. (1990). "A gene from the human sex-determining 
region encodes a protein with homology to a conserved DNA-binding motif." Nature 
346(6281): 240-244. 
 
Sisk, C. L., H. N. Richardson, et al. (2001). "In vivo gonadotropin-releasing hormone 
secretion in female rats during peripubertal development and on proestrus." 
Endocrinology 142(7): 2929-2936. 
 
Skinner, M. K. (2008). "What is an epigenetic transgenerational phenotype? F3 or 
F2." Reprod Toxicol 25(1): 2-6. 
 
Skinner, M. K., M. Manikkam, et al. "Epigenetic transgenerational actions of 
environmental factors in disease etiology." Trends Endocrinol Metab 21(4): 214-222. 
 
Slob, A. K., R. den Hamer, et al. (1983). "Prenatal testosterone propionate and 
postnatal ovarian activity in the rat." Acta Endocrinol (Copenh) 103(3): 420-427. 
 
Smith, J. T., D. K. Clifton, et al. (2006). "Regulation of the neuroendocrine 
reproductive axis by kisspeptin-GPR54 signaling." Reproduction 131(4): 623-630. 
 
Smith, M. F., E. W. McIntush, et al. (1994). "Mechanisms associated with corpus 
luteum development." J Anim Sci 72(7): 1857-1872. 
 
Smith, M. S., M. E. Freeman, et al. (1975). "The control of progesterone secretion 
during the estrous cycle and early pseudopregnancy in the rat: prolactin, 
gonadotropin and steroid levels associated with rescue of the corpus luteum of 
pseudopregnancy." Endocrinology 96(1): 219-226. 
 
 
Page | 323  
 
Smith, P., T. L. Steckler, et al. (2009). "Developmental programming: differential 
effects of prenatal testosterone and dihydrotestosterone on follicular recruitment, 
depletion of follicular reserve, and ovarian morphology in sheep." Biol Reprod 80(4): 
726-736. 
 
Smith, W. N. (1970). "Transplacental influence of androgen upon ovulatory 
mechanisms in the rat." J Endocrinol 48(3): 477-478. 
 
Smith, W. N. and M. T. Peng (1966). "Influence of testosterone upon sexual 
maturation in the rat." J Physiol 185(3): 655-666. 
 
Soder, O. (2007). "Sexual dimorphism of gonadal development." Best Pract Res Clin 
Endocrinol Metab 21(3): 381-391. 
 
Sonderegger, S., J. Pollheimer, et al. "Wnt signalling in implantation, decidualisation 
and placental differentiation--review." Placenta 31(10): 839-847. 
 
Speroff, L. and R. L. Vande Wiele (1971). "Regulation of the human menstrual 
cycle." Am J Obstet Gynecol 109(2): 234-247. 
 
Spicer, L. J., J. L. Voge, et al. (2004). "Insulin-like growth factor-II stimulates 
steroidogenesis in cultured bovine thecal cells." Mol Cell Endocrinol 227(1-2): 1-7. 
 
Spradling, A. C., M. de Cuevas, et al. (1997). "The Drosophila germarium: stem 
cells, germ line cysts, and oocytes." Cold Spring Harb Symp Quant Biol 62: 25-34. 
 
Srinivas, S., T. Watanabe, et al. (2001). "Cre reporter strains produced by targeted 
insertion of EYFP and ECFP into the ROSA26 locus." BMC Dev Biol 1: 4. 
 
Srinivasan, M., C. Dodds, et al. (2008). "Maternal obesity and fetal programming: 
effects of a high-carbohydrate nutritional modification in the immediate postnatal life 
of female rats." Am J Physiol Endocrinol Metab 295(4): E895-903. 
 
Srinivasan, M., P. Mitrani, et al. (2008). "A high-carbohydrate diet in the immediate 
postnatal life of rats induces adaptations predisposing to adult-onset obesity." J 
Endocrinol 197(3): 565-574. 
 
 
Page | 324  
 
Steckler, T., M. Manikkam, et al. (2007). "Developmental programming: follicular 
persistence in prenatal testosterone-treated sheep is not programmed by androgenic 
actions of testosterone." Endocrinology 148(7): 3532-3540. 
 
Steckler, T., J. Wang, et al. (2005). "Fetal programming: prenatal testosterone 
treatment causes intrauterine growth retardation, reduces ovarian reserve and 
increases ovarian follicular recruitment." Endocrinology 146(7): 3185-3193. 
 
Steckler, T. L., C. Herkimer, et al. (2009). "Developmental programming: excess 
weight gain amplifies the effects of prenatal testosterone excess on reproductive 
cyclicity--implication for polycystic ovary syndrome." Endocrinology 150(3): 1456-
1465. 
 
Steiner, R. A., D. K. Clifton, et al. (1976). "Sexual differentiation and feedback 
control of luteinizing hormone secretion in the rhesus monkey." Biol Reprod 15(2): 
206-212. 
 
Stener-Victorin, E. and C. Lindholm (2004). "Immunity and beta-endorphin 
concentrations in hypothalamus and plasma in rats with steroid-induced polycystic 
ovaries: effect of low-frequency electroacupuncture." Biol Reprod 70(2): 329-333. 
 
Stener-Victorin, E., T. Lundeberg, et al. (2000). "Effects of electro-acupuncture on 
nerve growth factor and ovarian morphology in rats with experimentally induced 
polycystic ovaries." Biol Reprod 63(5): 1497-1503. 
 
Stener-Victorin, E., K. Ploj, et al. (2005). "Rats with steroid-induced polycystic 
ovaries develop hypertension and increased sympathetic nervous system activity." 
Reprod Biol Endocrinol 3: 44. 
 
Stevens, J. (1995). "Obesity, fat patterning and cardiovascular risk." Adv Exp Med 
Biol 369: 21-27. 
 
Stimson, R. H., G. E. Lobley, et al. (2010). "Effects of proportions of dietary 
macronutrients on glucocorticoid metabolism in diet-induced obesity in rats." PLoS 
ONE 5(1): e8779. 
 
Stocco, C. (2008). "Aromatase expression in the ovary: hormonal and molecular 
regulation." Steroids 73(5): 473-487. 
 
 
Page | 325  
 
Stocco, C., C. Telleria, et al. (2007). "The molecular control of corpus luteum 
formation, function, and regression." Endocr Rev 28(1): 117-149. 
 
Stouffs, K., H. Tournaye, et al. (2009). "Male infertility and the involvement of the X 
chromosome." Hum Reprod Update 15(6): 623-637. 
 
Stouffs, K., D. Vandermaelen, et al. (2009). "[Genetics and male infertility]." Verh K 
Acad Geneeskd Belg 71(3): 115-139. 
 
Stubbs, S. A., J. Stark, et al. (2007). "Abnormal preantral folliculogenesis in 
polycystic ovaries is associated with increased granulosa cell division." J Clin 
Endocrinol Metab 92(11): 4418-4426. 
 
Su, Y. Q., K. Sugiura, et al. (2008). "Oocyte regulation of metabolic cooperativity 
between mouse cumulus cells and oocytes: BMP15 and GDF9 control cholesterol 
biosynthesis in cumulus cells." Development 135(1): 111-121. 
 
Sugiura, K., Y. Q. Su, et al. (2010). "Estrogen promotes the development of mouse 
cumulus cells in coordination with oocyte-derived GDF9 and BMP15." Mol 
Endocrinol 24(12): 2303-2314. 
 
Svendsen, P. F., L. Nilas, et al. (2008). "Obesity, body composition and metabolic 
disturbances in polycystic ovary syndrome." Hum Reprod. 
 
Taylor, A. E., B. McCourt, et al. (1997). "Determinants of abnormal gonadotropin 
secretion in clinically defined women with polycystic ovary syndrome." J Clin 
Endocrinol Metab 82(7): 2248-2256. 
 
Templeton, A. (2000). "Infertility and the establishment of pregnancy--overview." Br 
Med Bull 56(3): 577-587. 
 
Tetsuka, M., P. F. Whitelaw, et al. (1995). "Developmental regulation of androgen 
receptor in rat ovary." J Endocrinol 145(3): 535-543. 
 
Thomas, P. and D. W. Waring (1997). "Modulation of stimulus-secretion coupling in 
single rat gonadotrophs." J Physiol 504 ( Pt 3): 705-719. 
 
 
Page | 326  
 
Thomas, S. G. and I. J. Clarke (1997). "The positive feedback action of estrogen 
mobilizes LH-containing, but not FSH-containing secretory granules in ovine 
gonadotropes." Endocrinology 138(3): 1347-1350. 
 
Tohei, A., H. Sakamoto, et al. (2001). "Dexamethasone increases inhibin and 
estradiol secretion mediated by endogenous FSH in equine chorionic gonadotropin 
(eCG)-primed immature female rats." Life Sci 69(3): 281-288. 
 
Tohei, A., S. Sakamoto, et al. (2000). "Dexamethasone or triamcinolone increases 
follicular development in immature female rats." Jpn J Pharmacol 84(3): 281-286. 
 
Tomlinson, J. W., J. Finney, et al. (2008). "Impaired glucose tolerance and insulin 
resistance are associated with increased adipose 11beta-hydroxysteroid 
dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity." 
Diabetes 57(10): 2652-2660. 
 
Toulis, K. A., D. G. Goulis, et al. (2009). "Adiponectin levels in women with 
polycystic ovary syndrome: a systematic review and a meta-analysis." Hum Reprod 
Update 15(3): 297-307. 
 
Trombly, D. J., T. K. Woodruff, et al. (2009). "Roles for transforming growth factor 
beta superfamily proteins in early folliculogenesis." Semin Reprod Med 27(1): 14-23. 
 
Trombly, D. J., T. K. Woodruff, et al. (2009). "Suppression of Notch signaling in the 
neonatal mouse ovary decreases primordial follicle formation." Endocrinology 
150(2): 1014-1024. 
 
Tsai, C. L., R. K. Rowntree, et al. (2008). "Higher order chromatin structure at the X-
inactivation center via looping DNA." Dev Biol 319(2): 416-425. 
 
Tsilchorozidou, T., J. W. Honour, et al. (2003). "Altered cortisol metabolism in 
polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated 
adrenal steroid production rates." J Clin Endocrinol Metab 88(12): 5907-5913. 
 
Ulloa-Aguirre, A., P. Damian-Matsumura, et al. (1990). "Effects of neonatal 
androgenization on the chromatofocusing pattern of anterior pituitary FSH in the 
female rat." J Endocrinol 126(2): 323-332. 
 
 
Page | 327  
 
Vainio, S., M. Heikkila, et al. (1999). "Female development in mammals is regulated 
by Wnt-4 signalling." Nature 397(6718): 405-409. 
 
Vasquez, S. B. and J. I. Kitay (1978). "Effects of prolactin on pituitary-adrenal 
function in intact and ovariectomized rats." Acta Endocrinol (Copenh) 88(4): 744-
753. 
 
Veiga-Lopez, A., O. I. Astapova, et al. (2009). "Developmental programming: 
contribution of prenatal androgen and estrogen to estradiol feedback systems and 
periovulatory hormonal dynamics in sheep." Biol Reprod 80(4): 718-725. 
 
Veiga-Lopez, A., J. S. Lee, et al. (2010). "Developmental programming: insulin 
sensitizer treatment improves reproductive function in prenatal testosterone-treated 
female sheep." Endocrinology 151(8): 4007-4017. 
 
Veiga-Lopez, A., W. Ye, et al. (2008). "Developmental programming: deficits in 
reproductive hormone dynamics and ovulatory outcomes in prenatal, testosterone-
treated sheep." Biol Reprod 78(4): 636-647. 
 
Vendola, K. A., J. Zhou, et al. (1998). "Androgens stimulate early stages of follicular 
growth in the primate ovary." J Clin Invest 101(12): 2622-2629. 
 
Venken, K., K. De Gendt, et al. (2006). "Relative impact of androgen and estrogen 
receptor activation in the effects of androgens on trabecular and cortical bone in 
growing male mice: a study in the androgen receptor knockout mouse model." J 
Bone Miner Res 21(4): 576-585. 
 
Visser, J. A., A. L. Durlinger, et al. (2007). "Increased oocyte degeneration and 
follicular atresia during the estrous cycle in anti-Mullerian hormone null mice." 
Endocrinology 148(5): 2301-2308. 
 
Vo, T. T., Y. M. Yoo, et al. (2010). "Potential estrogenic effect(s) of parabens at the 
prepubertal stage of a postnatal female rat model." Reprod Toxicol 29(3): 306-316. 
 
vom Saal, F. S. and F. H. Bronson (1978). "In utero proximity of female mouse 




Page | 328  
 
vom Saal, F. S. and F. H. Bronson (1980). "Sexual characteristics of adult female 
mice are correlated with their blood testosterone levels during prenatal 
development." Science 208(4444): 597-599. 
 
W.H.O. (2006). "What are the health consequences of being overweight?". Retrieved 
14th August, 2010, from www.who.int. 
 
Wang, Y., J. Fortin, et al. (2008). "Activator protein-1 and smad proteins 
synergistically regulate human follicle-stimulating hormone beta-promoter activity." 
Endocrinology 149(11): 5577-5591. 
 
Wang, Y., Y. Sun, et al. (2004). "Expression of resistin mRNA in adipose tissue of 
rat model with polycystic ovarian syndrome and its implication." J Huazhong Univ 
Sci Technolog Med Sci 24(6): 621-624. 
 
Ward, O. B., A. M. Wexler, et al. (1996). "Critical periods of sensitivity of sexually 
dimorphic spinal nuclei to prenatal testosterone exposure in female rats." Horm 
Behav 30(4): 407-415. 
 
Webb, R., P. C. Garnsworthy, et al. (2004). "Control of follicular growth: local 
interactions and nutritional influences." J Anim Sci 82 E-Suppl: E63-74. 
 
Webber, L. J., S. Stubbs, et al. (2003). "Formation and early development of follicles 
in the polycystic ovary." Lancet 362(9389): 1017-1021. 
 
Welsh, M., D. J. MacLeod, et al. "Critical androgen-sensitive periods of rat penis and 
clitoris development." Int J Androl 33(1): e144-152. 
 
Welsh, M., D. J. MacLeod, et al. (2010). "Critical androgen-sensitive periods of rat 
penis and clitoris development." Int J Androl 33(1): e144-152. 
 
Welsh, M., P. T. Saunders, et al. (2008). "Identification in rats of a programming 
window for reproductive tract masculinization, disruption of which leads to 
hypospadias and cryptorchidism." J Clin Invest 118(4): 1479-1490. 
 
Welt, C. K., A. E. Taylor, et al. (2005). "Follicular arrest in polycystic ovary 
syndrome is associated with deficient inhibin A and B biosynthesis." J Clin 
Endocrinol Metab 90(10): 5582-5587. 
 
 
Page | 329  
 
West, L. J. (2002). "Defining critical windows in the development of the human 
immune system." Hum Exp Toxicol 21(9-10): 499-505. 
 
White, J. O., P. A. Moore, et al. (1981). "The relationship of the oestrogen and 
progestin receptors in the abnormal uterus of the adult anovulatory rat. Effects of 
neonatal treatment with testosterone propionate or clomiphene citrate." Biochem J 
196(2): 557-565. 
 
Whittle, J. R., M. J. Powell, et al. (2007). "Sirtuins, nuclear hormone receptor 
acetylation and transcriptional regulation." Trends Endocrinol Metab 18(9): 356-364. 
 
Wild, R. A., E. Carmina, et al. (2010). "Assessment of cardiovascular risk and 
prevention of cardiovascular disease in women with the polycystic ovary syndrome: 
a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome 
(AE-PCOS) Society." J Clin Endocrinol Metab 95(5): 2038-2049. 
 
Wolf CJ, H. A., Ostby JS, LeBlanc GA, Gray LE Jr (2002). "ffects of prenatal 
testosterone propionate on the sexual development of male and female rats: a dose-
response study." Toxicol Sci 65(1): 71-86. 
 
Wolf, C. J., G. A. LeBlanc, et al. (2004). "Interactive effects of vinclozolin and 
testosterone propionate on pregnancy and sexual differentiation of the male and 
female SD rat." Toxicol Sci 78(1): 135-143. 
 
Wong, H. Y., J. A. Burghoorn, et al. (2004). "Phosphorylation of androgen receptor 
isoforms." Biochem J 383(Pt 2): 267-276. 
 
Wood, R. I. and D. L. Foster (1998). "Sexual differentiation of reproductive 
neuroendocrine function in sheep." Rev Reprod 3(2): 130-140. 
 
Workshop, R. (2004). "Revised 2003 consensus on diagnostic criteria and long-term 
health risks related to polycystic ovary syndrome (PCOS)." Hum Reprod 19(1): 41-
47. 
 
Wu, X. Y., Z. L. Li, et al. (2010). "Endocrine traits of polycystic ovary syndrome in 
prenatally androgenized female Sprague-Dawley rats." Endocr J 57(3): 201-209. 
 
Xu, N., R. Azziz, et al. "Epigenetics in polycystic ovary syndrome: a pilot study of 
global DNA methylation." Fertil Steril 94(2): 781-783 e781. 
 
Page | 330  
 
 
Xu, Q., H. Y. Lin, et al. (2007). "Infertility with defective spermatogenesis and 
steroidogenesis in male mice lacking androgen receptor in Leydig cells." Endocrine 
32(1): 96-106. 
 
Yao, H. H., M. M. Matzuk, et al. (2004). "Follistatin operates downstream of Wnt4 
in mammalian ovary organogenesis." Dev Dyn 230(2): 210-215. 
 
Yeh, S., M. Y. Tsai, et al. (2002). "Generation and characterization of androgen 
receptor knockout (ARKO) mice: an in vivo model for the study of androgen 
functions in selective tissues." Proc Natl Acad Sci U S A 99(21): 13498-13503. 
 
Yong, E. L., D. T. Baird, et al. (1992). "Hormonal regulation of the growth and 
steroidogenic function of human granulosa cells." J Clin Endocrinol Metab 74(4): 
842-849. 
 
Young, J. M. and A. S. McNeilly (2010). "Theca: the forgotten cell of the ovarian 
follicle." Reproduction 140(4): 489-504. 
 
Yu, Y. S., H. S. Sui, et al. (2004). "Apoptosis in granulosa cells during follicular 
atresia: relationship with steroids and insulin-like growth factors." Cell Res 14(4): 
341-346. 
 
Zhang, C., S. Yeh, et al. (2006). "Oligozoospermia with normal fertility in male mice 
lacking the androgen receptor in testis peritubular myoid cells." Proc Natl Acad Sci 
U S A 103(47): 17718-17723. 
 
Zhang, Z. W., Z. M. Yang, et al. (2010). "Transgelin induces apoptosis of human 
prostate LNCaP cells through its interaction with p53." Asian J Androl 12(2): 186-
195. 
 
Zheng, K., F. Yang, et al. (2010). "Regulation of male fertility by X-linked genes." J 
Androl 31(1): 79-85. 
 
Zhou, R., I. M. Bird, et al. (2005). "Adrenal hyperandrogenism is induced by fetal 
androgen excess in a rhesus monkey model of polycystic ovary syndrome." J Clin 
Endocrinol Metab 90(12): 6630-6637. 
 
 
Page | 331  
 
Zhu, J. Q., L. Zhu, et al. "Demethylation of LHR in dehydroepiandrosterone-induced 
mouse model of polycystic ovary syndrome." Mol Hum Reprod 16(4): 260-266. 
 
Zorn, A. M. (2008). Liver development. StemBook: Harvard Stem Cell Institute. L. 
G. H. S. C. Institute). 
 
 
 
